<SEC-DOCUMENT>0001144204-11-047255.txt : 20110815
<SEC-HEADER>0001144204-11-047255.hdr.sgml : 20110815
<ACCEPTANCE-DATETIME>20110815162425
ACCESSION NUMBER:		0001144204-11-047255
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20110630
FILED AS OF DATE:		20110815
DATE AS OF CHANGE:		20110815

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADEONA PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		111036730

	BUSINESS ADDRESS:	
		STREET 1:		3930 VARSITY DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3930 VARSITY DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v230931_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html>
<head>
    <title>Unassociated Document</title>
    <!--Licensed to: VF-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, DC 20549</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM 10-Q</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Mark One)</font></div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">x</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the quarterly period ended June 30, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">OR</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Wingdings">&#168;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 54pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the transition period from &#160;____________ to&#160;____________</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number: 1-12584</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADEONA PHARMACEUTICALS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Name of small business issuer in its charter)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="51%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nevada</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13-3808303</font></div>
</td>
</tr><tr>
<td valign="bottom" width="51%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(State&#160;or&#160;other&#160;jurisdiction&#160;of&#160;incorporation&#160;or&#160;organization)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(IRS&#160;Employer&#160;Identification&#160;Number)</font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="51%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="51%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3985&#160;Research&#160;Park&#160;Drive,&#160;Suite&#160;200</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="48%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="bottom" width="51%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ann&#160;Arbor,&#160;MI</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">48108</font></div>
</td>
</tr><tr>
<td valign="bottom" width="51%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(Address&#160;of&#160;principal&#160;executive&#160;offices)</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="48%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman">(Zip&#160;Code)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Registrant&#8217;s telephone number, including area code:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(734) 332-7800</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Common Stock, $0.001 par value per share</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Securities registered pursuant to Section 12(g) of the Act:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Title of Class)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">x</font> &#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;Yes&#160;&#160; <font style="DISPLAY: inline;" face="Wingdings">x</font> &#160;&#160;&#160;&#160;&#160;&#160;No&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#160;&#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act.&#160;&#160;(Check one):</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Large&#160;accelerated&#160;filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="bottom" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accelerated&#160;filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Non-Accelerated&#160;filer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">&#168;</font></font></div>
</td>
<td align="left" valign="bottom" width="49%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Smaller&#160;reporting&#160;company&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">x</font></font></div>
</td>
</tr><tr>
<td align="left" valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="41%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Do&#160;not&#160;check&#160;if&#160;a&#160;smaller&#160;reporting&#160;company)</font></div>
</td>
<td align="left" valign="bottom" width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160; <font style="DISPLAY: inline;" face="Wingdings">&#168;</font> &#160;&#160;&#160;&#160;&#160;&#160;No&#160; <font style="DISPLAY: inline;" face="Wingdings">x</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of August 10, 2011, the registrant had 28,127,644 shares of common stock outstanding.</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">&#160;</div>

<div>
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page2"><!--EFPlaceholder--></a><a name="eolPage2"><!--EFPlaceholder--></a>ADEONA PHARMACEUTICALS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FORM 10-Q</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TABLE OF CONTENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="6%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Page</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PART I.&#8212;FINANCIAL INFORMATION</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Financial Statements</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Balance Sheets&#160;&#160;as of June 30, 2011(Unaudited) and December 31, 2010</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Operations (Unaudited)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Consolidated Statements of Cash Flows (Unaudited)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Notes to Consolidated Financial Statements (Unaudited)</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Management&#8217;s Discussion and Analysis of Financial&#160;Information and Results of Operations</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Quantitative and Qualitative Disclosures About Market Risks</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Controls and Procedures</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">PART II&#8212;OTHER INFORMATION</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Legal Proceedings</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 1A.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk Factors</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 2.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Unregistered Sales of Equity Securities and Use of Proceeds</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 3.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Defaults Upon Senior Securities</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 4.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Reserved and Removed</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 5.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Information</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="10%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Item 6.</font></div>
</td>
<td align="left" valign="top" width="81%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exhibits</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" colspan="2" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">SIGNATURE</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" colspan="2" valign="top" width="92%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">GLOSSARY</font></div>
</td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PART I.&#8212;FINANCIAL INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_FINANCIAL_STATEMENTS"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1. FINANCIAL STATEMENTS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adeona Pharmaceuticals, Inc. and Subsidiaries<a name="FIS_BALANCE_SHEET"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Consolidated Balance Sheets</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June&#160;30,&#160;2011</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,&#160;2010</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Unaudited)</font></div>
</td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Assets</font></font></div>
</td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current Assets</font></div>
</td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="top"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,385,933</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,648,853</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts receivable &#8211; net</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">444,664</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 338,510</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">75,547</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">343,417</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Current Assets</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8,906,144</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3,330,780</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment, net</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">396,144</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 511,142</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Goodwill</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">178,229</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; 178,229</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deposits and other assets</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">40,300</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160; 90,848</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Assets</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9,520,817</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,110,999</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Liabilities and Stockholders' Equity</font></font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current Liabilities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">286,836</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">265,722</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22,718</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210,027</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant liability</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">88,324</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Current portion of capital lease</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">24,400</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Current Liabilities</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">397,878</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">500,149</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Long Term Liabilities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,335</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">32,335</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Liabilities</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">400,213</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">532,484</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stockholders' Equity</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Preferred stock,&#160;&#160;$0.001 par value; 10,000,000 shares authorized,</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">none issued and outstanding</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; -</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Common stock,&#160;&#160;$0.001 par value; 100,000,000 shares authorized,</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28,079,126 issued and 27,997,644 outstanding</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">and 23,420,189&#160;issued and 23,338,707&#160;outstanding</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27,998</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23,339</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Additional paid-in capital</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">56,683,202</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47,279,416</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accumulated deficit</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(47,590,596</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160; &#160;(43,724,240</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Stockholders' Equity</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9,120,604</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160; 3,578,515</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Liabilities and Stockholders' Equity</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">9,520,817</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4,110,999</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to unaudited consolidated financial statements</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adeona Pharmaceuticals, Inc. and Subsidiaries<a name="FIS_INCOME_STATEMENT"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Consolidated Statements of Operations</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Unaudited)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;months&#160;ended&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June&#160;30,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Six&#160;months&#160;ended&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June&#160;30,</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Revenues:</font></div>
</td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">License revenue, net</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,125,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,125,000</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laboratory revenues, net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">355,562</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">69,888</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">678,700</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">129,927</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Revenues</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">355,562</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,194,888</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">678,700</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,254,927</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Operating Costs and Expenses:</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">General and administrative</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">694,281</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">662,627</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,967,817</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,398,456</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Research and development</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">279,641</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">426,572</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">511,959</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">733,722</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Costs of&#160;&#160;laboratory services</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">301,142</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">132,406</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">545,000</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">237,825</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Operating Costs and Expenses</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,275,064</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,221,605</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,024,776</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,370,003</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Loss from Operations</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(919,502 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">973,283</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,346,076 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(115,076 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other Income (Expense):</font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant expense</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(775,996 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,491,996 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value of warrant liability</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16,386</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(77,471 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other income (expense)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(783</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,499</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">49,187</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,336</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total Other Income (Expense), net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(760,393 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,499</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,520,280 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">7,336</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Income (Loss)</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,679,895</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">979,782</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,866,356</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(107,740</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Income (Loss) Per Share &#8211; Basic</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.06</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.05</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.15</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.00</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average number of common shares outstanding during the period &#8211; Basic</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">27,885,479</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">21,706,472</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">26,560,448</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">21,633,985</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Income (Loss) Per Share &#8211; Dilutive</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.06</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.05</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.15</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(0.00</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted average number of common shares outstanding during the period &#8211; Dilutive</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">27,885,479</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">21,883,414</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">26,560,448</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">23,782,010</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to unaudited consolidated financial statements</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="Page5"><!--EFPlaceholder--></a></font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V222442_10Q_HTM_EOLPAGE5"><!--EFPlaceholder--></a>&#160;Adeona Pharmaceuticals, Inc. and Subsidiaries<a name="FIS_CASH_FLOW"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Consolidated Statements of Cash Flows</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Unaudited)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Six&#160;months&#160;ended&#160;June&#160;30,</font></font></div>
</td>
<td align="left" valign="top" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2011</font><font style="DISPLAY: inline">&#160;&#160;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">2010</font><font style="DISPLAY: inline">&#160;&#160;</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash Flows From Operating Activities:</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net loss</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,866,356</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(107,740</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adjustments to reconcile net loss to net cash&#160; used in operating activities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Recognition of stock-based compensation</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">427,166</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">236,574</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock option modification expense</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">397,767</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock issued for consulting fees</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">58,270</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33,269</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock issued as compensation</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">75,840</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46,613</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant expense</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,491,996</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value of warrant liability</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">77,471</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Depreciation</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">108,106</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">180,076</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Provision for uncollectible accounts receivable</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">188,466</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20,147</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Gain) loss on sale of equipment</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,692</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(3,443</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gain on settlement of accounts payable</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(62,996</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Changes in operating assets and liabilities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts receivable</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(294,620</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(153,574</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Other current assets</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">267,870</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">791</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Deposits and other assets</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,548</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accounts payable</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">54,109</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(27,884</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Accrued liabilities</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(187,309</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">191,309</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Cash Provided By (Used In) Operating Activities</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,207,980</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">416,138</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash Flows From Investing Activities:</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Purchase of property and equipment</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(2,070</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from the sale of equipment</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,200</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">60,890</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Cash Provided By Investing Activities</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,200</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">58,820</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash Flows From Financing Activities:</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Repayments under capital lease</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(24,400</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(8,503</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from issuance of common stock for stock option exercises</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7,650</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">89,157</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proceeds from the issuance of common stock, net of offering costs of $539,390</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,960,610</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Cash Provided By Financing Activities</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">6,943,860</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">80,654</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net increase in cash</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5,737,080</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">555,612</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash at beginning of period</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,648,853</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,715,044</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash at end of period</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">8,385,933</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,270,656</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Supplemental disclosures of cash flow information</font> :</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid for interest</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td valign="top" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; -</font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2,169</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cash paid for taxes</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">Supplemental disclosure for non-cash item:</font></font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Reclassification of derivative liability to additional paid in capital</font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,481,143</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">See accompanying notes to unaudited consolidated financial statements</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="Page6"><!--EFPlaceholder--></a></font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V222442_10Q_HTM_EOLPAGE6"><!--EFPlaceholder--></a>Adeona Pharmaceuticals, Inc. and Subsidiaries<a name="FIS_NOTES_TO_FINANCIAL_STATEMENT"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Notes to Consolidated Financial Statements</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">(Unaudited)</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;Organization</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adeona Pharmaceuticals, Inc. (the &#8220;Company&#8221; or Adeona&#8221;) is a pharmaceutical company&#160;&#160;focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company&#8217;s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer&#8217;s disease. The Company is currently preparing to make the following products commercially available: <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>, a medical food for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease, and <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>, a homeopathic over-the-counter drug for reducing the symptoms associated with the common cold. Adeona also operates a wholly owned clinical reference laboratory, Adeona Clinical Laboratory that provides a broad array of chemistry and microbiology diagnostic tests.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_3"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;Basis of Presentation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The financial information as of December 31, 2010, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010. The unaudited condensed interim financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K, which contains the audited financial statements and notes thereto, together with the Management&#8217;s Discussion and Analysis, for the year ended December 31, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended June 30, 2011, are not necessarily indicative of results for the full year.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has eight subsidiaries, Pipex Therapeutics, Inc. (&#8220;Pipex Therapeutics&#8221;), Adeona Clinical Laboratory (formerly Hart Lab, LLC), Effective Pharmaceuticals, Inc. (&#8220;EPI&#8221;), Solovax, Inc. (&#8220;Solovax&#8221;), CD4 Biosciences, Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals, Inc. (&#8220;Epitope&#8221;), Healthmine, Inc. (&#8220;Healthmine&#8221;) and Putney Drug Corp. (&#8220;Putney&#8221;). As of June 30, 2011, EPI, Adeona Clinical Laboratory, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Principles of Consolidation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant inter-company accounts and transactions have been eliminated in consolidation.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="V222442_10Q_HTM_EOLPAGE7"><!--EFPlaceholder--></a>Use of Estimates</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives&#160;for intangible assets and for property and equipment, the fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing operating losses.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates.</font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="Page7"><!--EFPlaceholder--></a>Accounts Receivable and Allowance for Doubtful Accounts</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company estimates and reviews the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assesses the state of its billing operations in order to identify issues that may impact the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense. Receivables deemed uncollectible are charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue Recognition</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;The Company has two streams of revenue, license revenue and laboratory revenue.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">License Revenues</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Laboratory Revenues</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company primarily recognizes revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, are recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company maintains a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looks at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 18 months, otherwise known as the yearly average adjustment amount. The actual sales allowance taken for each period is the averaged yearly average adjustment amount for these prior periods multiplied by the period&#8217;s actual gross revenues.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company generated reimbursements from&#160;3 significant insurance providers for the six months ended June 30, 2011 and 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="40%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Customer</font></font></div>
</td>
<td nowrap valign="bottom" width="4%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="4%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="4%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="24%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">68</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="23%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="24%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">B</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="23%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="24%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">C</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="25%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="23%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></td>
<td nowrap valign="bottom" width="4%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Risks and Uncertainties</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company's operations are subject to significant risk and uncertainties including financial, operational, regulatory and other risks, including the potential risk of business failure. The recent global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions not only limit&#160;the Company&#8217;s&#160;access to capital, but also make it difficult for the Company&#8217;s customers, the Company&#8217;s vendors and the Company to accurately forecast and plan future business activities.<a name="Page8"><!--EFPlaceholder--></a></font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Cash and Cash Equivalents</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.&#160;&#160;As of June 30, 2011, and December 31, 2010, respectively, the Company had no cash equivalents.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company minimizes credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed the federally insured limit of $250,000 per depositor, per bank. At June 30, 2011 and December 31, 2010, the balance exceeded the federally insured limit by $7.9 million and $2.1 million, respectively.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Warrant / Derivative Liabilities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In&#160;assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Net&#160;Income (Loss) per Share</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Basic earnings (loss) per share is computed by dividing the net income (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of share equivalents.&#160;&#160;Common equivalent shares, consisting of options and warrants for the purchase of common stock, are not included in the per share calculation where the effect would be anti-dilutive.&#160;The Company&#8217;s share equivalents at June 30, 2011 consist of 2,781,093 stock options and 3,368,738 warrants, respectively, and for the period ended June 30, 2010 consist of 2,312,759 and 1,070,472, respectively. The&#160;computations of basic and diluted net income (loss) attributable to common share are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Three&#160;months&#160;ended&#160;June&#160;30,</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="6" valign="bottom" width="22%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Six&#160;months&#160;ended&#160;June&#160;30,</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,679,895)</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">979,782</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(3,866,356</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(107,740</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic weighted-average shares</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">27,885,479</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">21,706,472</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">26,560,448</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">21,633,985</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effect of dilutive securities:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Stock options</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">175,527</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrants</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1,415</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dilutive&#160;&#160;weighted-average shares</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">27,885,479</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">21,883,414</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">26,560,448</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">23,782,010</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net income (loss) per share:</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Basic</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.06</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">0.05</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.15</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.00</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Dilutive</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.06</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">0.05</font></font></div>
</td>
<td valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(015</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(0.00</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development Costs</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.</font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page9"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Share-Based Payment Arrangements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Generally, all forms of share-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date, based on the estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. The expense resulting from share-based payments are recorded in cost of goods sold, research and development or general and administrative expenses in the consolidated statement of operations, depending on the nature of the services provided.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Recent Accounting Pronouncements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2011, the FASB updated the accounting guidance on Topic 220, entitled &#8220;Comprehensive Income&#8221;, relating to presentation of comprehensive income. This guidance requires companies to present total comprehensive income, the components of net income and the components of other comprehensive income, or OCI, either in a single continuous statement of comprehensive income or in two consecutive statements. Additionally, companies are required to present on the face of the financial statements the reclassification adjustments that are reclassified from OCI to net income, where the components of net income and the components of OCI are presented. This guidance is effective beginning 2012. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In June 2011, the FASB updated the accounting guidance on alignment of disclosures for GAAP and the International Financial Reporting Standards, or IFRS, by updating Topic 820 entitled &#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS&#8221;, relating to presentation of fair value measurements reported in financial statements. The updated guidance requires companies to align fair value measurement and disclosure requirements between GAAP and IFRS. The updated guidance is effective beginning in the year 2012 and earlier adoption is not permitted. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s financial position or results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Reclassifications</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To conform prior period amounts to current year classifications, the Company has reclassified laboratory services, and research and development expenses to general and administrative expenses. These reclassifications had no impact on the Company&#8217;s previously reported results of operations or cash flows.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;Property and Equipment</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Property and Equipment consisted of the following at June 30, 2011, and December 31, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_4"><!--EFPlaceholder--></a><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June&#160;30,&#160;2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">December&#160;31,&#160;2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Leasehold improvements</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,070</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">864,429</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Manufacturing equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">400,045</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">410,997</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Computer and office equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">160,478</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">160,478</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Laboratory equipment</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">213,908</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">213,908</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Total</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">776,501</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,649,812</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Less accumulated depreciation</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(380,357 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1,138,670 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Property and equipment, net</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">396,144</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">511,142</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The decrease in leasehold improvements during the six months ended June 30, 2011, reflects the relocation of the Company&#8217;s headquarters within Ann Arbor, Michigan.&#160;&#160;During the six months ended June 30, 2011, the Company sold equipment, with a net book value of $6,892, for $1,200, resulting in a loss of $5,692.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Depreciation expense for the six months ended June 30, 2011 and 2010 was $108,106 and $180,076, respectively.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;Stock-Based Compensation</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During 2001, Pipex Therapeutics&#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of June 30, 2011, there were 1,320,354 options issued and outstanding under the 2001 Stock Plan.<a name="Page10"><!--EFPlaceholder--></a></font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On March 20, 2007, the Company&#8217;s board of directors approved the Company&#8217;s 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2011, there are 1,228,239 options issued and outstanding under the 2007 Stock Plan.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven years after the grant date. As of June 30, 2011, there are 232,500 options issued and outstanding under the 2010 Stock Plan.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the six months ended June 30, 2011 and 2010, are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="32%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="6" valign="bottom" width="22%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Three&#160;Months&#160;Ended&#160;June&#160;30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="4" valign="bottom" width="42%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Six&#160;Months&#160;Ended&#160;June&#160;30,</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td align="left" valign="bottom" width="32%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2011</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2010</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise price</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.73</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.21&#160;-&#160;$2.22</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.82 - $0.87</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected dividends</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected volatility</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">184</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">184% - 188%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">203% - 204%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free interest rates</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.88</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.81% - 3.58%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.59% - 3.63%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected life options</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">7&#160;years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5 years - 7 years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10&#160;years</font></div>
</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="32%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected forfeitures</font></div>
</td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">immediate vesting,</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">one-half vesting immediately and the remainder over three years</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">quarterly over three years,</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">annually over three years,</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">one-third immediate vesting and remaining annually over two years,</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">one-half immediate vesting with remaining vesting over nine months; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">one quarter immediate vesting with the remaining over three years.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the six months ended June 30, 2011, the Company granted 332,002 options to employees and consultants having a fair value of $445,671 based upon the Black-Scholes option pricing model.&#160; During the same period of 2010, the Company granted 425,000 options to employees having a fair value of $349,750 based upon the Black-Scholes option pricing model.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 18, 2011, the Company amended the terms of 228,773 stock options held by a member of the Board of Directors.&#160;&#160;In connection with the modification, the Company extended the expiration date of the stock options by 5 years.&#160;&#160;The extension is considered a modification, which in substance is the issuance of a new stock option award.&#160;&#160;As a result, the Company computed the fair value of this award to be $397,767, using the Black-Scholes valuation model.&#160;&#160;&#160;The fair value was based upon the following management assumptions:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="Page11"><!--EFPlaceholder--></a><br>
</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="top" width="80%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercise price</font></td>
<td valign="top" width="20%" style="TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.09</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="80%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected dividends</font></div>
</td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="80%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected volatility</font></div>
</td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">187.1%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="80%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected term</font></div>
</td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5 years</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="80%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free interest rate</font></div>
</td>
<td valign="top" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.03%</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of stock option activities as of June 30, 2011, and for the year ended December 31, 2010, is as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_6"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Options</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Weighted&#160;Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Contractual</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Life</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="3" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Aggregate</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Intrinsic</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Value</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; December 31, 2009</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,561,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.26</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">743,332</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.80</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">( 255,954 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.44</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited or expired</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(509,619 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.69</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; December 31, 2010</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,539,091</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.32</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">332,002</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.61</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited or expired</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(80,000 </font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.56</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(10,000 </font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.56</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; June 30, 2011 - outstanding</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,781,093</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.38</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.38 years</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">431,508</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="52%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="52%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; June 30, 2011 &#8211; exercisable</font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,299,189</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.50</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.95 years</font></font></div>
</td>
<td align="left" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">402,549</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The options outstanding and exercisable as of June 30, 2011, are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_7"><!--EFPlaceholder--></a></font></div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="7" valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Options&#160;Outstanding</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="8" valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Options&#160;Exercisable</font></font></div>
</td>
</tr><tr>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Range&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">outstanding</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font> </div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="21%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining </font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contractual Life</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercisable</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contractual&#160;Life</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">0.09 - 4.57</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">2,691,094</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.23</font></div>
</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: center">6.48 years</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">2,209,190</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.32</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.06 years</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.58 - 9.05</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">89,999</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5.93</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">3.26 years</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">89,999</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.93</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3.26 years</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">2,781,093</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1.38</font></font></div>
</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: center">6.38 years</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">2,299,189</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.50</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5.95 years</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The options outstanding and exercisable as of June 30, 2010, are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_8"><!--EFPlaceholder--></a></font></div>

<div>
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" colspan="2" valign="bottom" width="10%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="7" valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Options&#160;Outstanding</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="8" valign="bottom" width="43%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Options&#160;Exercisable</font></font></div>
</td>
</tr><tr>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Range&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">outstanding</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></font></font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font> </font></font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font> </font></font></div>

<div><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></font></font></div>
</td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="21%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining </font></font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contractual Life</font></font></font></font></div>
</div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercisable</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Price</font></font></div>
</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contractual&#160;Life</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">0.09 - 4.57</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">2,222,760</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right">1.19</td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="21%" style="TEXT-ALIGN: center">3.65 years</td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">1,763,593</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.31</font></font></td>
<td nowrap valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.93 years</font></div>
</td>
</tr><tr bgcolor="white">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">4.58 - 9.05</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">89,999</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right">5.93</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="21%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">4.26 years</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">88,124</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">5.93</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">4.20 years</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="1%" style="TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">2,312,759</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right">1.37</td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="21%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: center">6.56&#160;years</td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;</font><font style="DISPLAY: inline">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt">1,851,717</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></td>
<td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">1.53</font></font></td>
<td nowrap valign="bottom" width="1%" style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td valign="bottom" width="20%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">5.85 years</font></font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.&#160;&#160;&#160;Stock Purchase Warrants</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns.&#160;&#160;The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015.&#160;&#160;&#160;Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost.&#160;&#160;The result of the transaction has a $0 net effect to equity.&#160;&#160;As of June 30, 2011, 30,303 of these warrants remained outstanding.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors.&#160;&#160;As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock.&#160;&#160;&#160;Each warrant was exercisable&#160;for thirteen months&#160;at $2.00 per share. We have entered into an agreement pursuant to which we have agreed to exchange the original warrants for new warrants with substantially the same&#160;terms as the original warrants except that the expiration date will be extended two months. The warrants had an anti-dilution&#160;&#160;price protection feature; if the Company issues securities at a price per share that&#160;&#160;is less than&#160;&#160;$2.00&#160;&#160;per share,&#160;&#160;the&#160;&#160;warrant&#160;&#160;holders&#160;&#160;will be ratcheted&#160;&#160;down&#160;&#160;to&#160;&#160;the lower&#160;&#160;offering&#160;&#160;price. However, the Company has instituted a floor price of $1.40 per share in connection with the price protection.&#160;&#160;On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40.&#160;&#160;Due to the re-set to the floor price, the warrant liability was marked-to-market and reclassified to additional paid in capital since it ceased to contain the provisions of a derivative liability.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The warrants were recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent reporting period.&#160;&#160;At April 6, 2011, the fair value of the warrant liability was $1,481,143, which represented an increase in fair value of $765,143. The fair value was measured using the Black Scholes valuation model, which is based, in part, upon unobservable inputs for which there is little or no market data, requiring the Company to develop its own assumptions. The assumptions used by the Company are summarized in the following table:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Commitment</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Date</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remeasurement</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Date&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">April&#160;6,&#160;2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Closing stock price</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.39</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.08</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected dividend rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected stock price volatility</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">117.1</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">104.6</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free interest rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.28</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.29</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected life (years)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.08</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.85</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor.&#160;&#160;As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock.&#160;&#160;&#160;The warrant was initially exercisable&#160;for thirteen months&#160;at $2.0725 per share. The warrant had an anti-dilution&#160;&#160;price protection feature; that provided if the Company issues securities at a price per share that&#160;&#160;is less than&#160;&#160;$2.0725&#160;&#160;per share,&#160;the&#160;exercise price of the warrant&#160;will be ratcheted&#160;&#160;down&#160;&#160;to&#160;&#160;the lower&#160;&#160;offering&#160;&#160;price.&#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&#160;three months to August 12, 2012,&#160;and (iv) the warrant&#8217;s initial exercise date was changed to January 2012. <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Due to this warrant exchange, the warrant liability will be eliminated on a go-forward basis since the new warrant no longer contains the provisions that cause it to be treated as a derivative liability. See Note 8 &#8211; Subsequent Event.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The warrant is&#160;recorded as a liability at&#160;its estimated fair value on the commitment date, which was $775,995 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent period.&#160;&#160;At June 30, 2011, the fair value of the warrant liability was $88,323, which represented a decrease in fair value of $687,672.&#160;&#160; The fair value is measured using the Black Scholes valuation model, which is based, in part, upon unobservable inputs for which there is little or no market data, requiring the Company to develop its own assumptions. The assumptions used by the Company are summarized in the following table:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Commitment</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Date</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remeasurement</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Date&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">June&#160;30,&#160;2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Closing stock price</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.08</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$0.86</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected dividend rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected stock price volatility</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">112.1</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105.4</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free interest rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.29</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.19</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected life (years)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.08</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.77</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The following table summarizes the estimated fair value of the warrant liabilities:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_12"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at December 31, 2010</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Warrant liability</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,491,995</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Change in fair value of warrant liability</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">77,471</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Reclass to stockholders&#8217; equity</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(1,481,143</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)&#160;</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="88%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="88%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance at June 30, 2011</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">88,323</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A summary of warrant activities as of June 30, 2011, and for the year ended December 31, 2010, is as follows:</font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">12</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_UNIDENTIFIED_TABLE_9"><!--EFPlaceholder--></a><a name="FIS_UNIDENTIFIED_TABLE_13"><!--EFPlaceholder--></a><a name="Page13"><!--EFPlaceholder--></a>&#160;<br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="76%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Warrants</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">&#160;Exercise&#160;Price</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; December 31, 2009</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,070,472</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.27</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">60,606</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.32</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">-</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited or expired</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">-</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; December 31, 2010</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,131,078</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.49</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Granted</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2,272,963</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.65</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Forfeited or expired</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(19,688</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.32</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exercised</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">(15,615</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">)</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1.19</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; June 30, 2011 - outstanding</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,368,738</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2.27</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td valign="bottom" width="76%" style="PADDING-BOTTOM: 4px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Balance &#8211; June 30, 2011 &#8211; exercisable</font></div>
</td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,368,738</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">$</font></font></div>
</td>
<td align="right" valign="top" width="9%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">2.27</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The warrants outstanding as of June 30, 2011, are as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_UNIDENTIFIED_TABLE_10"><!--EFPlaceholder--></a><a name="FIS_UNIDENTIFIED_TABLE_14"><!--EFPlaceholder--></a></font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Range&#160;of</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Exercise&#160;Price</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="26%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Number</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">outstanding</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Weighted</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Average</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remaining</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Contractual&#160;Life</font></font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.32</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30,303</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;&#160;&#160; </font></td>
<td valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.51 years</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.40</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1,428,572</font></div>
</td>
<td valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.85 years</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.0725</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">844,391</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.77 years</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">2.22</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">626,809</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">5.01 years</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.30</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">61,207</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.92 years</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3.75</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">50,000</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.63 years</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="25%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">6.36</font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">327,456</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1.36 years</font></font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="BORDER-BOTTOM: black 4px double"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="25%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">3,368,738</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 4px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="bottom" width="45%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">1.80 years</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;Stockholders&#8217; Equity</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the six months ended June 30, 2011, the Company issued 15,000 shares of common stock in connection with the exercise of stock options and warrants for proceeds of $7,650 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company also issued 45,600 shares of common stock for employment service, having a fair value of $75,840 ($1.66 average per share) and 41,796 shares of common stock for consulting services, having a fair value of $58,270 ($1.39 average per share), based on the quoted closing trading prices.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&#160;1,428,572 shares of common stock&#160;for $4,000,000. Direct offering costs were approximately $300,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 6, 2011, the Company sold 1,688,782 shares of common stock and a warrant exercisable for 844,391 shares of common stock&#160;for $3,500,000. Direct offering costs were approximately $250,000.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;&#160;Subsequent Event</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 28, 2011, the Company exchanged&#160;the warrant issued in connection with the&#160;April 6, 2011 financing&#160;for a new warrant with substantially the same terms as the original warrant except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional three months to August 10, 2012,&#160;and (iv) the warrant&#8217;s initial exercise date was changed to January 2012.&#160;&#160;&#160;Due to this warrant exchange, the warrant liability&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">will be eliminated on a go-forward basis since the new warrant no longer contains the provisions that cause it to be treated as a derivative liability.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company measured the fair value of the warrant at $253,317 using a Black-Scholes valuation model;&#160;As a result of modifying the terms of the warrant, it was not&#160;considered&#160;indexed to the Company&#8217;s common stock.&#160;&#160;The fair value of this warrant upon exchange was based upon the following management assumptions:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">13</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="Page14"><!--EFPlaceholder--></a><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="50%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="82%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="bottom" width="16%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Remeasurement</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">Date&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">July&#160;28,&#160;2011</font></font></div>
</td>
<td align="left" valign="top" width="1%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="82%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Closing stock price</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">$</font></div>
</td>
<td align="right" valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.84</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="82%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected dividend rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="82%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected stock price volatility</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">105.6</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="white">
<td align="left" valign="bottom" width="82%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Risk free interest rate</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">0.21</font></div>
</td>
<td align="left" valign="top" width="1%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">%</font></div>
</td>
</tr><tr bgcolor="#ccffcc">
<td align="left" valign="bottom" width="82%">
<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Expected life (years)</font></div>
</td>
<td align="right" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="right" valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">1.04</font></div>
</td>
<td align="left" valign="top" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date will be&#160;extended by two months.</font></div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">14</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;<!--EFPlaceholder--></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL INFORMATION AND RESULTS OF OPERATIONS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The following discussion should be read in conjunction with the attached unaudited consolidated financial statements and notes thereto, and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 31, 2010, found in our Annual Report on Form 10-K. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intends,&#8221; or similar expressions. Our actual results could differ materially from those anticipated by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under &#8220;Risk Factors&#8221; in this 10-Q and as applicable in Part I, Item 1A of our Annual Report on Form 10-K.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Overview</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. Our strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. We are developing, or have partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer&#8217;s disease. We are currently preparing to make the following products commercially available: <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">TM</font></font></font>, a medical food for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease, and <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">TM</font></font></font>, a homeopathic over-the-counter drug for reducing the symptoms associated with&#160;the common cold. We also operate our wholly owned clinical reference laboratory, Adeona Clinical Laboratory.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Product Pipeline:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><img src="pg15.jpg"></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Drug Candidates:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Trimesta<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> (estriol) is our drug candidate being developed for the treatment of relapsing-remitting multiple sclerosis in women. A randomized, double-blind, placebo-controlled clinical trial is currently underway at 15 centers in the United States. As of August 1, 2011, 140 out of 150 patients have been enrolled.</font></div>
</td>
</tr></table>
</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">&#160;</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Effirma<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font></font> (flupirtine) is our drug candidate being developed for the treatment of fibromyalgia. On May 6, 2010, we and Pipex Therapeutics, Inc. (Pipex), our wholly owned subsidiary, entered into a sublicense agreement with Meda AB, a multi-billion dollar international pharmaceutical company, covering all of our patents&#8217; rights on the use of flupirtine for fibromyalgia in the U.S., Canada and Japan. According to Meda&#8217;s 2010 Annual Report, flupirtine for fibromyalgia is currently in Phase II development.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AEN-100 (zinc) and AEN-200 (copper) are our drug candidates being developed for the treatment of Amyotrophic lateral sclerosis (ALS), or Lou Gehrig&#8217;s disease. We intend to sponsor a Phase IIb multi-center, double-blind, placebo-controlled clinical trial in ALS patients. It is anticipated that the clinical trial will enroll at least 60 patients and that patients will be dosed and monitored for up to 12 months.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AEN-100 (zinc) is our drug candidate being developed for the treatment of mild to moderate Alzheimer&#8217;s disease. We intend to conduct a randomized, double-blind, placebo-controlled clinical study in patients diagnosed with mild to moderate Alzheimer&#8217;s disease who are age 70 and over. It is anticipated that the clinical study will enroll over 100 patients and that the evaluation period will be at least 12 months.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">15</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="MARGIN-LEFT: 27pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June 30, 2011, we have discontinued our ZincMonoCysteine (zinc monocysteine) clinical development program. While results from an 80-patient, randomized, double-blind, placebo-controlled, Investigational Review Board (IRB) approved clinical trial conducted by the late Dr. Newsome in patients with dry age-related macular degeneration were published in a peer-reviewed journal in 2008, the decision to discontinue this program was driven by economic factors, anticipated time to market and the perceived relative clinical and market potential. We will continue to focus our efforts on developing innovative medicines for the treatment of&#160;&#160;other serious central nervous system diseases and to explore new opportunities.</font></div>

<div style="MARGIN-LEFT: 27pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Near-Term Product Candidates:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">reaZin<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: normal">TM</font></font></font> (zinc cysteine) is our product candidate for the dietary management of zinc deficiency associated with Alzheimer's disease, being developed as a medical food, available only by prescription.&#160; In 2011, results from a multi-center, randomized, double-blind, placebo-controlled clinical study showed that the primary outcomes of increasing serum zinc and decreasing serum free copper were effectively demonstrated in patients administered <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin.</font>&#160;In addition, the cognitive function of the placebo group, on average, declined over 6 months in comparison to patients managed with <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font>. The cognitive function trends favoring the patients managed with <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> were observed in all three standardized cognitive tests utilized in our study and suggest that <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> may provide an important benefit to the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 45pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td style="TEXT-ALIGN: justify">
<div style="TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> (zinc lozenge) is our product candidate to reduce the duration and severity of symptoms caused by the common cold. On July 28, 2011, we announced that we acquired exclusive access to two sets of clinical data demonstrating, with statistical significance, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold. Based on the reduction of common cold symptoms demonstrated by the 13.3 mg zinc acetate formulation, we intend to commercialize an oral zinc lozenge as a homeopathic over-the-counter (OTC) drug under the brand name <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#8482;</font>.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our source of liquidity as of June 30, 2011, is cash of $8,385,933. Our projected uses of cash include funding further clinical development of our drug candidates and commercialization of our medical food candidate and homeopathic drug, working capital and other general corporate activities.&#160;&#160;We may also use our cash for the acquisition of businesses, technologies and products that will complement our existing assets.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On January 28, 2011, we entered into a Securities Purchase Agreement with institutional investors, relating to the offering and sale of 2,857,144 shares of common stock, par value $0.001 per share and warrants to purchase 1,428,572 shares of common stock. We raised gross proceeds of $4,000,000, before estimated offering expenses of approximately $300,000, which includes placement agent fees.&#160;The offering was made pursuant to the our shelf registration statement on Form S-3 (File No. 333-166750), which was declared effective by the Securities and Exchange Commission (SEC) on June 14, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 6, 2011, we entered into a Securities Purchase Agreement with an institutional investor, relating to the offering and sale of 1,688,782 shares of common stock, par value $0.001 per share and&#160;a warrant&#160;to purchase 844,391 shares of common stock. We raised gross proceeds of $3,500,000, before estimated offering expenses of approximately $250,000, which includes placement agent fees. The offering was made pursuant to the our shelf registration statement on Form S-3 (File No. 333-166750), which was declared effective by the Securities and Exchange Commission (SEC) on June 14, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We believe that with the additional proceeds of the January and April 2011 equity financings, our cash will be sufficient to fund our planned operations for at least the next 12 months.&#160;&#160;We will need additional capital to continue the development of our product candidates and clinical programs beyond 12 months. The sale of any equity or debt securities may result in additional dilution to our stockholders, and we cannot be certain that additional financing will be available in amounts or on terms acceptable to us, if at all. If we are unable to obtain financing, we may be required to reduce the scope and timing of the planned clinical and preclinical programs, which could harm our financial condition and operating results.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">16</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V222442_10Q_HTM_V216123_10K_HTM_PAGE5"><!--EFPlaceholder--></a><a name="V222442_10Q_HTM_V216123_10K_HTM_PAGE6"><!--EFPlaceholder--></a>Clinical Drug Development Programs</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Relapsing-Remitting Multiple Sclerosis in Women</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Trimesta (estriol)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Disease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page17"><!--EFPlaceholder--></a>Multiple sclerosis is a progressive neurological disease in which the body loses the ability to transmit messages along central nervous system nerve cells, leading to a loss of muscle control, paralysis, cognitive impairment and in some cases death. According to the National Multiple Sclerosis Society, currently, more than 2.5 million people worldwide (approximately 400,000 patients in the United States) have been diagnosed with multiple sclerosis. Young adults, ages 20 to 50, and two to three times as many women than men are predominantly diagnosed with multiple sclerosis. According to the National Multiple Sclerosis Society, approximately 85% of multiple sclerosis patients are initially diagnosed with the relapsing-remitting form, compared to 10-15% with other progressive forms. Despite the availability of multiple FDA-approved therapies for the treatment of relapsing-remitting multiple sclerosis, the disease is highly underserved and exacts a heavy economic toll. Multiple sclerosis costs the United States more than $10.6 billion annually in medical care and lost productivity according to the Society for Neuroscience.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Background</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It has been scientifically demonstrated that pregnant women with certain autoimmune diseases experience a spontaneous reduction of disease symptoms during pregnancy, particularly in the third trimester. The PRIMS (Pregnancy In Multiple Sclerosis) study, a landmark clinical study published in the <font style="DISPLAY: inline; FONT-STYLE: italic">New England Journal of Medicine</font> followed 254 women with multiple sclerosis during 269 pregnancies and for up to one year after delivery. The PRIMS study demonstrated that relapse rates were significantly reduced by 71 percent (p &lt; 0.001) through the third trimester of pregnancy compared to pre-pregnancy-rates, and that relapse rates increased by 120 percent (p &lt; 0.001) during the first three months after birth (post-partum) before returning to pre-pregnancy rates. It has been hypothesized that the female hormone, estriol, produced by the placenta during pregnancy, plays a role in&#160;&#160;&#8220;fetal immune privilege&#8221;, a process that prevents&#160;a mother&#8217;s immune system from attacking and rejecting&#160;her fetus.&#160;Maternal levels of estriol increase in a linear fashion through the third trimester of pregnancy until birth, whereupon they abruptly return to low circulating levels. The anti-autoimmune effects of esteriol may also be responsible for the beneficial effects of pregnancy on multiple sclerosis.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) multiple sclerosis program, UCLA Department of Neurology, has found that pregnancy levels of estriol has potent immunomodulatory effects. She further postulated&#160;&#160;that estriol may have a therapeutic benefit when administered to non-pregnant female multiple sclerosis patients by, in effect, mimicking the spontaneous reduction&#160;in relapse rates seen in multiple sclerosis patients during pregnancy.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Estriol has been approved and marketed for over 40 years throughout Europe and Asia for the treatment of post-menopausal hot flashes. It has never been approved by the FDA for any indication in the United States.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Clinical Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Trimesta (estriol) drug candidate is for the treatment of relapsing-remitting multiple sclerosis in women. An investigator-initiated, 10-patient, 22-month, single-agent, crossover clinical trial was completed in the United States to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female relapsing-remitting multiple sclerosis patients. The total volume and number of gadolinium-enhancing lesions were measured by brain magnetic resonance imaging (an established neuroimaging measurement of disease activity in multiple sclerosis) and showed a statistically significant decrease, both in lesion volumes and the number of lesions, during Trimesta treatment compared to baseline and while on drug holiday.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A Phase II randomized, double-blind, placebo-controlled clinical trial under an Investigational New Drug (IND) application is currently underway at 15 centers in the United States. The purpose of this clinical trial is to study whether 8 mg of oral Trimesta taken daily over a 2 year period will reduce the rate of relapses in a large population of female patients with relapsing-remitting multiple sclerosis. Investigators are administering either Trimesta or matching placebo, in addition to glatimer acetate (Copaxone&#174;) injections, an FDA-approved therapy for multiple sclerosis, to women between the ages of 18 to 50 who have been recently diagnosed with relapsing-remitting multiple sclerosis. The primary endpoint is relapse rates at two years. As of August 1, 2011, 140 out of 150 patients have been enrolled in this clinical trial. Tentatively, we anticipate full enrollment prior to December 31, 2011; however, no assurances can be given that such study enrollment will be completed by such time period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This ongoing clinical trial previously received a $5 million grant from the National Multiple Sclerosis Society (NMSS) in partnership with the NMSS&#8217;s Southern California chapter, with support from the National Institutes of Health and $860,440 in grant funding through the American Recovery and Reinvestment Act. In November 2010, the Trimesta multiple sclerosis trial was awarded $244,480 under the Qualifying Therapeutic Discovery Project Program. In March 2011, additional grant funding of $409,426 was received from the NMSS, and in May 2011, grant funding of $1,594,553 was received from the National Institutes of Health/National Institute of Neurological Disorders and Stroke. These recent grants resulted after review of the clinical program. With over $8 million in grant funding to date, the ongoing Trimesta clinical trial should be funded to its completion.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It has been noted that cognitive loss affects 50-65% of multiple sclerosis patients. In the investigator-initiated, 10-patient, 22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant14% improvement from baseline in Paced Auditory Serial Addition Test (PASAT) cognitive testing scores (p = 0.04) was observed in the multiple sclerosis patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety of neuropsychological disorders such as multiple sclerosis. We are exploring the sponsorship of a larger, randomized, double-blind, placebo-controlled clinical trial to evaluate Trimesta&#8217;s effect on cognition in female multiple sclerosis patients.</font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">17</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="Page18"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Fibromyalgia</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Effirma (flupirtine)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Disease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue, insomnia and mood symptoms. Fibromyalgia affects an estimated 2-4% of the population worldwide, including an estimated 4 million patients in the United States. There are presently three products approved for this indication in the United States &#8211; Lyrica&#174;, Cymbalta&#174; and Savella&#174;. Flupirtine is differentiated from these products in that it employs a unique mode of action. Meda AB of Sweden estimates the United States market for fibromyalgia to be near $1 billion at the time of potential market launch of flupirtine.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Clinical Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our Effirma (flupirtine) product candidate is for the treatment of fibromyalgia. Effirma is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties. Effirma is a non-opioid, non-NSAID, non-steroidal, analgesic. Preclinical data and clinical experience suggest that Effirma should also be effective for neuropathic pain since it acts in the central nervous system via a mechanism of action distinguishable from most marketed analgesics. Effirma is especially attractive because it operates through non-opiate pain pathways, exhibits no known abuse potential, and lacks withdrawal effects. In addition, no tolerance to its antinocioceptive effects has been observed. One common link between neuroprotection, nocioception and Effirma may be the N-methyl-D-aspartic acid glutamate system, a major receptor subtype for the excitotoxic neurotransmitter, glutamate. Effirma has strong inhibitory actions on N-methyl-D-aspartic acid-mediated neurotransmission. Flupirtine was originally developed by Asta Medica (subsequently acquired by Meda AB) and has been approved and is marketed by Meda AB in Europe since 1984, as well as other countries, for the treatment of pain, although it has never been approved by the FDA for any indication.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Corporate Partnership</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 6, 2010, we and Pipex, our wholly owned subsidiary, entered into a sublicense agreement with Meda AB, a multi-billion dollar international pharmaceutical company, pursuant to which Meda AB assumed all future development costs and may commercialize flupirtine for fibromyalgia in the U.S. As consideration for such sublicense, we received an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon the FDA&#8217;s acceptance of the New Drug Application (NDA) for flupirtine for fibromyalgia and $10 million upon FDA approval of&#160;such NDA. Pursuant to the sublicense agreement, we will also receive a 7% royalty on sales of flupirtine for fibromyalgia in the United States, Canada and Japan, with such royalties being shared equally with our licensor, McLean Hospital, a Harvard teaching hospital.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Flupirtine is approved and marketed by Meda AB and its distributors in Europe and other countries for indications other than fibromyalgia and has been prescribed to millions of patients worldwide. We believe that such substantial human experience of flupirtine should greatly assist the U.S. FDA in its evaluation of the safety of flupirtine upon review of an NDA of flupirtine for fibromyalgia. According to Meda&#8217;s 2010 Annual Report, flupirtine for fibromyalgia is currently in Phase II development.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Amyotrophic Lateral Sclerosis (ALS)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">AEN-100 (zinc) and AEN-200 (copper)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Disease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ALS, also known as Lou Gehrig&#8217;s Disease, is a devastating progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord in people of&#160;&#160;predominantly older ages and both sexes. It is estimated that as many as 30,000 Americans may have the disease at any given time. The progressive degeneration of the motor neurons in ALS eventually leads to the death of the patient. Motor neurons reach from the brain to the spinal cord and from the spinal cord to the muscles throughout the body. When motor neurons die, the ability of the brain to initiate and control muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may become totally paralyzed. While non-invasive ventilation and gastrostomy tubes prolong life by 6-12 months, the average lifespan from time of symptom onset is 2-5 years. Currently, RILUTEK<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> is the only FDA-approved drug for ALS. RILUTEK is an NMDA receptor antagonist and has been shown to prolong life in patients with ALS by 3 months. Presently, there is no cure for ALS, nor is there a known cause.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Background</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical investigators at the PNA Center for Neurological Research cite multiple lines of scientific research that suggest a potential benefit of zinc therapy for ALS patients, including:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the 1950&#8217;s, an epidemic of ALS was discovered on the island of Guam and the Trust Territories of the Pacific that revealed a form of ALS that was 100 times more prevalent than in the rest of the world.</font></div>
</td>
</tr></table>
</div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">18</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="Page19"><!--EFPlaceholder--></a><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Research on this cluster of ALS cases linked the neurological disease to the neurotoxin BMAA, a non-essential amino acid produced by cyanobacterium and found in large concentrations in food consumed by the people on Guam. Subsequent to the observations of a cluster of ALS cases on Guam, several groups have identified high concentrations of BMAA in the brain tissues of patients from North America and Europe with neurodegenerative diseases such as ALS.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It has been demonstrated that BMAA binds strongly to transition metal ions such as zinc, copper, and nitrogen. If BMAA crosses into the brain and enters a compartment in which glutamate is bound to zinc, the glutamate/zinc complex separates and the BMAA binds with the zinc, leaving high levels of unbound glutamate. These elevated levels of unbound glutamate are believed to be highly neurotoxic in ALS patients. Zinc is thought to serve as an endogenous antioxidant in the central nervous system and helps protect the blood-brain barrier (BBB) against oxidative stress and may prevent the neurotoxin, BMAA, from crossing into the brain.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The use of zinc therapy for ALS patients is further supported in animal models of ALS. Approximately 2% of ALS diagnoses are associated with a mutation in the superoxide dismutase (SOD1) gene. In ALS mutant SOD1 animal models, zinc supplementation has been shown to delay death.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Genetic mutations affecting the ability of a protein known as copper/zinc superoxide dismutase (SOD1) to properly bind zinc are associated with the familial form of ALS, which shares many of the same features as the more prevalent sporadic form of ALS.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Zinc is an important modifier of glutamate toxicity, a neurotransmitter linked to cell death in ALS patients.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Clinical Development</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Preparations are underway to evaluate the safety and efficacy of our proprietary drug candidates, AEN-100, a gastroretentive, sustained-release zinc-based tablet, and AEN-200, a copper tablet, in a multi-center, double-blind, placebo-controlled clinical trial in ALS patients intended to be conducted under an IND application. We will provide the study medications and fund the clinical trial, which will be conducted by the neurology team at the PNA Center for Neurological Research.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Efforts are also underway for the manufacturing of clinical trial medications and protocol review by an Institutional Review Board. The multi-center trial is intended to take place at up to six major ALS centers in the United States. It is anticipated that the trial will enroll at least 60 ALS patients, who will continue on RILUTEK<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> (riluzole) as the standard of care treatment. The patients will be randomized into treatment and matching placebo groups and will receive clinical trial medications for up to 12 months with periodic monitoring. The treatment group will receive our drug candidates &#8211; AEN-100 and AEN-200.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The planned co-primary endpoints are: 1) determining the safety of AEN-100 (elemental zinc) at 150 mg (two 75mg tablets) given to patients once daily with ALS by assessing adverse events and measuring zinc and copper levels every three months; and 2) determining the efficacy of AEN-100 by assessing the rate of disease progression as measured by the ALSFRS-R, a revised ALS functional rating scale that incorporates assessments of respiratory function.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The planned secondary endpoints are: 1) measuring levels of beta-methylamino-L-alanine (BMAA) in blood and urine to determine if there is a decline in these levels over the course of treatment; 2) following disease progression as measured by Forced Vital Capacity (FVC), a measurement of lung function that has been shown to correlate with disease survival; and 3) following progression of muscle weakness through quantitative strength measurements using hand-held dynamometry.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently the clinical investigators at the PNA Center for Neurological Research are conducting a Phase I/II open label study under an IND application of zinc therapy in ALS patients to determine the safety of zinc in conjunction with low doses of copper. To date, no safety issues related to zinc therapy have been observed in the ALS patients.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Mild to Moderate Alzheimer&#8217;s Disease</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">AEN-100 (zinc)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Disease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alzheimer's is a progressive neurodegenerative disease in which affected nerve cells in the brain die, making it increasingly difficult for the brain's memory and learning areas to function properly. A person with Alzheimer's disease has problems with memory, judgment and thinking, making it hard for the person to work or take part in normal day-to-day activities. The death of the nerve cells occurs gradually over a period of years. According to the Alzheimer&#8217;s Association, it is estimated that today over 5 million Americans have Alzheimer&#8217;s disease and that America spends $183 billion caring for people with Alzheimer&#8217;s and other dementias. Revised guidelines have recently been published for diagnosing Alzheimer&#8217;s disease that could double the population size. We believe that dysfunction of proper zinc and copper handling in the brain is implicated in Alzheimer&#8217;s disease.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">19</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="Page20"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Clinical Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">After presenting the top-line results in April 2011 from the clinical study evaluating <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> that demonstrated, on average, that the cognitive function (as measured by three standardized cognitive tests) of the patients managed with <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> remained relatively stable over six months, while the placebo group showed deterioration, we conducted further analyses to determine if certain subgroups in the patient sample benefitted from <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> more than others. After analyzing a number of independent variables associated with the patients enrolled in the clinical study on a <font style="DISPLAY: inline; FONT-STYLE: italic">post-hoc</font> basis, the strongest relationship was found to be between age and cognitive outcomes. Patients in the study ranged from 52 to 86 years of age. Patients in the placebo group, on average, showed age-related cognitive decline &#8211; the older the patient, the greater the rate of cognitive decline. In contrast, patients in the <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> treatment group, on average, showed cognitive stabilization, no matter what their age. Therefore, the older the <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> treatment patient, the greater the amount of cognitive benefit compared to the placebo patients of the same age.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These observations were supported by an age-related subgroup analysis that showed dosing-compliant patients age 70 and over (approximately the oldest three quartiles of the patients evaluable at the end of the study) demonstrated statistically significant improvements in two of the three cognitive scoring measurements in the <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> treatment group compared to the placebo group. As presented below, in this subgroup, two of the three standard cognitive measures reached statistical significance (p &lt; 0.05) as determined by the p-values (the average changes in cognitive scores from baseline to 6 months in the treatment group compared to the placebo group). The p-values were as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADAS-Cog - Alzheimer's Disease Assessment Scale - Cognitive Subscale p-value: 0.037</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CDR-SOB - Clinical Dementia Rating Scale - Sum of Boxes p-value: 0.032</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">MMSE - Mini Mental State Examination p-value: 0.067</font></div>
</td>
</tr></table>
</div>

<div>&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based upon the apparent cognitive benefit observed in older patients who were managed with <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> (our medical food) in comparison to patients who received the matching placebo, we are preparing a larger clinical study protocol to evaluate patients diagnosed with mild to moderate Alzheimer&#8217;s disease who are age 70 and over. It is anticipated that the clinical study will enroll over 100 patients and that the evaluation period will be at least 12 months. The intention is to develop our proprietary AEN-100, a zinc-based tablet, as a drug and to conduct this new clinical study under an Investigational New Drug application to be filed with the Food &amp; Drug Administration.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Product Development Programs</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Zinc Deficiency Associated with Alzheimer&#8217;s Disease</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">reaZin (zinc cysteine)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Disease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Alzheimer's is a progressive neurodegenerative disease in which affected nerve cells in the brain die, making it increasingly difficult for the brain's memory and learning areas to function properly. A person with Alzheimer's disease has problems with memory, judgment and thinking, making it hard for the person to work or take part in normal day-to-day activities. The death of the nerve cells occurs gradually over a period of years. According to the Alzheimer&#8217;s Association, it is estimated that today over 5 million Americans have Alzheimer&#8217;s disease and that America spends $183 billion caring for people with Alzheimer&#8217;s and other dementias. Revised guidelines have recently been published for diagnosing Alzheimer&#8217;s disease that could double the population size. We believe that dysfunction of proper zinc and copper handling in the brain is implicated in Alzheimer&#8217;s disease.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Product Development</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> (zinc cysteine) product candidate is being developed as a medical food to be sold by prescription only for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease. <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> is a proprietary, once-daily, gastroretentive, sustained-release, oral tablet formulation of zinc and cysteine. All constituents included in <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> are believed to have Generally Recognized as Safe (GRAS) status according to Food and Drug Administration (FDA) standards. <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> was invented and developed by us to achieve the convenience of once-daily dosing, high bioavailability (the quantity or fraction of the ingested dose that is absorbed) and to minimize gastrointestinal side effects of oral zinc therapy.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our clinical study evaluating <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> was divided into two parts. Part 1 was a 13-patient, three-arm, single-dose, comparator study in Alzheimer's disease patients that compared the tolerability and bioavailability of oral <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> to Galzin&#174; (the only FDA-approved zinc preparation) and placebo. On April 14, 2010, we announced results from Part 1 of the study demonstrated a superior serum zinc bioavailability and a substantially lower incidence of adverse effects in Alzheimer's disease patients in favor of <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> compared to Galzin&#174;.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On April 14, 2011, top-line results from Part 2 of the clinical study (a controlled, randomized, double-blind, placebo-controlled clinical study at 2 centers in the United States) were presented at the 63rd Annual Meeting of the American Academy of Neurology. Findings from 42 of 57 subjects were evaluable at the end of the study (21 subjects in the <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> group and 21 subjects in the placebo group). The primary outcomes of the study were effectively demonstrated as the patients administered <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> showed significant reductions in serum free copper levels and elevations in serum zinc levels over the placebo group, resulting in a highly statistically significant change in the free copper to zinc ratio of p &lt; 0.0006. In addition, the cognitive function of the placebo group, on average, declined over 6 months in comparison to patients managed with <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font>. The cognitive function trends favoring the patients managed with <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> were observed in all three standardized cognitive tests utilized in our study and suggest that <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> may provide an important benefit to the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease.<a name="Page21"><!--EFPlaceholder--></a></font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">20</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on results from this clinical study, we intend to commercialize <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> as a medical food to be sold by prescription only for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease. On April 20, 2011, we announced that we had executed an agreement with TG United, Inc. of Brooksville, Florida, to provide commercial-scale manufacturing for <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font>.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In November 2010, we were awarded a grant in the amount of $244,480 under the Qualifying Therapeutic Discovery Project Program to support our Alzheimer&#8217;s disease program.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Common Cold</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">wellZin (zinc lozenge)</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Disease</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">According to the &#8220;Zinc for the Common Cold Review&#8221; prepared by The Cochrane Collaboration&#174; and published in 2011, the common cold is one of the most widespread illnesses, with adults having two to four episodes annually. In the United States, the common cold leads to 75 to 100 million physician visits annually at a conservative cost estimate of $7.7 billion per year. Americans spend $2.9 billion on over-the-counter drugs and another $400 million on prescription medicines for symptomatic relief. More than one-third of patients who saw a doctor received an antibiotic prescription, which has implications for antibiotic resistance from overuse of such drugs. An estimated 22 to 189 million school days are missed annually due to the common cold. As a result, parents missed 126 million workdays to stay home to care for their children. When added to the 150 million work days missed by employees suffering from a cold, the total economic impact of cold-related work loss exceeds $20 billion per year. This accounts for 40% of time lost from work. The complications of the common cold include otitis media, sinusitis and exacerbations of reactive airway diseases. Rhinoviruses are the most frequent cause and may account for nearly 80% of common colds during autumn.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Product Development</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We intend to commercialize an oral zinc lozenge as a homeopathic over-the-counter (OTC) drug under the brand name <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font>. Plans for manufacturing, packaging and marketing of <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> are currently underway. Our proprietary <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> lozenge is intended to contain 13.3 mg of zinc acetate based on clinical findings from two independent, randomized, double-blind, placebo-controlled studies conducted by Ananda S. Prasad, M.D., Ph.D. <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> is intended to be marketed for adults in the United States.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We acquired exclusive access to two sets of clinical data demonstrating, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold. Pursuant to the agreement with Dr. Prasad, a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine, an Adeona Scientific Advisory Board member and the Principal Investigator of two separate clinical studies that evaluated a particular zinc lozenge for symptoms of the common cold, we have obtained exclusive access to statistically significant clinical data, including the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A randomized, double-blind, placebo-controlled study of 50 participants demonstrated that compared to the placebo group, the zinc lozenge group (13.3 mg of zinc acetate) had a mean overall reduction of the following (<font style="DISPLAY: inline; FONT-STYLE: italic">JID</font>, 2008; 197:795-802):</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Duration of the cold (4.0 versus 7.1 days; P-value &lt; 0.0001)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cough (2.1 versus 5.0 days; P-value &lt; 0.0001)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nasal discharge (3.0 versus 4.5 days; P-value &lt; 0.02)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A randomized, double-blind, placebo-controlled study of 48 participants demonstrated that compared to the placebo group, the zinc lozenge group (12.8 mg of zinc acetate) had a mean overall reduction of the following (<font style="DISPLAY: inline; FONT-STYLE: italic">Ann Intern Med</font>, 2000; 133:245-252):</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Duration of the cold (4.5 versus 8.1 days; P-value &lt; 0.01)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cough (3.1 versus 6.3 days; P-value &lt; 0.001)</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">o</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Nasal discharge (4.1 versus 5.8 days; P-value &lt; 0.025)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Both of the clinical studies demonstrated that these zinc lozenges were well-tolerated by the treatment participants and that the zinc and placebo groups did not differ significantly in the incidences of adverse effects. Clinical data from Dr. Prasad&#8217;s two studies are included in the &#8220;Zinc for the Common Cold Review&#8221; (&#8220;Cochrane Review&#8221;) prepared by The Cochrane Collaboration<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> and published in 2011. In the Cochrane Review, the authors included 15 studies that enrolled a combined 1,360 participants and concluded that zinc administered within 24 hours of onset of symptoms reduces the duration and severity of the common cold in healthy people.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Critical Accounting Policies</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page22"><!--EFPlaceholder--></a>In December 2001, the SEC requested that all registrants discuss their most &#8220;critical accounting policies&#8221; in management&#8217;s discussion and analysis of financial condition and results of operations. The SEC indicated that a &#8220;critical accounting policy&#8221; is one which is both important to the portrayal of the company&#8217;s financial condition and results and requires management&#8217;s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. We believe that the following discussion regarding research and development expenses, general and administrative expenses and non-cash compensation expense involve our most critical accounting policies.</font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">21</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Accounts Receivable and Allowance for Doubtful Accounts</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. We estimate and review the collectability of our receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, we regularly assess the state of our billing operations in order to identify issues, which may impact the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense. Receivables deemed uncollectible are charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Revenue Recognition</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We record revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;We recognize milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;During the six months ended June 30, 2011 our sole revenue was laboratory revenue and for the six months ended June 30, 2010, our stream of revenue was license and laboratory revenues.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">License Revenues</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When we have substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When we have no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, we have not received any royalty revenues.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-STYLE: italic">&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Laboratory Revenues</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We primarily recognize revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, are recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We maintain a sales allowance to compensate for the difference in our billing practices and insurance company reimbursements. In determining this allowance, we look at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 18 months, otherwise known as the yearly average adjustment amount. The allowance taken is the averaged yearly average adjustment amount for these prior periods and multiplied by the period&#8217;s actual gross sales to determine the actual sales allowance for each period.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Warrant / Derivative Liabilities</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, we use the Black-Scholes option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, we will continue its evaluation process of these instruments as derivative financial instruments.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.<a name="Page23"><!--EFPlaceholder--></a></font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">22</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Research and Development Expenses</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We expense research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Share-Based Payment Arrangements</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Generally, all forms of share-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date, based on the estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. The expense resulting from share-based payments are recorded in cost of goods sold, research and development or general and administrative expenses in the consolidated statement of operations, depending on the nature of the services provided.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Results of Operations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Three Months Ended June 30, 2011 and 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Revenues, net</font>. Total net revenues for the three months ended June 30, 2011 and 2010 were $355,562 and $2,194,888, respectively.&#160;Revenues consisted of $355,562 of laboratory revenues for the three months ended June 30, 2011 and $2,125,000 from the flupurtine sublicense fee with Meda and $69,888 of laboratory revenues from Adeona Clinical Laboratory for the three months ended June 30, 2010. The increase in laboratory revenues for the three months ended June 30, 2011, reflects an approximate 409% increase in laboratory revenues from the three months ended June 30, 2010.&#160;This significant change in laboratory revenue resulted from an increase in the client base and the expansion of in-house diagnostic testing services to include a full array of microbiology testing at Adeona Clinical Laboratory.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">General and Administrative Expenses</font>. General and administrative expenses increased to $694,281 for the three months ended June 30, 2011, from $662,627&#160;for the three months ended June 30, 2010. The non-cash charge relating to stock-based compensation expense was $51,614 for the three months ended June 30, 2011, compared to $32,460 for the three months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and Development Expenses</font>. Research and development expenses decreased to $279,641 for the three months ended June 30, 2011, from $426,572 for the three months ended June 30, 2010. This decrease of approximately 34% is primarily the result of decreased costs associated with our product candidates. Research and development expenses also include a non-cash charge relating to stock-based compensation expense of $5,751 for the three months ended June 30, 2011, compared to $18,487 for the three months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Costs of Laboratory Services</font>. Costs of laboratory services increased to $301,142 for the three months ended June 30, 2011, from $132,406 for the three months ended June 30, 2010.&#160;This increase of approximately 127% is primarily the result of increased costs associated with the increased client base and expansion of in-house diagnostic testing services to include a full array of microbiology testing at Adeona Clinical Laboratory, including salary and supply costs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Income (Expense)</font>.&#160;&#160;Other expense was $760,393 for the three months ended June 30, 2011, compared to $6,499 of other income for the three months ended June 30, 2010.&#160;&#160;Other expense for the three months ended June 30, 2011, includes $759,610 relating to the estimated fair value of the warrants associated with the January 2011 and April 2011 financings, adjusted for the change in their fair value at June 30, 2011.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Net Loss.</font> Our net loss was $1,679,895, or $0.06 per common share for the three months ended June 30, 2011, compared to net income of $979,782, or $0.05 per common share for the three months ended June 30, 2010.&#160;&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Six Months Ended June 30, 2011 and 2010</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; TEXT-DECORATION: underline">Revenues, net.</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt">Total net revenues for the six months ended June 30, 2011 and 2010 were $678,700 and $2,254,927, respectively.&#160;Revenues consisted of $678,700 of laboratory revenues for the six months ended June 30, 2011 and $2,125,000 from the flupurtine sublicense fee with Meda and $129,927 of laboratory revenues from Adeona Clinical Laboratory for the six months ended June 30, 2010. The increase in laboratory revenues for the six months ended June 30, 2011, reflects an approximate 422% increase in laboratory revenues from the six months ended June 30, 2010.&#160;This significant change in laboratory revenue resulted from an increase in the client base and the expansion of in-house diagnostic testing services to include a full array of microbiology testing at Adeona Clinical Laboratory.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">23</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="Page24"><!--EFPlaceholder--></a><font style="DISPLAY: inline; TEXT-DECORATION: underline">General and Administrative Expenses.</font> General and administrative expenses increased to $1,967,817 for the six months ended June 30, 2011, from $1,398,456 for the six months ended June 30, 2010. This increase of 41% is primarily the result of the increase in stock-based compensation expense for the six months ended June 30, 2011. The non-cash charge relating to share-based compensation expense was $810,324 for the six months ended June 30, 2011, compared to $183,607 for the six months ended June 30, 2010. The stock-based compensation for the six months ended June 30, 2011 includes a one-time charge of $397,767 relating to the modification of certain stock options, prior to expiration, held by a member of the Board of Directors.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Research and Development Expenses</font>. Research and development expenses decreased to $511,959 for the six months ended June 30, 2011, from $733,722 for the six months ended June 30, 2010. This decrease of 30% is primarily the result of decreased costs associated with our product candidates. Research and development expenses also include a non-cash charge relating to share-based compensation expense of $14,609 for the six months ended June 30, 2011, compared to $52,967 for the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Costs of Laboratory Services</font> . Costs of laboratory services increased to $545,000 for the six months ended June 30, 2011, from $237,825 for the six months ended June 30, 2010.&#160;This increase of approximately 129% is primarily the result of increased costs associated with the increased client base and expansion of in-house diagnostic testing services to include a full array of microbiology testing at Adeona Clinical Laboratory, including salary and supply costs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Income (Expense), net.</font> Other expense was $1,520,280 for the six months ended June 30, 2011, compared to other income of $7,336 for the six months ended June 30, 2010. Other expense for the six months ended June 30, 2011, includes $1,569,467 relating to the estimated fair value of the warrants associated with the January 2011 and April 2011 financings, adjusted for the change in their fair value at June 30, 2011. Other income for the six months ended June 30, 2011 included $62,996 relating to the settlement of accounts payable previously accrued in prior periods.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Net Loss</font>. Our net loss was $3,866,356, or $0.15 per common share for the six months ended June 30, 2011, compared to a net loss of $107,740, or $0 per common share for the six months ended June 30, 2010.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Liquidity and Capital Resources</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have financed our operations since inception primarily through proceeds from equity financings and various private financings, primarily involving private sales of our common stock and other equity securities, corporate partnering license fees and from the&#160;proceeds from the sale of our common stock under our registration statement on Form S-3, laboratory testing revenues and miscellaneous equipment sales.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><a name="V222442_10Q_HTM_EOLPAGE20"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our cash totaled $8,385,933 as of June 30, 2011, an increase of $5,737,080 from December 31, 2010.&#160;&#160;&#160;During the six months ended June 30, 2011, the primary sources of cash were net proceeds from the issuances of common stock to institutional investors&#160;of $6,960,610 and stock option exercises of $7,650.&#160;The primary use of cash during the six months ended June 30, 2011 was for working capital requirements. Our cash, cash equivalents and investment in debt securities&#160;at July 31, 2011 was approximately $8.1 million.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our continued operations will primarily depend&#160;on whether we are able to generate revenues and profits through partnerships, joint ventures or sales of diagnostic clinical laboratory services and/or raise additional funds through various potential sources, such as license fees from a potential corporate partner, equity and debt financing. Such additional funds may not become available on acceptable terms and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term. We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can give no assurances that any additional capital that we are able to obtain will be sufficient to meet our needs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Current and Future Financing Needs</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have incurred an accumulated deficit of approximately $47.6 million&#160;as of&#160;June 30, 2011. With the exception of the quarter ended June 30, 2010, we have incurred negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business strategy, including our planned product development efforts, our clinical trials, and our research and discovery efforts.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on our current plans, we believe that our cash will be sufficient to enable us to meet our planned operating needs for at least the next 12 months.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">However, the actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the progress of our research activities;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the number and scope of our research programs;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the progress of our preclinical and clinical development activities;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the progress of the development efforts of parties with whom we have entered into research and development agreements;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">costs associated with additional clinical trials of our drug candidates;</font></div>
</td>
</tr></table>
</div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">24</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to maintain current research and development&#160;licensing arrangements&#160;and to establish new research and development and licensing &#160;&#160;arrangements;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to achieve our milestones under licensing arrangements;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the costs and timing of regulatory approvals;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">marketing costs associated with our near-term product candidates, clinical laboratory diagnostic and microbiology services business; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">profitability of our near-term product candidates and clinical laboratory diagnostic and microbiology services business.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit our operations and our business, financial condition and results of operations would be materially harmed.</font></div>

<div><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">25</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Not applicable.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_CONTROL_AND_PROCEDURES"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 4. CONTROLS AND PROCEDURES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(a)&#160;&#160;&#160;</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Evaluation of disclosure controls and procedures</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (&#8220;Exchange Act&#8221;), the Company carried out an evaluation, with the participation of the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who also serves as our principal financial and accounting officer, of the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company&#8217;s CEO concluded that the Company&#8217;s disclosure controls and procedures are effective as of June 30, 2011 to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including the Company&#8217;s CEO, as appropriate, to allow timely decisions regarding required disclosure.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">(b) &#160;&#160;</font> <font style="DISPLAY: inline; FONT-WEIGHT: bold">Changes in Internal Control over Financial Reporting</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during our fiscal quarter ended June 30, 2011, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">26</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_PART_II"><!--EFPlaceholder--></a>PART II&#8212;OTHER INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_LEGAL_PROCEEDING"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_RISK_FACTORS"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 1A. RISK FACTORS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">An investment in our securities is highly speculative and involves a high degree of risk. Therefore, in evaluating us and our business you should carefully consider the risks set forth below, which are only a few of the risks associated with our business and our common stock. You should be in a position to risk the loss of your entire investment.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RISKS RELATING TO OUR BUSINESS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We currently have very minimal revenues and expect we will need to raise additional capital to operate our business.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">With the exception of the quarter ended June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. We expect to incur additional operating losses in the future and therefore our cumulative losses to increase. To date, other than the licensing fee we received from Meda AB for the development of and commercialization of Effirma (flupirtine) for fibromyalgia in the U.S., Canada and Japan and laboratory revenues from Adeona Clinical Laboratory, we have generated very minimal revenues. As of June 30, 2011, our accumulated deficit totaled approximately $47.6 million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for our prescription drug product candidates, we will not be permitted to sell our drugs and therefore will not have product revenues. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings, cash on hand, licensing fees, and grants.&#160;&#160;If the upfront licensing fee we received together with the proceeds from our recent financings and laboratory revenue are not sufficient to sustain our operations, we will need to seek additional sources of financing and such additional financing may not be available on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue product development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity or debt securities, which will have a dilutive effect on our stockholders.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We have not been able to sustain profitability.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Other than with respect to the quarter ended June 30, 2010, we have a history of losses and we have incurred&#160;and continue to incur substantial losses and negative operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates, we may still incur substantial losses for the foreseeable future and may not sustain profitability. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will substantially increase in the foreseeable future as we do the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">continue to undertake preclinical development and clinical trials for our product candidates;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">seek regulatory approvals for our product candidates;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">implement additional internal systems and infrastructure;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">lease additional or alternative office facilities; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">hire additional personnel, including members of our management team.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may experience negative cash flow for the foreseeable future as we fund our technology development with capital expenditures. As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. Our failure to achieve or maintain profitability could negatively impact the value of our common stock and underlying securities.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our research and development efforts may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We must continue to explore opportunities that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at any point in the process, including after significant funds have been invested.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">27</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Regardless of whether our clinical trials are deemed to be successful, promising new product candidates may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if we successfully develop new products or enhancements, they may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors' innovations. Innovations may not be accepted quickly in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether any of our products under development will be launched, whether we will be able to develop, license, or otherwise acquire drug candidates or products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, which may limit our ability to achieve profitability.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We have a limited operating history on which investors can base an investment decision.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have not yet demonstrated our ability to perform the functions necessary for the successful commercialization of any of our product candidates. The successful commercialization of our product candidates will require us to perform a variety of functions, including:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">continuing to undertake preclinical development and clinical trials;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">participating in regulatory approval processes;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">formulating and manufacturing products; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">conducting sales and marketing activities.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our operations have been limited to organizing and staffing our company, acquiring, developing, and securing our proprietary technology, and undertaking preclinical trials and Phase I/II, and Phase II and Phase III clinical trials of our principal product candidates. These operations provide a limited basis for you to assess our ability to commercialize our product candidates and the advisability of investing in our securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We have limited experience in commercializing medical food and homeopathic OTC drug products and therefore we may not be effective in developing and commercializing products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have no experience in marketing a medical food such as <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin,</font> nor can we provide any assurance that the results of our <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> clinical study will be perceived as demonstrating sufficient clinical benefit to permit us to be accepted by the market, obtain reimbursement from health insurance payers or&#160;profitably market such medical food with or without health insurance reimbursement.&#160;&#160;Even if we are able to successfully manufacture <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> and establish distribution channels, there can be no assurance that <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> will receive market acceptance.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have no experience in marketing a homeopathic OTC drug product such as <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin,</font> nor can we provide any assurance that clinical data we acquired in July 2011 will be perceived as demonstrating sufficient clinical benefit to permit us to be accepted by the market or profitably market such a homeopathic drug product.&#160;&#160;Even if we are able to successfully manufacture <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> and establish distribution channels, there can be no assurance that <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> will receive market acceptance.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may not generate additional revenue from our relationships with our corporate&#160;collaborators.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On May 6, 2010 we and Pipex, our wholly owned subsidiary, entered into a sublicense agreement with Meda AB whereby we may receive milestone payments totaling $17.5 million (including an upfront payment of $2.5 million that has already been received), plus royalties on our flupirtine program. There can be no assurance that Meda AB will successfully develop flupirtine for fibromyalgia in the U.S., Canada or Japan that would allow us to receive such additional $15 million in milestone payments and royalties on sales in connection with such agreement. The successful achievement of the various milestones set forth in the sublicense agreement is not within our control and we will be dependent upon Meda AB for achievement of such milestones. According to Meda&#8217;s 2010 Annual Report, flupirtine for fibromyalgia is currently in Phase II development.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">28</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may not be able to generate any significant revenue from copper and zinc status tests or any other tests we may develop.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have committed significant research and development resources to the development of copper and zinc status tests. Although there may be a large potential market for such testing, there is no guarantee that we will successfully generate significant revenues from this or any other tests for any use. In November 2009, we launched a copper and zinc status test panel through Adeona Clinical Laboratory, our CLIA-certified reference laboratory.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">However, sales of our zinc and copper status test panel have generated only very limited revenue and there is no guarantee that we will be able to successfully market this test panel or other diagnostic tests. If we are not able to successfully market or sell our diagnostic tests we may develop for any reason, we will not generate any revenue from the sale of such tests. Even if we are able to develop diagnostic or other tests for sale in the marketplace, a number of factors could impact our ability to generate any significant revenue from the sale of such tests, including the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">reliance on our Adeona Clinical Laboratory operations, which are subject to routine governmental oversight and inspections for continued operation pursuant to CLIA and other regulations;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to establish and maintain adequate infrastructure to support the commercial launch and sale of our diagnostic tests through our Adeona Clinical Laboratory subsidiary, including establishing adequate laboratory space, information technology infrastructure, sample collection and tracking systems and electronic ordering and reporting systems and other infrastructure and hiring adequate laboratory and other personnel;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the availability of adequate study samples for validation studies for any diagnostic tests we develop, the success of such validation studies and our ability to publish study results in peer-reviewed journals;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the availability of alternative and competing tests or products and technological innovations or other advances in medicine that cause our technologies to be less competitive;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">compliance with federal, state and foreign regulations governing laboratory testing and the sale and marketing of diagnostic or other tests, including copper and zinc;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">status tests;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the accuracy rates of such tests, including rates of false-negatives and/or false-positives;</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">concerns regarding the safety effectiveness or clinical utility of our tests;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">changes in the regulatory environment affecting health care and health care providers, including changes in laws regulating laboratory testing and/or device manufacturers and any laws regulating diagnostic testing;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the extent and success of our sales and marketing efforts and ability to drive adoption of our diagnostic tests;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">coverage and reimbursement levels by government payers and private insurers;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the level of physician and customer adoption of any diagnostic tests we develop;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">pricing pressures and changes in third-party payer reimbursement policies;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">general changes or developments in the market for Alzheimer&#8217;s disease diagnostics or diagnostics in general;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">ethical and legal issues concerning the appropriate use of the information resulting from Alzheimer&#8217;s disease diagnostic tests or other tests;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">our ability to promote and protect our products and technology; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">intellectual property rights held by others or others infringing our intellectual property rights.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We are dependent on a limited number of customers, the loss of any of which would have a material adverse effect upon our revenue.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">During the six months ended June 30, 2011 we generated revenues from three significant insurance providers, which accounted for 68%, 4% and 20% of our revenue for such six month period.&#160;&#160;During the six months ended June 30, 2010, we generated revenues from the same significant insurance providers, which accounted for 60%, 16% and 11% of our revenues for such six month period.&#160;&#160;The loss of revenue from these insurance providers could have an immediate significant adverse effect upon our revenue and results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We have experienced several management changes.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have had significant changes in management in the past three years. Effective June 26, 2009, Max Lyon was appointed our Chief Executive Officer and President, while Steve Kanzer remained as Chairman of our Board. Effective February 6, 2010, James S. Kuo, M.D., M.B.A., was appointed as Chairman of our Board, Chief Executive Officer and President and Mr. Lyon resigned from his position as Chief Executive Officer, President and director.&#160;&#160;Changes in our key positions, as well as additions of new personnel and departures of existing personnel, can be disruptive, might lead to additional departures of existing personnel and could have a material adverse effect on our business, operating results, financial results and internal controls over financial reporting.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We only acquired our CLIA-certified reference laboratory in July of 2009 and have limited experience operating a diagnostic and microbiology testing laboratory. Our ability to successfully develop and commercialize diagnostic and microbiology tests will depend on our ability to successfully operate our CLIA-certified reference laboratory and obtain and maintain required regulatory certifications.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We acquired Adeona Clinical Laboratory, our CLIA-licensed clinical reference laboratory located in Bolingbrook, IL, in July of 2009. Because there is substantial distance between Adeona Clinical Laboratory and our corporate headquarters in Ann Arbor, Michigan, we may have logistical and operational challenges in effectively managing and operating Adeona Clinical Laboratory. In November of 2009, we launched&#160;a panel of&#160;copper and zinc status tests through Adeona Clinical Laboratory. If we are unable to successfully commercialize our serum based copper and zinc diagnostic test panels through Adeona Clinical Laboratory, we may not be able to achieve significant revenues and profitability with respect to such activities.&#160;&#160;Our ability to successfully develop and commercialize diagnostic tests and microbiology testing will depend on our ability to successfully operate Adeona Clinical Laboratory and obtain and maintain required regulatory approvals.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;</font></div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">29</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As a clinical reference laboratory, Adeona Clinical Laboratory is subject to CLIA regulations, which are designed to ensure the quality and reliability of clinical laboratories by mandating specific standards in the areas of personnel qualifications, administration and participation in various areas, including proficiency testing, patient test management, quality control, quality assurance and inspections. The sanction for failure to comply with CLIA requirements may be suspension, revocation or limitation of a laboratory&#8217;s CLIA certificate, which is necessary to conduct business, as well as significant fines and/or criminal penalties. Adeona Clinical Laboratory is also subject to regulation of laboratory operations under state clinical laboratory laws. State clinical laboratory laws may require that laboratories and/or laboratory personnel meet certain qualifications, specify certain quality controls and require maintenance of certain records. Certain states, including California, Maryland, New York, Pennsylvania and Rhode Island, require that you obtain licenses to test specimens from patients residing in those states and additional states may require similar licenses in the future. If we are unable to obtain licenses from these states or there is delay in obtaining such licenses, we will not be able to process any samples from patients located in those states until we have obtained the requisite licenses. Potential sanctions for violation of these statutes and regulations include significant fines and the suspension or loss of various licenses, certificates and authorizations, which could adversely affect our business and results of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may not obtain the necessary United States or worldwide regulatory approvals to commercialize our product candidate(s).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will need FDA approval to commercialize some of our product candidates in the United States&#160;and approvals from equivalent regulatory authorities in foreign jurisdictions to commercialize our prescription drug product candidates in those jurisdictions. In order to obtain FDA approval for any of our product candidates, we&#160;must submit to the FDA an NDA, demonstrating that the product candidate is safe for humans and effective for its intended use and that the product&#160;candidate can be consistently manufactured and is stable. This demonstration requires significant research and animal tests, which are referred to as &#8220;preclinical studies,&#8221; human tests, which are referred to as &#8220;clinical trials&#8221; as well as the ability to manufacture the product candidate, referred to as&#160;&#8220;chemistry, manufacturing, and controls&#8221; or &#8220;CMC.&#8221; We will also need to file additional IND applications and protocols in order to initiate clinical testing of our drug candidates in new therapeutic indications and delays in obtaining required FDA and institutional review board approvals to&#160;&#160;commence such studies will delay our initiation of such planned additional studies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Satisfying the FDA&#8217;s regulatory requirements typically takes many years, depending on the type, complexity, and novelty of the product candidate, and requires substantial resources for research development, and testing. We cannot predict whether our research and clinical approaches will result in drugs that the FDA considers safe for humans and effective for indicated uses. The FDA has substantial discretion in the drug approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The approval process may also be delayed by changes in government regulation, future legislation or administrative action, or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may do the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">delay commercialization of, and our ability to derive product revenues from, our product candidates;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">impose costly procedures on us; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">diminish any competitive advantages that we may otherwise enjoy.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The on-going and future development and commercialization of Effirma (flupirtine) for fibromyalgia is the responsibility of Meda AB and no assurance can be given that Meda will gain the FDA&#8217;s acceptance of the NDA or obtain NDA approval from the FDA of flupirtine for fibromyalgia.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Even if we comply with all FDA requests, the FDA may ultimately reject one or more of our NDAs. We cannot be sure that we will ever obtain regulatory clearance for our product candidates. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by reducing our number of salable products and, therefore, corresponding product revenues.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In foreign jurisdictions, we must receive approval from the appropriate regulatory authorities before we can commercialize our drugs. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize our product candidate for sale outside the United States.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our diagnostic and microbiology tests are subject to changes in CLIA, FDA and other regulatory requirements.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We initially plan to develop assays and commercialize our tests in the form of laboratory developed tests (LDTs) through Adeona Clinical Laboratory, our CLIA-certified laboratory. Although LDT testing is currently solely under the purview of CMS and state agencies who oversee LDTs, the FDA and the United States Department of Health and Human Services have been reviewing their approach to regulation in the area of LDTs, and the laws and regulations may undergo change in the near future. The FDA has indicated that it does intend to regulate some LDTs as medical devices under the Federal Food, Drug, and Cosmetic Act. Although we have no current plans in our LDT strategy to utilize analyte specific reagents (ASRs) or In Vitro Diagnostic Multivariate Index Assay (IVDMIAs), which have been the focus of recent regulatory actions by the FDA, we cannot predict the extent of the FDA&#8217;s future regulation and policies with respect to LDTs. Concurrently with our LDT commercialization activities, we may conduct the development, validation, and other activities necessary to file submissions with the FDA seeking approval for selected diagnostic tests. If we are required to obtain FDA authorization to market a laboratory test as a device, that will substantially delay the marketing of the test and increase the costs of entering the market. In addition, devices are subject to various other regulatory requirements, such as the need to comply with the Quality System regulation and to comply with various FDA reporting requirements. If we are unable to successfully launch any diagnostic tests as LDTs or if we are otherwise required to obtain FDA premarket clearance or approval prior to commercializing any diagnostic tests or maintain Adeona Clinical Laboratory&#8217;s CLIA-certified laboratory status, our ability to generate revenue from the sale of such tests may be delayed and we may never be able to generate significant revenues from sales of diagnostic products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">30</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="eolPage25"><!--EFPlaceholder--></a>If the medical relevance of copper and zinc in Alzheimer&#8217;s disease is not demonstrated or is not recognized by others, we may have less demand for our products and services and may have less opportunity to enter into diagnostic product development and commercialization collaborations with others.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of the products we have developed and additional products that we hope to develop involve new and unproven approaches or involve applications in markets that we are only beginning to explore. They are based on the assumption that information about the roles of copper and zinc in the progression and development of neurodegenerative diseases such as Alzheimer&#8217;s disease and dementia may help scientists and clinicians better understand and treat conditions or complex disease processes. We cannot be certain that this type of information will play a key role in the development of&#160;&#160;therapeutics, diagnostics or other products in the future, or that any of our findings would be accepted by clinicians, researchers or by any other potential market or industry partner or customer. If we are unable to generate additional valuable information and data about the usefulness of copper and zinc status testing, the demand for our products, applications, and services will be reduced and our business will be harmed.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may not be able to retain rights licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need to develop, manufacture, and market our products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition to our own patent applications, we also currently rely on licensing agreements with third party patent holders/licensors for our products. Pipex, our wholly owned subsidiary, has an exclusive license agreement with the McLean Hospital relating to the use of flupirtine to treat fibromyalgia which was recently sublicensed to Meda AB and an exclusive license agreement with the Regents of the University of California relating to our Trimesta technology. Each of these agreements requires us or our sublicensee to use our best efforts to commercialize each of the technologies as well as meet certain diligence requirements and timelines in order to keep the license agreement in effect. In the event we or our sublicensee are not able to meet our diligence requirements, we may not be able to retain the rights granted under our agreements or renegotiate our arrangement with these institutions on reasonable terms, or at all.&#160;&#160;Furthermore, we currently have very limited product development capabilities, and limited marketing or sales capabilities. For us to research, develop, and test our product candidates, we would need to contract with outside researchers, in most cases those parties that did the original research and from whom we have licensed the technologies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We can give no assurances that any of our issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection or be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability, nor does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Developments by competitors may render our products or technologies obsolete or non-competitive.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Companies that currently sell or are developing both generic and proprietary pharmaceutical compounds to treat central nervous system diseases include: Pfizer, GlaxoSmithKline Pharmaceuticals, Merck &amp; Co., Eli Lilly &amp; Co., Biogen Idec, Forest Laboratories, Novartis, Teva Pharmaceuticals, Prana Biotechnology, Merz &amp; Co., Alcon and Bausch and Lomb. Companies that currently sell or are developing homeopathic OTC drugs to reduce the duration and severity of symptoms caused by the common cold include: ProPhase Labs, Inc. and Matrixx Initiatives, Inc. Many of our competitors have significant financial and human resources. In addition, academic research centers may develop technologies that compete with our Trimesta, modified release zinc and copper preparations (<font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font>, AEN-100 and AEN-200), <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> and flupirtine technologies. Should clinicians or regulatory authorities view these therapeutic regiments as more effective than our products, this might delay or prevent us from obtaining regulatory approval for our products, or it might prevent us from obtaining favorable reimbursement rates from payers, such as Medicare, Medicaid and private insurers.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No assurance can be given that our once daily <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin, </font>a medical food for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease, or our <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font>, a homeopathic OTC zinc acetate lozenge to reduce the duration and severity of symptoms caused by the common cold, will be viewed as more effective than current zinc therapies or any newly developed therapies or demonstrate sufficient clinical benefit to gain market acceptance.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Competitors could develop and/or gain FDA approval of our products for a different indication.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since we do not have composition of matter patent claims for flupirtine and estriol, others may obtain approvals for other uses of these products that are not covered by our issued or pending patents. For example, the active ingredients in both Effirma (flurpirtine) and Trimesta (estriol) have been approved for marketing in overseas countries for different uses and an oral immediate release form of zinc is approved in the U.S. and Europe for the treatment of Wilson&#8217;s disease. Other companies, including the original developers or licensees or affiliates may seek to develop Effirma or Trimesta or their respective active ingredient(s) for other uses in the United States or any country we are seeking approval for. We cannot provide any assurances that any other company may obtain FDA approval for products that contain flupirtine or estriol in various formulations or delivery systems that might adversely affect our ability or the ability of our sublicensee to develop and market these products in the United States. We are aware that other companies have intellectual property protection using the active ingredients and have conducted clinical trials of flupirtine, estriol and zinc for different applications than what we are developing. Many of these companies may have more resources than us. Should a competitor obtain FDA approval for its product for any indication prior to us, we might be precluded under the Hatch-Waxman Act to obtain approval for our product candidates for a period of five years. We cannot provide any assurances that our products will be FDA approved prior to our competitors.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If the FDA approves other products containing our active ingredients to treat indications other than those covered by our issued or pending patent applications, physicians may elect to prescribe a competitor&#8217;s products to treat the&#160;&#160;diseases for which we are developing&#8212;this is commonly referred to as &#8220;off-label&#8221; use. While under FDA regulations a competitor is not allowed to promote off-label uses of its product, the FDA does not regulate the practice of medicine and, as a result, cannot direct physicians as to which source it should use for these products they prescribe to their patients. Consequently, we might be limited in our ability to prevent off-label use of a competitor&#8217;s product to treat the diseases we are developing, even if we have&#160;issued patents for that indication. If we are not able to obtain and enforce these patents, a competitor could use our products for a treatment or use not covered by any of our patents. We cannot provide any assurances that a competitor will not obtain FDA approval for a product that contains the same active ingredients as our products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None of our drug candidates or our <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> medical food product candidate contain the patented ingredient zinc-monocysteine and is instead the subject of pending United States and international patent applications initially filed in January 2006 (see. U.S. Ser. No 11/621,962), which may not provide substantial protection from competitive products until such pending patents issue, if at all. As a medical food, no regulatory protection is afforded through FDA regulations to prevent others from marketing similar products. Similarly, the CopperProof Test Panel offered by our Adeona Clinical Laboratory subsidiary is the subject of pending patent applications that are expected to require a substantial amount of time to issue in order to provide protection from potential competitors.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We rely primarily on method patents and patent applications and various regulatory exclusivities to protect the development of our technologies, and our ability to compete may decrease or be eliminated if we are not able to protect our proprietary technology.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our competitiveness may be adversely affected if we are unable to protect our proprietary technologies. We do not have composition of matter patents for Trimesta or Effirma, or their respective active ingredients estriol and flupirtine. We rely on issued patent and pending patent applications for use of Trimesta to treat multiple sclerosis (issued United States Patent No. 6,936,599) and various other therapeutic indications, which have been exclusively licensed to us. We have exclusively licensed an issued patent for the treatment of fibromyalgia with flupirtine, which we have sublicensed to Meda AB.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> medical food and AEN-100 drug candidate (gastroretentive, sustained-release zinc-based tablets)&#160;are the subject of United States and international pending patent applications, such as published United States patent application Ser. No. 11/621,962 and corresponding international applications that claim priority to January 10, 2006 as well as additional unpublished patent applications. AEN-200 is the subject of a pending patent application and our oral zinc lozenge. <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font>, is currently not covered by any issued or pending patents. No assurance can be given that such pending patent applications will issue or issue with claims satisfactorily broad enough to prevent others from developing and marketing competing products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The patent positions of pharmaceutical companies are uncertain and may involve complex legal and factual questions. We may incur significant expense in protecting our intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other infringement litigation by or against us could cause us to incur significant expense and divert the attention of our management.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may also rely on the United States Drug Price Competition and Patent Term Restoration Act, commonly known as the &#8220;Hatch-Waxman Amendments,&#8221; to protect some of our current product candidates, specifically Trimesta and other future product candidates we may develop. Once a drug containing a new molecule is approved by the FDA, the FDA cannot accept an abbreviated NDA for a generic drug containing that molecule for five years, although the FDA may accept and approve a drug containing the molecule pursuant to an NDA supported by independent clinical data. Recent amendments have been proposed that would narrow the scope of Hatch-Waxman exclusivity and permit generic drugs to compete with our drug.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Others may file patent applications or obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in any such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how they will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another party claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large sum if we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign our product, which may not be possible.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We also rely on trade secrets and proprietary know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors, current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may fail to retain or recruit necessary personnel, and we may be unable to secure the services of consultants.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">As of June 30, 2011, we had 15 employees. We have also engaged regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory authorities. Our future performance will depend in part on our ability to successfully integrate newly hired officers into our management team and our ability to develop an effective working relationship among senior management.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Certain of our directors Jeffrey Kraws, Jeffrey Wolf, Steve Kanzer, and Jeff Riley,&#160;scientific advisors, and consultants serve as officers, directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology companies that might be developing competitive products to ours. Other than corporate opportunities, none of our directors are obligated under any agreement or understanding with us to make any additional products or technologies available to us. Similarly, we can give no assurances, and we do not expect and stockholders should not expect, that any biomedical or pharmaceutical product or technology identified by any of our directors or affiliates in the future would be made available to us other than corporate opportunities. We can give no assurances that any such other companies will not have interests that are in conflict with our interests.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Losing key personnel or failing to recruit necessary additional personnel would impede our ability to attain our development objectives. David A. Newsome, M.D., our former Senior Vice President of Research and Development recently passed away. There is intense competition for qualified personnel in the drug-development field, and we may not be able to attract and retain the qualified personnel we would need to develop our business.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;We rely on independent organizations, advisors, and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval, clinical management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may not always be available to us on a timely basis when we need them.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may experience difficulties in obtaining sufficient quantities of our products or other compounds.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In order to successfully commercialize our product candidates, we and our sublicensees must be able to manufacture our products in commercial quantities, in compliance with regulatory requirements, at acceptable costs, and in a timely manner. Manufacture of the types of biopharmaceutical products that we propose to develop present various risks.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For manufacturing and nonclinical information for Trimesta (estriol), we have relied upon an agreement with Organon, a division of Schering-Plough for access to clinical, nonclinical, stability and drug supply relating to estriol, the active ingredient in Trimesta, which is currently in clinical trial for multiple sclerosis. Should Organon terminate our agreement or be unable or unwilling to continue to supply Trimesta to us, this might delay enrollment and commercialization plans for our Trimesta clinical trial program. Organon has manufactured estriol, the active ingredient of Trimesta, for the European and Asian market for approximately 40 years but has never been approved in the United States. Organon informed us of its decision to discontinue supply of estriol tablets beyond that required to satisfy the planned future needs of the ongoing clinical trial in relapsing-remitting multiple sclerosis. Accordingly, prior to initiation of additional clinical studies and/or commercial launch of estriol, we may need to identify and execute supply agreement(s) on terms suitable to us with an alternate supplier of estriol tablets.&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our plans to launch <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> as a medical food for the dietary management of zinc deficiency in Alzheimer&#8217;s disease&#160;and clinical testing of AEN-100 and AEN-200 will depend upon the successful cGMP manufacture, quality control and acceptable results of stability studies. In April 2011, we engaged TG United, Inc. of Brooksville, Florida, a third party contract manufacturer, to provide commercial-scale manufacturing for <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin.&#160;</font>There can be no assurance that TG United, Inc. will be able to manufacture <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> in such quantities on a timely basis as we require.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our plans to launch <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font> zinc lozenge as a homeopathic OTC drug to reduce the duration and severity of symptoms caused by the common cold will depend on the successful cGMP manufacture and quality control of <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin.</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Historically, our manufacturing has been handled by contract manufacturers and compounding pharmacies. We can give no assurances that we will be able to continue to use our current manufacturer or be able to establish another relationship with a manufacturer quickly enough so as not to disrupt commercialization of any of our products, or that commercial quantities of any of our products, if approved for marketing, will be available from contract manufacturers at acceptable costs.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, any contract manufacturer that we select to manufacture our product candidates might fail to maintain a current &#8220;good manufacturing practices&#8221; (cGMP) manufacturing facility or fail to comply with other potentially applicable requirements, such as Hazard Analysis and Risk-Based Preventive Controls requirements under the Federal Food, Drug, and Cosmetic Act, as amended by the FDA Food Safety Modernization Act. Failure of a manufacturer to maintain cGMP or to comply with other potentially applicable requirements could subject us to penalties, restrictions, and/or prohibitions affecting our ability to further manufacture and distribute our products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The cost of manufacturing certain product candidates may make them prohibitively expensive. In order to successfully commercialize our product candidates we may be required to reduce the costs of production, and we may find that we are unable to do so. We may be unable to obtain, or may be required to pay high prices for compounds manufactured or sold by others that we need for comparison purposes in clinical trials and studies for our product candidates.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">33</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The manufacture of our products is a highly exacting process, and if we or one of our materials suppliers encounter problems manufacturing our products, our business could suffer.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The FDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance with cGMP or similar requirements that the FDA or foreign regulators establish. We, or our materials suppliers, may face manufacturing or quality control problems causing product production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing our products. Any failure to comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to market and develop our products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although medical foods and homeopathic OTC drugs do not require pre-market approval by the FDA, manufacturers of medical foods and homeopathic OTC drugs must meet applicable regulatory criteria, be registered with the FDA and are subject to inspection by the FDA.&#160;&#160;If the outcome of any inspection is negative or the manufacturer or we fail to comply with any regulatory requirements, we could be subject to penalties, restrictions and/or prohibitions affecting on our ability to further manufacture and distribute our products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">If our laboratory facilities are damaged, our business would be seriously harmed.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our only laboratory facility for copper and zinc testing products and general reference lab services is located in Bolingbrook, IL. Damage to our facility due to war, fire, natural disaster, power loss, communications failure, terrorism, unauthorized entry, or other events could prevent us from conducting our business for an indefinite period, could result in a loss of important data or cause us to cease development and production of our products. We cannot be certain that our limited insurance to protect against business interruption would be adequate or would continue to be available to us on commercially reasonable terms, or at all.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">If the parties we depend on for supplying our drug substance raw materials and certain manufacturing-related services do not timely supply these products and services, it may delay or impair our ability to develop, manufacture and market our products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We rely on suppliers for our drug substance raw materials and third parties for certain manufacturing-related services to produce material that meets appropriate content, quality and stability standards and use in clinical trials of our products and, after approval, for commercial distribution. To succeed, clinical trials require adequate supplies of drug substance and drug product, which may be difficult or uneconomical to procure or manufacture. We and our suppliers and vendors may not be able to (i) produce our drug substance or drug product to appropriate standards for use in clinical studies, (ii) perform under any definitive manufacturing, supply or service agreements with us or (iii) remain in business for a sufficient time to successfully produce and market our product candidates. If we do not maintain important manufacturing and service relationships, we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilities which could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreements with them on terms and conditions favorable to us and, there could be a substantial delay before a new facility could be qualified and registered with the FDA and foreign regulatory authorities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Clinical trials are very expensive, time-consuming, and difficult to design and implement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We estimate that clinical trials of our product candidates would take at least several years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">obtaining an IND application with the FDA to commence clinical trials;</font></div>
</td>
</tr></table>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">identification of, and acceptable arrangements with, one or more clinical sites;</font></div>
</td>
</tr></table>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">obtaining IRB approval to commence clinical trials;</font></div>
</td>
</tr></table>
</div>
</div>
</div>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">unforeseen safety issues;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">determination of dosing;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">lack of effectiveness during clinical trials;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">slower than expected rates of patient recruitment;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">inability to monitor patients adequately during or after treatment;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">inability or unwillingness of medical investigators to follow our clinical protocols; and</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">&#160;</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">unwillingness of the FDA or IRBs to permit the clinical trials to be initiated.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In addition, we, IRBs or the FDA may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs or the FDA finds deficiencies in our submissions or conduct of our trials.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">34</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">The results of our clinical trials may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily predictive of future results.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">To date, long-term safety and efficacy have not yet been demonstrated in clinical trials for any of our diagnostic product candidates. Favorable results in our early studies or trials may not be repeated in later studies or trials. Even if our clinical trials are initiated and completed as planned, we cannot be certain that the results will support our product candidate claims. Success in preclinical testing and Phase II clinical trials does not ensure that later Phase II or Phase III clinical trials will be successful. We cannot be sure that the results of later clinical trials would replicate the results of prior clinical trials and preclinical testing. In particular, the limited results that we have obtained for our diagnostic tests may not predict results from studies in larger numbers of subjects drawn from more diverse populations over a longer period of time. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Any such failure could cause us or our sublicensee to abandon a product candidate and might delay development of other product candidates. Preclinical and clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization. Any delay in, or termination of, our clinical trials would delay our obtaining FDA approval for the affected product candidate and, ultimately, our ability to commercialize that product candidate.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Physicians and patients may not accept and use our technologies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Even if&#160;&#160;our products demonstrate sufficient clinical benefit and the FDA approves our drug product candidates, physicians and patients may not accept and use them. Acceptance and use of our products will depend upon a number of factors, including the following:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the perception of members of the health care community, including physicians, regarding the safety and effectiveness of our product candidates;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the cost-effectiveness of our product relative to competing products;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">availability of reimbursement for our products from government or other healthcare payers; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Because we expect sales of our clinical laboratory services and current product candidates (when required, if approved), to generate substantially all of our revenues for the foreseeable future, the failure of any of these drugs to find market acceptance would harm our business and could require us to seek additional financing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We depend on third parties, including researchers and sublicensees, who are not under our control.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since we have in-licensed some of our product candidates and have sublicensed a product candidate, we depend upon our sublicensee and independent investigators and scientific collaborators, such as universities and medical institutions or private physician scientists, to conduct our preclinical and clinical trials under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs or the timing of their procurement of clinical-trial data or their compliance with applicable regulatory guidelines. Should any of these scientific inventors/advisors or those of our sublicensee become disabled or die unexpectedly, or should they fail to comply with applicable regulatory guidelines, we or our sublicensee may be forced to scale back or terminate development of that program. They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking those programs ourselves. Failing to devote sufficient time and resources to our drug-development programs, or substandard performance and failure to comply with regulatory guidelines, could result in delay of any FDA applications and our commercialization of the drug candidate involved.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">These collaborators may also have relationships with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors at our expense could harm our competitive position. For example, we are highly dependent on scientific collaborators for our Trimesta development program. Specifically, all of the clinical trials have been conducted under physician-sponsored investigational new drug applications (INDs), not corporate-sponsored INDs. Generally, we have experienced difficulty in collecting data generated from these physician-sponsored clinical trials for our programs.&#160;&#160;We cannot provide any assurances that we will not experience any additional delays in the future.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are also highly dependent on government and private grants to fund certain of our clinical trials for our product candidates. For example, Trimesta (estriol) has received grants totaling over $8 million,&#160;predominantly from the Southern California Chapter of the National Multiple Sclerosis Society and the National Institutes of Health which funds a majority of the ongoing 150 patient clinical trial in relapsing-remitting multiple sclerosis for women. Although we believe that the grant funding received to date is sufficient to complete the current clinical trial based upon current cost estimates, if we experience any additional unanticipated costs or require further clinical trials, and our scientific collaborator is unable to maintain or receive additional grants, we might be forced to scale back or terminate the development of this product candidate. We will also need to cross reference our IND with the inventor/IND holder for this program should we elect to file our own corporate IND for our Trimesta (estriol) program. The on-going and future development and commercialization of Effirma (flupirtine) for fibromyalgia is the responsibility of Meda AB and no assurance can be given that Meda will gain the FDA&#8217;s acceptance of the NDA or obtain NDA approval from the FDA of flupirtine for fibromyalgia.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We have no experience selling, marketing, or distributing products and do not have the capability to do so.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We currently have no sales, marketing, or distribution capabilities. We do not anticipate having significant resources in the foreseeable future to allocate to selling and marketing our proposed products. Our success will depend, in part, on whether we are able to enter into and maintain collaborative relationships with a pharmaceutical or a biotechnology company charged with marketing one or more of our products. We may not be able to establish or maintain such collaborative arrangements or to commercialize our products in foreign territories, and even if we do, our collaborators may not have effective sales forces.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">35</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we do not, or are unable to, enter into collaborative arrangements to sell and market our proposed products, we will need to devote significant capital, management resources, and time to establishing and developing an in-house marketing and sales force with technical expertise. We may be unsuccessful in doing so.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">If we fail to maintain positive relationships with particular individuals, we may be unable to successfully develop our product candidates, conduct clinical trials, and obtain financing.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If we fail to maintain positive relationships with members of our management team or if these individuals decrease their contributions to our company, our business could be adversely impacted. We do not carry key employee insurance policies for any of our key employees.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We also rely greatly on employing and retaining other highly trained and experienced senior management and scientific personnel. The competition for these and other qualified personnel in the biotechnology field is intense. If we are not able to attract and retain qualified scientific, technical, and managerial personnel, we probably will be unable to achieve our business objectives.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may not be able to compete successfully for market share against other drug companies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The markets for our product candidates are characterized by intense competition and rapid technological advances. If our prescription drug product candidates receive FDA approval, they will compete with existing and future drugs and therapies developed, manufactured, and marketed by others. Our&#160;&#160;medical food product and our homeopathic OTC drug will also compete with existing and future comparable products. Competing products may have greater market acceptance and/or provide greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost. If our products fail to capture and maintain market share, we may not achieve sufficient product revenues and our business will suffer.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will compete against fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical companies, academic institutions, government agencies, or other public and private research organizations. Many of these competitors have therapies to treat central nervous system diseases already approved or in development. In addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development programs than we do, have substantially greater financial resources than we do, and have significantly greater experience in the following areas:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">developing drugs;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">undertaking preclinical testing and human clinical trials;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">obtaining FDA and other regulatory approvals of drugs;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">formulating and manufacturing drugs; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">launching, marketing and selling drugs.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated with lawsuits.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If any other person files patent applications, or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference proceedings in the United States Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to participate in interference proceedings involving our issued patents and pending applications of another entity.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We cannot guarantee that the practice of our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition proceedings, either by opposing the validity of another&#8217;s foreign patent or by persons opposing the validity of our foreign patents.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may also face frivolous litigation or lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could distract management from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect on our ability to continue our operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">If we infringe the rights of others we could be prevented from selling products or forced to pay damages.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If our products, methods, processes, and other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling to offer us a license on commercially acceptable terms.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">36</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our products, if approved, may not be commercially viable due to change in health care practice and third party reimbursement limitations</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Recent initiatives to reduce the federal deficit and to change health care delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative benefits, controls on health care spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, price controls on pharmaceuticals, and other fundamental changes to the health care delivery system. Any changes of this type could negatively impact the commercial viability of our products, if approved. Our ability to successfully commercialize our product candidates, if they are approved, will depend in part on the extent to which appropriate reimbursement codes and authorized cost reimbursement levels of these products and related treatment are obtained from governmental authorities, private health insurers and other organizations, such as health maintenance organizations. In the absence of national Medicare coverage determination, local contractors that administer the Medicare program may make their own coverage decisions. Any of our product candidates, if approved and when commercially available, may not be included within the then current Medicare coverage determination or the coverage determination of state Medicaid programs, private insurance companies or other health care providers. In addition, third-party payers are increasingly challenging the necessity and prices charged for medical products, treatments and services.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our medical food product and our homeopathic OTC drug may not be eligible for third-party reimbursement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We do not currently have product liability or malpractice insurance and may not be able to obtain adequate insurance coverage against product liability claims.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our business exposes us to potential product liability and other types of claims and our exposure will increase as we prepare to commercialize <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin, </font>a medical food for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease, and <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font>, a homeopathic OTC zinc acetate lozenge to reduce the duration and severity of symptoms caused by the common cold. We do not currently have any product liability or malpractice insurance that would cover us against any product liability, or malpractice claims. Any such claim would have to be paid out of our cash reserves, which would have a detrimental effect on our financial condition.&#160;&#160;Even if it is available, product liability insurance for the pharmaceutical and biotechnology industry generally is expensive. Adequate insurance coverage may not be available at a reasonable cost. We cannot assure you that we can or will be able to obtain product liability or malpractice insurance policies on commercially acceptable terms, or at all.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RISKS RELATING TO OUR STOCK</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We will seek to raise additional funds in the future, which may be dilutive to stockholders or impose operational restrictions.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We expect to seek to raise additional capital in the future to help fund development of our proposed products. If we raise additional capital through the issuance of equity (as we recently have) or of debt securities, the percentage ownership of our current stockholders will be reduced. We may also enter into strategic transactions, issue equity as part of license issue fees to our licensors, compensate consultants or settle outstanding payables using equity that may be dilutive. Our stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock. If we cannot raise additional funds, we will have to delay development activities of our products candidates.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We are substantially controlled by our current officers, directors, and principal stockholders.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Currently, our directors, executive officer, and principal stockholders beneficially own a substantial number of shares of our common stock. As a result, they will be able to exert substantial influence over the election of our board of directors and the vote on issues submitted to our stockholders. Our executive officer, directors and principal stockholders beneficially owned approximately 12.1 million shares of our common stock, including the stock options and warrants exercisable within 60 days of June 30, 2011. Because our common stock has from time to time been &#8220;thinly traded&#8221;, the sale of these shares by our executive officer, directors and principal stockholders could have an adverse effect on the market for our stock and our share price.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our shares of common stock are from time to time thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares to raise money or otherwise desire to liquidate their shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Our common stock has from time to time been &#8220;thinly-traded,&#8221; meaning that the number of persons interested in purchasing our common stock at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non&#173;-existent, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give stockholders any assurance that a broader or more active public trading market for our common shares will develop or be sustained, or that current trading levels will be sustained.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">37</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Our compliance with the Sarbanes-Oxley Act and SEC rules concerning internal controls may be time consuming, difficult and costly.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although individual members of our management team have experience as officers of publicly traded companies, much of that experience came prior to the adoption of the Sarbanes-Oxley Act of 2002. It may be time consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures required by Sarbanes-Oxley. We may need to hire additional financial reporting, internal controls and other finance staff in order to develop and implement appropriate internal controls and reporting procedures. If we are unable to comply with Sarbanes-Oxley&#8217;s internal controls requirements, we may not be able to obtain the independent accountant certifications that Sarbanes-Oxley Act requires publicly traded companies to obtain.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We cannot assure you that the common stock will be liquid or that it will remain listed on the NYSE Amex.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We cannot assure you that we will be able to maintain the continued listing standards of the NYSE Amex (formerly the American Stock Exchange) or NYSE Alternext US. The NYSE Amex requires companies to meet certain continued listing criteria including certain minimum stockholders' equity&#160;and equity prices per share&#160;as outlined in the Exchange Company Guide. We may not be able to maintain such minimum stockholders' equity or prices per share or may be required to effect a reverse stock split to maintain such minimum prices and/or issue additional equity securities in exchange for cash or other assets, if available, to maintain certain minimum stockholders' equity required by the NYSE Amex.&#160;If we are delisted from the Exchange then our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the Exchange could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of institutional investor interest and fewer business development opportunities.&#160;&#160;In order to remain listed on NYSE Amex, we are required to maintain a minimum stockholders&#8217; equity of $6 million. Due to the accounting treatment of warrant liability and the fact that such amount changes every quarter, it is difficult to predict with any certainty what our future stockholders&#8217; equity will be and whether will be able to remain in compliance with such provision.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">There may be issuances of shares of preferred stock in the future.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Although we currently do not have preferred shares outstanding, the board of directors could authorize the issuance of a series of preferred stock that would grant holders preferred rights to our assets upon liquidation, the right to receive dividends before dividends would be declared to common stockholders, and the right to the redemption of such shares, possibly together with a premium, prior to the redemption of the common stock. To the extent that we do issue preferred stock, the rights of holders of common stock could be impaired thereby, including without limitation, with respect to liquidation.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We have never paid dividends.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We have never paid cash dividends on our common stock and do not anticipate paying any for the foreseeable future.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">RISKS RELATED TO OUR INDUSTRY</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We are subject to government regulation, compliance with which can be costly and difficult.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the United States, the formulation, manufacturing, packaging, storing, labeling, promotion, advertising, distribution and sale of our products are subject to regulation by various governmental agencies, including (1) the Food and Drug Administration, or FDA, (2) the Federal Trade Commission, or FTC, (3) the Consumer Product Safety Commission, or CPSC, (4) the United States Department of Agriculture, or USDA. Our proposed activities may also be regulated by various agencies of the states, localities and foreign countries in which our proposed products may be manufactured, distributed and sold. The FDA, in particular, regulates the formulation, manufacture and labeling of over-the-counter, or OTC drugs, prescription drugs, medical foods, conventional foods, homeopathic OTC drugs, dietary supplements, and cosmetics such as those that we intend to distribute. FDA regulations require us and our suppliers to meet relevant current good manufacturing practice, or cGMP, regulations for the preparation, packing, labeling, and storage of all drugs and foods.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing FDA regulation, including record-keeping requirements, reporting of adverse experiences, submitting periodic reports, drug sampling and distribution requirements, manufacturing or labeling changes, record-keeping requirements, and compliance with FDA promotion and advertising requirements. Drug manufacturers and their subcontractors are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced inspections for GMP compliance, imposing procedural and documentation requirements upon us and third-party manufacturers. Failure to comply with these regulations could result, among other things, in suspension of regulatory approval, recalls, suspension of production or injunctions, seizures, or civil or criminal sanctions. We cannot be certain that we or our present or future subcontractors will be able to comply with these regulations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">38</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The FDA regulates prescription drug labeling and promotion activities. The FDA actively enforces regulations prohibiting the marketing of products for unapproved uses. The FDA permits the promotion of drugs for unapproved uses in certain circumstances, subject to stringent requirements. We and our product candidates are subject to a variety of state laws and regulations which may hinder our ability to market our products. Whether or not FDA approval has been obtained, approval by foreign regulatory authorities must be obtained prior to commencing clinical trials, and sales and marketing efforts in those countries. These approval procedures vary in complexity from country to country, and the processes may be longer or shorter than that required for FDA approval. We may incur significant costs to comply with these laws and regulations now or in the future.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We may seek to market some of our proposed products as medical foods for the dietary management of certain diseases. Medical foods are defined in section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3)) as "a food which is formulated to be consumed or administered enterally under the supervision of a physician and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation." We believe our product may qualify as a medical food provided we are able to generate, and have published, sufficient clinical data to support such claims. Medical foods are required to be utilized under a medical doctor&#8217;s supervision and as such, our distribution channels may be limited and/or complicated.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Some of the products marketed by us are considered medical foods and will be labeled as such. Within the United States, this category of products is subject to the Federal Food, Drug, and Cosmetic Act (FFDC Act) and pertinent amendments thereto. The ingredients added to medical foods must either be FDA-approved food additives or generally recognized as safe (GRAS) by qualified experts. <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> is comprised of zinc (a GRAS ingredient) and cysteine (an amino acid that also has GRAS status). While many chelated zinc products are currently on the market and are generally not considered to contain unapproved food additives or non-GRAS substances, we cannot provide any assurance that <font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font> will be similarly considered by the FDA.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Furthermore, in the last few years, FDA has issued several warning letters to companies marketing medical foods, questioning the basis upon which the products qualified as a medical food and objecting to certain claims made for the products. Because there is little guidance on what constitutes a medical food, and given the current regulatory climate for these products, we cannot provide any assurance that FDA would agree with the positioning of our products as medical foods.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We intend to develop our zinc and copper candidates, AEN-100 and AEN-200, respectively, as drugs and intend to file an IND with the FDA in order to conduct necessary clinical trials to support new medical claims and ultimately file one or more NDA with respect to such products which would subject us to time, expense and uncertainty associated with achieving approval of such NDA by the FDA.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">It is anticipated that the marketing of <font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font>, a homeopathic OTC drug, will involve claims that this product assists in reducing the duration and severity of the common cold. Under FDA and FTC rules, we are required to obtain scientific data to support any claims we make concerning our products. Although we have scientic data to support our intended product claims, we cannot be certain that these scientific data will be deemed acceptable to the FDA, FTC or other regulatory bodies. If any regulatory body requests supporting information and we are unable to provide support that is acceptable, either the FDA or FTC could force us to stop making the claims in question or restrict us from selling the affected products. Further, because there is no premarket review or approval of homeopathic OTC drug products, we cannot provide any assurance that the FDA would agree with the positioning of any of our products as a homeopathic OTC drug.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The FTC, which exercises jurisdiction over the advertising&#160;&#160;of our proposed homeopathic OTC, medical food and lab test products, has in the past several years instituted enforcement actions against several dietary supplement and food companies for false and misleading advertising related to health. These enforcement actions have resulted in consent decrees and monetary payments by the companies involved. In addition, the FTC has recently updated its guides on the use of testimonials and endorsements in advertising. As a result, the FTC appears to have increased its scrutiny of the use of testimonials, which we could utilize, as well as the role of expert endorsers and product clinical studies. It is unclear whether the FTC will subject our advertisements to increased surveillance to ensure compliance with the principles set forth in its newly revised endorsements/testimonial advertising guidances.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The FDA, comparable foreign regulators and state and local pharmacy regulators impose substantial requirements upon clinical development, manufacture and marketing of pharmaceutical products. These and other entities regulate research and development and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising, and promotion of our products. The drug approval process required by the FDA under the Food, Drug, and Cosmetic Act generally involves:</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">preclinical laboratory and animal tests;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">submission of an IND, prior to commencing human clinical trials;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">adequate and well-controlled human clinical trials to establish safety and efficacy for intended use;</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">submission to the FDA of a NDA; and</font></font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt;" face="Symbol, serif">&#183;</font></font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">FDA review and approval of a NDA.</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approval will be granted on a timely basis, if at all.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">39</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Preclinical tests include laboratory evaluation of the product candidate, its chemistry, formulation and stability, and animal studies to assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated. In some cases, long-term preclinical studies are conducted concurrently with clinical studies.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We will submit the preclinical test results, together with manufacturing information and analytical data, to the FDA as part of an IND, which must become effective before we begin human clinical trials. The IND automatically becomes effective 30 days after filing, unless the FDA raises questions about conduct of the trials outlined in the IND and imposes a clinical hold, in which case, the IND sponsor and FDA must resolve the matters before clinical trials can begin. It is possible that our submission may not result in FDA authorization to commence clinical trials.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical trials must be supervised by a qualified investigator in accordance with good clinical practice regulations, which include informed consent requirements. An independent Institutional Review Board (&#8220;IRB&#8221;) at each medical center reviews and approves and monitors the study, and is periodically informed of the study&#8217;s progress, adverse events and changes in research. Progress reports are submitted annually to the FDA and more frequently if adverse events occur.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Human clinical trials of drug candidates typically have three sequential phases that may overlap:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase I: The drug is initially tested in healthy human subjects or patients for safety, dosage tolerance, absorption, metabolism, distribution, and excretion.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase II: The drug is studied in a limited patient population to identify possible adverse effects and safety risks, determine efficacy for specific diseases and establish dosage tolerance and optimal dosage.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Phase III: When phase II evaluations demonstrate that a dosage range is effective with an acceptable safety profile, Phase III trials to further evaluate dosage, clinical efficacy and safety, are undertaken in an expanded patient population, often at geographically dispersed sites.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We cannot be certain that we will successfully complete Phase I, Phase II, or Phase III testing of our product candidates within any specific time period, if at all. Furthermore, the FDA, an IRB or the IND sponsor may suspend clinical trials at any time on various grounds, including a finding that subjects or patients are exposed to unacceptable health risk. Concurrent with these trials and studies, we also develop chemistry and physical characteristics data and finalize a manufacturing process in accordance with good manufacturing practice (&#8220;GMP&#8221;) requirements. The manufacturing process must conform to consistency and quality standards, and we must develop methods for testing the quality, purity, and potency of the final products. Appropriate packaging is selected and tested, and chemistry stability studies are conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life. Results of the foregoing are submitted to the FDA as part of a NDA for marketing and commercial shipment approval. The FDA reviews each NDA submitted and may request additional information.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Once the FDA accepts the NDA for filing, it begins its in-depth review. The FDA has substantial discretion in the approval process and may disagree with our interpretation of the data submitted. The process may be significantly extended by requests for additional information or clarification regarding information already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee, typically a panel of clinicians. Manufacturing establishments often are inspected prior to NDA approval to assure compliance with GMPs and with manufacturing commitments made in the application.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Submission of a NDA with clinical data requires payment of a fee. In return, the FDA assigns a goal of ten months for issuing its &#8220;complete response,&#8221; in which the FDA may approve or deny the NDA, or require additional clinical data. Even if these data are submitted, the FDA may ultimately decide the NDA does not satisfy approval criteria. If the FDA approves the NDA, the product becomes available for physicians prescription. Product approval may be withdrawn if regulatory compliance is not maintained or safety problems occur. The FDA may require post-marketing studies, also known as phase IV studies, as a condition of approval, and requires surveillance programs to monitor approved products that have been commercialized. The agency has the power to require changes in labeling or prohibit further marketing based on the results of post-marketing surveillance.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Satisfaction of these and other regulatory requirements typically takes several years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve any of our products on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from preclinical and clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or uses.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delays in obtaining, or failures to obtain regulatory approvals would have a material adverse effect on our business.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">40</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The FDA&#8217;s policies may change, and additional government regulations may be enacted which could prevent or delay regulatory approval of our potential products. Increased attention to the containment of health care costs worldwide could result in new government regulations materially adverse to our business. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-STYLE: italic"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Failure to adhere to the quality control and other regulatory requirements could result in additional expense to us or the suspension of such certification necessary to perform clinical testing.</font></font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We are subject to numerous federal, state and local laws relating to safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances. We may incur significant costs to comply with these laws and regulations. The regulatory framework under which we operate will inevitably change in light of scientific, economic, demographic and policy developments and such changes may have a material adverse effect on our business.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Clinical laboratories in the United States are subject to regulation under the Clinical Laboratory Improvements Act of 1988 (&#8220;CLIA&#8221;) as well as corresponding state regulations.&#160;&#160;Failure to adhere to the quality control and other regulatory requirements of CLIA could result in the suspension of such certification necessary to perform clinical testing and generate revenues.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Changes in the health care regulatory environment may adversely affect our business.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 were signed into law on March&#160;23, 2010 and March&#160;30, 2010, respectively. A number of the provisions of those laws require further rulemaking action by governmental agencies to implement. The laws change access to health care products and services and create new fees for the pharmaceutical and medical device industries. Future rulemaking could increase rebates, reduce prices or the rate of price increases for health care products and services, or require additional reporting and disclosure. We cannot predict the timing or impact of any future rulemaking.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Failure to comply with requirements of the European Union can be costly and time consuming.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Prior regulatory approval for human healthy volunteer studies (Phase I studies) is required in member states of the European Union (E.U.). Summary data from successful Phase I studies are submitted to regulatory authorities in member states to support applications for Phase II studies. E.U. authorities typically have one to three months (which often may be extended in their discretion) to raise objections to the proposed study. One or more independent ethics committees (similar to United States IRBs) review relevant ethical issues.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For E.U. marketing approval, we submit to the relevant authority for review a dossier, or MAA (Market Authorization Application), providing information on the quality of the chemistry, manufacturing and pharmaceutical aspects of the product as well as non-clinical and clinical data.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Approval can take several months to several years, and can be denied, depending on whether additional studies or clinical trials are requested (which may delay marketing approval and involve unbudgeted costs) or regulatory authorities conduct facilities (including clinical investigation site) inspections and review manufacturing procedures, operating systems and personnel qualifications. In many cases, each drug manufacturing facility must be approved, and further inspections may occur over the product&#8217;s life.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The regulatory agency may require post-marketing surveillance to monitor for adverse effects or other studies. Further clinical studies are usually necessary for approval of additional indications. The terms of any approval, including labeling content, may be more restrictive than expected and could affect the marketability of a product.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Failure to comply with these ongoing requirements can result in suspension of regulatory approval and civil and criminal sanctions. European renewals may require additional data, resulting in a license being withdrawn. E.U. regulators have the authority to revoke, suspend or withdraw approvals, prevent companies and individuals from participating in the drug approval process, request recalls, seize violative products, obtain injunctions to close non-compliant manufacturing plants and stop shipments of violative products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="V222442_10Q_HTM_V218064_424B5_HTM_EOLPAG"><!--EFPlaceholder--></a>We are subject to pricing controls that may not result in favorable arrangements for our products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pricing for products under approval applications is also subject to regulation. Requirements vary widely between countries and can be implemented disparately intra-nationally. The E.U. generally provides options for member states to control pricing of medicinal products for human use, ranging from specific price-setting to systems of direct or indirect controls on the producer&#8217;s profitability. U.K. regulation, for example, generally provides controls on overall profits derived from sales to the U.K. National Health Service that are based on profitability targets or a function of capital employed in servicing the National Health Service market. Italy generally utilizes a price monitoring system based on the European average price over the reference markets of France, Spain, Germany and the U.K. Italy typically establishes price within a therapeutic class based on the lowest price for a medicine belonging to that category. Spain generally establishes selling price based on prime cost plus a profit margin within a range established yearly by the Spanish Commission for Economic Affairs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">41</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">There can be no assurance that price controls or reimbursement limitations will result in favorable arrangements for our products.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt">&#160;&#160;</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">If we are not able to receive third-party reimbursements we may not be able to sell products at competitive prices.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the United States, the E.U. and elsewhere, pharmaceutical sales are dependent in part on the availability and adequacy of reimbursement from third party payers such as governments and private insurance plans. Third party payers are increasingly challenging established prices, and new products that are more expensive than existing treatments may have difficulty finding ready acceptance unless there is a clear therapeutic benefit.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In the United States, consumer willingness to choose a self-administered outpatient prescription drug over a different drug or other form of treatment often depends on the manufacturer&#8217;s success in placing the product on a health plan formulary or drug list, which results in lower out-of-pocket costs. Favorable formulary placement typically requires the product to be less expensive than what the health plan determines to be therapeutically equivalent products, and often requires manufacturers to offer rebates. Federal law also requires manufacturers to pay rebates to state Medicaid programs in order to have their products reimbursed by Medicaid. Medicare, which covers most Americans over age 65 and the disabled, adopted an insurance regime that offers eligible beneficiaries limited coverage for outpatient prescription drugs that became effective January 1, 2006. The prescription drugs that are covered under this insurance are specified on a formulary published by Medicare. As part of these changes, Medicare has adopted new payment formulas for prescription drugs administered by providers, such as hospitals or physicians that are generally expected to lower reimbursement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The E.U. generally provides options for member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement. Member states can opt for a &#8220;positive&#8221; or &#8220;negative&#8221; list, with the former listing all covered medicinal products and the latter designating those excluded from coverage. The E.U., the U.K. and Spain have negative lists, while France uses a positive list. Canadian provinces establish their own reimbursement measures. In some countries, products may also be subject to clinical and cost effectiveness reviews by health technology assessment bodies. Negative determinations in relation to our products could affect prescribing practices. In the U.K., the National Institute for Clinical Excellence (&#8220;NICE&#8221;) provides such guidance to the National Health Service, and doctors are expected to take it into account when choosing drugs to prescribe. Health authorities may withhold funding from drugs not given a positive recommendation by NICE. A negative determination by NICE may mean fewer prescriptions. Although NICE considers drugs with orphan status, there is a degree of tension on the application of standard cost assessment for orphan drugs, which are often priced higher to compensate for a limited market. It is unclear whether NICE will adopt a more relaxed approach toward the assessment of orphan drugs.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We cannot assure you that any of our products will be considered cost effective, or that reimbursement will be available or sufficient to allow us to sell them competitively and profitably. Our medical food product and our homeopathic OTC drug may not be eligible for third-party reimbursement.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">There is no certainty that our medical food products will be reimbursed by private insurance, government programs such as Medicaid and Medicare and workers compensation insurers. If these entities do not reimburse for the costs of such products, this could have a material adverse effect on our business and results of operations.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inasmuch as medical foods are distinguished by the FDA and other organizations from prescription drugs and exempt from certain regulations that apply to prescription drugs, it is possible that private insurance, government programs such as Medicaid and Medicare and workers compensation insurers will not reimburse costs incurred for medical foods in the same manner as prescription drugs. There is no certainty that we will be able to maintain the necessary requirements for insurance reimbursement of our medical food products. If our physician clients do not continue to be reimbursed for dispensing our medical food products, they may choose not to purchase them and our business and results of operations may be adversely affected.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">It is unlikely that our homeopathic OTC drug products will be reimbursed by private insurance, government programs such as Medicaid and Medicare and workers compensation insurers. If these entities do not reimburse for the costs of such products, this could have a material adverse effect on our business and results of operations.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Inasmuch as homeopathic OTC drug products are distinguished by the FDA and other organizations from prescription drugs and exempt from certain regulations that apply to prescription drugs, it is likely that private insurance, government programs such as Medicaid and Medicare and workers compensation insurers will not reimburse costs incurred for homeopathic OTC drugs.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">42</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We could be subject to challenges under fraud and abuse laws.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The United States federal Medicare/Medicaid anti-kickback law and similar state laws prohibit remuneration intended to induce physicians or others either to refer patients, or to acquire or arrange for or recommend the acquisition of health care products or services. While the federal law applies only to referrals, products or services receiving federal reimbursement, state laws often apply regardless of whether federal funds are involved. Other federal and state laws prohibit anyone from presenting or causing to be presented false or fraudulent payment claims. Recent federal and state enforcement actions under these statutes have targeted sales and marketing activities of prescription drug manufacturers. As we begin to market our products to health care providers, the relationships we form, such as compensating physicians for speaking or consulting services, providing financial support for continuing medical education or research programs, and assisting customers with third-party reimbursement claims, could be challenged under these laws and lead to civil or criminal penalties, including the exclusion of our products from federally-funded reimbursement. Even an unsuccessful challenge could cause adverse publicity and be costly to respond to, and thus could have a material adverse effect on our business, results of operations and financial condition. We intend to consult counsel concerning the potential application of these and other laws to our business and to our sales, marketing and other activities to comply with them. Given their broad reach and the increasing attention given them by law enforcement authorities, however, we cannot assure you that some of our activities will not be challenged.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"><a name="eolPage38"><!--EFPlaceholder--></a>&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">We do not have a guarantee of patent restoration and marketing exclusivity of the ingredients for our drugs even if we are granted FDA approval of our products.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="V222442_10Q_HTM_V218064_424B5_HTM_V21612"><!--EFPlaceholder--></a>The United States Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) permits the FDA to approve Abbreviated New Drug Applications (&#8220;ANDAs&#8221;) for generic versions of innovator drugs, as well as NDAs with less original clinical data, and provides patent restoration and exclusivity protections to innovator drug manufacturers. The ANDA process permits competitor companies to obtain marketing approval for drugs with the same active ingredient and for the same uses as innovator drugs, but does not require the conduct and submission of clinical studies demonstrating safety and efficacy. As a result, a competitor could copy any of our drugs and only need to submit data demonstrating that the copy is bioequivalent to gain marketing approval from the FDA. Hatch-Waxman requires a competitor that submits an ANDA, or otherwise relies on safety and efficacy data for one of our drugs, to notify us and/or our business partners of potential infringement of our patent rights. We and/or our business partners may sue the company for patent infringement, which would result in a 30-month stay of approval of the competitor&#8217;s application. The discovery, trial and appeals process in such suits can take several years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period, the stay is lifted and the FDA may approve the application. Hatch-Waxman also allows competitors to market copies of innovator products by submitting significantly less clinical data outside the ANDA context. Such applications, known as &#8220;505(b)(2) NDAs&#8221; or &#8220;paper NDAs,&#8221; may rely on clinical investigations not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use and are subject to the ANDA notification procedures described above.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The law also permits restoration of a portion of a product&#8217;s patent term that is lost during clinical development and NDA review, and provides statutory protection, known as exclusivity, against FDA approval or acceptance of certain competitor applications. Restoration can return up to five years of patent term for a patent covering a new product or its use to compensate for time lost during product development and regulatory review. The restoration period is generally one-half the time between the effective date of an IND and submission of an NDA, plus the time between NDA submission and its approval (subject to the five-year limit), and no extension can extend total patent life beyond 14 years after the drug approval date. Applications for patent term extension are subject to United States Patent and Trademark Office (&#8220;USPTO&#8221;) approval, in conjunction with FDA. Approval of these applications takes at least nine months, and there can be no guarantee that it will be given at all.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Hatch-Waxman also provides for differing periods of statutory protection for new drugs approved under an NDA. Among the types of exclusivity are those for a &#8220;new molecular entity&#8221; and those for a new formulation or indication for a previously-approved drug. If granted, marketing exclusivity for the types of products that we are developing, which include only drugs with innovative changes to previously-approved products using the same active ingredient, would prohibit the FDA from approving an ANDA or 505(b)(2) NDA relying on our safety and efficacy data for three years. This three-year exclusivity, however, covers only the innovation associated with the original NDA. It does not prohibit the FDA from approving applications for drugs with the same active ingredient but without our new innovative change. These marketing exclusivity protections do not prohibit the FDA from approving a full NDA, even if it contains the innovative change.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 2, 2011, we issued 130,000 restricted shares of our common stock in consideration of financial advisory services to be provided. The issuance qualified for exemption on section 4(2) of the Securities Act of 1933 since the issuance did not involve a public offering because it was made to an insubstantial number of persons and because of the manner in which it was made. There was no general solicitation or advertising by us. Based on an analysis of the above factors, we have met the requirements to qualify for exemption under section 4(2) of the Securities Act of 1933 for this issuance.<a name="FIS_DEFAULT_SECURITIES"><!--EFPlaceholder--></a></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">43</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">None.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 4.&#160;&#160;RESERVED AND REMOVED</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_OTHER_INFORMATION"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 5.&#160;&#160;OTHER INFORMATION</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On July 28, 2011, we exchanged the warrant issued in connection with the April 6, 2011 financing for a new warrant with substantially the same terms as the original warrant except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00,&#160;<a name="FIS_EXHIBITS_REPORTS"><!--EFPlaceholder--></a>(iii) the expiration date was extended for an additional three months to August 10, 2012, and (iv) the initial exercise date was changed to January 2012.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">On August 10, 2011, we entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrant the expiration date will be&#160;extended two months.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<a name="FIS_EXHIBITS_REPORTS"><!--EFPlaceholder--></a></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ITEM 6. EXHIBITS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.1&#160;</font></div>
</td>
<td valign="top" width="90%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Warrant issued in exchange of the warrant issued in connection with the April 6, 2011 financing *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">4.2&#160;</font></div>
</td>
<td valign="top" width="90%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Form of Warrant issued in exchange of the warrant issued in connection with the January 28, 2011 financing *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.1&#160;</font></div>
</td>
<td valign="top" width="90%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exchange Agreement entered into in exchange for the warrant issued in connection with the April 6, 2011 financing *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">10.2&#160;</font></div>
</td>
<td valign="top" width="90%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Exchange Agreement entered into in exchange for the warrant issued in connection with the January 28, 2011 financing *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>
</div>
</div>
</div>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.1</font></div>
</td>
<td valign="top" width="90%" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">31.2</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">32.1</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Certification pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 *</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*Filed herewith</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">44</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_SIGNATURES"><!--EFPlaceholder--></a>SIGNATURE</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="40%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/&#160;James S. Kuo</font></font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">James S. Kuo, M.D., M.B.A.</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">President and Chief Executive Officer</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Principal Executive Officer and Principal</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Financial Officer)</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: August 15, 2011</font></div>
</td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">45</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><a name="FIS_UNIDENTIFIED_TABLE_15"><!--EFPlaceholder--></a>GLOSSARY</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="20%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Term</font></div>
</td>
<td valign="top" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Definition</font></div>
</td>
</tr><tr>
<td valign="top" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adverse Event</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Any adverse change in health or &#8220;side-effect&#8221; that occurs in a person participating in a clinical trial, from the time they consent to joining the trial until a pre-specified period of time after their treatment has been completed.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Bioavailability</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The quantity or fraction of the ingested dose that is absorbed by the body.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AEN-100 (zinc)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adeona&#8217;s proprietary, once-daily, gastroretentive, sustained-release oral tablet formulation of zinc acetate.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">AEN-200 (copper)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adeona&#8217;s proprietary oral tablet formulation of copper sulfate.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Clinical Study/Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A research study that is conducted to find out if a treatment or procedure is safe and/or effective in humans.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Controlled Clinical Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A clinical study that compares patients receiving a specific treatment to patients receiving an alternate treatment for the condition of interest. The alternate treatment may be another active treatment, standard of care for the condition and/or a placebo (inactive) treatment.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Double-blinded Study/Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Both the participant and the researcher are unaware of who is receiving the active treatment or the placebo.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Effirma (flupirtine)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proposed tradename of Adeona&#8217;s centrally-acting investigational oral drug for the treatment of fibromyalgia syndrome</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">FDA &#8211; Food &amp; Drug Administration</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The U.S. government agency that ensures that medicines, medical devices, medical foods and radiation-emitting consumer products are safe and effective. Authorized by Congress to enforce the Federal Food, Drug, and Cosmetic Act and several other public health laws, the agency monitors the manufacture, import, transport, storage, and sale of $1 trillion worth of goods annually.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Gastroretentive</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Medications designed to be retained in the upper gastrointestinal system.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">GMP &#8211; Good Manufacturing Practice</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Regulations that require that manufacturers, processors, and packagers of drugs, medical devices, some food, and blood take proactive steps to ensure that their products are consistently produced, pure, and stable. GMP regulations require a quality approach to manufacturing, enabling companies to minimize or eliminate instances of contamination, mix-ups, and errors.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">GRAS &#8211; Generally Recognized As Safe</font></font></div>
</div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">If the use of a substance in food is generally recognized as safe (GRAS) by qualified experts, then that use is exempted from the premarket approval requirements that apply to food additives under the Federal Food, Drug, and Cosmetic Act (FFDCA).</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">IND &#8211; Investigational New Drug</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">An application submitted to the FDA for a new drug or biologic that, if allowed, will be used in a clinical trial.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Open-label Clinical Study/Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A trial in which both the treating physician and the patient know they are receiving the experimental treatment.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase I Clinical Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A Phase I trial represents an initial study in a small group of patients to primarily test for safety.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase II Clinical Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A Phase II trial represents a study in a larger number of patients to assess the safety and efficacy of a product.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase III Clinical Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Phase III trials are initiated to establish safety and efficacy in an expanded patient population and at multiple clinical trial sites and are generally larger than trials in earlier phases of development.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Placebo</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">An inactive pill or liquid. Many studies compare an active drug to a placebo to determine whether any changes seen during the study can be attributed to the active drug.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">46</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Principal Investigator</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">This is the study director who is ultimately responsible for the conduct of the study.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Prospective Clinical Study/Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A clinical study/trial in which participants are identified and then followed throughout the study going forward in time.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Protocol</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">A clinical study/trial&#8217;s plan &#8212; includes the schedule of tests, requirements for participation, procedures, and medications.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Randomized Study/Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Participants in a study are assigned by chance to either one or more of the active treatment group(s) or the placebo group.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">reaZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> (zinc cysteine)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tradename of Adeona&#8217;s oral medical food product containing zinc and cysteine, available only by prescription, that is being developed for the dietary management of zinc deficiency associated with Alzheimer's disease.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Single-blinded Study/Trial</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">One party, either the participant or the researcher, does not know if the participant is taking the active treatment or the placebo.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Study/Trial Coordinator</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Staff member who is often the primary contact for research participants and coordinates their care and evaluations throughout the study.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Trimesta (estriol)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Proposed tradename of Adeona&#8217;s investigational oral drug for the treatment of relapsing- remitting multiple sclerosis.</font></div>
</td>
</tr><tr>
<td valign="middle" width="20%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="78%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="20%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline; FONT-STYLE: italic">wellZin</font><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">TM</font> (oral zinc lozenge)</font></div>
</td>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="78%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tradename of Adeona&#8217;s oral zinc lozenge being developed to reduce the duration and severity of symptoms caused by the common cold.</font></div>
</td>
</tr></table>
</div>
</div>

<div align="left">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">47</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>v230931_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: vintage filings llc-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 4.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This warrant is in exchange for the warrant (CSW73) issued on April 11, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="logo.jpg">&#160; </font></td>
<td align="right" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adeona Pharmaceuticals, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3985 Research Park Drive, Suite 200</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ann Arbor, MI 48108</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADEONA PHARMACEUTICALS, INC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">WARRANT TO PURCHASE COMMON STOCK</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrant No.: CSW73-2</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number of Shares of Common Stock:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of Issuance:&#160;&#160;July 28, 2011 ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Issuance Date</font>")</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adeona Pharmaceuticals, Inc., a company organized under the laws of Nevada (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, __________________ the registered holder hereof or its permitted assigns (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Holder</font>"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant</font>"), at any time or times on or after January 28, 2012 (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial Exercisability Date</font>"), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), ________________) fully paid nonassessable shares of Common Stock, par value $0.001 per share, subject to adjustment as provided herein<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant Shares</font>").&#160;&#160;Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 16.&#160;&#160;This Warrant is issued in exchange for the Warrant to purchase Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">SPA Warrants</font>") issued to the Holder on April 11, 2011 pursuant to Section 1 of that certain Securities Purchase Agreement, dated as of April 6, 2011 (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Subscription Date</font>"), by and among the Company and the investors (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buyers</font>") referred to therein (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Securities Purchase Agreement</font>").&#160;&#160;Capitalized terms used herein and not otherwise defined shall have the definitions ascribed to such terms in the Securities Purchase Agreement.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">EXERCISE OF WARRANT.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Mechanics of Exercise</font>.&#160;&#160;Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder on any time or times on or after the Initial Exercisability Date, in whole or in part, by (i)&#160;delivery of a written notice, in the form attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exercise Notice</font>"), of the Holder's election to exercise this Warrant and (ii)&#160;(A) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Aggregate Exercise Price</font>") in cash or by wire transfer of immediately available funds or (B) by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).&#160;&#160;The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder.&#160;&#160;Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.&#160;&#160;On or before the first (1<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font>) Trading Day following the date on which the Company has received the Exercise Notice, the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and the Company's transfer agent (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Transfer Agent</font>").&#160;&#160;On or before the third (3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font>) Trading Day following the date on which the Company has received the Exercise Notice (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Share Delivery Date</font>") so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font>) Trading Day following the date on which the Company has received the Exercise Notice,&#160;&#160;the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">DTC</font>") Fast Automated Securities Transfer Program, upon the request of the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder's or its designee's balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise.&#160;&#160;The Company shall be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC, if any.&#160;&#160;Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder's DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.&#160;&#160;If this Warrant is submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three (3) Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.&#160;&#160;No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number.&#160;&#160;The Company shall pay any and all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>.&#160;&#160;For purposes of this Warrant, "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exercise Price</font>" means $1.00.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 2 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company's Failure to Timely Deliver Securities</font>.&#160;&#160;If the Company shall fail for any reason or for no reason to issue to the Holder within three (3) Trading Days of receipt of the Exercise Notice so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font>) Trading Day following the date on which the Company has received the Exercise Notice, a certificate for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s share register or to credit the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s exercise of this Warrant, then, in addition to all other remedies available to the Holder, the Company shall pay in cash to the Holder on each day after such fifth (5th) Trading Day that the issuance of such shares of Common Stock is not timely effected an amount equal to 1.0% of the product of (A) the number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is entitled and (B) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the last possible date which the Company could have issued such shares of Common Stock to the Holder without violating Section 1(a).&#160;&#160;In addition to the foregoing, if within five (5) Trading Days after the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s receipt of the facsimile copy of an Exercise Notice the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s share register or credit the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s exercise hereunder or pursuant to the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s obligation pursuant to clause (ii) below, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buy-In</font>"), then the Company shall, within three (3) Trading Days after the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s request and in the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s discretion, either (i) pay cash to the Holder in an amount equal to the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s total purchase price (including brokerage commissions and other reasonable out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buy-In Price</font>"), at which point the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s obligation to deliver such certificate (and to issue such shares of Common Stock) or credit such Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit such Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Bid Price on the date of exercise.&#160;&#160;Nothing herein shall limit the Holder's right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cashless Exercise</font>. <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Notwithstanding anything contained herein to the contrary, if the Registration Statement (as defined in the Securities Purchase Agreement) covering the issuance of the Warrant Shares that are subject to the Exercise Notice (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Unavailable Warrant Shares</font>") is not available for the issuance of such Unavailable Warrant Shares, the Holder may exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the "Net Number" of shares of Common Stock determined according to the following formula (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Cashless Exercise</font>"):<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 3 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="MARGIN-LEFT: 108pt" align="left">
<table cellpadding="0" cellspacing="0" width="27%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Number =</font></div>
</td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">(A x B) - (A x C)</font></font></div>
</td>
</tr><tr>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">D</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>For purposes of the foregoing formula:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the total number of shares with respect to which this Warrant is then being exercised.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the arithmetic average of the Weighted Average Prices of the Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">D=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Weighted Average Price of the Common Stock on the Exercise Date.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disputes</font>.&#160;&#160;In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Limitations on Exercises.</font>&#160;&#160;The Company shall not effect the exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that after giving effect to such exercise, such Person (together with such Person<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s affiliates) would beneficially own in excess of 4.99% (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Maximum Percentage</font>") of the shares of Common Stock outstanding immediately after giving effect to such exercise.&#160;&#160;For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein.&#160;&#160;Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">1934 Act</font>").&#160;&#160;For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160;&#160;For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160;&#160;In any case, the number of outstanding shares Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the SPA Warrants, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported.&#160;&#160;By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% specified in such notice; provided that (i) any such increase will not be effective until the sixty-first (61<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font>) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to the Holder and not to any other holder of SPA Warrants.&#160;&#160;The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 4 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Insufficient Authorized Shares</font>.&#160;&#160;If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least a number of shares of Common Stock equal to 100% of the number of shares of Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Required Reserve Amount</font>") as shall from time to time be necessary to effect the exercise of all of this Warrant then outstanding (an "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Authorized Share Failure</font>"), then the Company shall immediately take all action necessary to increase the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding.&#160;&#160;Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock.&#160;&#160;In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font> approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES</font>.&#160;&#160;The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Voluntary Adjustment By Company</font>.&#160;&#160;The Company may at any time during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 5 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustment upon Subdivision or Combination of shares of Common Stock</font>.&#160;&#160;If the Company at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased.&#160;&#160;If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased.&#160;&#160;Any adjustment under this Section 2(b) shall become effective at the close of business on the date the subdivision or combination becomes effective.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Events</font>.&#160;&#160;If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(c) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">RIGHTS UPON DISTRIBUTION OF ASSETS</font>.&#160;&#160;If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Distribution</font>"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchase Rights</font>.&#160;&#160;In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Purchase Rights</font>"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 6 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fundamental Transactions</font>.&#160;&#160;The Company shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section (4)(b) pursuant to written agreements in form and substance satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each holder of the SPA Warrants in exchange for such SPA Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and satisfactory to the Required Holders and (ii)&#160;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market.&#160;&#160;Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the "Company" shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.&#160;&#160;Upon consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of the publicly traded common stock or common shares (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been converted immediately prior to such Fundamental Transaction, as adjusted in accordance with the provisions of this Warrant.&#160;&#160;In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Corporate Event</font>"), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the Corporate Event but prior to the Expiration Date, in lieu of shares of Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Corporate Event, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Corporate Event had this Warrant been exercised immediately prior to such Corporate Event.&#160;&#160;Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Required Holders.&#160;&#160;The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 7 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the event of a Fundamental Transaction, at the request of the Holder delivered before the ninetieth (90<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>) day after the consummation of such Fundamental Transaction, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of such Fundamental Transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">NONCIRCUMVENTION</font>.&#160;&#160;The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.&#160;&#160;Without limiting the generality of the foregoing, the Company (i)&#160;shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii)&#160;shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the SPA Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the SPA Warrants, 100% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the SPA Warrants then outstanding (without regard to any limitations on exercise).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">WARRANT HOLDER NOT DEEMED A STOCKHOLDER</font>.&#160;&#160;Except as otherwise specifically provided herein, the Holder, solely in such Person's capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person's capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.&#160;&#160;In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.&#160;&#160;Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 8 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">REISSUANCE OF WARRANTS</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer of Warrant</font>.&#160;&#160;If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Lost, Stolen or Mutilated Warrant</font>.&#160;&#160;Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exchangeable for Multiple Warrants</font>.&#160;&#160;This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Issuance of New Warrants</font>.&#160;&#160;Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 9 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTICES</font>.&#160;&#160;Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities&#160;&#160;Purchase Agreement.&#160;&#160;The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor.&#160;&#160;Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">AMENDMENT AND WAIVER</font>.&#160;&#160;Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">GOVERNING LAW</font>.&#160;&#160;This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CONSTRUCTION; HEADINGS</font>.&#160;&#160;This Warrant shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be construed against any person as the drafter hereof.&#160;&#160;The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">DISPUTE RESOLUTION</font>.&#160;&#160;In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder.&#160;&#160;If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder&#160;&#160;or (b) the disputed arithmetic calculation of the Warrant Shares to the Company's independent, outside accountant.&#160;&#160;The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed determinations or calculations.&#160;&#160;Such investment bank's or accountant's determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 10 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</font>.&#160;&#160;The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.&#160;&#160;The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.&#160;&#160;The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">TRANSFER</font>.&#160;&#160;This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">SEVERABILITY</font>.&#160;&#160;If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.&#160;&#160;The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CERTAIN DEFINITIONS</font>.&#160;&#160;For purposes of this Warrant, the following terms shall have the following meanings:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Black Scholes Value</font>" means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day immediately following the public announcement of the applicable Fundamental Transaction for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately following the public announcement of the applicable Fundamental Transaction, (iii) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non -cash consideration, if any, being offered in the Fundamental Transaction and (iv) a 360 day annualization factor.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bloomberg</font>" means Bloomberg Financial Markets.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 11 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Business Day</font>" means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Closing Bid Price</font>" and "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Closing Sale Price</font>" means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the "pink sheets" by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.).&#160;&#160;If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.&#160;&#160;If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12.&#160;&#160;All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>" means (i)&#160;the Company's shares of Common Stock, par value $0.001 per share, and (ii)&#160;any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Convertible Securities</font>" means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Eligible Market</font>" means the Principal Market, The NASDAQ Global Market, The NASDAQ Global Select Market, The New York Stock Exchange, Inc., or The Nasdaq Capital Market.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Expiration Date</font>" means August 10, 2012</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 12 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Fundamental Transaction</font>" means that (A) the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, <!--EFPlaceholder-->transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or (iii) allow another Person to make a purchase, tender or exchange offer that is accepted by the holders of more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination), or (v) reorganize, recapitalize or reclassify its Common Stock or (B) any "person" or "group" (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act) is or shall become the "beneficial owner" (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Option Value</font>" means the value of an Option based on the Black and Scholes Option Pricing model obtained from the "OV" function on Bloomberg determined as of the day prior to the public announcement of the applicable Option for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of the applicable Option as of the applicable date of determination, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately following the public announcement of the applicable Option, (iii) the underlying price per share used in such calculation shall be the highest Weighted Average Price during the period beginning on the day prior to the execution of definitive documentation relating to the issuance of the applicable Option and the public announcement of such issuance and (iv) a 360 day annualization factor.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Options</font>" means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Parent Entity</font>" of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common shares or common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Person</font>" means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Principal Market</font>" means NYSE Amex Equities.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 13 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

&#160;&#160;&#160;

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Required Holders</font>" means the holders of the SPA Warrants representing at least a majority of the shares of Common Stock underlying the SPA Warrants then outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Successor Entity</font>" means the Person (or, if so elected by the Required Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Trading Day</font>" means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; provided that "Trading Day" shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Weighted Average Price</font>" means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg through its "Volume at Price" function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the "pink sheets" by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.).&#160;&#160;If the Weighted Average Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.&#160;&#160;If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12 with the term "Weighted Average Price" being substituted for the term "Exercise Price." All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[Signature Page Follows]</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 14 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="30%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;EXHIBIT A</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXERCISE NOTICE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WARRANT TO PURCHASE COMMON STOCK</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADEONA PHARMACEUTICALS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The undersigned holder hereby exercises the right to purchase _________________ of the Common Stock ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant Shares</font>") of Adeona Pharmaceuticals, Inc., a company incorporated under the laws of Nevada (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>"), evidenced by the attached Warrant to Purchase Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant</font>").&#160;&#160;Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.&#160;&#160;Form of Exercise Price.&#160;&#160;The Holder intends that payment of the Exercise Price shall be made as:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cash Exercise"</font> with respect to _________________ Warrant Shares; and / or</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;a <font style="DISPLAY: inline; TEXT-DECORATION: underline">"Cashless Exercise"</font> with respect to _______________ Warrant Shares.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.&#160;&#160;Payment of Exercise Price.&#160;&#160;In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.&#160;&#160;Delivery of Warrant Shares.&#160;&#160;The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: _______________ __, ______</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="65%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td colspan="2" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name of Registered Holder</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td colspan="2" valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="30%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="65%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="30%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ACKNOWLEDGMENT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The Company hereby acknowledges this Exercise Notice and hereby directs Corporate Stock Transfer Inc.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated April 6, 2011 from the Company and acknowledged and agreed to Corporate Stock Transfer Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>v230931_ex4-2.htm
<DESCRIPTION>EXHIBIT 4.2
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: vintage filings llc-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 4.2</font></div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This warrant is in exchange for the warrant (CSW__) issued on February 2, 2011</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><img src="logo.jpg">&#160; </font></td>
<td align="right" valign="bottom" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Adeona Pharmaceuticals, Inc.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">3985 Research Park Drive, Suite 200</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Ann Arbor, MI 48108</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADEONA PHARMACEUTICALS, INC.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; FONT-VARIANT: small-caps">WARRANT TO PURCHASE COMMON STOCK</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Warrant No.:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Number of Shares of Common Stock:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of Exchange: August __, 2011 (&#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exchange Date</font>&#8221;)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date of Issuance:&#160;&#160;February 2, 2011 ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Issuance Date</font>")</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Adeona Pharmaceuticals, Inc., a company organized under the laws of Nevada (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ____________ the registered holder hereof or its permitted assigns (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Holder</font>"), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant</font>"), at any time or times on or after the Issuance Date (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Initial Exercisability Date</font>"), but not after 11:59 p.m., New York time, on the Expiration Date, (as defined below), __________________fully paid nonassessable shares of Common Stock, par value $0.001 per share, subject to adjustment as provided herein<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>(the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant Shares</font>").&#160;&#160;Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 16.&#160;&#160;This Warrant is one of the Warrants to purchase Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exchange Warrants</font>") issued pursuant to Section 1 of those certain Exchange Agreements, dated as of August __, 2011, each by and between the holder of Existing Warrants (as defined below) and the Company, on the Exchange Date in exchange for the Warrants to purchase Common Stock (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Existing Warrants</font>&#8221;) issued pursuant to that certain Securities Purchase Agreement, dated as of January 28, 2011 (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Subscription Date</font>"), by and among the Company and the investors (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buyers</font>") referred to therein (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Securities Purchase Agreement</font>").&#160;&#160;Capitalized terms used herein and not otherwise defined shall have the definitions ascribed to such terms in the Securities Purchase Agreement.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">EXERCISE OF WARRANT.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Mechanics of Exercise</font>.&#160;&#160;Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1(f)), this Warrant may be exercised by the Holder on any time or times on or after the Initial Exercisability Date, in whole or in part, by (i)&#160;delivery of a written notice, in the form attached hereto as <font style="DISPLAY: inline; TEXT-DECORATION: underline">Exhibit A</font> (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exercise Notice</font>"), of the Holder's election to exercise this Warrant and (ii)&#160;(A) payment to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Aggregate Exercise Price</font>") in cash or by wire transfer of immediately available funds or (B) by notifying the Company that this Warrant is being exercised pursuant to a Cashless Exercise (as defined in Section 1(d)).&#160;&#160;The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder.&#160;&#160;Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase the remaining number of Warrant Shares.&#160;&#160;On or before the first (1<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font>) Trading Day following the date on which the Company has received the Exercise Notice, the Company shall transmit by facsimile an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and the Company's transfer agent (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Transfer Agent</font>").&#160;&#160;On or before the third (3<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">rd</font>) Trading Day following the date on which the Company has received the Exercise Notice (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Share Delivery Date</font>") so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font>) Trading Day following the date on which the Company has received the Exercise Notice,&#160;&#160;the Company shall (X) provided that the Transfer Agent is participating in The Depository Trust Company ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">DTC</font>") Fast Automated Securities Transfer Program, upon the request of the Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder's or its designee's balance account with DTC through its Deposit / Withdrawal At Custodian system, or (Y) if the Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company's share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise.&#160;&#160;The Company shall be responsible for all fees and expenses of the Transfer Agent and all fees and expenses with respect to the issuance of Warrant Shares via DTC, if any.&#160;&#160;Upon delivery of the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder's DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be.&#160;&#160;If this Warrant is submitted in connection with any exercise pursuant to this Section 1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no event later than three (3) Trading Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 7(d)) representing the right to purchase the number of Warrant Shares issuable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.&#160;&#160;No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock to be issued shall be rounded up to the nearest whole number.&#160;&#160;The Company shall pay any and all taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exercise Price</font>.&#160;&#160;For purposes of this Warrant, "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Exercise Price</font>" means $1.40, subject to adjustment as provided herein.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 2 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Company's Failure to Timely Deliver Securities</font>.&#160;&#160;If the Company shall fail for any reason or for no reason to issue to the Holder within three (3) Trading Days of receipt of the Exercise Notice so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">nd</font>) Trading Day following the date on which the Company has received the Exercise Notice, a certificate for the number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s share register or to credit the Holder's balance account with DTC for such number of shares of Common Stock to which the Holder is entitled upon the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s exercise of this Warrant, then, in addition to all other remedies available to the Holder, the Company shall pay in cash to the Holder on each day after such fifth (5th) Trading Day that the issuance of such shares of Common Stock is not timely effected an amount equal to 1.0% of the product of (A) the number of shares of Common Stock not issued to the Holder on a timely basis and to which the Holder is entitled and (B) the Closing Sale Price of the Common Stock on the Trading Day immediately preceding the last possible date which the Company could have issued such shares of Common Stock to the Holder without violating Section 1(a).&#160;&#160;In addition to the foregoing, if within five (5) Trading Days after the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s receipt of the facsimile copy of an Exercise Notice the Company shall fail to issue and deliver a certificate to the Holder and register such shares of Common Stock on the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s share register or credit the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC for the number of shares of Common Stock to which the Holder is entitled upon the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s exercise hereunder or pursuant to the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s obligation pursuant to clause (ii) below, and if on or after such Trading Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buy-In</font>"), then the Company shall, within three (3) Trading Days after the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s request and in the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s discretion, either (i) pay cash to the Holder in an amount equal to the Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s total purchase price (including brokerage commissions and other reasonable out-of-pocket expenses, if any) for the shares of Common Stock so purchased (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Buy-In Price</font>"), at which point the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s obligation to deliver such certificate (and to issue such shares of Common Stock) or credit such Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate or certificates representing such shares of Common Stock or credit such Holder<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s balance account with DTC and pay cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the Closing Bid Price on the date of exercise.&#160;&#160;Nothing herein shall limit the Holder's right to pursue any other remedies available to it hereunder, at law or in equity, including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company's failure to timely deliver certificates representing shares of Common Stock (or to electronically deliver such shares of Common Stock) upon the exercise of this Warrant as required pursuant to the terms hereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cashless Exercise</font>. <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Notwithstanding anything contained herein to the contrary, if the Registration Statement (as defined in the Securities Purchase Agreement) covering the issuance of the Warrant Shares that are subject to the Exercise Notice (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Unavailable Warrant Shares</font>") is not available for the issuance of such Unavailable Warrant Shares, the Holder may exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the "Net Number" of shares of Common Stock determined according to the following formula (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Cashless Exercise</font>"):<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 3 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="MARGIN-LEFT: 108pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table cellpadding="0" cellspacing="0" width="27%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="12%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Net Number =</font></div>
</td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman; TEXT-DECORATION: underline"><font style="DISPLAY: inline">(A x B) - (A x C)</font></font></div>
</td>
</tr><tr>
<td valign="top" width="12%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="15%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">D</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>For purposes of the foregoing formula:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the total number of shares with respect to which this Warrant is then being exercised.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the arithmetic average of the Weighted Average Prices of the Common Stock for the five (5) consecutive Trading Days ending on the date immediately preceding the date of the Exercise Notice.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left">
<table border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 81pt">&#160;</td>
<td align="right" style="WIDTH: 18pt">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">D=</font></div>
</td>
<td align="left">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the Weighted Average Price of the Common Stock on the Exercise Date.</font></div>
</td>
</tr></table>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disputes</font>.&#160;&#160;In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance with Section 12.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Limitations on Exercises.</font>&#160;&#160;The Company shall not effect the exercise of this Warrant, and the Holder shall not have the right to exercise this Warrant, to the extent that after giving effect to such exercise, such Person (together with such Person<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s affiliates) would beneficially own in excess of 4.99% (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Maximum Percentage</font>") of the shares of Common Stock outstanding immediately after giving effect to such exercise.&#160;&#160;For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein.&#160;&#160;Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">1934 Act</font>").&#160;&#160;For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1) the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160;&#160;For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1) Business Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160;&#160;In any case, the number of outstanding shares Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including the Exchange Warrants, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported.&#160;&#160;By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% specified in such notice; provided that (i) any such increase will not be effective until the sixty-first (61<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font>) day after such notice is delivered to the Company, and (ii) any such increase or decrease will apply only to the Holder and not to any other holder of Exchange Warrants.&#160;&#160;The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(f) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 4 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Insufficient Authorized Shares</font>.&#160;&#160;If at any time while this Warrant remains outstanding the Company does not have a sufficient number of authorized and unreserved shares of Common Stock to satisfy its obligation to reserve for issuance upon exercise of this Warrant at least a number of shares of Common Stock equal to 100% of the number of shares of Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Required Reserve Amount</font>") as shall from time to time be necessary to effect the exercise of all of this Warrant then outstanding (an "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Authorized Share Failure</font>"), then the Company shall immediately take all action necessary to increase the Company<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font>s authorized shares of Common Stock to an amount sufficient to allow the Company to reserve the Required Reserve Amount for this Warrant then outstanding.&#160;&#160;Without limiting the generality of the foregoing sentence, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than sixty (60) days after the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock.&#160;&#160;In connection with such meeting, the Company shall provide each stockholder with a proxy statement and shall use its best efforts to solicit its stockholders<font style="DISPLAY: inline; TEXT-DECORATION: underline">'</font> approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that they approve such proposal.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES</font>.&#160;&#160;The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Adjustment upon Subdivision or Combination of shares of Common Stock</font>.&#160;&#160;If the Company at any time on or after the Subscription Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased.&#160;&#160;If the Company at any time on or after the Subscription Date combines (by combination, reverse stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased.&#160;&#160;Any adjustment under this Section 2(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 5 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Other Events</font>.&#160;&#160;If any event occurs of the type contemplated by the provisions of this Section 2 but not expressly provided for by such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features), then the Company's Board of Directors will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; provided that no such adjustment pursuant to this Section 2(b) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise determined pursuant to this Section 2.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">RIGHTS UPON DISTRIBUTION OF ASSETS</font>.&#160;&#160;If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Distribution</font>"), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">PURCHASE RIGHTS; FUNDAMENTAL TRANSACTIONS</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Purchase Rights</font>.&#160;&#160;In addition to any adjustments pursuant to Section 2 above, if at any time the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Purchase Rights</font>"), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 6 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Fundamental Transactions</font>.&#160;&#160;The Company shall not enter into or be party to a Fundamental Transaction unless (i) the Successor Entity assumes in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section (4)(b) pursuant to written agreements in form and substance satisfactory to the Required Holders and approved by the Required Holders prior to such Fundamental Transaction, including agreements to deliver to each holder of the Exchange Warrants in exchange for such Exchange Warrants a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant, including, without limitation, an adjusted exercise price equal to the value for the shares of Common Stock reflected by the terms of such Fundamental Transaction, and exercisable for a corresponding number of shares of capital stock equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and satisfactory to the Required Holders and (ii)&#160;the Successor Entity (including its Parent Entity) is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market.&#160;&#160;Upon the occurrence of any Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the "Company" shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.&#160;&#160;Upon consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the shares of Common Stock (or other securities, cash, assets or other property) issuable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of the publicly traded common stock or common shares (or its equivalent) of the Successor Entity (including its Parent Entity) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been converted immediately prior to such Fundamental Transaction, as adjusted in accordance with the provisions of this Warrant.&#160;&#160;In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Corporate Event</font>"), the Company shall make appropriate provision to insure that the Holder will thereafter have the right to receive upon an exercise of this Warrant at any time after the consummation of the Corporate Event but prior to the Expiration Date, in lieu of shares of Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of this Warrant prior to such Corporate Event, such shares of stock, securities, cash, assets or any other property whatsoever (including warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Corporate Event had this Warrant been exercised immediately prior to such Corporate Event.&#160;&#160;Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Required Holders.&#160;&#160;The provisions of this Section shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the event of a Fundamental Transaction, at the request of the Holder delivered before the ninetieth (90<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font>) day after the consummation of such Fundamental Transaction, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five (5) Business Days after such request (or, if later, on the effective date of the Fundamental Transaction), cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of such Fundamental Transaction.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 7 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">NONCIRCUMVENTION</font>.&#160;&#160;The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation or Bylaws, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder.&#160;&#160;Without limiting the generality of the foregoing, the Company (i)&#160;shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii)&#160;shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as any of the Exchange Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Exchange Warrants, 100% of the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the Exchange Warrants then outstanding (without regard to any limitations on exercise).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">WARRANT HOLDER NOT DEEMED A STOCKHOLDER</font>.&#160;&#160;Except as otherwise specifically provided herein, the Holder, solely in such Person's capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person's capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant.&#160;&#160;In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.&#160;&#160;Notwithstanding this Section 6, the Company shall provide the Holder with copies of the same notices and other information given to the stockholders of the Company generally, contemporaneously with the giving thereof to the stockholders.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">REISSUANCE OF WARRANTS</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer of Warrant</font>.&#160;&#160;If this Warrant is to be transferred, the Holder shall surrender this Warrant to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 7(d)), registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with Section 7(d)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 8 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Lost, Stolen or Mutilated Warrant</font>.&#160;&#160;Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary form and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to the Holder a new Warrant (in accordance with Section 7(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exchangeable for Multiple Warrants</font>.&#160;&#160;This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office of the Company, for a new Warrant or Warrants (in accordance with Section 7(d)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; provided, however, that no Warrants for fractional shares of Common Stock shall be given.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Issuance of New Warrants</font>.&#160;&#160;Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a) or Section 7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">NOTICES</font>.&#160;&#160;Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with Section 9(f) of the Securities&#160;&#160;Purchase Agreement.&#160;&#160;The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the reason therefor.&#160;&#160;Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii) at least fifteen (15) days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property to holders of shares of Common Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">AMENDMENT AND WAIVER</font>.&#160;&#160;Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 9 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">GOVERNING LAW</font>.&#160;&#160;This Warrant shall be governed by and construed and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CONSTRUCTION; HEADINGS</font>.&#160;&#160;This Warrant shall be deemed to be jointly drafted by the Company and all the Buyers and shall not be construed against any person as the drafter hereof.&#160;&#160;The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">DISPUTE RESOLUTION</font>.&#160;&#160;In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) Business Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder.&#160;&#160;If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3) Business Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company shall, within two (2) Business Days submit via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder&#160;&#160;or (b) the disputed arithmetic calculation of the Warrant Shares to the Company's independent, outside accountant.&#160;&#160;The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten Business Days from the time it receives the disputed determinations or calculations.&#160;&#160;Such investment bank's or accountant's determination or calculation, as the case may be, shall be binding upon all parties absent demonstrable error.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</font>.&#160;&#160;The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the other Transaction Documents, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.&#160;&#160;The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach may be inadequate.&#160;&#160;The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">TRANSFER</font>.&#160;&#160;This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 10 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">SEVERABILITY</font>.&#160;&#160;If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties.&#160;&#160;The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">CERTAIN DEFINITIONS</font>.&#160;&#160;For purposes of this Warrant, the following terms shall have the following meanings:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Black Scholes Value</font>" means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the "OV" function on Bloomberg determined as of the day immediately following the public announcement of the applicable Fundamental Transaction for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately following the public announcement of the applicable Fundamental Transaction, (iii) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non -cash consideration, if any, being offered in the Fundamental Transaction and (iv) a 360 day annualization factor.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Bloomberg</font>" means Bloomberg Financial Markets.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Business Day</font>" means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Closing Bid Price</font>" and "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Closing Sale Price</font>" means, for any security as of any date, the last closing bid price and last closing trade price, respectively, for such security on the Principal Market, as reported by Bloomberg, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing bid price or the closing trade price, as the case may be, then the last bid price or the last trade price, respectively, of such security prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if the Principal Market is not the principal securities exchange or trading market for such security, the last closing bid price or last trade price, respectively, of such security on the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of such security in the over-the-counter market on the electronic bulletin board for such security as reported by Bloomberg, or, if no closing bid price or last trade price, respectively, is reported for such security by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market makers for such security as reported in the "pink sheets" by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.).&#160;&#160;If the Closing Bid Price or the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Closing Bid Price or the Closing Sale Price, as the case may be, of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.&#160;&#160;If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12.&#160;&#160;All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 11 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>" means (i)&#160;the Company's shares of Common Stock, par value $0.001 per share, and (ii)&#160;any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Convertible Securities</font>" means any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Eligible Market</font>" means the Principal Market, The NASDAQ Global Market, The NASDAQ Global Select Market, The New York Stock Exchange, Inc., or The Nasdaq Capital Market.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Expiration Date</font>" means the date fifteen months after the Initial Exercisability Date or, if such date falls on a day other than a Business Day or on which trading does not take place on the Principal Market (a "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Holiday</font>"), the next day that is not a Holiday.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Fundamental Transaction</font>" means that (A) the Company shall, directly or indirectly, in one or more related transactions, (i) consolidate or merge with or into (whether or not the Company is the surviving corporation) another Person, or (ii) sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to another Person, or (iii) allow another Person to make a purchase, tender or exchange offer that is accepted by the holders of more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), or (iv) consummate a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination), or (v) reorganize, recapitalize or reclassify its Common Stock or (B) any "person" or "group" (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act) is or shall become the "beneficial owner" (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding shares of Common Stock.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 12 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->(j)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Option Value</font>" means the value of an Option based on the Black and Scholes Option Pricing model obtained from the "OV" function on Bloomberg determined as of the day prior to the public announcement of the applicable Option for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of the applicable Option as of the applicable date of determination, (ii) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the day immediately following the public announcement of the applicable Option, (iii) the underlying price per share used in such calculation shall be the highest Weighted Average Price during the period beginning on the day prior to the execution of definitive documentation relating to the issuance of the applicable Option and the public announcement of such issuance and (iv) a 360 day annualization factor.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(k)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Options</font>" means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(l)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Parent Entity</font>" of a Person means an entity that, directly or indirectly, controls the applicable Person and whose common shares or common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of consummation of the Fundamental Transaction.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(m)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Person</font>" means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(n)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Principal Market</font>" means NYSE Amex Equities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(o)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Required Holders</font>" means the holders of the Exchange Warrants representing at least a majority of the shares of Common Stock underlying the Exchange Warrants then outstanding.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(p)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Successor Entity</font>" means the Person (or, if so elected by the Required Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(q)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Trading Day</font>" means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; provided that "Trading Day" shall not include any day on which the Common Stock is scheduled to trade on such exchange or market for less than 4.5 hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York time).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 13 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 108pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->(r)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;"<font style="DISPLAY: inline; FONT-WEIGHT: bold">Weighted Average Price</font>" means, for any security as of any date, the dollar volume-weighted average price for such security on the Principal Market during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg through its "Volume at Price" function or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the over-the-counter market on the electronic bulletin board for such security during the period beginning at 9:30:01 a.m., New York time (or such other time as the Principal Market publicly announces is the official open of trading), and ending at 4:00:00 p.m., New York time (or such other time as the Principal Market publicly announces is the official close of trading), as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the "pink sheets" by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.).&#160;&#160;If the Weighted Average Price cannot be calculated for a security on a particular date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder.&#160;&#160;If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section 12 with the term "Weighted Average Price" being substituted for the term "Exercise Price." All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[Signature Page Follows]</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">- 14 -</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set out above.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="30%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="top" width="30%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;EXHIBIT A</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXERCISE NOTICE</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">TO BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WARRANT TO PURCHASE COMMON STOCK</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ADEONA PHARMACEUTICALS, INC.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The undersigned holder hereby exercises the right to purchase _________________ of the Common Stock ("<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant Shares</font>") of Adeona Pharmaceuticals, Inc., a company incorporated under the laws of Nevada (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>"), evidenced by the attached Warrant to Purchase Common Stock (the "<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant</font>").&#160;&#160;Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>1.&#160;&#160;Form of Exercise Price.&#160;&#160;The Holder intends that payment of the Exercise Price shall be made as:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 108pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a "<font style="DISPLAY: inline; TEXT-DECORATION: underline">Cash Exercise"</font> with respect to _________________ Warrant Shares; and / or</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 72pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 108pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">____________</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a <font style="DISPLAY: inline; TEXT-DECORATION: underline">"Cashless Exercise"</font> with respect to _______________ Warrant Shares.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>2.&#160;&#160;Payment of Exercise Price.&#160;&#160;In the event that the holder has elected a Cash Exercise with respect to some or all of the Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________ to the Company in accordance with the terms of the Warrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>3.&#160;&#160;Delivery of Warrant Shares.&#160;&#160;The Company shall deliver to the holder __________ Warrant Shares in accordance with the terms of the Warrant.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: _______________ __, ______</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td colspan="2" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="65%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td colspan="2" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name of Registered Holder</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td colspan="2" valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="65%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="31%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="top" width="65%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">ACKNOWLEDGMENT</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The Company hereby acknowledges this Exercise Notice and hereby directs Corporate Stock Transfer Inc.<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated August [__], 2011 from the Company and acknowledged and agreed to Corporate Stock Transfer Inc.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="25%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
<td valign="top" width="25%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>v230931_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: vintage filings llc-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.1</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; TEXT-DECORATION: underline">EXCHANGE AGREEMENT</font></font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">THIS EXCHANGE AGREEMENT </font>(this &#8220;Agreement&#8221;), dated as of July __, 2011, is entered into by and between Adeona Pharmaceuticals, Inc., a Nevada corporation (the &#8220;Company&#8221;) and ___________ (&#8220;_______&#8221;).</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WITNESSETH:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-WEIGHT: bold">WHEREAS,</font> in connection with a financing that was consummated on April 11, 2011, the Company issued to _______________ a warrant exercisable for ___ shares of the Company&#8217;s common stock at an exercise price of $2.0725 (the &#8220;Original Warrant&#8221;); and</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">WHEREAS</font>, the Company and _______________ desire to exchange the Original Warrant for a new warrant (the &#8220;Replacement Warrant&#8221;), in the form annexed hereto.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font><font style="DISPLAY: inline; FONT-WEIGHT: bold">NOW, THEREFORE,</font> in consideration for the foregoing, the parties hereto agree as follows:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The Company and _______________ hereby agree to exchange the Original Warrant for the Replacement Warrant.&#160;&#160;Upon approval from the NYSE/AMEX of the proposed exchange, the Company shall deliver to _______________ the Replacement Warrant and _______________ shall deliver to the Company the Original Warrant for cancellation.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________ represents and warrants to, and covenant and agree with, the Company as follows:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________ is exchanging the Original Warrant for the Replacement Warrant for its own account, for investment only and not with a view towards the public sale or distribution thereof, and not with a view to or for sale in connection with any distribution thereof.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________ is the sole owner of all rights, title and interest in and to the Original Warrant and _______________ has not assigned, transferred, licensed, pledged or otherwise</font></div>
</td>
</tr></table>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 54pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">encumbered the Original Warrant or agreed to do so.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_______________ is not a U.S. Person as that term is defined in Regulation&#160;S promulgated under the Securities Act. _______________&#8217;s principal address is outside the United States and _______________ has no present intention of becoming a resident of (or moving its principal place of business to) the United States. At the time of purchase of the Warrants, including without limitation at the time _______________ executed and delivered this Agreement and otherwise agreed to purchase the Warrants, it was located outside the United States. The Warrants are being acquired solely for _______________&#8217;s own account and not for the account or the benefit of a U.S. person.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York.&#160;&#160;A facsimile transmission of this signed Agreement shall be legal and binding on all parties hereto.&#160;&#160;This Agreement may be signed in one or more counterparts, each of which shall be deemed an original.&#160;&#160;The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.&#160;&#160;If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability of this Agreement in any other jurisdiction.&#160;&#160;This Agreement may be amended only by an instrument in writing signed by the party to be charged with enforcement.&#160;&#160;This Agreement contains the entire agreement of the parties with respect to the subject matter hereto, superseding all prior agreements, understandings or discussions.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 18pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This Agreement is subject to the Company&#8217;s receipt of the approval of the NYSE/AMEX to the transactions contemplated hereby, including the exchange and issuance of the Replacement Warrants.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> the Company and _______________ have caused this Agreement to be executed by their duly authorized representatives on the date as first written above.</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:&#160;&#160;James Kuo</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: Chief Executive Officer</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="47%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
<td colspan="2" valign="top" width="3%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="3%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="47%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>v230931_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: vintage filings llc-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div><br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Exhibit 10.2</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WARRANT EXCHANGE AGREEMENT</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">THIS WARRANT EXCHANGE AGREEMENT</font> (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Agreement</font>&#8221;) is dated as of August __, 2011, by and between Adeona Pharmaceuticals, Inc. (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Company</font>&#8221;), and <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">_____________ </font>(the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Investor</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 72pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">WHEREAS:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company, the Investor and certain other investors (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Other Investors</font>&#8221; and together with the Investor, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Investors</font>&#8221;) are parties to that certain Securities Purchase Agreement, dated as of February 2, 2011 (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Existing Securities Purchase Agreement</font>&#8221;), pursuant to which, among other things, the Investor purchased from the Company a Warrant (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Existing Warrant</font>&#8221;), which is currently exercisable into ____shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Common Stock</font>&#8221;).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and the Investor desire to enter into this Agreement, pursuant to which, among other things, the Company and the Investor shall exchange the Existing Warrant currently held by the Investor for a warrant in the form attached hereto as <font style="DISPLAY: inline; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Exhibit A</font> (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant</font>&#8221;) initially exercisable into ______<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font>shares of Common Stock (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrant Shares</font>&#8221;), which Warrant shall be identical to the Existing Warrant except that the exercise date shall be extended for an additional two months.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;As a closing condition to the transactions contemplated hereby, each of the Other Investors are executing agreements identical to this Agreement (other than proportional changes in the numbers reflecting (x) such warrants (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Other Warrants</font>&#8221;, and together with the Warrant, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Warrants</font>&#8221;) exercisable into such different number of shares of Common Stock (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Other Warrant Shares</font>&#8221;) to be issued to each such Other Investor in exchange for the Existing Warrant of such Other Investor concurrently with the Closing (as defined below)</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The exchange of the Existing Warrant for the Warrant at the Closing is being made in reliance upon the exemption from registration provided by Section&#160;3(a)(9) of the Securities Act of 1933, as amended (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">1933 Act</font>&#8221;); and</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Warrant, the Other Warrants, the Warrant Shares and the Other Warrant Shares are collectively referred to herein as the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Securities</font>&#8221;.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">F.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Capitalized terms used but not otherwise defined herein shall have the meanings as set forth in the Existing Securities Purchase Agreement as amended hereby.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants hereinafter contained, the parties hereto agree as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXCHANGES.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Exchange</font>.&#160;&#160;Subject to the satisfaction or waiver of the conditions with respect to the Closing set forth in Sections 5 and 6 below, at the Closing the Investor and the Company shall, pursuant to Section 3(a)(9) of the 1933 Act, exchange the Existing Warrant for the Warrant, as follows (the <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#8220;Exchange</font>&#8221;):<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Closing</font>. The issuance of the Warrant (the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">Closing</font>&#8221;) shall occur at the offices of Greenberg Traurig, LLP, MetLife Building, 200 Park Avenue, New York, NY 10166.&#160;&#160;The date and time of the Closing shall be 10:00 a.m., New York time, on the first (1<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">st</font>) Business Day on which the conditions to the Closing set forth in Sections 5 and 6 below are satisfied or waived (or such later date as is mutually agreed to by the Company and each Investor).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Consideration</font>.&#160;&#160;At the Closing, the Warrant shall be issued to the Investor in exchange for the Existing Warrant without the payment of any additional consideration.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Delivery</font>.&#160;&#160;In exchange for the Existing Warrant, the Company shall, at the Closing, deliver or cause to be delivered to the Investor certificates for the Warrant.&#160;&#160;The Investor shall deliver or cause to be delivered to the Company (or its designee) the original Existing Warrant, as soon as commercially practicable following the Closing.&#160;&#160;As of the Closing Date,&#160;&#160;the Existing Warrant shall be null and void and any and all rights arising thereunder shall be extinguished.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">COMPANY REPRESENTATIONS AND WARRANTIES.</font></font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Authorization and Binding Obligation</font>.&#160;&#160;The Company has the requisite power and authority to enter into and perform its obligations under this Agreement and to issue the Warrant in accordance with the terms hereof and thereof.&#160;&#160;The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Warrant and the reservation for issuance and issuance of Warrant Shares issuable upon exercise of the Warrant, in each case, have been duly authorized by the Company's Board of Directors and no further filing, consent, or authorization is required by the Company, its Board of Directors or its stockholders.&#160;&#160;This Agreement has been duly executed and delivered by the Company, and constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors' rights and remedies and except as rights to indemnification and to contribution may be limited by federal or state securities laws.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Conflict</font>.&#160;&#160;The execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Warrant and reservation for issuance and issuance of the Warrant Shares) will not (i) result in a violation of the Certificate of Incorporation (as defined below) or other organizational documents of the Company or any of its subsidiaries, any capital stock of the Company or any of its subsidiaries or Bylaws (as defined below) of the Company or any of its subsidiaries, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any of its subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including foreign, federal and state securities laws and regulations and the rules and regulations of the NYSE Amex applicable to the Company or any of its subsidiaries or by which any property or asset of the Company or any of its subsidiaries is bound or affected except, in the case of clause (ii) or (iii) above, to the extent such violations that could not reasonably be expected to have a material adviser effect on the Company or its subsidiaries.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Securities Law Exemptions</font>.&#160;&#160;Assuming the accuracy of the representations and warranties of the Investor contained herein, the offer and issuance by the Company of the Securities is exempt from registration under the Securities Act.&#160;&#160;The offer and issuance of the Securities is exempt from registration under the Securities Act pursuant to the exemption provided by Section 3(a)(9) thereof.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Issuance of Securities</font>.&#160;&#160;The issuance of the Warrants are duly authorized and upon issuance in accordance with the terms of the Exchange Documents shall be validly issued, fully paid and non-assessable and free from all taxes, liens, charges and other encumbrances with respect to the issue thereof.&#160;&#160;Upon issuance or upon exercise of the Warrants, the Warrant Shares, in each case, when issued, will be validly issued, fully paid and nonassessable and free from all preemptive or similar rights, taxes, liens, charges and other encumbrances with respect to the issue thereof, with the holders being entitled to all rights accorded to a holder of Common Stock.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer Taxes</font>.&#160;&#160;On the Closing Date, all share transfer or other taxes (other than income or similar taxes) which are required to be paid in connection with the issuance of the Warrants to be exchanged with the Investor hereunder will be, or will have been, fully paid or provided for by the Company, and all laws imposing such taxes will be or will have been complied with.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disclosure</font>.&#160;&#160;The Company confirms that neither it nor any other Person acting on its behalf has provided any of the Buyers or their agents or counsel with any information that constitutes or could reasonably be expected to constitute material, non-public information concerning the Company or any of its subsidiaries, other than the existence of the transactions contemplated by this Agreement and the other Agreements. The Company understands and confirms that each of the Buyers will rely on the foregoing representations in effecting transactions in securities of the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Investor's Representations and Warranties</font>.&#160;&#160;As a material inducement to the Company to enter into this Agreement and consummate the Exchange, Investor represents, warrants and covenants with and to the Company as follows:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Ownership of Existing Warrant</font>.&#160;&#160;The Investor owns the Existing Warrant free and clear of any liens (other than the obligations pursuant to this Agreement and applicable securities laws).</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->3.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reliance on Exemptions</font>.&#160;&#160;The Investor understands that the Securities are being offered and exchanged in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of, and the Investor&#8217;s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Investor set forth herein and in the Exchange Documents in order to determine the availability of such exemptions and the eligibility of the Investor to acquire the Securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Governmental Review</font>.&#160;&#160;The Investor understands that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Validity; Enforcement</font>.&#160;&#160;This Agreement and the Exchange Documents to which the Investor is a party have been duly and validly authorized, executed and delivered on behalf of the Investor and shall constitute the legal, valid and binding obligations of the Investor enforceable against the Investor in accordance with their respective terms, except as such enforceability may be limited by general principles of equity or to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar laws relating to, or affecting generally, the enforcement of applicable creditors&#8217; rights and remedies.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">No Conflicts</font>.&#160;&#160;The execution, delivery and performance by the Investor of this Agreement and the Exchange Documents to which the Investor is a party, and the consummation by the Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Investor to perform its obligations hereunder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table align="center" border="0" cellpadding="0" cellspacing="0" id="hangingindent" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr valign="top">
<td style="WIDTH: 36pt">
<div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</td>
<td style="WIDTH: 36pt">
<div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td>
<div align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">COVENANTS.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reasonable Best Efforts</font>.&#160;&#160;The Company shall use its reasonable best efforts to timely satisfy each of the conditions to be satisfied by it as provided in Section 5 of this Agreement.&#160;&#160;The Investor shall use its reasonable best efforts to timely satisfy each of the conditions to be satisfied by it as provided in Section 6 of this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Disclosure of Transactions and Other Material Information</font>. On or before 9:30&#160;a.m., New York time, on the fourth Business Day following the date of this Agreement, the Company shall file a Quarterly Report on Form 10-Q describing all the material terms of the transactions contemplated by the Agreement in the form required by the Securities Exchange Act of 1934, as amended, and attaching this Agreement and the form of the Warrant thereto as exhibits (including all attachments, the &#8220;<font style="DISPLAY: inline; FONT-WEIGHT: bold">10-Q Filing</font>&#8221;).&#160;&#160;From and after the issuance of the 10-Q Filing, the Company shall have disclosed all material, non-public information (if any) delivered to any of the Investors by the Company or any of its subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated by this Agreement.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Holding Period</font>.&#160;&#160;For the purposes of Rule 144, the Company acknowledges that the holding period of the Warrants and the Warrant Shares (if acquired using a cashless exercise) may be tacked onto the holding period of the Existing Warrants, and the Company agrees not to take a position contrary to this Section 4.3.&#160;&#160;The Company agrees to take all actions, including, without limitation, the issuance by its legal counsel of any necessary legal opinions, necessary to issue the Warrant Shares (if acquired using a cashless exercise) without restriction, without any restrictive legend and without the need for any additional action by the Holder.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Listing</font>.&#160;&#160;&#160;The Company shall use reasonable best efforts to maintain the authorization for quotation of the Common Stock on the Principal Market or if such authorization is not able to be maintained, on another Eligible Market (as defined in the Warrants).&#160;&#160;The Company shall not take any action which would be reasonably expected to result in the delisting or suspension of the Common Stock on the Principal Market.&#160;&#160;The Company shall pay all fees and expenses in connection with satisfying its obligations under this Section 4(e).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Pledge of Securities</font> .&#160;&#160;The Company acknowledges and agrees that the Securities may be pledged by any holder of Securities (an " <font style="DISPLAY: inline; FONT-WEIGHT: bold">Investor</font> ") in connection with a bona fide margin agreement or other loan or financing arrangement that is secured by the Securities.&#160;&#160;The pledge of Securities shall not be deemed to be a transfer, sale or assignment of the Securities hereunder, and no Investor effecting a pledge of Securities shall be required to provide the Company with any notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction Document.&#160;&#160;The Company hereby agrees, subject to applicable securities laws, to execute and deliver such documentation as a pledgee of the Securities may reasonably request in connection with a pledge of the Securities to such pledgee by an Investor.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Variable Securities</font>.&#160;&#160;So long as any Buyer beneficially owns any Warrants, the Company shall not issue any other securities that would cause a breach or default under the Warrants.&#160;&#160;For so long as any Securities remain outstanding, the Company shall not, in any manner, issue or sell any rights, warrants or options to subscribe for or purchase Common Stock or directly or indirectly convertible into or exchangeable or exercisable for Common Stock at a price which varies or may vary with the market price of the Common Stock, including by way of one or more reset(s) to any fixed price, unless the conversion, exchange or exercise price of any such security cannot be less than the highest then applicable Exercise Price (as defined in the Warrants) with respect to the Common Stock into which any Warrant is exercisable.&#160;&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Corporate Existence</font> .&#160;&#160;For so long as any Buyer beneficially owns any Warrants, the Company shall not be party to any Fundamental Transaction (as defined in the Warrants) unless the Company is in compliance with the applicable provisions governing Fundamental Transactions set forth in the Warrants.<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Reservation of Shares</font>.&#160;&#160;The Company shall take all action necessary to at all times have authorized, and reserved for the purpose of issuance, no less than the maximum number of shares of Common Stock issuable upon exercise of the Warrants (without taking into account any limitations on the exercise of the Warrants set forth in the Warrants).</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Register</font>.&#160;&#160;The Company shall maintain at its principal executive offices (or such other office or agency of the Company as it may designate by notice to each holder of Securities), a register for the Warrants in which the Company shall record the name and address of the Person in whose name the Warrants have been issued (including the name and address of each transferee)), the number of Warrant Shares issuable upon exercise of the Warrants held by such Person.&#160;&#160;The Company shall keep the register open and available at all times during business hours for inspection of any Buyer or its legal representatives.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.10&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Transfer Agent Instructions</font>.&#160;&#160;The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent transfer agent, to issue certificates or credit shares to the applicable balance accounts at DTC, registered in the name of each Buyer or its respective nominee(s), for the Warrant Shares <font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font> in such amounts as specified from time to time by each Buyer to the Company upon exercise of the Warrants.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONDITIONS TO COMPANY&#8217;S OBLIGATIONS HEREUNDER.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The obligations of the Company to the Investor hereunder are subject to the satisfaction of each of the following conditions (except to the extent such condition is expressly conditional to a specific closing, in which case such condition shall only apply to such specific closing), provided that these conditions are for the Company&#8217;s sole benefit and may be waived by the Company at any time in its sole discretion by providing the Investor with prior written notice thereof:</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Investor shall have duly executed this Agreement and delivered the same to the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the Other Investors shall have duly executed the Other Agreement of such Other Investor and delivered the same to the Company.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The representations and warranties of the Investor shall be true and correct in all material respects as of the date when made and as of each Closing Date as though made at that time (except for representations and warranties that speak as of a specific date which shall be true and correct as of such specified date), and the Investor shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Investor at or prior to each Closing Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONDITIONS TO INVESTOR&#8217;S OBLIGATIONS HEREUNDER.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The obligations of the Investor hereunder are subject to the satisfaction of each of the following conditions (except to the extent such condition is expressly conditional to a specific closing, in which case such condition shall only apply to such specific closing), provided that these conditions are for the Investor&#8217;s sole benefit and may be waived by the Investor at any time in its sole discretion by providing the Company with prior written notice thereof:<!--EFPlaceholder--></font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall have duly executed and delivered this Agreement to the Investor.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each and every representation and warranty of the Company shall be true and correct in all material respects as of the date when made and as of each Closing Date as though originally made at that time (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such date) and the Company shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required to be performed, satisfied or complied with by the Company at or prior to each Closing Date.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the transactions contemplated by this Agreement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions contemplated by this Agreement.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">6.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;At the Closing, the Company shall have duly executed and delivered (or caused to be delivered) to the Investor the certificate with respect to the Warrant.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;MISCELLANEOUS.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Miscellaneous Provisions</font>.&#160;&#160;Section 9 of the Existing Securities Purchase Agreement is hereby incorporated by reference herein, <font style="DISPLAY: inline; FONT-STYLE: italic">mutatis mutandis</font>.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Termination.&#160;&#160;In the event that the Closing does not occur on or before five (5) Business Days from the date hereof due to the Company&#8217;s or the Investor&#8217;s failure to satisfy the conditions set forth in Sections 5 and 6 hereof (and the nonbreaching party&#8217;s failure to waive such unsatisfied conditions(s)), the nonbreaching party shall have the option to terminate this Agreement with respect to such breaching party at the close of business on such date without liability of any party to any other party.&#160;&#160;Upon such termination, the terms hereof shall be null and void and the parties shall continue to comply with all terms and conditions of the Transaction Documents, as in effect prior to the execution of this Agreement</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Legends</font>. No restrictive legends shall be placed on the certificates representing the Securities.</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">7</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<br>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--EFPlaceholder-->7.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">Most Favored Nation</font>.&#160;&#160;The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered to any Person with respect to any consent, release, amendment, settlement or waiver relating to the terms, conditions and exchange transactions contemplated hereby (each an &#8220;MFN<font style="DISPLAY: inline; TEXT-DECORATION: underline"> Document</font>&#8221;), is or will be more favorable to such Person than those of the Investor and this Agreement.&#160;&#160;If, and whenever on or after the date hereof, the Company enters into an MFN Document, then (i) the Company shall provide notice thereof to the Investor immediately following the occurrence thereof and (ii) the terms and conditions of this Agreement, the other Exchange Documents and the Securities (other than any limitations on conversion or exercise set forth therein) shall be, without any further action by the Investor or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Investor shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in such MFN Document, provided that upon written notice to the Company at any time the Investor may elect not to accept the benefit of any such amended or modified term or condition, in which event the term or condition contained in this Agreement or the Securities (as the case may be) shall apply to the Investor as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred with respect to the Investor.&#160;&#160;The provisions of this Section 7.4 shall apply similarly and equally to each MFN Document.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">[The remainder of the page is intentionally left blank]</font></div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">8</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 72pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> the Investor and the Company have caused their respective signature pages to this Agreement to be duly executed as of the date first written above.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="90%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">COMPANY:</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="40%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">ADEONA PHARMACEUTICALS, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="4%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="60%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="36%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
</tr><tr>
<td valign="top" width="60%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="40%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">9</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">IN WITNESS WHEREOF,</font> the Investor and the Company have caused their respective signature pages to this Agreement to be duly executed as of the date first written above.</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="85%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">INVESTOR:</font></div>
</td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="35%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td colspan="2" valign="top" width="35%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="4%" style="PADDING-BOTTOM: 2px">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td valign="top" width="31%" style="BORDER-BOTTOM: black 2px solid"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name:</font></div>
</td>
</tr><tr>
<td valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" colspan="2" valign="top" width="35%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title:</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">10</font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>v230931_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT 31.1</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="FIS_CERTIFICATION"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO RULE 13a-14&#160;OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;I, James S. Kuo, M.D., M.B.A., certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this quarterly report on Form 10-Q of Adeona Pharmaceuticals, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant's other certifying officer(s) and I are&#160;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&#160;for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&#160; material&#160;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant's other certifying officer(s) and I&#160;have&#160;disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: August 15, 2011</font></div>
</td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
</td>
<td align="left" valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">/s/&#160;James S. Kuo, M.D., M.B.A.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name: James S. Kuo, M.D., M.B.A,</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title: President and Chief Executive Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;(Principal Executive Officer)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><!--EFPlaceholder--><!--EFPlaceholder--><!--EFPlaceholder--><br>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>v230931_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT 31.2</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><a name="FIS_CERTIFICATION_2"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO RULE 13a-14&#160;OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;I, James S. Kuo, M.D., M.B.A., certify that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">1.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">I have reviewed this quarterly report on Form 10-Q of Adeona Pharmaceuticals, Inc.;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">3.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">4.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant's other certifying officer(s) and I are&#160;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&#160;for the registrant and have:</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&#160; material&#160;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">c)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">d)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">5.</font></div>
</td>
<td align="left" valign="top" width="90%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The registrant's other certifying officer(s) and I have disclosed, based on&#160;our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">a)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="3%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">b)</font></div>
</td>
<td align="left" valign="top" width="86%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="53%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date: August 15, 2011</font></div>
</td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
</td>
<td align="left" valign="top" width="37%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline">/s/&#160;James S. Kuo, M.D., M.B.A.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Name: James S. Kuo, M.D., M.B.A.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Title: President and Chief Executive Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="53%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="37%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Principal Financial Officer)</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>v230931_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
    <title></title>
    <!--Licensed to: Vintage Filings-->
    <!--Document Created using EDGARizerAgent 5.3.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<font style="DISPLAY: inline; FONT-WEIGHT: bold">EXHIBIT 32.1</font>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><a name="FIS_CERTIFICATION_3"><!--EFPlaceholder--></a><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">CERTIFICATION&#160;PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160; Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Adeona Pharmaceuticals, Inc. (the &#8220;Registrant&#8221;) hereby certifies, to such officer&#8217;s knowledge, that:</font></div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(1)</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">the accompanying Quarterly Report on Form 10-Q of the&#160;Registrant for the quarter ended June 30, 2011 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><a name="v222442_ex32_1_htm_hangingindent"><!--efplaceholder--></a><a name="hangingindent"><!--efplaceholder--></a>(2)</font></div>
</td>
<td align="left" valign="top" width="91%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>

<div align="left">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="50%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Date: August 15, 2011</font></div>
</td>
<td align="left" colspan="2" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="45%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">By:</font></div>
</td>
<td align="left" valign="top" width="45%" style="BORDER-BOTTOM: black 2px solid">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">/s/&#160;James S. Kuo, M.D., M.B.A.</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Name: James S. Kuo, M.D., M.B.A.</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Title: President and Chief Executive Officer</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="5%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160; </font></td>
<td align="left" valign="top" width="45%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">(Principal Executive Officer and Principal Financial <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Officer)</font></font></div>
</td>
</tr></table>
</div>

<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div>

<div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>

<div id="PN">
<div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>

<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">&#160; </font></div>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M```L`0```0```"P!```!````4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`'4`
MLP,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^****`"J\<F;BYB)R4\F0>RRH4`'_``*%SZY)[8Q8K*$FS6S$
M#Q-I8D8<?>M[HHI]266=@.N`AQCG/D9KC5@9Y34E)1I5LWP^"J:V<GC:&*PV
M'BE=7;QE7#-JS]U2=M+K2G'F51)7:IN2\N6492?_`("I?,U:***]<S"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KD[JX\OQ=IT6
M>)K$V_4?>:/5+HKMZYVV:-GT&!U-=97E-WJ`F^(&DQJ0536KS3E(/7[%X4-U
M-C!Q\LNJF-SR0R!2!Q7XWXS<0PX?P?AY*53DEFOB[X=9.H\RBY0Q^?4J,KW^
MRY2ITWI9SJ4X;SB>GEE!UY8U)7]GEN-J]=/9TG+]+^B;Z'JU%%%?LAY@4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`445#<W$%I;SW5S*D
M-O;123SS2$*D442EY)')Z*JJ23Z"LJU:CAJ-7$8BK3H8>A2J5J]>M.-*C1HT
MHN=6K5J3<84Z=.$93G.<E&$4Y2:2;&DY-1BFY-I))-MMNR22U;;T26K9G:IJ
MD.GM:PLX66Y::1B2,06-C$;G4+R3)&V*&%5B#G@7%Q;K_%7A/AJ\DU'QAX(N
M)`1+JC^,O%4JD'*1:H]Q:V8))&`MK81JO<J4XP5%5O$WB2ZU+0[_`%N-72]\
M<7@\+^%;4@B6#P[;W&V\N0N<K)J=T0L^.3OMU!*QJ1H>#(HY_BK?V]O\UIX3
M\.1:%`P^Z&LEM+*4CL/,N7NWR#R2<<'`_P`R>/?%J?BQXR^%.5Y54J3X>AXA
M^&M7*L)9PE5P.<<6Y;QWDF;UJ4N6?ML3PIX5XKBFG/DA5H9!XC</X3&0A7IS
MB?=X/+EEV69C4J)*M]2QZJ2T:4Z6&G@ZM)-=(XG,8X=J]G6P5:46XL^AJ***
M_P!.SX,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`IZAJ%
MII=E<:A?3+!:VT9DE<Y)[!411\TDLCE8XHT!>21E1`68"O%_B1K=YK]_H7P\
MTLO;7>N/;7&N@,'DLK(CSQ:S%.`R11R7=RH.-D,2`LDQ)VO&.I1WWB_PSH,D
MJ_V5I=O>>+]:VME)$TD3_8HY,<%(KNWD9T)(,FW(#1UXYH^L3PZ;XY^)=X<:
MIJ<\FA:&S9S#=:@H:=X,Y/\`H-B(EB(X"Q/'GDX_SF^DQXZRSG&Y]X4X/%SR
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M_P!DS\P"BBB@`HKYJ^'W[9/[*'Q7^,WC?]G7X9_M%?!WQY\>/AK_`,))_P`+
M!^$/A7Q[X>UOXA^#/^$.UVS\,>*O^$D\*V-]-J^D_P#".^(M1L-$UC[9;1?8
M-3O+>SN/+GE1#]*T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'Q+J'B
MMK5O%LU\2+[3OAWK>GW!8MO%U;_$&?P]>1Y95.=LB3-@[@LZ$<<UD:YJT,FE
M?"CP/:`_:]>L(-=>)63<]QXHU!H;"5UW;F$=M&0&P<1D]-K*,_\`::\.W7AC
M5O$>M6@8:5XR\(^*I%8#,=OK%C8:=X@U*!F*E(OM#>#]-FL49M]Y?:UJFV-O
M(W#R+2O%L:_&BTUEY!)IOPV^`^B>,5CW*4SIOPLTR[L"RAPOS:SK-O(A950R
M;?FP1N_QC\0/!K$8'/<ZX-S2OBZ5#,,5PYX>9AF#G-5ZN09IQK/C7/L^IN3Y
MHSQ>5<*9'5JU$[RPU\,VZ<IPE]QAN)HT_9U.2"G2G/$0C;155A)8:C!JS]V#
MKUI1\W?>S7N6LZGI_B_XE67A+3'+6EA>V7A*Q6,$HMGI+_9[R=2,`J6CO+HL
M#DJ02<GC[IBB2&*.&)0D<4:11H!@*D:A44#L%4``>@K\O/V)X[KQI\0O$/BB
M]9YX/"^DEQ+)N;=K&ORRV\+[FW9;[%#JK,=^Y69"P)*L/>_V]],_;@UC]FOQ
M5IG_``3Q\2_"#PC^TY?ZUX3L?#7B#XW:7=ZIX*TGPY?Z]9V/C'5DCMH[Z"#6
M]$T*YN=<TN34=!\46-RVF3:8?#U]=W]H]O\`UG]!W@.IEN0>(_BIF5"-+./%
M7C3%8JA",;4L'P]D4\11R[+\&G_"PF#S#'9M@J-&FHTX8;!8.FERT81AY.?Y
MK''K`8:E_`P&&]FG?6=:IR^UJ2_FE-0A)RW<G)O5L^RZ*_E!US_@DO\`\'#&
MLZ-=>.YO^"^MQ!\7Q`=0M?`6C_`JST'X0MJ\8\R+2VU;2I[6VBT@R9A:Z?X/
M76^,*\^D399!U7_!!7_@KW^U3^TO\?/VGO\`@FC_`,%%=(\.)^V?^R6WB*YE
M^('AG3]+T2V^(V@>"/%]CX"\;6^NZ1H=O9^&SKWA_7=7\/ZAI/B+PM8Z9H_B
MWPQKT=Y_8NGW.DS7VM?W2?.G]2E%?C+_`,%M/^"OG@7_`()%?LSZ9\0CX<LO
MB1\??BUJNI>#_P!G[X57EY<6FGZ]K^FVMM<:[XM\5S6)74H_`_@F#4=+FUF'
M3&BU/6M3U;0O#EC=Z6^L2:UI?YH_L^?L7_\`!QS^UUX$T']H7]HW_@K19_L-
M^(O'VFVGBSPS^SA\*_V8?A[XYB\`Z/K$2:AI.C>-5U._\)K8:Q;6LD`OO#^H
M:KX\U.R5_L>M>(/[5BO[2,`_,[_@B-_RM<_\%>/K^WM_ZV'\*:_OYK_.U_X-
MV/#7Q*\&?\'*W_!27PC\9/B);_%WXM>&/`/[96@_$KXIVOANP\'6WQ&\<Z3^
MU1\'+'Q/XV@\)Z66TWPU%XGUB"[UA-#L&:STL7GV.W9HH5)_IH_X+H_\%>]<
M_P""9?PP^$WPY^`/@;3_`(N_MM?M7^*9/`/[.OPYU""ZU+3+"?[=I.C7GC;7
M]%TVXM-0UI8]<\1:!X=\)^&HKW3CXF\2:IS>G3M#UB!P#]XJ*_D<T[_@E_\`
M\')/C/P%'\:?%?\`P6WM?`/[1VH:=_PD<'[/VB_";0YO@MHNL3P"]M_!VI^*
M]'M[7PX%M)'_`+,O[FS^#GB32HYHF:&ZUJV"WTOTY_P0<_X*^_'']M3Q/^T9
M^PW^W;X4T3P/^WU^QOJVI:9X_;0K*UT;3OB7X8\/^)3X(\0^)/["L))=)T[Q
M%X3\6G3M-\2R^'3#X4UJT\2^&M<\-VEG:7MS:6X!_2/17\X/_!?#_@LO\2O^
M"?4?P,_9-_8Z\(Z5\1?V]?VN-4L-'^%VF:M91:WIOP^T+6_$EMX*T/Q+<>&Y
M)H8O$'BGQCXONI/#GP_TC47&@F\TK7M7UY;NTTB'1M9^6_$/_!-/_@Y#\&_"
M6[^/OAO_`(+43>//VHM)\/R>,+G]FB;X,>$(_@SK>MVMM_:%U\/-#\4ZBDGA
MF>ZN%BDTO2[Z[^$&A:/?:E)#!-<Z)9.^MQ@']<5%?@/_`,$"_P#@LAJ'_!5C
MX&_$+0?C+X5TCX=_M>?LV:WIOA7XY>$=%@NM-T77K/5FU.V\/_$#0-$U&>YU
M#0DU&_T+7=#\3^');J]&@>(](E:*XBT[6-*M(/RL_P""UO\`P4^_X*;>'_\`
M@KK^SW_P2G_8A^.7@#]FW1?CIH'P6M+7XF7?P[T/Q3XGA\4_%GQ'XDT>ZN];
MUCQ/I7C%;30M'AT>UEL[;PMX<TO578W"W&H7`F0P`']I=%?R-_$;_@DW_P`'
M#/PT\"ZS\3/@Q_P7=\7?&+XQ>'=*NM=TWX2>,_@]IOACP3XKU&QMY+Q_#EAK
M6M>)/B#X?^U:BZ-8Z3_;?@"QTF:YEMX]0N='M#)=6WTO_P`&Z'_!9_XD?\%2
MOA5\8OAE^TOX>T/P_P#M5_LPZCX=LO'6J^'-.&@Z1\1?"OB:;6]/TOQ4WA@.
M\/ASQ3I.M>&]4T3QGI>FF/0_M4ND:EI-KID6IR:/IH!_2;17XY?\%+/@Y_P6
M.^.'Q&^%_@?_`()V?M0_`;]E#X%7GA+5;CXR?$_Q?X%7QG\8;+Q?!K`BL-.\
M(V&K:)XJT6^T?4="N89[5+6R\)W]CJ.EZDU]XJ>&_P!.LXOQ*_:[_9!_X.)?
M^"<_P2\>_MD?"7_@L'?_`+8EA\$/#NH?$GXH_!KXF?!C1-$MM2\!>&89=6\8
MW6@Z7KNI_$+2M8@T71H;W5=2L+*_\"ZR^B65\V@:C_:T%A87`!_:%17Y7?\`
M!&O_`(*2:=_P51_86^'_`.U!+X;T_P`%_$&+6M>^&OQD\&Z//<W.B>'_`(H>
M#OL+ZLV@37KRWH\/^(M%U;P_XNT:UO9[N\TJQ\01:+>7^I7>FSZA<_JC0`44
M44`<9X_\%:9X_P#"VI>&M412EW&9+2<J&:SU"(,;6Z4$'<J.2D\1!6>VDFMW
M!25A7XH:T=<\(2?&BSUA)H->TW]F?3?#%Y&^/,2;P?\`$OPC\+[_`!AHPRW>
MGZ!;ZBCC"W%EJ%O<)O290?WBK\ROVUOA?/;^(&\9:1:'[%\1_`_CWP!KC0[E
MQXHN?"\.L^$VF(')UC6_`_AC2;*!2%-\9Y2OFW3R'^?_`!VX)I9QE5'B3"8>
M,LQRVEB<!B'&"YJF&S/"8K+,-BJC6LI996Q]1P;TA0Q>)J3DHTHVX,?SPI>V
MIWO!VDEU4_=4FUK[C:?DFVWH=C_P3AT3[/\`!#5O%,J$7/BOQEJ3)(R@,^GZ
M';6FF6Z9Y++'>C4R/F(#.^`#DGI?^"@O_!0?]G#_`()I?LZZ[^TE^TOXBOM,
M\+6-_;^'?"OA?P[:0ZIXW^(_C;4+:\N])\%>"M'GNK&WO=8O;:PO;V>YO[[3
M]'TC2[&^U75]1LK&UDEK4_X)_>6W[)GPLFC^]<'QC+,Q!W--_P`)WXEB8L22
M6*K&L8;^)44X'2OY,/\`@]4\*^-O^$5_X)R?%&]TG5]:^`?@CXK?%;1?B3!9
M12RZ7;^)_$EM\,]5\-6VJ*KQP+>:[X7\)>/++1I;AD4&UU.WCFA:Z*S?=^$>
M5T,G\,>!<#AHQC37#.5XMJ"2C[;,L-#,<3+32\\3BZLF^LFV]6;X23GAL/-N
M[G1IS?\`V_!2_4_17X/_`+:G_!P3_P`%'O"^E?%O]D[]E3]D;]@G]FOQO#%J
MWP[\??MD:[X_^(OQB\7^$+M1/I7B[0_`_@F+3;:QL]8LV@O=.'B?P;9:9J%G
M<Q7>BZSK&FRVVK3?BS_P12T+XW>%O^#IG]MSP_\`M'>/O"_Q.^.6G?"OX\VO
MQ/\`'O@?PW_PAWA'Q3XE_MCX,S7-_H/A@*G]DZ:(VMH8+61?,)M_/DS+(S'^
M[G]GOX[?`K]H#X->`_BS^S]X]\&>-OA'XE\+:/J7A36O".JZ==:39Z,VGPFV
MTNY@M9<Z'?Z/`HT_4M#OXK/4-%N[6?3K^TM;FUEA3^)O_@F)JNF:U_P=[?\`
M!1K4]&U*PU;3;GP=^T+]GU#3+RWO[&X\C5?@O;S"&[M));>4PW$,L$HCD;RY
MHI(GVR(RC]%.@PO^"Z,R_'S_`(.=?^"4G[.WCD"_^&/A9_V5I6\.7G[W2M2?
MQ9^T#XM\3>+1+;N3&W_"2V/AS0?#VHX4>=::;:QD$Q@G^_.OX7?^#K/X`_%S
M]G?]KC]@3_@LO\(O"][XFT7]G?Q+\-?"?Q3_`+/@F:W\.:W\+/BM+\4_A3J7
MB*6W25K70?'$VN^)O!%[JUPB65G>V.@Z5/(USKNGP2_UL?LE_M_?LE_MK_!/
MPM\=_@)\:_`7B;PEXAT*QU;5=,E\4Z'9^*O`=_<6J3:AX9^('AV>_74O"GB'
M1)S+::C9:I!`C-#]KLIKO3I[6\G`/XT/^"(W_*US_P`%>/K^WM_ZV'\*:RO^
M"TG[2GAGX2_\'1G[#WC[XQ>#?B9\3?AG^S;\(?A=XCT?X=_"3PA)\0/B%K6N
ME/C-XU\/OX,\%F_T]-:UL_$*]\.W,P2\M&BM-&%TTO\`Q+UR[_@A;K6C>)/^
M#J+_`(*S:_X>U;3->T+6;/\`;NU+1]:T6_M=4TC5=.O/VOOA//:7^FZE8RSV
M=]974+I-;75K-+!/$ZR12,C`GWS_`(.=OA5\6?V.OV_?^">__!:_X6^#;_QA
MX+^"&N>`O`/QIM]+AD\O2[KP'X]U3Q5X8AU^ZCCD&FZ9\4?"GB[Q?X`AUVX4
M6>FZGI6E6-Q,+O6-)MK@`_5R7_@MW^V?\3L1_LL?\$(O^"AGCU;I_+TW6?V@
M8_"?[+>@3EF:..>34/%D'B>T2`OY;.9;VW"0.9I)(T`+?"?_``33_P""=G_!
M4E?^"Y/Q1_X*M_M.?LT?#W]DOX8_'3P7XXT?QQ\*](^.O@KXI:_93ZUX`\*:
M+I%I"?!D]]'JKW_BWP7HWB/6KN^72!#>27,D5HP2+?\`T5?LR_\`!3W]@O\`
M:W^$_ASXP_!S]J+X-W_A_7]+LK^]T+Q%\0/"GA3QQX.O;J`2S^'_`!QX-UW5
M[/7/#.N:?*)K:YMK^T6WG:![G3;J_P!/>"\F]E^#7[8G[*W[17CGXA?#;X"?
MM"?"3XS>-?A38>'M3^(NB?#'QOH7C<^$K/Q5<:Q:Z$VJZAX=N]0TI)KRXT'5
M(I+2&^FO+%H(O[1@M!>V)N0#^)']IVYD^+O_``>G_L]^$/&`:^T3X6R?">#P
MG:7:"6*R3PA^RYKOQLTAK>.7*(L7CW5KS5H70`QW3_:$_>KFO[_Z_@@_X.`/
M"GB;_@G'_P`%S?V!O^"P,GAG6-4^`/B36OAGX=^+6NZ-8RW;Z3XB^'XU'P3X
M\T29HE\J+5_$/P(U>VOO!EK=RPMKE_X;\06T#>5I=P\?]??BW_@I7^P;X,_9
MSO?VKM5_:L^"-Q\#;7PG-XOM/%^E?$/PSJ;ZW9I8?;H-'T#1K747UK5O%M\3
M'I]EX/M+!_$DNKRII3:8E_N@4`_CJ_X(?74OPQ_X.E_^"K_PK\+++9^#/$C_
M`+9/VW2;6-5L(I=&_:5\!>(M)N7A3$5O'I\VH:E963H@\E=3-M'LCG=31_X*
MJ_\`*WG_`,$Z/^OG]CC_`-3OQU7KO_!JM\(_B#^TY^W)_P`%(_\`@L'XT\+:
MEX;\&?&WQ?\`$KP/\+GU."18]8UCXM?%BW^+OQ`@TFY=0+VV\`:;H/@GPS<W
MT#S6D][K=W9)*UWI=XD/D7_!57_E;S_X)T?]?/[''_J=^.J`/]`>O\_3_@T4
M_P"4D?\`P5A_Z\)?_5\^,*_T"Z_S]/\`@T4_Y21_\%8?^O"7_P!7SXPH`_I*
M_P""I/\`P6\^$O\`P3Q^('PX_9C^''PF\:?M=_MR_&H:<OPQ_9C^%]TEIJ$<
M>NW<FG^'=2\=^(4T_6Y_#UOKUY#<_P!AZ3IN@ZWKFI6UC>:A<VFD:(L>M-^>
M_P"U&O\`P<A_'/\`8\_:=\;?&F\_X)Y?L6?!T?LY?&K6/&/P<\-Z-XY^-7QN
MO/`T/PW\17GB+PGJ7BBXU/Q'\-[/Q!J6A17NDPZSH.KQQ6%Y=_;!:AXDCA_,
M6_\`''A/]E3_`(/(_&_Q%_;(U;3_``/X-^)>A2Q?`_XC^/YX-,\'Z<GCC]GC
M0?!'P[U2WU_56M]-TS3'O])\3_#)-4:9+.P\2SW-A=7$)6YN$_LG_P""B7B?
MPU9_\$]OVT]7N_$.AVNDWG[)7[0D=GJEQJUA!IUW)?\`PC\6P6*6U[+<+;3O
M>S2Q0VBQ2NUQ++''"'=U!`/YU?\`@RO9C_P3)^/2EB57]MCQV54DE5+?!;X$
M[B!T!;`R1UP,]!7]@U?Q\?\`!E=_RC*^/?\`V>OXZ_\`5+?`FO[!Z`"BBB@`
MKD_''A'3_'/AC4_#6HDQ)>)!/97J(LD^E:OI]S%J&C:Q:*_R_:]*U2VM+^`$
MA7D@$<F8W=3UE%8XG#T<7AZ^%Q-.-7#XFC4H5Z4K\M2E5@Z=2$K6=I0DT[-/
M71IBE%2BXR2<9)II[-/1H^0OV/\`2;KP'X9^('P=U*W2QOOAO\1-=DT^R0L8
MAX5\9R'Q/HD]HT@62:PCOKK7-)MKLQQK='299E1=VT>X?&/X+_";]H7X;^*/
M@_\`''X=^$?BK\,/&EC_`&=XH\#>.-$LM?\`#VL6RRI<0&XL+Z*5([NRNHH;
MW3=0MS#?Z9J%O;:AI]S;7MO!/'9U[0O[+\6:;\0M-CQ,M@WASQ?!$IW:CX<E
MG%S8:BRKCS+OPOJ6ZZB=]QCT;4?$$<2O/+`I]$!!`((((R".00>A![@UXG#.
M`>3992R%MRAD_-A<%-V7M,KYYRRUI122^KX;EP%165ZV#JSBE3G3;QP\/94U
M1Z4O=@^]/>G_`.`QM#U@[:6/YP];_P"#5'_@CWJ&L:EJ7A[X8_&OX>:9JT[3
MWOA/P+^T1\3M/\+R;V8O"+35]7US4!;LCM"(3JA2.$^7#Y8`Q^BG[#__``2%
M_P"">'_!.K5=0\4?LG?LX^'/`/CW5]'N/#^J_$O5]9\4^//B+>:)>7%K=7VD
M1^+?'.MZ_J>DZ7?W-C93W^F:%)I6GWLMI:O=6LIMX=GZ445]";G,^-/!7@_X
MC^$_$/@/X@>%O#WC?P1XNTF]T'Q3X1\6:/I_B#PUXCT3486M[_2=;T35;>ZT
M[4].O(7:*XM+RWF@E0D.AK^>WXC_`/!J;_P1B^(7BV_\66OP'\??#DZG<R7=
MYX;^&WQF\>Z'X2\^64RR_8M$U34==32+9B2D>GZ-/I^FVL9\NSL[=%4#^CBB
M@#\W?V&?^"1W_!/G_@G%>ZMKW[)/[/&@?#WQOK^AR^&=?^).J:UXH\<_$75O
M#]Q>V&I7>B2>+?&NLZ[J>G:->ZCI>F7U[HVAOI6DW=WIMA<7%C)+9VS1??'C
MCP+X+^)OA#Q'\/\`XC>$O#GCOP+XOTF[T+Q5X.\7Z+I_B+PSXCT6_C,5YI>M
M:)JUO=:=J5A<QDK-;7=O+$_!*Y`(ZJB@#^<3XC?\&I/_``1?^(/BR]\5VWP%
M\>_#S^T+E[NZ\-_#GXS>/M&\)^?+)YLHLM'U74M>_LFV8Y1+#1[C3["VC.RT
MM8%5=OZ7?L,?\$J?V#/^";\&OR?LA?`+1/AIX@\6Z9#HWBSQQ>:WXH\9^//$
MFDP7<5_%I6H^+/&>M:[JT6D"^@M[TZ-ILUAI#7=O!=&Q,\,<B_H;10!Y)\<_
M@+\&?VF?A?XH^"WQ^^&OA+XM?"SQG:+9^(_!/C328-7T:_6*036MTD<H$]AJ
MFG7*1WFE:SIL]GJVDWT4-]IE[:7<,4R?@OIO_!J!_P`$6M.\<)XQ;X#?$;4=
M.BU`:A'\/]2^.GQ,G\#*RR"1+-X(];@\3W%@K*`UK=>*)UECS#.9828S_2'1
M0!P?PP^%WPX^"O@#PK\*_A'X'\+_``V^&_@?28-#\(^"/!FC6/A_PUX>TJV+
M-'9Z9I6G0P6MNC2/+<3R+&9KJZFGN[J2:YGFE?XP^+/_``2P_8>^-_[8?PW_
M`&]?B7\(+G7_`-J7X2-X+?P%\1D\?_$/2H-%;X?:A?ZIX3+^$=(\46/@[4?[
M-O=3O96&I:%=B]$HCO?M$<<:+^A=%`!7YY_L>_\`!*_]AW]@SXE_%SXO_LN?
M""Z^'7Q`^.<9B^)NMS^/_B)XN3Q"A\07OB<A--\8^*-=TS2LZUJ%U=YTBTL3
MB06X(MT2)?T,HH`^'_VV/^";_P"Q3_P41\*:1X2_:^^`OA3XM0^&_M?_``B?
MB.YEU;PWX[\(?;_+:^C\+^/?">HZ)XMT>SO9(8)K_2K;5QI&HS6UM+J&GW3V
MT#1_DSIO_!J1_P`$?+6YM1JOP[^.WBK0+*836_@WQ%^T;\39/"T01F,4*6NE
M:GI.HI#"K&.,)J:R>62KR.68G^D:B@#YT_9>_9'_`&;/V+/AA!\&OV6?@[X-
M^"GPVAU2XUV;PWX/LIHAJNOWEK96-WX@\0:MJ%Q?:YXDU^ZL=-TZRN-;U_4M
M2U26SL+*U>Z-O:6\<?T7110`4444`%%%%`!UZU5MXQ`7MU),481XE./W4<C2
M`0+@#]W$8R(@>5C*Q_=0$E%2XIRC*WO+F2?6TE=KT;C%M/2Z3W2`M44450!1
E110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pg15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg15.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!&`*``P$1``(1`0,1`?_$`/L``0`!!`,!`0``````
M```````(`0(&!P,$!0D*`0$!``,!`0$!`````````````0(#!`4&!P@0```%
M`@,"!`\&#@D,#0<+!0$"`P0%!@<`$0@A$A.7"1DQ05%AD2+3%-05%E;7&%B2
MU997F%EQ@=$R4G+2(U15E=87&J'A8E.3XY3D)['!0K(S)"5U)K8W"O"B-$2T
M-D=WMR@X>#G"0[7'2(@I\8)C<X.S-46%9X>$I4:&:!$``@`#`@D*!`0%!`$#
M!0$```$1`@-1!"$Q89$2$Q0%%?!!<8&AL5+24P;1X187P2(R!_%"<I(S8H(T
M-2.BPB2RXD-C5'/_V@`,`P$``A$#$0`_`/V3:P-9%K=$]%4I75V6%92D/6-8
M1E"PR%'Q*<U+A,JHNW95'":KAN44CI(F'Z[,=T<L>)O3>]'<-/65G^1KES,W
M3U)994L6,A2;EQM(Q3[@49J``X;0*-LUBFV!L,)1D@$`#K[,?!5OW>W+)4U4
M</7Y3AFO%#3@YGF^1?SX^D[8/D5J!R'H#^C-3;]#_".W&K[M[GM[_*77T/&\
MPY\;2=YE:@N+-3WQP^[6Z+>_RC7W?QO,5#EQ=)XYY43J#'+:.5LE1R#JCE([
M`P^[6Z+>_P`HUU#QO,6\^1I-R$?(O4#D'1']&:F0?1'QCD&'W:W/;W^4:ZAX
MWF*ARX^DX0S"B]0(@/0$+9J"`_0$)'+#[M;HM[_*-=0\;S#GQM)WF5J"XLU/
M?'#[M;HM[_*-?=_&\Q:/+C:21$-ZB=00F$=T/Z,5QS-EF!0W9'(3;O2#&2_=
MW=*4(\O[1KZ'B>;Y%2\N/I,$`$E%Z@1((=J(6S4$!#K#XR'IXGW;W0\,>_RC
M7T/&\Q7GQM)WF5J"XLU/?'$^[6Z+>_RC7W?QO,4Y\C2;YEZ@>+-3WQP^[6Z+
M>_RC7T/&\Q7GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[
M6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3W
MQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N
M+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=Y
ME:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\
M;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&
M\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-
M?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM
M[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[
MM;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/
M?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"
MXLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)W
MF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#G
MQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\
M;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`H
MU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>
M_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[
M6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3W
MQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N
M+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=Y
ME:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\
M;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&
M\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-
M?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM
M[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[
MM;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/
M?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)WF5J"
MXLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#GQM)W
MF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\;S#G
MQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`HU]W\
M;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>_P`H
MU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[6Z+>
M_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3WQP^[
M6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N+-3W
MQP^[6Z+>_P`HU]W\;S#GQM)WF5J"XLU/?'#[M;HM[_*-?=_&\PY\;2=YE:@N
M+-3WQP^[6Z+>_P`HU]W\;S%IN7$TE&`>%HO4$!0`V7]&2O1$HATI'H]3KXQ?
M[P[GHS+#AF<.?RFRG>KO3C^=X<A*O1WR@EE-:-3W.I>U,-<6*?VO:4TZG_+F
ME34ZBHA4!7B+`L>H9TX%RL!F!Q4*(%W2B4=N>/L]U>X*>_I76H_HA'.^A6F:
MJR5$]!Q(`_ZP/GZNNG_M<P#4G3)-W/+>,-*5.($$0Z`F`!Z^/@OWEO-6[[J4
MTD5+!X<QQWJ>?0C+:_P/BK;.U-R;S5(O1]L*?4J2=:Q+NH'30CZ/BTF,0Q52
M2>++2,EEOM4%7*9%#&$"E,H`".W'\<7>X[ZWDY[Y=:5:I0D<7-+*W*NEI8#Y
M^:>HZJ23;9U;B6OKZT4TC3]R:5EJ3F74>:6:-Y(@NT7\6"G!#)Q3UJ06KEAP
M@;O"D$Q.EGC:[CO>7]5.JGT,V-WB5_FDF3>0P$%2B!S;QLDQ`%!$IPW!,H5$
M-X!#,H<*<"Y]`!$,17+>S<%3J1Z'\`IKP\"DFS'&L?[R94IUB`F3A@73(L<I
M2;QTP.42!P:A1.40R$1#,,8U;KO2@U+6DJ23/$FFH]A87GTY\Q(.&TJ:A9VA
M&=S(FV-035)2,2I.L9B.F8I9W(PB13F4DVM+IYOW;%($C9J$*8`W1QT3[IW]
M3DEJ5*%>62913<K@TN=8,2,E3OCPJE4:2CB9'Y(`*43@4Z8*.!;B!DU$C$=$
M4X`6RY#@":#GA0W=S8(CTL:-CWKX*F9_`QA>?3GS'+O9E,?M]T@*&..1LDP2
MW^$X39FGN\&;HY9Y#EAL>]?3J9G\"_\`R?!/F,YHBU]9W-"L?)=!DJA;ZDG]
M>U.N^=C'*QE,Q2J:$BLS*INBZDDE5B#N@&Q-0O2'#8M[/%)5S/X#1O3Q4Y\5
MAK])PF*+=0#;I%SIHMQ*F=,BRJHF!)%$-W(ZQQ*/:ES',!Q-EWIX*F9_`B5Z
M].?,<@+IF*4X'-N'^L,(&`#@/"[29@&__<#]#/ZT>IALN\_!4S/X%A>O3GS'
M4[<,S&(L4I"IJ'$R:A0(FJ&\DH<3%`"IJ%#,IAV#B['O7TZF9_`0O7@GS'=*
M<#9[IA$`<+M-[:"??38A5'#8%!R3,NBF<!,4!S`!Q'==Z2J+DJ)=#^!'M*47
M)/#H.S&-7<V\91\.U=R;^2>IQT<S9MUEG+^057(V29-$2DWW#E1PH4@$*`B)
MA`,;ENW?4TFL5&LZ=NBX9X&.E7\,V8YY.-DH61?P\PQ>1<M%.UV$G&/T5&KY
M@]:JF0<M7;98"JHKH+$,4Q1#,#`(8\YUJJJNBY__`#+&HX5U$FJU9/URM=*.
MCGUQ[.,M.OXC#:6,^N/9PTZ_B&TL9]<>SAIU_$-I8SZX]G#3K^(;2QGUQ[.&
MG7\0VEC/KCV<-.OXAM+&?7'LX:=?Q#:6,^N/9PTZ_B&TL9]<>SAIU_$-I8SZ
MX]G#3K^(;2QGUQ[.&G7\0VEC/KCV<-.OXAM+&?7'LX:=?Q#:6,^N/9PTZ_B&
MTL9]<>SAIU_$-I8SZX]G#3K^(;2QGUQ[.&G7\0VEC/KCV<-.OXAM+&?7'LX:
M=?Q#:6,^N/9PTZ_B&TL9]<>SAIU_$-I8SZX]G#3K^(;2QGUQ[.&G7\0VEC/K
MCV<-.OXAM+&?7'LX:=?Q#:6,^N/9PTZ_B&TL9]<>SAIU_$-I8SZX]G#3K^(;
M2QGUQ[.&G7\0VEC/KCV<-.OXAM+&?7'LX:=?Q#:6,^N/9PTZ_B&TL9]<>SAI
MU_$-I8SZX]G#3K^(;2QGUQ[.&G7\0VEC/KCV<-.OXAM+&?7'LX:=?Q#:6,^N
M/9PTZ_B&TL9]<>SAIU_$-I8SZX]G#3K^(;2QGUQ[.&G7\0VEC/KCV<-.OXAM
M+&?7'LX:=?Q#:6,^N/9PTZ_B&TL9]<>SAIU_$-I8SZX]G#3K^(;2QGUQ[.&G
M7\0VEC/KCV<-.OXAM+&?7'LX:=?Q#:6,^N/9PTZ_B&TL9]<>SAIU_$-I8SZX
M]G#3K^(;2QGUQ[.&G7\0VEC/KCV<-.OXAM+&?7'LX:=?Q#:6,^N/9PTZ_B&T
ML9]<>SAIU_$-I8SZX]G#3K^(;2QGUQ[.&G7\0VEC/KCV<-.OXAM+&?7'LX:=
M?Q#:6,^N/9PTZ_B&TL9]<>SAIU_$-I9QJB/!FVC]<GT__I"XY+PKW/6HN5MR
M2U(NQ*&-G)>[S4A+H)QB?7GD%A_IXUN?XGLL.>S\#G\?W%^TTM"KNC2ISRSS
M:"3@TX83W=T5)YY7IJ&`WY_K`W_9VT_?]YVE%.C_`&!:3JDIC?0`38Y/WFE=
M;V],Y>:/<COO/^-=+_`^9.C:I:2@ZHO9%576-/442M].MTK=0LS4CAPE$$JB
MJEX4D0W>*L6[QPDW4*W4.=0J9BE(0=N>0#_/O[<;WNUTN-XN]\:5!IIQCBBK
M$SPIGHUI9HP@R8M(7UM'::@J>M@WN'1U=5I:+3=<".B*WD8!U/4\YK^I9EH]
M@:.I0:G:N'DDSCP3$15.BDF7[+=V8^[>^O:B_FE?Y;'@R89#K=[A@TE-^7DL
M)YJ5?6>JNW]/7-JFX]LDZJ?:3+AVLEZ/"/8QU5O;V5"^.LQDF,4WARQ0BNN=
M)--118A$R9"`[!''3<KS[9WE>):%W<JJ+#S^5&RA>I8QP?I[;38NN&'?4YIV
MD("AX6GF],04G:(U?G;H0K`U+O'-*Q[=C3M"-#4FQ1EVT[(H"]?/49!V":IA
M3$``QA#F]][IN=UHR5J>C!-=.(ZMI>K>+1BNG$^N!J2VM<VO:MM%5U9Z^](T
MZWTYVXG(ZX-(-1F'=9S]1-Y>>>)0K6)BHQ*/=LYSADFJPBL5,NX`Y[NW"AOK
M<DMQN\E_:C+*TL>+G_E95>U+!QZ5;V&7U%?*SP:9TQH%A:5=E(45-/:@HFH9
M4(VJH>Z#RIGM3L'C:GO)B5<U#+"*Y"$=*21$$4B\%GEMQCQCVG#'+V^0QVJ5
M2\V'O/1E;]:3$*PM3/`K3D@SO1=&CKJWR;#3)TFUNY.CZ$:0<!3RB:#8@'@S
MU4CWV]02,L@8F\8"B)A`<WOCVE@<98O"\#P?^CK-CO5.*<5%X7@Q.S\<!QU1
M>VUK>HK@)50\M<B]?:;;B4LUJ.B*K4J]]7*4O54.YAX60%C35/1;5ZO&-#&0
M1%$O>:!`145,H7>-@]\^U8XY,3YGY#!WO#CEQ-8%C/<JFY]G)A(\*2M+4591
MM45UIU;Z8*#HV(CV]6T`XCY)J->KU:4L$R?Q9'A-\BY%W"RCK>R$``<\>Q+>
MO:%226;\D6ES?_86:])X$T^9?,V#7]SK*TE=FEH:[=:V>FW<#JUF']+M:;I6
M'8)6UM&:BY6)-#5^V")`'0%J,VZ3+A!!0V?UNW&<]Y]H2IIZ$4WS/R%FO,LK
MT)G+%3/FYC3U-ZJZ(J6+MU$5Q45KB-JEI;4C%7-56M_!(*DAV2<@WL=")J,(
ML56Z"Q.#7;JHCPX&``5W!QXO&?:>#]'.L3ZOY"*^2I*,,36+,>#-W@LHIIHH
M2`I9A9Z5HP+>VRIZ6B:@GP85U2UR86H5I.8E6U)&IF1+(2@+[HKO!?E(L@8"
M[PB`AC"KO;VFZ6BM%MI<SMCX#"M>Y%2:4&]%9XQ?P,FN!JFMR[J^HY!A5-$*
MMZ$U4VFG+4*1=(0\<ZC+5+0[%M70M5$H8AEF[-=14JG?&ZL/UY"CD`X]NEO[
MVI+<W*M%]7X:!QN]K2BFL#7,?/O5[.NJIU"7"J!Q6U(7"0DY$LA"U%1Z#5DT
M1IEV*PT]"O6R;)HLK,14?NIO%ASX1;MLS=''X?[IEW-/>YKQNW1ULT^&%F9'
M+?:VM;A!K2YB-./E#@&`&`&`&`&`&`&`&`&`&`&`&`&`+1.4!R$0`<`5`0$,
MPZ&`*X`8`8`8`8`8`8`8`8`8`L$Y`'(3``A@"[`%<`,`,`,`,`,`,`,`,`,`
M,`,`,`,`,`,`,`,`,`,`,`,`4$0`,QZ&`+0.41R`P".`+\`,`,`,`,`,`,`,
M`,`,`4$0*&8CD&`.(YRF((`(".\G_P#>DQMI_HGZ#54YND^O?(+?Z=];O^);
M+?\`!)_']>?L9_UE3H7>?0[JQ/H_$WK_`*P:NFAIPL$JL(E*34O2J1B@`F4$
MSBF*G3()2E`W:@(")A_L0VX[/W3JR3[EGN4T=>T^;!G/3O%.::1:,.4#\\)Z
M\HS?X->:8.BE,)BH.VAE`V#L`ZI&Y=\!$>AC^1]V^W]\RT;Q3<LBEJ12_-EZ
M#YZ\4*C<%")Q&KFCSH%0/-,%BD4,J4'""PB4=T122;*I(@HW(17(>CM`,NGA
M]'[V_P!/]QR;->,F<Y6]=48@J5RG/-$')2IK&410<)"9T`[10<($1=MSDZ1@
M-NB/1#&N;VW[JN-2G>-U:O7*=:49TOR\^.5X<D#93H7B1QP9S+J@U"2]30\7
M3]1W5JBJ8*$R4B(BHZIJ*39LS)FWT2*-GBSAHN9!3:FH)=XA<R@.0CCZ??5+
MW3O2XR4(2:^588SJ'_TFW1KV+.8DG7-$B0`6GT=Y(HHIJ(LRI*BF90SDQTU2
MMMXIS+K'`=_/,`#+'@3>V-_7BE)+>5(IY%#!-'\$-"ODSEI:\HH#;XR4>)R9
ME3<`BH$@8@[1X1QWOP8[>MC5]'[V_P!.<:%?)G+1KFC!,94\VS.<P;OWI%9)
MP)>D58YD!;JEV]3,</H[>O\`I_N&A7R9RY&N:'2!("RK%(Q'7?0JMVHHJ[H$
MW.]!W6^X*:HAOF$.B8</H[>W^G.-"O8LYSL;C4S'/&[YA4X,';1RD_9OF*KI
MD_:/6Z@*MURKMF6\*I#`&T!'++&?TMOU8$Y8?U?(:%XL6<[4E<ZG)B0?S<Q5
M196;F71GLH_>+R"SIZZ$PG,>5<'9"9^F<QA'(,AS';A]+;]>-R_W+X$T*]BS
MGGKUY11QWO'""@F$%%03(=N914H@)#)*`V$6^Z(!M#&'T?O;)_<70KY,Y4:[
MHU4YA5FV6ZHED<X=^'<".8&X-<3,BHKFS#Z[9B_26\Z?YZD-!8\)C/3O$TL,
M&<Y"U]1_"*KDFVH*K"99R(I&`#)E3$BQ0S;=N84,P`.B([`QMI^U=Y3O\KP=
M)HV6\9,YTRW!H5)5!(:BAB+.#/"LT6J1VYED&@)'6R3%$%G9F_"EX0P!NIB.
M0]''75]IWZE352FDYV\.$CHU9%I3XCM^7U'_`(]:>X<=PQS_`$YO7PRY_D8P
M>4>7U'].=:^X<]QQ5[:WL\4LG]WR-DE*>=1E0\OJ._'S7^#<]QQ?IG>WAD_N
M^1EL]6Q#R^H[\?-?X-SW'#Z9WMX9/[OD-GJV(>7U'?CYK_!N>XX?3.]O#)_=
M\AL]6Q#R^H_\>M?X-SW#',]Q[R3@Z;BLC^`V>ID'E]1_X]:_P;GN&"W'O)N"
MIN+Z?@-GJ9!Y?4=^/FO\&Y[CCI^F=[>&3^[Y#9ZMB'E]1WX^:_P;GN.'TSO;
MPR?W?(;/5L0\OJ._'S7^#<]QP^F=[>&3^[Y#9ZMB'E]1WX^:_P`&Y[CA],[V
M\,G]WR&SU;$/+ZCOQ\U_@W/<</IG>WAD_N^0V>K8AY?4?TIUJ/\`\QSW#&N?
MV]O.FX32RQ_J^1A/3FD<)AY?4?\`CQK[ASW#&'`MX^&7/\C"#.LO7M&EWU5*
MA9))))%67643>E1;HB90IUEU0:BFFDB5,3J&S[0FT<:9=T;PGJNC+3;F61PS
MP$&<R=?4:*:9B5`Q53.0BB2R0.3I+)*%`Z2R1^``#I+)F`Q#=`Q1`<95]R[R
MNRC5I30R)O\``09?Y?4?^/&ON'/<,9K<>\6DU++!Y?D(,>7U'_CUK[ASW#&2
MW!O*9P4LL7E^15*YG!8V5\OJ.'9X^:[?_HW/<<;OIG>WAD_N^1MV>K8BHUY2
M`!F,\TRZQ'/<,/IG>WAD_N^1=FJY,Y;Y?4=^/FO\&Y[CA],[V\,G]WR)L]6Q
M%0KVCA__`#]F7KG*Y*'T`'@!VXUU/;V]:23FD3C8X]R+LU7(4-7]&%RSJ)AM
MZ@.1Z'_V&-/!-Y^D\S^`V:JK"@7`HT?K9]F;KE(Y'+K?W#&2W%O)XY$NEP[T
M:YZ<TC@ROE]1_P"/&ON'/<,7@6\?#+G^1A!CR^H_\>M?<.>X8JW#O*9P4LL>
MGY"#.HXKZBD2K+N:FCFC=(S<%7#HKU%N07:[5JW`RQFFYFJY>)IAMVG'+'3+
M[6WQ-BED_N^0@[&=P:\I$@B0\VV*<@B4Q3)N0,4Q=ABF`4,P$!#:&-7TWO7P
MRY_D,Y3R^H_\>M/<.>X8C]N[T2BY98=/R$'E'E]1_P"/&ON'/<,:^!;Q\,N?
MY"#'E]1_3G6ON'/<<9R>W]YSN$LLL>GY&4LDT[A+C'E]1WX^:_P;GN.-GTSO
M;PR?W?(V;/5L0\OJ._'S7^#<]QP^F=[>&3^[Y#9ZMB'E]1WX^:_P;GN.'TSO
M;PR?W?(;/5L0\OJ/Z4ZU]PY[CC7/[?WG(X32RQZ?D:YI)I'";&/+ZC_QXU]P
MY[AC#@6\?#+G^1C!CR^H_P#'C7W#GN&'`MX^&7/\A!CR^H_\>-?<.>X8<"WC
MX9<_R$&6*7#HI'@@6J..14<+(MF:*JATUGSE9!TY*V8IG(4SEP5!FH<Q"[2E
M+GC5P?>/I39G\!AL9?Y?4?\`CUK[ASW#%6Y=XMPU<RZ4U^`'E]1_X\:^X<]P
MQLX%O'PRY_D(,>7U'_CUK[ASW#$>XMY+^1/H<?P,Y*<T[A*/+ZC_`,>M?X-S
MW#$X)O+TWF?P,]GJ9!Y?4=^/6O\`!N>XXVT_;V]*J;ED22M</P&SU<@\OJ._
M'S7^#<]QQL^F=[>&3^[Y#9ZMB'E]1WX^:_P;GN.'TSO;PR?W?(;/5L0\OJ._
M'S7^#<]QP^F=[>&3^[Y#9ZMB'E]1_P"/6ON'/<,:7N#>4K@Y98K+\C4Y7*X/
M&AY?4?\`CQK[ASW#$X%O'PRY_D2#'E]1_P"/&ON'/<,.!;Q\,N?Y"#'EW2*G
M:%G6@&-L#>*X*&?1R$10R#/%6X=Y/`I$WD?R$&=1O7M'J$[Y3GF*J!5SM#JI
M&.J4CLA3\.T/P1#B1RU.02*D'(4SAD.-<^Y=YR?JI39G\!!Y3M^7U'_CQK[A
MSW#&%/=-_JS.661II1PQ7>A!CR^H_P#'C7W#GN&-W`MX^&7/\A!CR^H_\>M?
M<.>X8CW'O)?R1Z(O\#9)2GG491Y?4?\`CUK_``;GN&)P3>7IO,_@9;/4R#R^
MH[\>M?X-SW'&^3VYO6I+I*25+*X/-`;/5R#R^H[\?-?X-SW'&7TSO;PR?W?(
M;/5L0\OJ._'S7^#<]QP^F=[>&3^[Y#9ZMB'E]1WX]:_P;GN.#]M;V2CHR?W?
M(;/56&"'E]1_X\:^X<]PQHX%O'PRY_D:8,>7U'_CQK[ASW##@6\?#+G^0@SC
M4KVD#%R"<:YYA_8.>X8<"WCX9<_R$&<'EW2!`$QYYH0N:89\$\/MX4@[03:G
M$`R#HY98Z*/M_>4TD\)9<$OB^1'1GJM*7F/M+R!#YG)7OUM.V#A-TV4A;+[B
MR8B`"/>E0;!(<"JE'Z)0Q_4O[)4YZ%PJTJGZX+O/H]VT)Z:>E#$30Y9DAUJ/
MT8ME.!%%UK7MLB\2402=)K(^*ZG$""5<,LLP#I998^F_<.[76M1EC#2?1D/5
MJ_IP$@*B:43`-)ZHIN(IJ.A(%C+S$N^4IR+5(RC(=!5X_=&31CU%3E1;HF-D
M4!,.6S'YI<=QW799ZL$H*/-\#PJWZT:##4AI4-9J(U!!5%$?HAG'R<5'U>-)
M(\"I+.5>!91@QX0XR7?3LY3CEP62::9CGW29#B<-NULO+J-9OI".I)P#/@:?
MI=120:,WK-H6(I[Q@NW?)ME&ZI(TS8KT43E=!DIN;AMT<APX;=K5RZ@:^JNO
M;2T=4:]*R<)'.YEM1-85\LV@Z,CILQ(2AI*-B9]`21[%8XRY'LL@5%KEPJX&
M$2`(`.'#;M;+RZ@;`CH^D))FQ>)T]3K4)*/:RC1L_@()F\.Q=-DWA%E&BK4%
MT.";JE%4#E#@C9D-D8!##AMVMEY=0,.J&K;4TQ,VUA96/IOA;LU4-&4:[84[
M#2;-Y4"46_EWC1=5BR7X`K%I'FX4P["B<O7PX;=K9>74#OTS/VJJ][7$;`M:
M6=R%MZG7HVM6ZM.P[,D%4K>,93*D8Y=/&2#43C&2"2Q3%,)#%-L'8.'#;M;+
MRZ@<U<REN+<T;45?53$TVTI>FHIQ,NGR%/P3I1\P;BE]]AVJ+8SF4X4BQ3%X
M(INU',=F'#;M:N74#J4_/6ZJ5U/-8^FXUN%-MX%S*/IBD(J&BA3J2'2G8LT=
M*2#-!G*I!'K%%PH@8Q&I^T4$IL.&W:U<NH&7$B:.4.)$HBD53`V<O1*G%4Z=
M3Q>T1(X7E"H@WX8\2FF<=YR4HI%$HYCAPV[6R\NH&&1-4VHJ&4I&-IMA3]3(
MUU'3<M3,Y3U*QDO3CMC3YV:4B9],LV*C.&=(JO2E,@Y%-8N0B8H!APV[6KEU
M`S!",I!R3A4(.E5$=PYN&+$4V=,#I@W`Z1C%1,0I^$<;@`(@)A(80`0#/&$^
MZ[M/+HQ47RL!VBP%+G(FX1IRF':0&:J)K(0<*YCUE-WAU"(R#1FJU<%9G3`B
M@D,).$'=SQTW;<EVE<&E'ED!#VX\-"):YM*+<L/#][/;&:HW;EL2'B46:S@)
M*W'`J+,4V8-UE&P"8$SF[8H".71QZ5;<=U5)-I8\GP*J>LP6$PAIZFP-N^3E
M.]#//Q!#>!8Y>"W3PK,O@791Y/4WYMTZ/_Z!"^!8YZVZKK(TE!<N@Q=/58+3
M35T[P6#LO(4W#W#)%1DS6#.?>TQ$1=O5*DDI=O3!&"LXLDU@H1ZH@WCF\B11
M550"ID(`B(AC3PVZVR\NH+";!IJ1M?6=/Q%64B%!5%2]0(I+0,]'LJ:\72G?
M*RC5FBFJX;HF0<.7B1T=Q0I3$5*)3Y8<,NT(Q7+J$'"/,9"E!TFJ9/=A*4%-
M5,JR9RQ%/G.9`RQ4#.S($;"HDQ(8Y1X<^ZD)3`(&VX+=MV;@FH\L@2BX+&8]
M4,A:^DJ?FZNJ<:!@Z4IN/&4GJC=M*94BHUH159-<RR[1!QO*($1WQ(7,PE,7
M(!$<L;N(;DI_^.>C*YI<#P2XT6&&!B5N+C65NK$2$]2*$(2,BWK)D\-5%$HT
M:]/W\S,]2=QD=4T3&NIEDJB4.`4;`H#H1^];V#WAN.I_XY*4JFFP)PEP-B!M
M%6`I=)8C8\!2Z3E5<C9%JZA8!F[754;"^3X!JZ:I++)BP#AS&*`E33VF$,:>
M&W:V7EU$-?535ML*/J2CZ2F(*(\?5UY5>3T>TI:&=.%_)&GV]2R)7**34RK-
M1Q&.0%N50I3*G[4-HAAPR[6R\NH'0GK@6BIFV\;=6<AHV,I66;T^X8)O:+8-
MIY8M1O&4>S*-/J1X2I#(.WI2K?>\B`439Y9#APV[6R\NH&?OVU"QB<LO(1U%
MLFT$V%_-*O(ZG&ZD/'%**QW\JS.V[\CFY&A16'A2%'@P'I[,.&W:V7EU`X8H
M+?3D9"R\0TH5^PJ1JDZ@':+2EP:2P*&5`4FCQ5!-NHHF5$QC9"(99=4,.&W:
MV7EU`]@L!3!R)*I4]3JB*Z17#=8*=B2IN$%!,4BR0G8%$Q#&3,'0`=GT,8O<
M]UJ8<#Y=`U.LPE?)ZF_-RG?R!#>!8G!+KX5F7P&RY#3NHF`I]#3U?IPA`4^D
MNC9:ZCA%8D&P16053HB90!5)9N"0E435<HG((%#(2FVYY9]5P>Z+I>'0JTI7
M4EQX)2[*4T[0D"XT\V!7<4_`*N5K'6B6<+*0L6LHLY5MY3BCA915=JHLH=98
MQCB)C"(B..W>EYW*Z?\`AES2C93<?D]3?FY3OY`AO`L>.MRW2=:2E4'AQ+X$
MV7(5)3E.G,4A*;IT3G,!"@,#"AF8P[I0S%GD&8CT\5;ENLKTH+!T?`NS:.&P
MTY="[5AK-#3"5Q0AH1[699P]-L&=`&GWSY&FF[=U/NQ;0L(]4;L8ENXWU5C@
M"8%*(YY8SX;=K9>740V'3ZEO*JAH.HZ<\@YVGZF9-)&GY1A'TZ="79R"15F"
M[5(6A77!NDU";HF(``8X%,(#APV[6R\NH0/::P=*ORD48T_3+M)591!)5"#@
M5"'716[W<MA,1J8A'K5P!BJ("/"EW<\LA##AMVM7+J!H6/U!:8)2I*"I)E45
M#C.W/J6L*1H1FZI-NW\H:@H.;=4_5$>U,I$`5-2.DVADQ$XE`PB`!M'+&<G#
M=W?FO$LLZFP+$X9X`\B9U-:6J?:TVZDY"GU0JUU7C2";Q%N'DX[76ME,+P=<
MG7;Q4`X4:-*??(""ZZ@`D4HAMQLXIN/T9<TH-\4NM;JM:=AJNI)E1<_2]1,$
M96!G8>(A'4=+1KDN\B[;K%9`)39@)3IF`%$CE$IP`0RQHJ77=V\WM%"2661*
M&)8UU,NHUGYCWO)ZF_-RG?R!#>!8PX)=?"LR^!-ER%/)ZF_-RG?R!#>!8DFX
M[JIXP4.KX%V7(0]U[PD,STOU<Z9PL"V<^6]C6G?#>&:-5B,'MZJ&,Z2*LV%(
M=]7+<'("@)!$,>W=]QW698N[X#963.D:>IH)!^`4U3A`[]=9%"!AQ`H<.ID4
M!,S$P@4-FT1''-P6Z1AHK,O@79<ATPIZF_-RG?R!#>!8PGW+=-!_E6*Q?`FR
MLKY/4WM_R<IW8`C_`/@$-MR#/(/[RZ(XX>!W7PKL^`V7(:YNC6]G;,4ZPJJX
MS2&AX65F(6GHI1C1"4_(2D[.)+J-(N/B(>)=R+MV04<CE(F.6]F&8`(XJW/=
MJ?YH)<N@FHU?YC&*.O/I^N!4%/T[1SBDYMS4]+3]71+Y&FHMO%>+:6J)O2U1
M,I%Z[CT"Q<]$S3HJ2K%8"N`R,.[VHXRX;=;5RZ@;M2@*34<I,O$U)E>K$,LD
MS&&@3.UVI.$!5XU:%:B[=-4C)Y"<B8AM#I9X<-NULO+J$&='Q;1XIG5+"T@*
M:*R[)RJ+"ER-F<N@@5P:&>.SI%:-WZB2A!(!C@4XGR`<P')PV[6R\NH&,5K4
M5J;=HTVXJ]K3<.A5]50]%TT=6EF"@R]23ZI4XB/:IHQIS&[^(8%$S_6&)M`<
M8S;FNT[C!/ET%V?3_,9H%/4Z(9C35/%`=I,X"%[<G2.`=YY@`CGL'(0$-N)P
M.Z^%=GP&RY"OD]3?FY3OY`AO`L."77PK,O@39<@\GJ;\W*=_($-X%@MRW25J
M9RJ"R+X#9<A#S4_!0A;LZ$2HP5/)I2&JMRS>I)0,2U(\;+V6NB9!N[!!MDLB
MC(E15R$!V$'IY8]3:-RK`Z,L>B4RV9DP?)ZF_-NG?R##>!8UU9MSWFFZ%.E*
MIYE!.$I-E+O)ZF_-RG?R!#>!8\_@EU\*S+X$V7(4&GJ;\W*=_($-X%C.G=-W
M;L>OO$BFD>#$O@AJ=7^8UI<ZOK,6<BX68N*A"PK*HZ@:TK`D94.G4$C+U"];
M.GC6*CXF$B'D@Z<*MF2IQW29%(01$0`,;N*;B]&7-*#P*(O'8*XU3,Z4HU:E
M)Q_(4"G<MJ];TY$DACTR>HW=*J$-*+L4FQ)QI,L%DEX_/OI$2=L3,0QA.MV;
MP_-=I99%+CQ+'T`W*C"TFX<]XMX2DG$@FBFY=1[:)I]P\9H+N#M6ZBS9-IWQ
MDNN7<#(@B!Q`H[<8<,N^'"L'*PL'CYD=<\?1)&+B3\740:,9G<IO)/O*F"QC
M91HJHW<(FD#H%:J.TG9.!,@4PK%5'(2[!PX;=K5RZB&/UA,6QH%W2K"K&%-1
M;RM*J1HJG$2TQ&O/&53+-EWGBM!1K&J$.JFT;G.(@(ER#8(X<-NUJY=0+*%G
M+8W+I"&KRB(^FYRE*@+)*0\JE3<6@1ZC%R+B*<K%178)K)E[^:J$`#``]H.8
M8QX)=IGI-+#T?`NS:6$S(U.TV4PE&G:=S`1`?\`0W2'+\"Q.!W7PK,O@-ER%
M/)ZF_-RG?R!#>!8<$NOA69?`FRY#D0IRFCKH%-3E.[HKH;W^3T*?8"Q!$-T6
M8`;,`RRQTW/==PNMYEKUI$Z<KBU!?`JNKL(<Z*X6#<4->I9Y3U/*N2:MM3#,
MRQXB.=#NM[B.%6R"'?+0>]FC9!<2$(7H!LR`,>A>KQN3'J9<THV4F#Y/TWYM
MT[]'Q!#>!8\9TMU[P;I4*<LLTN%P2_"(V5E?)ZF_-RG?R!#>!8<$NOA69?`F
MRY"GD[3F9/\`)NG=PRA4S'\0PVZF)@'=,?\`O+/=$0R^B.-M-;JW4M7>*<LT
MT^%8%T<\!J]7@M-%U9?7370MP0M?5LM2\)6":5.JR"+NB?\``<,:K"#Y/MIJ
MIDX52%C'DHXW444E52F44.7+,!SQLXGN+T9<TH,WMQ5-K;J0!ZCI*+I]9BG4
M524P=%]34.RD1D:3EW$',J)QZK+OI1FC(-A*1;=`BA1S`<L\:YKM<;X]HH*6
M6G-B6#\`9@9A11&CAXK%T6F@W5.W4.+&ESD*Z(F=06:RR2*C=L[WDCEX-0X'
MS*.S+&+W9=ESKEU"!R&B*5(8J9Z?I;AU&JK]%HG#T\L]<L$')62SUJS3;"Z<
MM2NCE*4Y"&!0!`Q,R[<.&W:U<NH0-65'=:P=(S\O2]1.*9C*@@I2V$/+1BE'
MME'#)_>*85@[?(J\%%&*!IU\B8"AGF4`VY8<,NSP1EY=0A'`9;14Y;&XD0ZG
M:,84U-QC*I)ZDW;A&G(M$$)RF)!Q%S[,Q5V"8B,8^;"F<0V"80`,\8<#NMBS
M+X#9<AF'D]3?FY3OY`AO`L."77PK,O@-ER#R>IOS<IW\@0W@6'!+KX5F7P&R
MY"T]-TT8F\-.T\`I*MU2_P"`8K='<73S*<J:"(G*)1'8(Y9Y8PJ[EI*[U-4L
M.CRYB.EJFG:17Y.YDV8\HCRD;=HW;-$&L785%-NR0,S9D*M$SKD!29%74;)&
MR4R,)2E$1ZH8_0_VKNNST:J?+">S=<1[W+*GW:6T7FR$V6MJV8Y?1BJH,(?L
M8X_W"GK4+Q2NT=+3;PXH1AS&RK53IJ"QMK-`W/>6!FZGMK=6EZ<0%Q4-24-6
ML'!HG4(V(K+34.]9,$SKG!0B)!<+%`3"4P9=+'S<NMN=RU#C-K)81Q0ZL,3R
MZM-O\]A\H&NAN^:--S%ODXR$6M^6RZ-24O28OFP-8[5/45`PMO*F00*)D$"0
M,?%Q*KHJF0%(L\4W0W]H^9H5;6<V&PW3'Z=+PEU'*5Y*%J5]$&F:(JRA;@0%
M24<R:4G$1%#-J?E:'J2.F&2%2RU.0U6INA[U:HF!T14AS*$*3;="K'&(-<QI
MFBM'][86#J&/"VD3!5>73%=:R[FXGZ2`DIJ[-PJSJ:%6I^MY%N"R`01'[)NK
MPATS$7:D,4H&$0W\')4RE<8*"@;>-8.\\#-W9?#:ZD+CU]5U"Q#:W%T*UKIL
MFPI8T/;*,IQ>CGU/,%DW:SL*HB%4&JS<R:+P%@4=@(EWCS0JVN),-CB>;:33
M9>Z"N'0523-(Q]-4M`:A%KFN83RHI4@4M33ZR):1FTFL93BBD$V;2M9/%@23
M;J"J;<WU#`<V0-"K:Q!V'L2VDZN*NNM/NZMI>&D[8U5K*=7:J"+-4Y&+2;M9
M^@UK13!R]+'OFSY==&K&B0@V.J8,BB;%4E1/"W`JC'"L!I2HM'FHB4MW24!4
M]#0]S9B-T]5/:6GD92X3.&3L[6"EP)*995TS.WX9&;8&H)5HQ34<$'@A2`HF
M-MP4E2#BVV%@3BHOIQ8<9N"OM--Z'\_74L%--ZVHMS<JQ-;*VI)6C&.-<>B*
M,L\E;JI6:B_#'0@U8.IP*Y2;-P12?HG$RY#&`#A%+5A".`BTH0A@+9K3I>*I
M[ZT-4#RT]'4-;RG*TH]ZX2A9Z'5\6VV"A)EC4=+U(Z45&M*@4BY0B:22+$$V
MBH$`1!388;H5>9N!7&.!&#T?I*OK"4)0E*T53D3:=]1]I=4M`2DO$5BB#9_4
M]PYB,)1E6G8M3HD1<U"P9&044`BJ[<C@3IFWR!G-"K:S&$UAWQTFW6GH*IXR
M)MLQM72E05YI>1&UK2O$94K^/M=*+NKPW">3":Y6[-:K&C@4TV@B$HX*03`&
M9L@REEJ2S:1<..!,_2U;"?L]25QJ4E8EM"4\ZO5<N>M-"LG:CUK$VCF)!HXI
MQDU,],N\;D.NF=3@S*B;IY[NS'=2O=2G_*WUAQYE@,/N/]\UWZ14^#4#>L+J
MA#/=V!G)6XZ6]MQOJ;RJ5)5+H-0R_(Z;LVIFVN8F8<GWU3M3]H.YGNAMRVY_
M78Y]LJ>%G;IJPH)>L8/_`)H#_P"5CFKU*M9IP:@CCO3BU!<Q$"^-,7D97^L+
M>6U5O27(;V[HR]<%-P!ZP8T@X4<UE'4N6+,BJ]3=)NHXQH@Z<@0$Q$S978(;
MNW2I:RPIM'*G,L*1'ZTNCFJ*5KRVLK7S6FI2)IJV-ZY1\C!SKAY1]%7>N;<-
M.JJ6INGF"0HMI*$I$'1F[9PL"A4Q,<Q0`-F*Y*R<&V&IDX-832,]:K43:NP=
M2%K6F/$I;<:75+&,):/K=*>D:OJLUZHN5)51H:-(J9A%K0"AN'\:)K&*D<2@
M;@RES:%6T?FL-A6[M"O=?1_>RUUO(]:'JYY=T:F*K.II-:(K2HH92F*N)#T4
M[C&K%!:V[T\>2.5.EFBV1`ZFZ<#[@;53NS_52;?/A^0_-8;6OO36IJ_-'PL&
MYT_4K3RS4M21\Q!NJ[H^J*G924M2*C9C(4LLZ;,H&/C&LB0I2&,@=4B>Z9#@
M#YYG3NW\M)J;F<?D/S/F-8)Z1KUN'Q*SDH.->W$C)W2.I1]0N*R375@F5N(R
M#87G<-D5'IF1_&[1DNV>D53.#T%!`-W/+&G0JVLGYK"ZC-*UY8Z[B%5RM#1*
MLQ"U!JFDYJ\KBMFCN7N2RNO"RB5O6:T$L8S2G4(!R_(R;BW,(E;)%W=P0`0N
MA4A##$RPP2AAZ3"9K1_?-Q!T3%SE!Q=>2D=:O3Q24#6#RX7>DO:%U:FHTY*N
M("EXPRSE*JIRJ"E!RBX?'#>W>`4$Y>VQ%)4ASD2<,*PFU*ATS7EN'>JK9NJJ
M)HR*HBI$+YTO)3T+(PL;258TG6]$.65)JS#IL<*E<2"$V9,LF950Z*3LA"HD
M`ILRM"MCB/S6&LV>D:[QXRSS1];67IZDXFS=#4([HNCJZI=N[MQ7%(S:IZDK
M>#E)HSI]WG7#1!NL55F"2VYO)*`(`!ANA5M8P\R/L:D8RJ29S;QCG3;G4$YS
M.'"9RLVS<6RSDP%(L"'>^S=$P9F,.S/&R2>K34,)W75I2--<YR;H]0WN0^ZQ
MLUU;+F.G3EL--:CAW=.M_P`!$H"%C[L_7&`H[:26Z6?0VX]&YZFFU6JT'/.\
M;TH1[":Q6#3@7/3II]'(=MC+0]``$/\`1Y3G0'>#,-F.F]U+K>9='9G+_OC^
M`T\AN7='J&]R'W6/%=6JG!121=.6PM.4^X?=*<QMP^Z4I0WC#NCD4N1L]X1Z
M&(ZM9J&$PGF6@\',0\U$V3KZ[%VM/TO2E3U'0]+T<UO##W`JVEI)C&U0TA:P
MH9G$0T3%B\8O0,RF)%N=!?<`IR"IGO9ACGT*MK/+_-8:+>Z+IV,D-2#>WK8:
M11=V/HJV.E^HE*B=.'L,NA23B'K5FD58%$&"L^)`8K+'(8`4=<)F4`PT*KQM
MB#L-GZ?K`W!HR#F<ZCKNQKV3N!2T].0K$UJZIBY)C3].),I>*I>-91:\+3<&
M]D!`73@>#D'BI1.)LQ$`:%6UQ&&&)D=X?1'<R:"B8RKV4'2*]*DU4U33U01<
MDT7=4?7]>7:97&M/4")6)_O'C=9L7OL2<&3@Q.3H&V9R22N.OE<ZYL,(#\UA
MWK-V,U9V@=Z?ZYE;:PM>5W2U*:E:>K>E8FX</3T"28O+6D!54,^<O'S='QC&
M.09N>_%$DE-PIC`)!WP#&>KNB_\`PO\`N^0_-83GTQ6KF;.68@*'J!^SD9LL
M[6M3RYH47"M-QLE654R51NJ>II1P"15(:G#/P9IF2333,*0F`H9Y!DIM6M&C
M*Y9;,9W7:9*G!KG-^[H]0WN0^ZQ==6RYCITY;"NYUC>Y#[K'125?]>%IDTU8
M0VY0`V6EJL`W#CE7EA`Z`;?Z::%_=8]"2\UJ:_2\XT[$3/DC_P"$7_WH_P#N
MUUT@_?U.OCSG?*D7^5XQIY#@W/W)NP'W6([W5:A!\NH::L*@40$!W!-D8HY#
MNE#8(#O".8Y%+T1V;0#&G75LI=.6PBWJDM97MWHBRC"BI$T&_HV_U%W!GZG8
MR,='R%*0E.<,BK4T"M*-W+$7I2K;Y$S$$`,7+,1',,)YZTZAAQG/>)TZ?Y5A
MBB)ET]!J;Z94:T3385-%1FG>Z\;3%2U35@(U6[U(W#KL]8I5BN+5X@BD]%ZH
MH\!?--L42%2$N1PQJ<M5O&<#TF\6$YINP^H>I[P4)54E1$&=A2\Q;UU-5K`3
M%-1-3U<V:VI?TU6S&=J,$CS;NHWE4G(0$FQF\:F4Q3F3.8!$9H5;6/S<R,0#
M2MJ$9T%"4@C2+,]'4%=9:9);L)&B%+CW!HAS2`LCR%7NW)24/.3],5/('.US
M*DZ=))"8X@),-"KBBQ^:PDW4=B*Z/9K2M0U,-9&9E+07PM-7E0+U;,1;^HV%
M+TA+2CM\L]F(YDC"R#F(8.$TN#:)`FF3=2WC&()AW23UI%HK"=-*\.G+HN6/
M63DWP5$QB"(I\*XX,03R$4S.%3D$PB;MC&`V8CL#;C/75LILVM>#M^0W!ZAO
M<A]UAKJV4Z):BF2>B-T>H;W(?=8*M5CAC`RTY;"&^J)04[MZ`P[4<]6Z?]D`
M#ML]<OI9#U<>M_\`&_\`YW_?\B::L)D[@_NO<A]WC76=!4VZ=!RSPP/2C#J@
M-->$INCU#>Y#[K'FZZMES%TY;!NCT][W(?=8CFUGY:\KFDLQ'/>9DZ<$L,2+
M&IZU%?W36L(6W]025'NJ'OA#UG/UC#/8AG/4K3K>F*EBG<Q!H3K=]$RC]%>3
M3+WLLD8#IF,(9"`"$5.Z)Q5%QZ?D<,KF3BD1#NWH#WWM4Q]L:582,'&Z75Z9
MM1*3E4IH56A?66NU*5K)55)J(/44FDL[055?$42(1ND*H)D3#ZX<)Z<F*[RN
M1<^&,0X\R,AK"QE_:COQ$UO-49'MH%A(OI1_45-5=3T%.5'2$S9)Y2BD2YJ%
M85:B?5K)56;-MPZQFK(X`<I`4',->A6?.R)3/!`P`FEW4*-OJ(IQW2:+RF*#
MN95(FM\A-T(VK^M*'J6BVD*PJBJ',D(4;.W`I62(J(JI\&[5,"*JAA/M%H5;
M6(.PE)45E:X>TGHTIZ)1D72]D[D4/4]6/:QJ-F[J>%A(JBJLBUW4U(9M492I
M"O7"*#DR294A,3>()BB`X:%6T?FL-GZ1J!J^U&G6W]OJ\CF$?55/Q\TE(,V#
MY%XS*K,5%*3"1V[E(G!JD%L](<1+F&\80Z6-ZJUI94CU))UH+!S$CQ`QA$P@
M.9A$1R`HAF(Y[!W@S#&6NK93/35A3='J&]R'W6&NK9<PTY;#F;@8%T!R,.2R
M7]B'[X7]UCHNM>95Y75E<]/G6*/6-.6PAEHH'.A;V%W3!GK$U/"([H;/\NA'
M+Z[K8].I4N=3!LS2_K^1-8K"9&YD&P#>Y#[K'F5I:=%:="DY)GC<8X!IKG13
M='J&]R'W6.?75LN8NG+86'3S`I0SWEC*(F*8P$!1$C=5T=(@=MFLJ+<"E'HE
M$<]N,7JZN&O(YVL6&!Q7IQF4%S$%IW2K(W,U)78K>X$E44?9RJF-A):.IRF)
M)FT3K>8MF@[E4TJJ2[T-**-(B6;-MB2R0&$-H8FJNGHO/\CE_-8:(M]I'NW;
M.3I>L:<I*FX^L),NLUO=->3J$19U<PNB=_-6<IB8;+O,I!E)3CD4U03(V6;"
M(`580'&J:1J;_P`2<LG,L8PV&$H:3K^C15P$7%LE8FHW$[:^N:,I6!J.B8^G
M8:JZ;HZ3B:J=3M*I)E@'M)/Y8R**:9C*2()F*L98ZAAPT*N*+&&QFZH;3A=U
MQJ/C;B5JP7D(H:TMO6,-55O9VE$:<HUE2]`Q474M"*-ZA0=U@M1T?,QZB14&
M8CWRJH"@&V9"T*L<;&&)ZMZ-/%U*YN[<>NH2%B'D'4UR=&56Q\F2=:,W4DSL
MY4KF5N"JLV7446;I0;,Y#,BF#,RHFV`.88*6JFG%Q+*W+,IH<Y('2U;BL;66
M^J6GJQ9HMI&6NO>2J(Q-FNF^2<TO6-Q7%2P+XZB::()R3YHXX54-HE(40''1
MKJQV;7_^OM^1)C=']U[@/NL-=6RF<EY4\VCH0Y=!7='J&]R'W6&NK9<QOTY;
M"Q7,J2F>8;W!EVY%#,52#T=X>ICT;C5G=&NYI=)*G^)HK2JJDE@@R)')[F_^
M(WREQ-@Y1^GT<P-O?_X_,AT,?:?MQ>E55:12:,,./+T&^C-JTW`NY:HTVI1F
MC%M2S"/DZA=ZT+<C#,)>1\4,7;\D+4XI-G;K@U%4$%%!`#'(4QB%VY#T,3WW
M==?O6[RM<L!)XN65?ZG^!M!2F^4/57.L.FS36`J&,;<#4?6&09CGT?T8[VS'
MK5/;#J4Z::EBE#&@J,SF@VBAJ7Y1(Y@,?3=IJ$>`4:C_`-8NK@S;+G!1P3_1
M>(`JNH4HBI]>7+(,:OI'(LZ,MEE+!I7E$S'.L.G+3<5<1*=)9+475)3MG!4P
M0[Y;&4M2LH@J+8`)D4P$S[80$<7Z15BSH;+*7^2W*'COE/INTWF3,!BE*74?
M59#B14HE<F<+%M3ONG*X"/WTV1B9]KA](Y%G0V64YO$'*,``;NG+34!P.FH"
MGK%5:0W"(%W&QLV]KVY]Y`"D'Z[(QB9F`<QQ/I'(LZ&RRG%Y,\HF)0(;3AIM
M,4%A6,`ZC*M$%#`854RJ`>UAR"FFZ,*H%*!0$P[<^CB_2*L6=#992XU.<HL8
MARGTY:;3',/"D4'434X<$Z`1`KDA`M1N9$3.<H)_6=N(]$`Q/I%6+.ALJM*#
M2_*';H$#37IM`I4UT29ZCZL$1;K)`D#9<?T4_P!\-DRAF"9M@FVCA](Y%G0V
M64'IKE$C\$/JW::@,B?AR`&HFJ>!4<%2X!-5V@%J0*Z*1`1*)#"!3=$=H8OT
MBK%G0V64JG37*(ID*0--NFK<(J1=,/6+JK>352`"I<&L-JC.DT$D@$A4@4`F
MZ.'TET9T-F6*)<:G>44.`%'3?ILW.`,W,3UC*K`#D!8JK<3"%J@,)FH%W2#G
MGD.>>>)](Y%G0V56G`>EN45.&Z;3KIP$"[Q40'495.1"*?W3ABEM20CM<0'(
MBQP%9,/K3X?2.19T-EE.)2E^4033$WJTZ:EA*!"D*;4E5Z.X!?O:0)JGM<<$
MB(I&$H%RR'/JXOTED6=#99;2(5?P&N\NMW2YWU8'3N6IVUE-1Y8:(1O]5YHU
MW&+R-N0DW+R5-;G>([9G60X-,B61P.81$-W!>TI7@Y^7.8NAHXL9,0U,\H<8
MQC!IMTV=N.\(#J.J[(!RRR#^C+H8OTCT9S'5S6K.`ICE#^EILTU_*.K#^M;$
M<1^T>C.C.6AIK\S*!2W*(`<#AILTT&_L#E5U$U8L041SX5-(%+6"9N9P`[IS
ME',Q``!P^D58LZ+LLH3I?E$DP$OJWZ:E$S("T%);4351TRLQ*8.]$B%M6F1%
M%,PYIY!O$$-@[<3Z15BSH;*CD"G.45!,J)=.6G`B16ZS8`)J2K0J@$62(F("
M<ML@(J0#)@;=5*H43!MQ?I+(LZ&RJTH:F>41%/@RZ;M-I"%`W!%+J-JLA&ZB
MJ@F<J-T4K5)(HF>IY$6`I0!0H;<3Z1R+.ALJM*^3G*+@4"$TYZ<$T1'>4;DU
M)5L""A@>$=%,)/T:9E$A2<&&0Y;F'TCD6=#99;3A"E>42`@)AIRTW[F>9B^L
M95.9LC\,`;WZ*,R@+@`..7UPAD.S#Z15BSH;+*<@4QRB10$I--^FXI1`I1+Z
MQM5"7<3'-$@%&U.0`B(CE]'#Z15BSH;++:5&FN46X0JI-.FG!(Y=N:>HVJ0`
MQ@#[V90OZ*,C[HCM^SZ`CB_2.19T-EE+"TORBA#BH33GIN*?(I4S^L55`G23
M+GNIDSM1P>Z7>-N]KVH&'H[!P^DLBSH;++:5&EN40$3F'3?IN$QMA<M1E49%
M+MWLP-:<XF.?/:;,!P^D58LZ&RREH4ORB)>U]6[35N!_<TPU&5>!4\_KLOZ,
M0SWAV]+!>T<BATHQFHN7!*T/)CE#_9MTU_*.J_T98OTCD6<QU<UJSHTQJ+@]
M?#:P-]%)S3SIM80Q+/7#3EWJ&H:JW;II%KTZ[\;ND&PVS+PB[2.2$Z)1S`ZF
M0#L$,8S>VW24(*"RQ?+"'),E%PSG-IZIS7XI8"Q)H73QIPD(?]#%K2Q+Y?4+
M5[-=[%EH6!+'NG#0;:&[V7<,P(8Z8#D4XB`;,7Z<FYDH=*789*G-".`W#Y,<
MH?[-NFOY1M7^C+%^D8X8+.8ZN:U9T5"F>40`0$NF[384P;2F#4=5^93!M*8/
MZ,AVE';A](Y%G*J4S<&U#J*FICE$]\ITM-^FI+@RE*B'K%U>H5(N]PJOU]L/
MO@JK=OF/UH]#&/TBK%G1GLJ*>2W*([ZBGJVZ:>$/O`0QM157G*@140.N5%,;
M8;A!66*501#:!BATL7Z2R+.ALJM*#2G*'`(&1TW:;4/O1$3@GJ-JHH*)IB)B
M%,4EJ"$'(YS"(B43&$VT=F'TCD6=#9453I;E$$AS)INTW#L*0`4U'U:H`H%`
M2E;JC^BL!63(01`N\/:Y[.AA](K)G0V56E!I/E#3"<QM-NFXXB!TTR*:CZL5
M02;FW1(B5%6U1^V0$!W#@)3!F.>>)](JQ9T-EE.12F^434-OK:<--RJ@E(03
MGU'U?M*F7<(`$"V!$R;I0R[4`SZ([<5>T<BSHQFHN7!*U`X_)CE#_9MTU_*.
MJ_T98OTCD6<QU<UJSHM&F>4/]FW37\HZKO1EB/VU-)^5*6"RHRU<UJ(9Z]8K
M70VTRU8:JK":<XF*"N++)N7+#4-4SURD^)>>A@B$2HJV]1#<=K&`%,^V`!'=
MZ&)]/0_4DI<F'L3,7*UA<,Y-)Y3'*&+.W2I=.&FT2JN5U"CZQE7ES*=4YBCN
MC;(PES`<\A$<NKC+Z1Z,XU4V3.<?DQRA_LVZ:_E'5?Z,L/I'(LXU<UJSHM/2
M_*(&*(%TWZ:R".S>#4;5PB`9[=@VR$!W@V?3P^D>C.-7-:LZ'DKRAQP(F;39
MII%`F9.`]8JK-PS8V7"-#[UKC[Z1^J(9EZ6)](PYEG1E+1<S@VH=)4U*\HD?
MA`4TZ:<S%5#=4*&I"JR%5(4R9TT%P+:C[\U(H@F(ICD!A3#/$^D<BSHRV56G
M(>F>444$1/IQTV9GVJF+J*J@AC#]<)$3%M2'>S<RH`<4R!D(AT<7Z1R+.ALJ
M+"TMRB9>"(&F_3.1!(XJ%;M]0E3H(I*&VG6:$_14H5JNNJ)CJ'`#&.)ND&'T
MCD6=#95:%*6Y1)3Z[3?IL``$VZ">HRKD2E(KD#E(")6N(F";HI2@<```$0WL
MLQ'#Z2R+.ALLIR&IGE$3&$PZ;--(9Y9`7475Y"E*``!2@4MK\LB@&6'TBLF=
M#99;2P:8Y0_V;=-?RCJO]&08OTCD6<P=)IP34"GDQRA_LVZ:_E'5?Z,L/I'(
MLY-7-:LZ(<ZF8?7'^DS1`O-V(TX-'K;5$U&GFT??^HGB4G4!K47!(M'/3GH%
M-1%FDVX<^^F`J`*9<PVXQ^GFG""B\"Y_X!ROK>4F(%,\H?[-NFOY1U7^C+%^
MFIIWHM2P>5&6KFM1=Y,<H?[-NFOY1U7^C+%^D<BSF.KFM6=%0ICE#^EIMTU_
M*.K#^M;$<1^T<BSHREHN;!,U`&I3E#3Y`?35IJ,`9YAZQM7#F!BB40`3VM.`
M9@/1`,\/I%9,Z,MEEM*>2W**;Q3FTYZ;CF_\Z<VHJJ`47`-T";YPM1F44RID
M`!#;D7KCB?2*L6=#95:7(TSRBZ)!*&G73@;A#J*.!'4=5Y`<BJX1=&(H5*UZ
M9"H@NB!@*`;,Q`!`,/I%6+.ALJM./R4Y10R:::VG33<N!$BH'(OJ+JMR@JC]
M<HF9N[M6X(0JJO;B)!*8#=/#Z15BSH;+*<@4QRB91WR:<--A%1`V^?UBJJ.5
M0PY;IC)*VK4`2D+F`$SW0WAP^D<BSHFRJTH%-<HF!]XVF_32<"IBD0I]1-5Y
M)AMVERM>4,PSV;.AB_2'1G1BZ33@FH=)0*8Y0_(,]-NFL1RVCZQM7AF/5R"V
M609XOTCD6<FKFM6=#R8Y0_V;=-?RCJO]&6'TCD6<:N:U9T7%IKE#RF*8--NF
MH!*8IBYZC:P$-XH@)0$`MF`Y"8-N6W+#Z3T/S06#*54YHXUG1$'1S36NT:+N
M^%.6$TY2J"FJ?4"]?F=:@ZM;F;S;BL%25%&HBG;8Y5&T9*IBFB<<C*)AF8`'
M&"]O.9127=9:261S8H$NPIGE#_9MTU_*.J_T98R7M=U<#2SHKIS6HKY,<H?[
M-NFOY1U7^C+%^D<BSDU<UJSH>2_*("`Y:;=-.\&1D3#J+JXPH+E,42."?T8C
MF<I=XN0[!`PXC]HY%G1G+0TU^9G(--<HF95,Y]-VFH2IJ"IP9-1E8)`.^H@=
M4@');#>(FJ1`""4-F0B/1Q/I%6+.B[++:!IGE$3")U--^FXRITCHJ'#4=5H`
ML003%$5TS6K4*J=NLF"A#"("!L^EA](Y%G0V5'$%)\H:!2E]6?3"8$QR33/J
M"J@[9,F>^.3<;6[IEQ<`53A1$3`8O4P^D58LZ&RHO\EN40`YC%TW:;"Y\'L]
M8NJ3&S2."I#'5-:CAC',N&^<2F(!C=$,L7Z15BSH;*K2HTURC`BH;U=M-P&4
M1.@.6HBIP(">\*K8I2?HIR#O5P<Q\^BIO9&S#$^D<BSH;*K2A*8Y1(I"$'3=
MIJ'@RE%,0U&5@42K[G`J+AE;#_SC<13W/K2@.S%^D<BSH;*@-,<HAE_V;--?
MRCJP]&`8?2/1G0=W4JBGA+?)CE#_`&;=-?RCJO\`1EB_2.19S7JYK5G1PKTU
MRAY29#ILTTY"8,Q-J.J[8)1WR#D:V!@$!4*`#T-@CMQM7MK9KM6Q1FDAC&KF
MYVLYIODTT*Z0U_<HX2YT!2=,5\,3I^-4,)1=1NJJI]BJ:"FA139S#UC&N5LT
MLA,"B)#`/2#''[%NKNU:O*X8,&##B=I4G*ID\?S-E<KF02I:#!(<Q#'UV6I*
M)MQ%0P%<0U5\(!>&25`H#ELRZ&)[MJ3<9H2X()^4ZYJ,D%CQO\#[$+E`B:J@
M"(&*0YP$$RJ"`Y".PF69MO2Q]_).I:,DTV(:$JFTN>)ABE9PB%1QE&.YV'9U
M;,QLO)1L(JY0"2D&D.+0DB_CF)Q(HZ8Q*STA%CAVIC#D`]'+;KJ-O+G-G4<L
M;5L/-S%10T/4,,^E:2/&-JDA&:R#V3@I"59*O&C*:2;B<\>=VB)%4\P$1(4V
MS$U]!+\S)'(4=UI3\942-(R,RP;5*ZAY.I6D2L(HJN*>AG,.SE)-(YR;@M63
MR>:H'4$0`%%2AT\1WB[<SYN7,7J/0CJABY&3DX9K)M'DK"D:JRK)J*1UVA'Y
M3*L@4`I<B]\(]L00$<P*.#O-VYFB'"-6P):H-19Y5H%4^)!J-*$*8%))>"[_
M`/%03!6Z9!`C+QEFD(B/UP8;1=[2]6$R(XF*8P%VAO`FF42AF<XY;1'=S`B8
M_7"`99#BJO0:QX1U%""8X&*!RG5(?@C`F3853(N9Q!0I1W"B<!Z8"'0Q55HM
MP5HZC&Z4K"G*XADZ@I6::34,=W(,?&#-,YD.^H=TJPE6YA%,-Q5L^0.3+;M*
M(=+&.T7:TG49"*A@R$<\CD4,DF()E$YD_P"PX0Q0W>$Z("(!B;1=X8U'ED+U
M`R@E*=0YBD3+MS,4_:%`,S<,/!?>S%#I9#GAM-WA^I1'4="(F8VH6+.7@Y!&
M1B'F\9L\;`11)VGF8H&2$Y2'*5,Q#`(Y#GD/4Q9:]"9Z,K3F8/74(&X8<S=J
M&\&0B7:3M@VDW399AM#/:&S&Q.!(D!KJHE+RBNC[IC^@?5<GO&*F<X%\8VA'
M(%#$%0H;>@`Y#TP'%<T>9&+2FQD_E$B[.CT^D7[G$TF8:J7*6`F`=`1[!?N<
M(F<J4J@BNX'5'_:_<X1,HEBNZDF<YE"EW4S*AP@`!0(F&:AC"0AC"!2[>A@Q
M$U-!7OM75=0K4G2M=0,[4S<%>^H%DN89!KP`*'5,Y240(=#>*B<"%,`;V689
MXX:UYJ4TW+HQZ!$SR.G8^56D&\=((/58M]XN?<&0"BW>D23=KM#D,F'WY)JN
M01R'KXZ9;U=G*G,\,"GKF..\0I#%,541W#B*9`*`%$>U*("*XAEM`,L57B[Q
M6'Y]@ZB@'4$5`Z)DR)F,4J1NV$^>Z9,XD`AP4RV%S[7IXV:RA%)/^',#A([2
M7.H1JN@X[W<J-7()G*<452%(()&%,AB%5)O]L!A`>ET<:+S7DIT9IJ33J)+.
M%`A+>G5E5EH+A3])!0,-4L9%Q]HI./7:RTFTFG[:ZE=2U%`F9NM%C').8,81
M9T8G"[RQ1*0H`.W'D/>-\6"$F;YE<$;NLW>YM=^J+NPT=%D:0MMZBIB(@IY-
MXFY3K.*J6AJ=J]*?01!(AF"*#F959BD;>$3-Q-F&>6.VY7JM>)IE54J22Q(C
M:YC?FX'5'_:_<X]&)(E!3*/1$>P7[G")A-*IL+'!%Z_8+]SAI,QU4N4CYJM;
MD+IAU&B=,JP*V4N:!2%(!3GWJ,E$RH&,4-X_#K$`,_L=G2Q@Y96VWSC52Y3L
M:5RF6TP:;U#%3$QK"6>$W!&`R8'_`$>4[OE(8"G`Q"FS`!S'8&&A+875RY3?
M7`F^P_9_BL9Q9-5+E'!&^Q_9_BL(LJIRIQ*\&?[']G^*PB;(C@S_`&/[/\5A
M$1'!G^Q_9_BL(B(X,_V/[/\`%81$1P9_L?V?XK"(B4%(P]$O[/\`%81,)I5,
MXL<";[#]G^*PTF8ZJ7*4X`?L`[/\5C%RRMQ:PC5RY2!7*4I#ZIE5`**Z@EN/
M88XIM$7*ZQBA>R@B@4I6H%4$P]$1#80NT=F,="6P:J2$,)/<R1A,8=WHF$>C
MU_\`ZL<;(L.G*W$IP)OL/V?XK#28U4N4<";[#]G^*PTF-5+E'!&#H%_9_BL(
MLRED4KBBO!G^Q_9_BL(F<1P9_L?V?XK"(B.#/]C^S_%81$1P9_L?V?XK"(B.
M#/\`8_L_Q6$1$IP1OL?V?XK"+-;DEF<6.!-]A^S_`!6$6352Y2`>L(I%KO\`
M)]'.FZ`A-7KA,QD47@HHN4+'WB(D*XH;I"-E79-S?4[01,4,:]"4:J5..'&3
M[X`?L`[/\5C)2RIQ2PC5RY2O`F^P_9_BL9:3&JER@$C!T"_L_P`5A$REE4KB
MB.FKFZM4V(TTWHO%1S2$>U+;FA)FJ8EI417:D.Y=QB/"IH/B,2D<BDJ/:]J8
M,A$!SPB9Q/F!H_Y<_3??L(BE;T%+I\N0\2:-"%J5<5:!G)95$AE`BJEX`BC$
MJIA[0CHA`[<`W]@XA#[91<PPF&#*2CWK1ZP?D%9F^9.&[Z/>MS9<`LSD6(KM
M%45-X,C;VW%B6)ZJ15#$^_!N*@(@<A=P0(/1`H&`O;ANB&W9A$1.7<#JC_M?
MN<(B)3@B]?L%^YPBS6Z<K<6."+U^P7[G#29-5+E'!%Z_8+]SAI,:J7*7$2+O
M!M'I_8]3[7!N*@QJY<I!/0.D4:%OYEV@>N5J?,)2`4"B(W%>;V8;H_7&'>'K
MXUZN7$%2E5I.G@2]?L%^YQE*E+B&KERE>"+U^P7[G&6DQJI<H!,`Z`CV"_<X
M1,Y4I5!%=P.J/^U^YPB91&X'5'_:_<X1$1N!U1_VOW.$1$;@=4?]K]SA$1&X
M'5'_`&OW.$1$;@=4?]K]SA$1'!AU1[!?N<(D?YE!E."+U^P7[G#29KU4N4XE
M44S`4#%`X`<@@!@`0`=X``V0``"(9[,\PSQKKK2N]1/%H,JI2GR`T>"?G2.4
MX`RJQP)"Z=2@4ZRHI?\`%^:[8$-_O<BF6P3%(4P@`9B./E/;$BEO-XAXGWLL
MU*5S.,<)9RNG]QT%?]^ZT?\`Z&JO'B^[?^[H=/P-KQ+K_`^Q9@$2F`H@!A*.
M0B(@`;.CF&T,L?>S2.I=99)<;,.?K/GIJ1MW62EWHN]5`4>_J6I;.VJ:U!2*
M,8DB:1J9X6MY(U5T!%'7,1(96I*5>+`T1.()+R!6W"["@(<CN%;`HXOC$94:
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M6FX^7F6\NYKR-HEMJ)=U`6BW9FRB$V[K!6V)1X0A'1)$K0Y#F6%?,^(Z-YQ-
MO`@W@)3T'#UY%Z>*\C9&KKB/Y!VZJH:8D24+4L96],4Z][R!HQB(6I9^<K2?
M8PIB*F%=5<SUT9<Q4CEX,N7I7:Y5JE'3PX^PC9K2CW5>K+V2_231MY"T=#LJ
MKB&C:D5;@K2CVLXVL8US2M55J@_?(UC&Q$W2[!5P#*37601!?@Q*)2@..B7=
M]13)S1T8D[D:8IRA+ZQ$/2U.*%N/0<.FUN8]AWD+1U9318"N)VZTY)MI69B:
M1FHI%=!6D5$%$@DBN&0J";-+:;/QJM"\*=RN,$V4VNC3UWF\34D[6KB\\M&2
M^IRL$*UBX"8JQ.>3L@SAG3:E3TG`12A7S6G2RQ45E7#,R;P<Q("QR[`JH58)
MS.;]6'HP?/L*6T(G>^,JBT4E.Q%U:A8Q]25I#,:1E4ZNBB0ML96LY)2C*OJZ
M>3D$HI_5\%2I$DGC.<$ZIF8IJ%*+D3&-BJ%XRQY,)E;%-KU4]/Z>R5=$W`GI
MQ.F$8"MH.59U;!PU&HJ3=4MW%8^,&CMO23\CJ.5;`+)^@NY/N@*!B9CCJN%*
MM)>I'/&!(GT_4_N:GVAO[4<?3$($77_\171]_P`Q>J[_`(?:#`$_E.E]/^M@
M#CP`P!:8A3=',!RRWBB)399YY;P9#NCTPZ`XR>('SFO3;ZX#BKKG#0,)4T`-
M578TT-SSU%@WB)MW1Z*DLA<%RTDV::3IM&(1Z@D<J%."I=XP@(#D./)O/Z9K
M8KN948A*6]O2^N>]IGAKLL;:#=:\0HNHJK9QDJ]I&+TZTJ6W[AQ.M'J<RZ!U
M<$CC@555S*+K$$BICES+CQE0GFJ/#-H?F:S.'X1+D/$94SJ@C+4F59O+LN*Q
MJ>R=MINN#R,J]DG*-:L:^<-ZUC8)DI)F&GZEEZ"(0IV\8#9,2%X0@%6/O8BH
M5EHM.,5ASL1P=1[L3!W8IXEL92.E[LW`,UN'(34-14A2%RJ:A&=,RLC"L#-Y
MV8>U(YFXQ"FF9G;U$)T[Y%X7M"DRR#'7L]XQ88$B>4A2U8451]?49#4+=M5W
M-7WK*8D)Y*:N8^(G!2+9:3I.?AE8.<A59UO,*9-A19.F[-J.0J%$2CO;:5WJ
MJ9:<<>+FR?B.8F+8>D7M1VAM9+WKIEH]N\>W]&DKUQ44.S\I/'L415VB,P4Q
MG:K9=G);RZ`<*)TEC&$!`1''8[O@Q88#FRF^X6F*<ISOGR?@XJ&[\[V[[\6L
MD&??/>;<C1IPW`D)PG>[5(J9,_K2%`.@&.B[TM6VX`]W'408`8`T-J@430TX
M:@553G,0++7,6,F`%S`&U'R@@1$!*`"*IE.B81$#"&6`/PZ6[Y._E2YRWEOY
MJG;?7C=4_+T+1TG!N$;FK-DE(=]3<8YC!3;FG$S(D*R5(4"B4!``RRP!F/-M
M\K)\6UY^-17W_P``.;;Y63XMKS\:BOO_`(`<VWRLGQ;7GXU%??\`P`YMOE9/
MBVO/QJ*^_P#@!S;?*R?%M>?C45]_\`.;;Y63XMKS\:BOO_@!S;?*R?%M>?C4
M5]_\`.;;Y63XMKS\:BOO_@!S;?*R?%M>?C45]_\``#FV^5D^+:\_&HK[_P"`
M-?W-T&<H_05(J5/=&@KK,:1;244U=*RUPB2C5.<EIZ-AZ:3%HXFU4E^^Y51O
MD8P"9`^1B;HX`SWFU.5I(.X%M[RB!.T#=N]F00)VH;HGG!.)1`-F8B.71P!?
MS;?*R?%M>?C45]_\`.;;Y63XMKS\:BOO_@!S;?*R?%M>?C45]_\``#FV^5D^
M+:\_&HK[_P"`'-M\K)\6UY^-17W_`,`.;;Y63XMKS\:BOO\`X`<VWRLGQ;7G
MXU%??_`#FV^5D^+:\_&HK[_X`<VWRLGQ;7GXU%??_`#FV^5D^+:\_&HK[_X`
MU[6^A/E'Z:F;>1-<V[NHSEZWJ]&FK:&DK@E=G5KTT++R[9BS5/-F%@X3@8=U
M_?28E6.`F`QAVX`V%S;?*R?%M>?C45]_\`.;;Y63XMKS\:BOO_@!S;?*R?%M
M>?C45]_\`8+<[03RE5!6\K.M;H4%=)C;:F*=DY>NW,U<TSR-3IAH@8\IWTQ4
ME7I':8HAM+N9@';`("&`/G*S;KRKE.+:MUYF2F5BI1K.+CW,R[EU%"II),8N
M.:I*JNW7!B0NX0"D3$0$>C@#]07)-Z3.5+MZ]@:H4KY[8K3\N9HZD;9W?`]9
MO:BAQ*)E$H6C#\$XI!Z=(X[BH.D2!GM(8V`/U.ME`4(8P%*3(P!N@`@8H\&F
M(@H`E``4`1Z0F#++:.`.Q@!@!@!@"XGUP?3_`*@X`@GH&_XBW]_[Y&I[_I%=
MX`G5@!@!@!@!@!@!@!@!@!@!@#C4Z`?;D_MRXQJ_X*G]+[F5'Q[T>_\`BD\I
MW_B;3K_F_-8^6]L_\F\?U/O97^I]);RN0"9MH-R#,?7EM(8-FW>\3U3M^CMQ
MX7N__O*/2OP*\2Z6?84Q%!S'?3$HY[!W]H=0?OP!T/H8_0J<51IVJ!ASG$9$
MIB*$$B0D5+N*%R#(Q.@!1_OG9EGLRR''0YIGC;!7@@$2F$B0F)GN"(%[3/(<
MRAWSD`[.CT<8S?F4)L*!85LD0Q3$1;E.4,BG`A-X-F6>]WQGO9;,^CELSRQA
MJJ?A0.B[@HJ1.P4>Q<4[5B7:;^,6=LT7"\<^2!4J3QBN=119JZ3*L<`.0Q3`
M4Y@SR$0PU5.Q`[@LTLC%.BV-O9B8=P!$1,04S&$3+@8%#$$0$P=L(;,\-73L
M0BSF$F8@82I"(!D`B!<P#>`P@`]\9AF8`'Z.,U^5:,N!`XQ;IB!PX%O]],)U
M,B$**AS!NF4.)7`&.<Q=@B(YY8NE-:P#-DCYYI(=L=)0PE*4@F.@MPZ1C"1P
M7>$BW;;<\QZ.>-;IR-Q:40!;)F-OBDAOYD-O@4H'S3."A.W!R!MTIPSW<]W/
MI8:NGX4!WLEGGP*`B&8AF4H@&8F$<BBY$H`83CF&60@.70PU5.Q")<5`A`*4
MB:)0(8#%`"E[4P9Y&#-QT2YCE]CTLL%3D3BDDP%1,5,PF43(`!M,<Q`*`#LV
MB9<P;>AT,9@@7=4Y%N44T@<`<JA?T$ZKP%0JI!(4W?\`:`HAD4X&$P''Z0=?
M`$^S%4#+[X0W9_\`*6`,`6??.J7LE\(P`^^=4O9+X1@!]\ZI>R7PC%B"P4@$
MV^)4Q-M#>V9]L7=';WSTR[,:W3IS8TA$MX`N\)]PF\()`([P[>`.91+9WUEV
MASB(?1PU5-?RHL67B01$#"5+>*.\!LBY@;+=WLP<;3;NS,=N6&JI^%$+#($,
M?A#)HB?>(<3[I=XQDR&33$YN^,U-PAQ`-[,`SQE!6`HFW32$1321)F(#D4"@
M4-TA4R[A>^=U,`(0`R*`!D&$%8"\$@`V^!$@.)A.)P*4#"8P&*)C"#@!.(@8
M0VYY9[,-&6P%_P!\ZI?]KX1A!+$!]\ZI>R7PC%`^^=4O9+X1@!]\ZI>R7PC`
M$?M6`)FTP:BBBJ0%?T'70WBBHF3=(:D)?>,(F4,)`,!0`1$<NAT\`<VE<F>F
M#3=GN&']`5G,S"8#";^CJG-N\#@H&SZN6W`&^=S]RGV?YU@!N?N4^S_.L`-S
M]RGV?YU@!N?N4^S_`#K`#<_<I]G^=8`;G[E/L_SK`#<_<I]G^=8`;G[E/L_S
MK`#<_<I]G^=8`;G[E/L_SK`$!^4M30'254X$42$X7+L.!@%1'[V<UZJ%+N??
M#F`N\"I@`,Q':.`)^&W]XV7!_7#T0)GT>GFL`Y_2#`''N?N4^S_.L`-S]RGV
M?YU@!N?N4^S_`#K`#<_<I]G^=8`;G[E/L_SK`#<_<I]G^=8`;G[E/L_SK`#<
M_<I]G^=8`;G[E/L_SK`#<_<I]G^=8`@5K).@>\/)Z$3414(.L$0,'"(F`5$K
M#7D.4"[PB(J$%,#``=MF&`)Z[G[E/L_SK`#<_<I]G^=8`;G[E/L_SK`&F=1%
MHD;\V-NI99U+KTXTNC14W1+J>8-VCQY%-YUJ9FJZ;-'RYVSE<"G$"E-EM',!
MS#`$:=(_)NZ4=(4>@>VM`1E05JVW4WUSJS)'U-6+IT5$B:W>LBX`HPR`J`8Q
M6Z!"%2WL@,.`)^;@B.8@F([?KLC='HY@+D0'//I]#`%0*8N>[N%S',0`0RSV
M!T.^<@V!TMF`*_?.J7LE\(P`^^=4O9+X1@!]\ZI>R7PC`#[YU2]DOA&`*@)B
MB!CG(4H"`F$3%``#/IB*YNC]#`$$M`>84%?O>6*)C:R-38I??4C<('E^X$WU
MIR@(@("(AF`A@"=GWSJE[)?",`/OG5+V2^$8`??.J7LE\(P`^^=4O9+X1@!]
M\ZI>R7PC`#[YU2]DOA&`'WSJE[)?",`/OG5+V2^$8`??.J7LE\(P`^^=4O9+
MX1@!]\ZI>R7PC`%AS;@`94R8$S+F)E")@7MBY#O"L<!R'I=/&-3_``3_`-+[
MBH^/^CPPFY4CE.Q`2&2\3Z=0*<H)Y[X4]-;Y1,4PF'=Z^/EO;+3O%=KQ/O97
M^KK/`Y9"#8U-!:)H&;;J+0\UK4MQ#3#5&3>1+UQ%+0M5)F58/8]=N\:+;HY"
M=(Y%`*<<A#9CP?=R7&:#YV_*)EWDMQY,_1H/0M94&0C\=-]^AG_SF8_0J>"A
M3EL@3G*<V;HS^*RH..B^_I+QO(.;-T9_%94''1??TEX`IS9VC+XK)_CIOOZ2
M\`5YL[1F'0M94`?_`,TWW])>`'-G:,Q_Y+:@'_\`FF^_I+Z^`'-FZ,_BLJ#C
MHOOZ2\`4YL[1EEG^BR?RZOZ:;[Y?])>`*\V=HR^*RH-O_P"]-]_27@"SFS=%
MWQ65#GT\KSWXV#TP_P!)F`+^;-T9_%94''1??TEX`<V;HS^*RH..B^_I+P!8
MKR9VC4$E-VU]0I&$AB@H%Y;\'$HF#+/="Y>8]'Z6`(47-Y/O2:UUWZ6:30MM
M,IT_-V<U.2SQH-X+S.%U)&*<VM2;KM7ZEQ#RC%,I7Q^%115*BH(AOE$2A@";
M/-GZ-1$-ZUM0CVH=&]-]QVY_\Y>`*\V;HS^*RH..B^_I+P`YLW1G\5E0<=%]
M_27@!S9NC/XK*@XZ+[^DO`%@\F;HOS[:UM0;W3#]-%^/I?\`*9@"[FS=&72M
M94&6S+^FB^_TO^4O`%>;-T9_%94''1??TEX`H/)FZ,NG:RH,NG_31??J?\Y?
M4P!QFY,_1:4!$;6U!D'1_IGOQ_6N8.`+2\FEHL,(`%KJ@VY_\L]^>ET>C<L`
MV810.4.3-T89]K:RH,\NA^FB_'0XS!Z>`+N;-T9_%94''1??TEX`<V;HS^*R
MH..B^_I+P`YLW1G\5E0<=%]_27@#16IGDZM(D!IWOY*0]MIQG)QEG+A2;5=U
M>6^#ADDXB:4F)!HJ\:OKCJL7#-1<-Q5)0ATU";#@(;,`=G31R<VD&HM-^GN>
MD[7SBDC,6,M%)/CHWDO@BB9V\M]3JZ_`HM;D)M4404.($(D4J92@`%````P!
MNSFS=&?Q65!QT7W])>`'-FZ,_BLJ#CHOOZ2\`.;-T9_%94''1??TEX`<V;HS
M^*RH..B^_I+P`YLW1G\5E0<=%]_27@!S9NC/XK*@XZ+[^DO`#FS=&?Q65!QT
M7W])>`'-FZ,_BLJ#CHOOZ2\`.;-T9_%94''1??TEX`<V;HS^*RH..B^_I+P!
M"#E#^3XTE4CI;J>6@+<RS-ZA7MEF1#O;Q7K=MB%EKS4(B[WFTM<9TR.Z4!3)
M`XDWD3"`D$N`)P*\FAHQ55444M=41U%#G44.:]%^!,90YA,<QA_29M$QA$1'
M`%.;-T9_%94''1??TEX`<V;HS^*RH..B^_I+P`YLW1G\5E0<=%]_27@!S9NC
M/XK*@XZ+[^DO`#FS=&?Q65!QT7W])>`'-FZ,_BLJ#CHOOZ2\`.;-T9_%94''
M1??TEX`<V;HS^*RH..B^_I+P`YLW1G\5E0<=%]_27@!S9NC/XK*@XZ+[^DO`
M$(-6')_:4X"Z&AIC"VYF6B4]JM9P<N*MX[T.U/%I+0W16X".4D;F+KQTF?9O
M+-MQ<4MXN]NFRP!-_FS=&?Q5U!]*]%]_27@!S9NC/XK*@XZ+[^DO`%!Y,W1E
MEVUK*@R_YZ+[^DO`'$IR:VBMJ7A%+83R9!$N9U+U7X(F02B!RG,<;F;I=P2Y
M@(Y9#T\`53Y,_1@;-0EKZA.4X`8!_35?@2;HYB!BB-R\A`W5#`'+S9NC/XK*
M@XZ+[^DO`#FS=&?Q65!QT7W])>`'-FZ,_BLJ#CHOOZ2\`.;-T9_%94''1??T
MEX`<V;HS^*RH..B^_I+P`YLW1G\5E0<=%]_27@!S:&C5,0.2U-0',40$"_IK
MONGMSZ('_27VHEZ/TL`0IT.\GSI-J:A[RFF+=S<B5AJRU*PT:JVN_>N-;A&0
M=?K1;!<[=C<1`CY\Y:M2'574`RJAA,8QA';@":W-FZ,_BLJ#CHOOZ2\`.;-T
M9_%94''1??TEX`<V;HS^*RH..B^_I+P`YLW1G\5E0<=%]_27@!S9NC/XK*@X
MZ+[^DO`#FS=&?Q65!QT7W])>`'-FZ,_BLJ#CHOOZ2\`.;-T9_%94''1??TEX
M`<V;HS^*RH..B^_I+P`YLW1G\5E0<=%]_27@!S9NC/XK*@XZ+[^DO`'`OR:&
MC0A2B%IJC6$QMS=)>B^X&*4X"4Q\QN@EN[I1Z.8Y#MRQ*DT+O4EME*E$AMR>
M=M*/M'RBG*1T)04:ZBJ5AX33R6,;/YZ?J=\H"D%.*+K.9JI7LI+.A!4PE`%'
M*HE`,?*^V5*KQ74OZ=)PSE_F@L1F_*Z?W'05_P!^VT?_`*&JO'A>[?\`NZ'3
M\"O$NO\``^Q@_4_K8_09/\-,PYRF-X-47RN`>U5J*SN&G',Y92E8U*038/WX
MQ31=15XV8DX:3`AQ8)D,[S,J`=H4!''+>Z[N]+6*T$9:ZU/SUO:!D:JE3VIG
M)^/MO/5X,+1]13-0ME8V!J^E::.>+7(T[S=LF"57;CM05`5!T!"@7=$<O+XI
M.5IFUCZHK.(A'(JS4\>7GJU=T/$TXXIFH"U`_JHD9X\"+2A3L"/$4?%2`N4'
M*A`0[V*94#;@";&2WI,RP6,X0U26<(:<0<U"_C8^GX>JY0\Q(P<BUB9..H(J
MP5?XAD.]3H2[REA9'X0$C'$RI#9!VHY.*/FB2"+8S5O9:7E&].MYR;1F#S5/
MP)S2%*5$Q18OZK:D>4PZDUWL>@A'-YANH!DCJB0ASE4*41$ALMDF]Y998/&6
M!E!;\6U<1D>_92;V52D*;F:F;14/#R$G(GA(&79P,FFXB4D5%VSIM+OTT13,
M4#"=,P=$HAC/C,N/GQB!JX=6-(&K:D&S19->@):WMU:QDIYRU>EJEC.VWJNE
M*3DZ4\GCH]\$?#)5'F9`A15*=N0N7;!CGI[[E=1IXL(:6,RJ)U)T3/2E/%BU
M7I&LDI7[9^WEH6I86J$I6W4?$S$NP9TV+(3O%>]94H=#,^609B.6/1EWE3J2
MQR8GT?'$,.(VQ;VZ%(7+;S"]+NGG"P$QXFFHZ5C7,9+0\J9`CLB;J.?)I.FY
M';10%$S'(4#IF`Q<P''-=L*0P&RL>NL3,2Q3^YG^T-_:CC$$"+K?^(KH^_YB
M]5__``^T&`)_*=+Z?];`''@!@!C)X@1IOO>*5M5,VZBHQ*B`4N%.ST2>5N'4
M9Z7@XE&`IXTZ4R4DBW4$PN%$MPI#9F,<=G4QY-YP)OF*F1\G-7%9QLY5T'&T
MNR=+Q-QK96FB7#6&K"1CW585VQA).4J(LCXN`)*EHR.ESBW,4`.H5%,<@WP#
M'C4MZ32U'+8X!FX::U4VX4[TAZ@GXY:IG@5RY6:T@SJ&H&"4/;Z;)`S4O(*N
M&93QC1JZ,)%3'$I4U"B3/>*`8]JGO1:$9EA@,11CK+L*\6CQ;STT`R*%)2X'
M4IFHD^]J>K14L=1-420KL0*TINJI!8B#1WGNG5')42Y&QS<3FR\NHL$9#7=Q
MZ4K=.M;*Q+N;8U_4U)5LPI8CAM+TVSDYB)A.^0>P%0HBQ[Z.@Y=(*B=HL8Q2
M$,(]J`XPJ7UWF1T>=KN$$0N;V'U<1M%7$@D:DJ%(*CI&V<=$&7K]=^YI^>I.
M"IMS//XQ=55[)<%5=3MW:3G(PY)&$PAEA=:$ZPX2'U:8)+IMVH.2@#DK-!)R
M)CBLH!TB`7=[X':L!E=\V8[=N?3Q[=.1RX7C!W\;"#`#`$?M5:'#Z9]0J*8%
M!5:RES$R[Y4S%.HYHZ8;`(%7$J)U"I@(%*(]L(Y9;=H'QCL#R\&A.A;#60HJ
M65O$,I2-GK84U)=Y6Y.LT!_"4/!1SPK=4LD0JB1'#<P`(``;-@8`VW^L%:!/
MWR]G%HK[ZX`?K!6@3]\O9Q:*^^N`'ZP5H$_?+V<6BOOK@!^L%:!/WR]G%HK[
MZX`?K!6@3]\O9Q:*^^N`'ZP5H$_?+V<6BOOK@!^L%:!/WR]G%HK[ZX`?K!6@
M3]\O9Q:*^^N`'ZP5H$_?+V<6BOOK@!^L%:!/WR]G%HK[ZX`BSK)Y:/17?:PD
MY;RA%[IEJB4K:UDPT"9MXYC6HMJ2N52%43CI=VC)F%,S6&CE11S_`+J<N0=8
M"5!O]8*T`;QN#6O2H3>-N*!;%4H*$S'=.!3R8'*!R[0`=H=/`%OZP5H$_?+V
M<6BOOK@!^L%:!/WR]G%HK[ZX`?K!6@3]\O9Q:*^^N`'ZP5H$_?+V<6BOOK@!
M^L%:!/WR]G%HK[ZX`?K!6@3]\O9Q:*^^N`'ZP5H$_?+V<6BOOK@!^L%:!/WR
M]G%HK[ZX`?K!6@3]\O9Q:*^^N`'ZP5H$_?+V<6BOOK@"+-_^6>T;7-N!I.J:
MEW-W1C+0:A%[DUOWU;IVR.G2R]LK@4>BW8E;29^_G:+ZIV@G2#:7='>'`$I@
M_P!8*T!CMX2]G%HI[ZX`?K!6@3]\O9Q:*^^N`'ZP5H#_`'R]?T[:*#^P,I@"
M.FKGEM]&%[=,U[K2T&O=M*L+AV[J*D:>/*4*XAX\LE.LCL&YG,BA*<*U`AEL
MRF*`B!@#(,`?)+2+RRVK;2\E"4O5TP>^-M8YLS24IJY4DDG,1T>1N1$K:GJS
M9MU7S0J)$MULB[273,8,AW=HB!^H;2+RJFD[5JWCH6$KHE!7%<II'<6WN:X8
MT[/`Z'>WVT++%72B*BR,'WH$3%5,&69,\`?3%/=$!,4`+O&WC!N@4^]NAF*N
M7UR@@`#GTPRP!?@!@!@!@"XGUP?3_J#@"">@7_B+?SK:R-3V76_I%=]#J8`G
M5@!@!@!@!@!@!@!@!@!@!@#C4Z`?;D_MRXQJ_P""I_2^YE1\>]'O_BD\IU_B
M;3K_`)OS6/EO;/\`R:_]3[V5_J?2<7*ZG*".@L1,&0:[+3'$=HY%3AZJ`YAR
M`<@*)@S^CCPO=W_=T/ZO*5XEU_@?8X?J?UL?H,G^&F8<Y3&\&M[NV_2NI;BJ
M;>KR!HM&IVC9DK(%:I/1;)H2+-\<PM%OO3@IRM-P2FV"!L::]%5Z;IOEA!HF
M[VE6!NJB(,YQY0R![75/;1LV@Z>CU6S4*FK.A:Q/4:D<<C=,'J3ZB2$.@/:F
M37.)A#+'`]V4WB*V6P^FF10N'3%SZJKE]5=90=P'U=3#U.F8R':3AU+9RMJ8
MJ-:I-UC%BR143)]\;Q1$%=H#LQD]VRS3:4SC-'ES".&)ALYHE:U'#FI*:N)(
M.:2AJ>NQ!6^BVE,1;9Q1J]X4GZ%3S#I^#D#5`L@UDUB-TE`*`'/O]$-A[NE<
MJD;_`"K%U]0B;$=:9FCZ8JVH35=--'=53]E)P[=-@U$L;^A=!RVCV:28&.5R
MA.INS&<`;,""(@'0QS5=VS1<DF&1M/-')E98FKH_2?,+R6HAZM+OJ52KVN85
MU;LB*AII&$I",DV5:S$6HS8N&RKB"K*X<E+N7S$ZB9^`,B7>W`+EIX7-&*0B
M8-6NB"4BK=.F5"R2]158/Z2@/%$:1=*QCUO=^ZU`U[4/B]!5XM#Q3JGV-'K)
MM=Y;[Z9<`.("..>GNBI+4<97"(P0,PHW2Y5DQ3\>G//G]L'=.I7G@J//3)(1
MO4A8J[\%`QSVIZH/$/'T0A5L<]@052<-%CJGX8V8$$1R]:2XPDT;(O#CP_P)
M$WE86P:=EG-Q),LV>;D+DS]/3TD",,E3L='+PM/-J=(E%,2/I)T@D=LT*93A
MU3"81V#D.,KO2JRJ#E<!B)+8]-8B%BG]S4'J)F$>P.("!%UMO**Z0.J6Q6JT
M3!F&8`9_:'=$0Z^6`)_*=+Z?];`''@!@!C)X@1TOG9^J+GO*&EZ3JZ,HR?H&
M=D92+?35$,*]BGR<W$C"R+9Y#OI9BFD!6AA,1;+>(<`RZN/,KTZDWZ96\)<!
MP)V&7<B]>RM6O74O)7/MI<Z4>MHQ.+0<R-NX2FXTK=C')++)1[>6-!`*B93G
M`H#N@(Y8X*6ZGI:4R@VT\N#^)6S7M&Z0HRDI:?E4JNEG*U0T+>6@%#GC443M
M4+M5N\KI[*ANF$!&/=*E33S$04,4NW;CU*=PHRR-/'#ES$BSL>J+"#"/8A6K
M9]9-Q8NT]BC**QK5;=@[620S+6<3("B:CN1G%Q$BR0"`(;X[HYXTK=TB32>-
M0[4[,@B=BG-*_B:^-/WGDJU?U`\IJ;N%(Q+9]#)MY@B%P(-A!*Q$K4+=\KXT
M@Z?:1Y?%[<&K=%#>$!$Q@`<)+A+3>DL+4>W`(DQ,QZ7TL=U"G+(L.,A0,^GC
M?,U#`5PYBN,"#`#`$?\`54NHAIHU"G114.H6RMSC$,F)$S`H%'R)2;BJ^:)5
M_OF:8B&0"7`'PBL=_J^^EBMK)V;K.0NK?)L_JVU%N:E?-VLQ2XMD7DW1T-).
MDT!7IYRKP8+N#9;RAQRZ>`-H_JZ&DSXW+]?E>DOS7P`_5T-)GQN7Z_*])?FO
M@!^KH:3/C<OU^5Z2_-?`#]70TF?&Y?K\KTE^:^`'ZNAI,^-R_7Y7I+\U\`/U
M=#29\;E^ORO27YKX`?JZ&DSXW+]?E>DOS7P`_5T-)GQN7Z_*])?FO@!^KH:3
M/C<OU^5Z2_-?`#]70TF?&Y?K\KTE^:^`(T:N.0\TX6`LA+7)I*Y-Y9B9857;
MFGDVU02=+NH_O.L;@05,RN\BC2Q#"HDTE1%`<^U-D'3P!)I3_5T-)8G.);M7
MX(43&$I"2])[A"B(B!"9TP(@4@#D'6#`%GZNAI,^-R_7Y7I+\U\`/U=#29\;
ME^ORO27YKX`?JZ&DSXW+]?E>DOS7P`_5T-)GQN7Z_*])?FO@!^KH:3/C<OU^
M5Z2_-?`#]70TF?&Y?K\KTE^:^`'ZNAI,^-R_7Y7I+\U\`/U=#29\;E^ORO27
MYKX`?JZ&DSXW+]?E>DOS7P`_5T-)GQN7Z_*])?FO@"--_.1!TWVIKK3'2]/7
M0O.]9WROPG:ZJAEY6F%%6\"M;ZMJQ77A!1I<A4)(KRET]XXCM)GU-H$EOU=#
M29\;E^ORO27YKX`?JZ&DSXW+]?E>DOS7P`_5T-)GQN7Z_*])?FO@"/VJSD,-
M-=@--]Z;T4O=*\K^H;:V_J"K8=A.RU-J0[Z1AV9W3-K((M(1@X7267(4H$*?
M,3"&09X`^.>D7DOM6NK\T3-4C0:EO[<O5EBKW2K8'U.TV5$#D!96`CE"#/32
MZ*F]FDD3@%,PWC9"&`/U%Z1>1;TLZ:Q@ZMJV.-?"[$0!'*=9UTQX.#BY5,P#
MP].6_:*^)V!"&VE7,H=8X@!QR'9@#[#-D10(*8@0``P;@)G5,3<*0A";J:F?
M>Y0`F0)E$Q2ATQS'`'8P`P`P`P!<40`0$1R^CU]@?LX`@CH%,4:&O\`#F)=9
M6IXA@ZAOTANSY?1W1SP!.S`#`#`#`#`#`#`#`#`#`#`'$J(`4!$<@`Q-H_;E
MQC4_P3_TON94?'S1Z`CRI'*=FR'((C3J41R_LO)V:-EV!SQ\M[:_Y-?^I][*
M_P!768SRS,V-,4WHEJ%Q$STL6(UI6Y>K1U,-C2$DNF2&J<X)-6*8"L\<KB`%
M33(&9CFRV9X\+W=H\:H)1Q^4LV)=+)5FU[-!$<M)6NK+,<O^K;.AT^H+@1_9
M''Z#2<:%)]!ASE/7V:^R5KJ^3;.=WQO`]?9K[)6NKY-LYW?`#U]FOLE:ZODV
MSG=\`/7V:^R5KJ^3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^
MR5KJ^3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^3;.=W
MP`]?9K[)6NKY-LYW?`%BFOAF5)8Q])>NL"@D?,2Z;)T1^MZ0`L/]3`$+[E:U
M&3O79I9JD=+6L]H>'LSJ9BBPZFGN8\>/TY%U:U0LBT9'==\J,FYFF2AR`)2"
MH7>Z.0@35-KY:&$`#27KK'(`_P#9MGO_`"E^C@"WU]FOLE:ZODVSG=\`/7V:
M^R5KJ^3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^3;.=
MWP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^3;.=WP`]?9K[)6
MNKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^3;.=WP`]?9K[)6NKY-LYW?`#
MU]FOLE:ZODVSG=\`:7U'ZWV=2:=[[4^.E76Y&A+6DN-%FD)73O,,H]F5>C9=
M07SETNZ*@@U2$VZ8YQ`@"'1SP`TVZYFD5IST^Q@:5-;KP&%C+1-.^H[3K-.F
M#C@+>TZGPK1TFY,FX0/NYE.4=TP=#9@#='K[-?9*UU?)MG.[X`>OLU]DK75\
MFV<[O@!Z^S7V2M=7R;9SN^`'K[-?9*UU?)MG.[X`>OLU]DK75\FV<[O@!Z^S
M7V2M=7R;9SN^`'K[-?9*UU?)MG.[X`>OLU]DK75\FV<[O@!Z^S7V2M=7R;9S
MN^`'K[-?9*UU?)MG.[X`A3R@NM-I5NE^IH<NES6I#BXKNR[LS^;T]3#)D)8:
M\]"N!9&56=`FFL]!,2I`8`$XF[7/`$VEM>C4BRI?5,UT&W55"[Q--TZ8@[IQ
M#,AA<")B#EL'IA@#C]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^
M3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^3;.=WP`]?9
MK[)6NKY-LYW?`#U]FOLE:ZODVSG=\`4'7NT#_P!DO74.S,<M-LX;=^V$%Q`H
M_1Z6`*^OLTZ6DO72(=(2Z;IL0$.D("#@0$!P!"S5/K2;5)=70R^]5G6=')4Y
MJG3E%PE]/LJT6EA4L9=Q`J<<DH[X1=TDHX3[5,`-MZ`9#@":?K[-?9*UU?)M
MG.[X`>OLU]DK75\FV<[O@!Z^S7V2M=7R;9SN^`/+FM;M/U!%O8>=T;:W9R(?
MMEF[Z'DM,<N^CI%!0@E%N]9+NB-W2(CD.Z<<LPP!VF6NF*8-R-F6D'7&S:HE
M33:MD--4ZFFU;@D00:((%<"@U;-C9E(FGVI<MF8#@#M>OLU]DK75\FV<[O@!
MZ^S7V2M=7R;9SN^`'K[-?9*UU?)MG.[X`>OLU]DK75\FV<[O@!Z^S7V2M=7R
M;9SN^`'K[-?9*UU?)MG.[X`H.O9F(9&TC:Z52B)0%,=-TZ`&S.7+,0<`(`4=
MO1#H8`A[HMUI(4K1EYVBFF'6?-GF=5FI.<[\AM/LF^31*O<`^ZT<=YNCIHNT
MBG`IR*`50HE'/`$P_7V:^R5KJ^3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZOD
MVSG=\`/7V:^R5KJ^3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:
M^R5KJ^3;.=WP`]?9K[)6NKY-LYW?`#U]FOLE:ZODVSG=\`/7V:^R5KJ^3;.=
MWP`]?9K[)6NKY-LYW?`%A]>S3+,=).NL2ER.(!ILFS#D40-F!>^-N0AGA42V
M:J\&"3E`J(C\GK63>XW**\I+7+:EZXHPLU#Z>2GI^XU-*TK5;4S>`FR`9Y$K
MN5544C!L*`E#Z(X^4]L/2KUG;,WVEYS+N5R!8J>@T^^IOCKGM>WWDU>"`Z3B
M(J@0*J4"B!@R(&8=;'A>[H<:H8,,?*6;$NE_@?9`0^U]S]#KX_09/\-,PYRF
M[]K[G]O&\#=^U]S^W@!N_:^Y_;P`W?M?<_MXL,$0=1TZ3:AF=,Y\R'-]Z2`V
MTHD*1,1,<I2G744`I,Q`!-T1`-N-,]62G^J)8%Q7*!B%.!TQ`Y#'3RW!%0I"
M@<12`#CP@"F(&S+F&0XSI32U9=.5X&^<0+0>-Q,<@".^F)BF+P"NP2[![;=W
M`#Z>-FCAA%"!V2"4Y2G()#%,&93%`#%$.L(&$!VXQ(7;OVON?V\`-W[7W/[>
M`&[]K[G]O`'&L03(JE#@^V(8IM\ILMP?KP[4<\Q+GE@"`MTR&#E%='XB)AWK
M$:KD]TXIJ;H$?V?`HE/P0*!O`'0`<LNCF.`)]J%X(145.F!!W";Q@$>V,;=*
M`@`9``B(!]'`'7[\;]#>+F4QBJ`!0$Z(%,=/A%4P,*A4C+)B0#``@)NMMQ&T
ML;0+2O6YSJI@9/?1%<%"[Z&910,4`W@!8=SAP',F]EF`#GEB:<EJ!1%\@OEP
M8"81W>U`A3&R%44#'$I5#&`B:Y3$,.60&*.&E+:@<QUTTS`42FRWP(8_`F*4
MAC;NYGO[IC`<39`)0,&>&G):LX.,[U`@J_7&*@`\*HF@=0I#@=,G!@!-XZAL
MU-HE`Q2[ILQ`0PTY+4"HNT<SE('"G33X8R:12J'%`17*DN4"J"!DUSMS%(.>
M8CT<@VXCGD2;;6`!%X@ND55/(Q3$(<1`I#%()QW1(*Q%#('43/F4P$.;(0'%
MI32U9=*5X!`HF];+&(5(V^*B22Q1*D;=X)<!,B<QAR*4%2!F&8AU.CLQC-5I
MRU%3;_,RPP1`OFN^9,JJ*ATRB=4B9T3*)$*;<.=1(505*4A@$![7/,,NCC+3
MDM1"Q-^BH8P"FHD4F8&.LF0@`;=3$I=SA!6'A=\0(.[D82&R'++/)0FQ-8`7
M+OVC8@J+'$A`3!0P@W6.8N\H1(A#)ID,KPJAU``I`*)C=(,83SRT_P!30@6>
M,6O!+JF,4I&QER+B(H[J1F^^*A5#E6%-,P$*!LC"`@4Y<\A'(,)*].?$RP.V
MDHFL0#D$HAD01[7,`WR$4``.43)G[4X;2B(=?&]*.%$@1\U:'0)IAU&'71X=
M$MC+H"LF4P(\(@E2$LHHD*BH"F3?*KL'(0Z.>#4,`.]I7`I=,&F\NZ!-VP=G
M2[FZ902Y6[IWM1.0H%/N]#,,@Q`;Y[7K?P2GW.`':];^"4^YP`[7K?P2GW.`
M':];^"4^YP`[7K?P2GW.`':];^"4^YP`[7K?P2GW.`':];^"4^YP`[7K?P2G
MW.`':];^"4^YP!`;E+RMBZ2JG,Z*19`UR[#"8JYC@B4X7KH$4#CP2*BA026*
M7=#(<S``"(8`GT;+>-T.B/\`YLX]/J@&0X`IVO6_@E/N<`.UZW\$I]S@!VO6
M_@E/N<`.UZW\$I]S@!VO6_@E/N<`.UZW\$I]S@!VO6_@E/N<`.UZW\$I]S@"
M)&K?6':K1=2E(W"O(I4*%$U-6K:CEY>G6(R)H1\_:++-W,C'E,DJ>.2(W.90
MX"8Q`#84<`;>M3?*T-[:19UK:2XE,W%IAR5(I9BF'I)(B2AD.&!.201#OF(6
M*0.W(Z30$@[#9#@"*FLL2GN[R>9MWODBVK\JJ(<(D?=%.Q5VS@F@(!P2B>X0
MYMIBCF&S/9@#Z"[OVON?V\`-W[7W/[>`&[]K[G]O`#=^U]S^W@!N_:^Y_;P`
MW?M?<_MX`;OVON?V\`-W[7W/[>`&[]K[G]O`#=^U]S^W@!N_:^Y_;P!4"CF&
M66?6#(>OD(Y]+`$$-`*>Y05]TRD3221UB:G$DDD@*!2IA<)UGPH@0HJG%7,<
M]G1ZV6`)W;OVON?V\`-W[7W/[>`&[]K[G]O`#=^U]S^W@!N_:^Y_;P`W?M?<
M_MX`;OVON?V\`-W[7W/[>`&[]K[G]O`#=^U]S^W@!N_:^Y_;P!UW!#B4HIGW
M#%4(("4H9B`F`HES$P9`(&QC4CJ)X>%E1\@-'I?_`(I7*>&,;?'Q/IS*03*.
M%%"IA3LT(D'A53(D("AAW0(4,@Q\O[:_Y-?^I][*_P!3+>5T_N.@K_OW6C_]
M#57CP?=O_=T.GX%>)=?X'V,'ZG];'Z#)_AIF'.4QO`P`P`QE_*")^KNJ)5A0
M,10%.1]02M1W@J:+H1)G23A-O4R5*&4-*W#E(@ZJS8A7<?1S-R1$P*$,1=R0
MP?6XX;RF\7.4B_;N\\+3B6FQG=:HU:!7M+4]X[-5*M<>63@5Y%Y2=-M&E$NY
MQ=RN#)],3U-.8YZ;<45*+E<^0CCSY*M>3!*ORIL8V9?96;@*;U'S=/LI:$N\
MM<YW7]91URZ<J:0?5)1[*/<M)!*F+@4ZXD?%C=!-*7!I#*LFI2*,VI#*9F-O
M#DJMZC#XA+"?1Y,!`A0$!`0#(<Q*(YYCM$2`4HB/6`,>O3;<B;QP(R_&8&`&
M`+%/[FI]H;^U'`$"+K_^(KH^_P"8O5=_P^T&`)WRBAR))`F".:BQ$U#+'W"I
M(G$"G7(`@('41.)1*7IC@#Y;!=&IS:F6E\_$M=)6X2N@[TUNY,ZAFM"!18)C
M!(5%WB"H*O)<][3G0%P9(0*T3W@-N#CR=X3U)*LCECH0PPY8["K&:?I]>GYC
M3S>Z"1GJ2"NUY-2#J5S1UP:DDKN1$<]NH:*3D:D9O52LX1[%LGAQ140$4@W0
MW^USQY6MO$.?EUB"-XV4N!=&-U"W*HJ3IBIJSJZT]G+>T?)L%Y8D,TJYJ2L*
MG2@[GQLE,JA#.CS]*H-3O2D.*QGA51`H%$N,U5KIO23>"V'7RZ2X(F07%J5*
M$O/?MK058)O;E2FE.I)AC2QZV4G)%C6$4[4"/;1=,E6.E$J$:%S$Z!`.<>W`
M!SVR6M72FBW&&#IBOPB3`F1]6=TNTD*?CJ`J&2D++S#;32K?AR6K9I:`8.9B
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M0$,15-#,ZVZ`8Y+O6O,,;A'ESAPYL1]%M)YD?).Y+:&D9.4H5C>FOVEO'<DN
MX=$)32:T>9VQB';L3.'M/Q=4GD6S%<QC%6;I%,01()1Q[]VJWEK#'EUD,IU2
MI).=->H!)7@Q3&S=QFZ@+@GP0`I2DD<>U7R0/F&0]MLS``ZN/6D<SE3F_40_
M$[;GEGN4<I.WE`4O!5S3`PE.T124)$<-9R-<J^+(NGX]DQ!1R(I]\&*V1*&_
MNAO99]/&0,RY[[E,?/FE.)6,[I@!SWW*8^?-*<2L9W3`#GON4Q\^:4XE8SNF
M`'/?<ICY\TIQ*QG=,`.>^Y3'SYI3B5C.Z8`<]]RF/GS2G$K&=TP`Y[[E,?/F
ME.)6,[I@!SWW*8^?-*<2L9W3`#GON4Q\^:4XE8SNF`'/?<ICY\TIQ*QG=,`:
MVNORM>NV\M$.J#N-6<!)TN^DX28D&S6U$;$F%Y2U30E1PA$W1%R<&HWFXA/,
M##FJ`@!<\`;*'EON4RS'>K:E"&_LB!9:.$"&Z9`$ZF^(%'9MV]7`%.>^Y3'S
MYI3B5C.Z8`<]]RF/GS2G$K&=TP`Y[[E,?/FE.)6,[I@!SWW*8^?-*<2L9W3`
M#GON4Q\^:4XE8SNF`'/?<ICY\TIQ*QG=,`.>^Y3'SYI3B5C.Z8`<]]RF/GS2
MG$K&=TP!&O4YRB>K75W0D?;J_=30<W3,=4R-21K9A;UC2CA"<91KQF"2CTCM
M)-RW63>`)"9[X;INM@",MG+X76L%6*5?67N+/VUJ&//PBCRFY-=HA+%*8!!C
M/P?"J0$I'`(?6N$E#"`;3#@#]).FK6[JFU>5UH,+J"LDK3\#3VJ1J_BK[(MO
M)NF:]E5K*708$IYG3D@FDK(RA1DN%,Z9@#4`0/EM#`'ZDL`,`,`,`,`,`,`,
M`,`,`,`7$^N#Z?\`4'`$$]`W_$6_O_?(U/?](KO`$ZL`,`,`,`,`,`,`,`,`
M,`,`<:G0#[<G]N7&-7_!4_I?<RH^/>CW_P`4GE._\3:=?\WYK'RWMG_DWC^I
M][*_U/I.'E<#@HEH/[9,@)ZZ[6`4J@F!59="'JL"IHD`IM\IP`PB;9D`=?'A
M>[8\:H3<SF\I6L"Z3['Y?0[(?5Q^A4_\5,P>,9=<.R'U<;X*T#+Z'9#ZN,)V
MY5&518&7T.R'U<:M95\':!D/6[(?5QMIS33)Z:@#IN8]L[.DHNDDHHCO@F91
M-%84RJ%$BQ4N&*<$173,)#F)D<Q-F>6,*E%5.>'45.!YKJF81_F61BHF13X=
M-P4C^/:O1!5,``JN^Z*L85P`-W?Z.X`%Z`8PEE=&35RRZ4.<1YRYE3D1&JJK
ML(Z-9K+F`5UFK!HU64`3"*A3*-2(#D<N0=39MSQDZD_-36<'M%)NE`H"&10R
MV[H?L%`I>P&)K*O@[2%V0];LA]7%4]6.&7!T@9=<.R'U<;X*T#+Z'9#ZN&`%
MIR@)3`80*`@(".8;,]F?1Z^("`5U3*#RBVD`IB`42V&U6*&[<HAD>1M$!,NF
M(&`,\^EG@"?:Y%%B[I3%2'=-]\`$U#D,.0E$F_F4-TP;<P$!#9LP!XY8%H0A
M$R)MTTR'.?@DTQ(W,8RQE2JG:E7[V.N`J'.)Q((BN;A`R,&,9I)9G&91!Q-Z
M4I]HX=.VL+#-'3TBH/'+2+8-UWAU3;YCO54T@5>B*G;CPHGS4[;H]#'4TK$#
MT$(MN@X[[*5,7)TBH+.131%TX13*/!(+.3`=8S=)0QCD3SW"B;8&)J:7.A$Z
MZ<!%I/59--A'$DE0/G($9-"O1,8@$`3N0("QR``;2;P$'J8:FG8#A0IF';,N
M\$8Z-2:B)Q5;(1\>@T<BH50IA=-$D2I+;X*#O!LSZ66>&II6`JG`($9A&@#0
M(T"@AW@1DV(S!D)1,JR(TVM"-U5A`!)P8DX$-S=$>VQ)J%*9-0QH1#2FXID9
M`R#".1%H5PBU%JQ:M.`:NMT[A!,&Y4R)@LL4#FW"E*8P9B7>[;&5&E)0DT94
MF6)RC!M>",W*BS[W.<5E&PMDP:G<F='<F<]ZIG3;E7,=0QQ.!0.*V2@F$P8P
MGN].>KK80R"."!U$*3@FSIR]0AX1!Z]WP>/6\2P1>O"@MPJ`NW9"`L[40R`0
M,J)P%0`/D`AC/4T[$0]0L8W*OWP5-N5<2II'<%;M0<JH(@844%G`D%0Z:2QS
M*%Z&1A^CGG)+))&"6(8\)Y04G#)N2/D(Z+3D`,<RLH,:Q\;*J+%.DLN$FBFB
M\3<B@<2%.4P"!1$!W@V!JJ4*=3F@RIP.0:7AR,W$>VC8ELQ=\+WVQ2BV!6+P
M%DU4U2/6@)@DY(X*I]]W@WC@&P2YXUT[I2I\T1$]-A&MHQHBQ8I(M6;<B:39
MHW21;M6J*9"ID0:MT2D200(!=A0#HB..N71E4$@:$U7YGTR:BR%4.10MD[HI
M$,GDCN9T/*.!.9=0%4@W03V'$O:YY='!N+(>9I9I2EG6F+3BZ\G(#^^;"V?7
M[:%AC&S6M[3JAA,8S$1,8QC"(CTQ'$!O?R-I;S=I_P#(<+X#@!Y&TMYNT_\`
MD.%\!P`\C:6\W:?_`"'"^`X`>1M+>;M/_D.%\!P`\C:6\W:?_(<+X#@!Y&TM
MYNT_^0X7P'`#R-I;S=I_\APO@.`'D;2WF[3_`.0X7P'`#R-I;S=I_P#(<+X#
M@!Y&TMYNT_\`D.%\!P!`CE)J9AF>E&J'49"0K5\C<*R()K(QT2R.*:UY*+9*
MMN^4695"`Y;/#!N[>$+F39O#@"?`T;2N8Y4Y3X!F.0>(X;(`SV`&;$1R`.K@
M"GD;2WF[3_Y#A?`<`/(VEO-VG_R'"^`X`>1M+>;M/_D.%\!P`\C:6\W:?_(<
M+X#@!Y&TMYNT_P#D.%\!P`\C:6\W:?\`R'"^`X`>1M+>;M/_`)#A?`<`/(VE
MO-VG_P`APO@.`/E_RJ&B:NM8%FJ`M59AG1D%.M[L4[4$]+R_!P;9A2C!-49(
MY5X5@#MR<Y1S*@!B\()0#,-F`,!TA<B1I<T])PE6W"SU`W,9D;N6TU6+,$J)
M@G`ID.L-,405TK'FR5SW'$@+Q4Q<A,&]G@"26L!@A%W5Y.U@Q3:-VC;5NW2;
M-4D&K-JBS1LY=8A46K1$B;1%9/ARB`))E-ND$`P!]$<AZW9#ZN`&0];LA]7`
M#(>MV0^K@!D/6[(?5P`R'K=D/JX`9#UNR'U<`,AZW9#ZN`&0];LA]7`#(>MV
M0^K@!D/6[(?5P`R'K=D/JX`H)N##?$!$"Y9@7(1VB!=@`.WHX`@GH$,`T+?L
M@AFJ&LC5*1;<,4Z2:[:YKUNJF"@#VP;P=J.09Y#@"=N0];LA]7`#(>MV0^K@
M!D/6[(?5P`R'K=D/JX`9#UNR'U<`,AZW9#ZN`&0];LA]7`#(>MV0^K@!D/6[
M(?5P`R'K=D/JX`9#UNR'U<`<"Y@(!!-ENBH0!-OI@!,S!D8=XQ<PW@`,@S';
MT,8U?\$_]+[BH^/VC[<'E2.4Z$AP.(0^G4JN70(<:>FA`G5$=S(1Z@CECY;V
MS%7FO''I/O97^IGA<LG&/9>GM$47&3TC2[^2ULVNC6=11"+!>6@EG<)50>-(
MPDDV=LC/D=W,H*IG3'IE''@^[O\`NZ%D?*5XEU_@2S-I*OP4IC#RA&I@`*4Q
MA'R8L,.0`&8[`M8&>08_0=+1N\CB^GG?3A_$PYS6C^S]PXVX-.VP><I5J*;5
MO5M-R564Y3BU(6-*]EH2&61;R+ILX&V(-04*LY(4J)A!;88=T0`1#4Z\.?'B
MY1*>:RMM6TE4]64?%\I7J2EJBH>I::I&JHN+HBR;YS!SM7,U)*!;O.][7*`*
M3ED0=]0F9$C$-OB7H!G)>Z5-QG<5RR@Z!*#K->TS>]R'*5:DAMP^9,I=A/!1
M-D%>^8MV[;1Y%4606S2=N#*/W()`9,HE(.TP"`"(;>(75*/Y>76(,V>YTU7C
M9R#.(=<HWJ)0E7Z3U5E'J4[8(CV0)&B@D_.P:#;,7#D&Z[M',"@(@"@!M'&%
M6]TIG"2":>&'\1!G<3TKWT.4RA>41U''21."3H2TS8,!;J@7,X+"%M5.`,)C
MER3.`'+GMSZ6IWA<S?+K$#B#2U?5+?!WRB>HU`S=(3N=^E["(D`I2I"=R!S6
MX.!&B9CB03&V;VS/9MW27ZA)+HU(:7+*(,Y%M+=\4A;E-RAVI--1=,5DVYZ;
ML`99P4ATRBDVWK:H@HJIP@%((`8!$P#UAO$+M_IY=8@S$9^Q]U*8J"BZ;F>4
M;U*M9:X,NX@:48>1=D%%9"390KVHWJ:BZ%L%DF94XB/6$O#`GO*%R`1Z5XA=
M<7Y>76(,S!'2Q?-8HG+RB&I(`34%);?I:PY-U4A`.=(PFMGNI*9J%R`PY[!#
M;TCWA=L24L>6409U'6FF\4:S?R,KRCFHAA'Q:)74B\=P.GUJW8M50$4U':BE
MM3`V`FZ(&%3=S-T`QHVB7GF?+K$#L-]+=\G`M."Y1'4>J5\0JK0Z=-6!W'*(
M)%<"LV$UMM]V@LBH42'2*8I=N]U`RIUE-,I8X7RM!WO5-OP8BF7*%:ES<&)B
M',2E[#`&^3ZXA0-:_>S``Z79QU$(57,TPWH9Z[-*\$;71J'<R4I9K4T[0J9>
MG+*&F(IK&O;6"K&,MVW)&`M)`SH!5%1`ZF:">Z8NW`$V0TDWYSSYPC4S]:&S
MR8L-ET]O^BWH[,`7>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J3?GYP
M?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@
MQ8;T68`>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>B
MS`#U2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J
M3?GYP?4Q\&+#>BS`&CM3>EB^$=IVOH]>Z]M1TNSC[0U^_=1#RF+&%92[9I3,
MRJM&/SM;:-G7><B3[TMP:B:G!_6F`<`<VFO2I?%_IQT^OFNOC4?%-GMC[3.D
M(QE3-C!:1Z*]!0"B;-J+BV*R_>[8A@(3?.<^Z`9F$=N`-U^J3?GYP?4Q\&+#
M>BS`#U2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`
M>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>BS`#U2;\
M_.#ZF/@Q8;T68`X3:3;\E5*3G"=2V9P`$TAIBPI3JCGVYDSC:_(P)$VB&[]/
M`'(723?K+MN4'U,;P"8!_P`EK#%`<C"`"`#:XPY"`;-NWHX`A+RA>E^]$%I>
MJ.1E-=&H>IVI+AV43/$RU-V3(Q65=7AH5LW74&.MPP<@I'*&!=+)0"BJ0N^!
M@P!-XVDF_&\;+E!M3!0WAR*%,V&'(,]@9C:S,<L`6^J3?GYP?4Q\&+#>BS`#
MU2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J3?G
MYP?4Q\&+#>BS`#U2;\_.#ZF/@Q8;T68`>J3?GYP?4Q\&+#>BS`#U2;\_.#ZF
M/@Q8;T68`&TDWX,&Z;E!]3.[O)'[2F;#$/FD)A$.$+:P#B17/MBYY#E@"@:2
M+\@`!SA&ID<LMHTS87,?HB%K,`0@U::7KS1MT]"K&1US:AI]6<U4-HR/>R--
MV3(YIQ\VLI=R0"=B!96X:)>,5.]@2,"Y%D>#.;(F>W`$X/5)OS\X/J8^#%AO
M19@!ZI-^?G!]3'P8L-Z+,`/5)OS\X/J8^#%AO19@!ZI-^?G!]3'P8L-Z+,`/
M5)OS\X/J8^#%AO19@!ZI-^?G!]3'P8L-Z+,`/5)OS\X/J8^#%AO19@!ZI-^?
MG!]3'P8L-Z+,`/5)OS\X/J8^#%AO19@!ZI-^?G!]3'P8L-Z+,`/5)OS\X/J8
M^#%AO19@"XNDF_&\&?*#:F!#J>3-A@S^F%K,\`0NT2Z8[VSE&7H69Z[-1$"G
M'ZK]1L0HA&4S9#@Y%Q'UTX;K3#[ORV[LYI&342%=<2F!/A5#;I2AE@"9_JDW
MY^<'U,?!BPWHLP`]4F_/S@^ICX,6&]%F`'JDWY^<'U,?!BPWHLP`]4F_/S@^
MICX,6&]%F`'JDWY^<'U,?!BPWHLP`]4F_/S@^ICX,6&]%F`'JDWY^<'U,?!B
MPWHLP`]4F_/S@^ICX,6&]%F`'JDWY^<'U,?!BPWHLP`]4F_/S@^ICX,6&]%F
M`'JDWY^<'U,?!BPWHLP!8?25?@,A'E!M2PB`]KO4K810"F,`D*?=-:W=$Q!-
MF&>>T,)YH4*BACD>'G7/@*0SY/>E9RBN47Y2*F:EK^I+HS<9!:>$W=<U<T@6
M-0S`'@IPY>_VU,1D-"%%'>W2BDV3[4`SQ\I[:_Y-=1;_`#/"\;PO"7G,UY77
M8EH+_P"_=:+]F%JO'B>Y$JN_:2GQ*;X#^5=?X'V)4^M.&7]B8/V!^IC[B]/0
MI24U^AD6,@?J!M5<BHZ_:73MU"HR=5V]MM&S=NTW+EK&!)7&8UF[?/H"3<+%
M-WC%5'2;IPS5.&\4.'*.69`QQ.2E@:;32MRB#->4]8.Y]+S$>\9,-T9BX.FR
MM:[GXR=:-CR;Z/>W%GKLK`HEP"K^&AY.I&C)L0QC<,T$I`#=2QIJW?620I-Z
M2:YQA1I)[IBN^K:R#HF6M>_GZG0M7;*#HF20JM%I%6QFJ;JI^XK..[U2?$;"
MUD&"[<X*<"LHH!0*&PNSDV"MB>EG^8R$XKSVSDI^\5JZ^B:,/,NH*C[FTD:K
M4W"23BC9R=:TXM3<PZ2=OV)PB`<1C@JCMNFJNB8Q1*00'&_9J\LS<L8/ER96
M\,>8UYIQMC7U)UC'SDC2$Q;J&C+2Q-+W#0EIUG-H7*N8S?-EI*X<6#>8ERG;
MB@U44,NN"#A5-4""F&6,M3><$$TH9\I$S6\-I=JAY6M+S%9P,H*,A?2_\Y6P
M*5O+*&DK3SK:30M\R?$:2(-1B5I)9NJ1D!0%`Y@'9NXQ=UE:6MTM9ACA>+FP
M8B]QT:@L=>-S3$)"RE&S<_5"UH+7T=155-*GX0EI;ATU-3AIZ5?%4DD5'+1R
MFX:JF?%X8RA$"ER'+$5THX8Z4>EX,(@>5-Z>;S2ESX289TU(1U;1=57O?S]Z
MWE7G<PTO#5M;6IJ2H!NPIXCH%Q>I3LNWX%NBD@2,32$RBA@$<<<UTO.D]'],
M7#E$(Z]-Z:KA/$+<MIV'N$HR&Y=J7MTZ0J&8@*<ACTU2-%5VE4E31Z]/56]>
M5`L]J^89F>"8R!WB9"F,0,ARQV6])QQ/!RQA'3G-/=Y*MEKKH/;:HQ=+UA::
MX=*.*992<<V@9FJ(^L&DC02L1*+3BTA,FG(9N8Y'#XB'>QC;NT,;M"_/^'S$
M,)L!_8VX]078IR:-'UQ3%+-(BSAJ-\GS4L\6M@%,M4T:GI>5?.:C2DXM"1=E
M%1UWBV>%>HB`;!#'1=5>Y:ZGGAH+)\R-'TV!-0J1BYF4X,0`RBP;IC[K82&5
M*```"=0X[1V9YCCZ2C-+4Q@@==<`-RBFCX!^(K5?^R_M`']3&]RRJ2/\T5W$
M9/XQ0+EEU,NQT/ZN-0+<`,`,9-8`8!<*MV%N:5J.MIU9T2#I:'>3D@DR8D=N
M7#5H0!*U:ESX11\[6,":29=ISF*`;1QY]>\5*:;EA@+!<YK5?4=2SBEK5U52
MT-5=9H7B;.G-$QE.1+!S*NT&<&I4+U21:RDS`IQCA@S;J)JHF6$Q5BB4=H8*
M_4H+2QLD#QI+55;J&J*X5,3"]0QDY;.W4+=2IXAU3"R2X4O)IBLLVBEQ<JH2
M4Q$("DI*($,8S!-T@;,Q5,\9*^T6X1+`V55%UX.C[:J74E?&CNFB4^VJ5-M#
MPZ\G..64@S;R#)NFP:@8I%^]ELC"82ES',1#+'2Z]W[,HZ3"ZPU'4A1K"&E7
M#:IIYE*4:I<-8*:II617A*&;-6SIY4]2("N1=DS;)NB;Q$"J*".\!2B(8UU+
MU1DD<T>_X$*(ZDJ*-6+6C@)/NB.JCBZ+&M$H(4J);UC.T]'5!!4X,N+D_#2$
MNTD2&*!2"1$Y@14$JO:XE*]T)\9<1(5-1453IF*`@0"@<P9!N'%)$^[E_9;Y
MCF'/I98ZFY&ORXP=C&)!@!@".NK(%CZ9]1":90$Y['W/23*';`834E(;BRHA
MM231.<V\'3*&?2P!%C3=KVT606G6P,'+ZHK)QTK#V2M3%R4>]K^GV;QD^84)
M`MG;5TU<NTW#==%=,Q3%.4!#+`&Z.<+T.>U?8KC'ICP[`#G"]#GM7V*XQZ8\
M.P`YPO0Y[5]BN,>F/#L`.<+T.>U?8KC'ICP[`#G"]#GM7V*XQZ8\.P`YPO0Y
M[5]BN,>F/#L`.<+T.>U?8KC'ICP[`#G"]#GM7V*XQZ8\.P!\\>4\Y2.VE.Z6
M)R;TE:HJ`?7E85K0#F(;4'4\34LTYAD)HRE0D\4,Q=!),"QY![Y0*)=XF>\(
M9AF!&W23_K!,#,FB*,U=T=Y*RRPI,RW7H6.7<TR[<*;"O*EHW?5FX,JQC`8Z
MC0RK=$@#O;=@`?2K73=2WMY-$,W6-K:WINO*9DKB:?W+29I.1;3C<J*UZJ"5
M$KE-H8RK)4J0#F5<"')_9`&6`/J`/1'Z(_U<`4P`P`P`P`P`P`P`P`P`P!`'
M6?\`Z9.3P_[X7_J#O)@"?V`&`&`&`&`&`&`&`&`&`&`+B?7!]/\`J#@"".@0
M@%H2_8!TM9.I\0^B-Q7@?U!P!.S`#`#`#`#`#`#`#`#`#`#`'&IT`^W)_;EQ
MC5_P5/Z7W,J/CWH]_P#%)Y3O_$VG7_-^:Q\M[9_Y-X_J?>RO]3Z2WE=AR2T&
M#D(Y:[;1#D'1'*$JP<@ZXX\7W!_WU/\`J^`_E77^!]%]1%S#VKM1654-2.'$
MR1DW@Z89M6CEVY?U=4SH(BG&K5LT17=.C=_.R"<B1#G$"CD`CC[+>+T;K+,\
M9.<@-2UVZS4C+%T3/5W4TW5%M=5J5NZFJ^>27I6:KRBGUK;A5%2]659$+,H5
MN>'EP9&%<J;8A,HX.#`IAS'P9;S*TE&#CU<L?466$>LR6:NG?2LZDTXOXE2A
MHL]7W3NU$TP<DC42-"5E0D!;9XY0J:>CG2191=F>;3<^+TT2`4Z"2+H!W3E`
M.ZXWJ62HIIGCBOF'A1[=*ZQ+D5^A0#BB+5.9MU*4+;NN*Q@&#&1=N05K^=G(
M=>/@Y586;1.,@&<*=V23/O@Z;[Q<BG*&/26\:;:246S'#UF!,-9%?Q%,5/(4
MW`TM*L:%MI6]YJE=5A4<TM+/HBE[P5102E+PRR#/^]C.&4`"J"RX'(V,`%,!
MP-GB<2I`VQ4.I&ZE,+R-)/:/I>1KP]RJ6I&/"E23DS3K5M6M#2];L)*49-4R
M2DJLU%GW@JF@4I%SF!;>*39AQ*D#TZ.N[>&[]33-JI6D8RTS@MHFE456Z=JR
MJM;1#FK9.L*5*,+'$:*QY0*>"3D&PKK&,`.0*=/M`$>>>HJTVLEQ0,EB-AVS
MN+4+:X=2VAJMFUA8RF(-).@%)%25F9NMJ>IP&D6_JQ[/F*O"/$E5W!2.&AC%
M<-W.\4P`8,\8<\!SD6KBW^N/(5?0%1)I1,#1+:M]1]-DIJ*J:8:5M/NK=VFK
M=VW1JA(@GB$$W+YBF];)B(KQPE(H1,=H8P=^I2X&U@;67`0V%'ZJ:HIRF'=0
MU-37`0D18:*N-;QBL\EIN?N8:,HF)GJD!*K4VY8IZ>,6<%*[1.+9T4I>^3%$
MB@E"\0H\\"Y3F?:G;P1M,/WDQ;:GZ>JX\BQ/1S&>AZK1:75CRTE(U=/H4K"-
MBN9]%[2;)LF5TZ=$(D5,XF(`@&0X\0HK'`D,!=3>KJJ7S.EZNE*,3AJ*JZSQ
MKH4HBJO(R,K6-3C1SBJI2BH253WXI!_3K./57617!)4[58HI%WBCB3W^E-*T
MN=8"\YN#3K>>YEU#20UQ1(TW$#35,5/350MF,LSB)YK5;>1=>)V:\P832[N#
M09IBL[0`J)A5W=WIXWW6\-J+QP&,UU=@?_B+Z/0Z0V(U7"/T>_[._5Q[,M33
M748D_P!3I?3_`*V,@<>`&`&,GB!'C4!;JK+H1]&TQ!U&-+0#>NZ;JJMI-L<J
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M!&BEK)7SCV<;*1$+0YJAJG3RQT_UTV>U,ZX"E%62`-&E90;TL<"4RS,T,991
MBD1)50Q0`1S``#56W=55*9+&U^*!Z%):;J_IZ>:T4R-3)[7,;Z4S?E:IQDE!
MJ<SV,CH5V_I<*=,Q*@R1E*IBA=IK;X_WJL)=A@#&-VW=524;<8)_-DE4NU.(
M'+P*8&4$?OAU@.MO`;H?6$W0QZ]*BZ6%OF#.WC<08`8`C]JG<(M--NH-V;85
MM96Y2SA0HYY%0I&34!!9/;FBJ0V9LMNYF&`/R;6F_P!7FOY7%JK8UI'W]LU%
ML*NMW1-3LXY:`J]15DVGJ9BY1!LHHRCSM3F23=``B0PE'JX`V!^K>ZB/:,LK
M\':X][<`/U;W41[1EE?@[7'O;@!^K>ZB/:,LK\':X][<`/U;W41[1EE?@[7'
MO;@!^K>ZB/:,LK\':X][<`/U;W41[1EE?@[7'O;@!^K>ZB/:,LK\':X][<`/
MU;W41[1EE?@[7'O;@"+6L?D<[N:)[&S5]ZRN[:VMXJ)EH6G"P%.QE21LRZ7J
ME9S&)+,Y"6;M&S0S90^]D8X%.`#GG@"$.FW1OJ,U75&6$L=:Z6J)LHY*20JQ
MTQ)3E"0;90X`HZF*H7(O'.W"68B*2`*'4R'(0'8`'W;/R2;[1+IGJ&Z5;7RK
M"I:_<5[8@LC0U"RCNFK3H.7EY*#`X2<,J8350N@JID*Q\C*9;,`?JS-T1^C_
M`/+^S@"F`&`&`&`&`&`&`&`&`&`(`ZS_`/3)R>'_`'PO_4'>3`$_L`,`,`,`
M,`,`,`,`,`,`,`7$^N#Z?]0<`03T#?\`$6_O_?(U/?\`2*[P!.K`#`#`#`#`
M#`#`#`#`#`#`'&IT`^W)_;EQC5_P5/Z7W,J/CWH]_P#%)Y3O_$VG7_-^:Q\M
M[9_Y-X_J?>RO]3Z3&^6.J.!IFGM#T_4LRWIZ!@-<%N9B:J&27!./B8:!A:I%
M\]D5SCNII!OEWC#L`,\/<N[+I2FDO=2JY:N!Q;M@\&`?HP38D2ME.4-Y-^;\
M7>-]6&G"4"*DVLW&@_K^G7(,)ABN5TRDV8*KF!N^:.2`HFJ7(Q#@`@(#CKNU
M\W7/<IJ=6\2U()X7-&'0VD^P;116/1CU'@RVN3DNYR2>3,OJ2TM2<P_.R5>2
MCZL:6<OG*L;'24/'J+.E#F6.HRBIEVV2-GF1%RH0.U.8!XW5W*\,UXD;MC\B
M;12C'\O8>33FLGDK*4+%)4SJ&TIP:<$Y<O81.+J^F&X0[MY'A$.W$84JF3%1
MS%?WL<4]W>1[0=FS&VC>MP49M*>O3<L.=_(PGO%-RP32*'UA\E."D`N74#I2
M26I5L@PII5.K:80-`L6KQ21;,HHR2A19M&[]0RR:1<B$4,)@`!$<=/$_;?JT
MH]*^!IUTOB7;\#F;ZSN2P11?-D=0VD]-O)0Z]/2*"=4TB"3V`=R+B8=0SM/8
M5>,<RSI5RHB8!(==0QQ`3"(XV2;T]N)8*E!],/@;J=XI2K\S3.[,:V^2]J!!
M^VG-2.EN50E5V3J23>UC2ZP/G,<S&/CW#@14WE%V3`112-GF1(=T,@V8S>]?
M;GCN^9?`V;30R'=@]>')E4PY*\@=3^F6&>EBHZ#!VPKFG&SKQ+$'64BHH7!%
MP5,PCU%U#(I".ZF)Q$`VCBK?.X)<$M2@EU?`;31R'%%ZZ^3"A)V5JB'U,Z7X
MVHYT%PF)QG6U,HR<D#I9)PY!V[*MPJI7#A`AS@(Y&.4!',0PXUN'U:'9\";1
M2R=AXJNL'DHW$V_J96_FDU6?EEGKF1F3U/22D@^<2<:YAY)PX<F,)U%Y")>K
M-ECCVRJ"IB&$2B(8Y9MX>V9IG--/0TGT?`FTT?\`2=EEK,Y*^-=N7[#4-I59
MO'<.2GW+A"K*5(=6"(Q2C"Q!@X3@PCO%R!$!2``(*)0*("`98BO_`+8BOST.
MSX#::7^D\<FK/DER1J<,6_.E#Q2E(JRJ,>:KZ94:HR;A!)JX?(IJ'-P+E=J@
M1,YBB7>3*!1V;,;N)>V_%=LR^!HUTOB[STXK61R5$$]8241J"THQCR)B4X*,
M<,ZKI5`\="HQZT2G%L=U3=:L21;A1L"9``.`.)/K1RQ5O/VY*XRS79/HE^`U
MTOB[SU:1UU\E]0`/BT3J7TOTLG**I+22<+7%.1Z3LZ)!22.LFBL"8F12,($#
M(``!RQDM[[A2A+5H+-\!KI?$NTBY<7E!-$#_`%WZ7*N;:J[&/("`LKJ7B9F<
M1N!#>+(F0F)"UBL2S<K<(*:;N229+;@"8#&!`VP=F>Y;[W(I7HUJ4<&&*S&4
MM>FGA:)L#REV@+IZQ-/OT[E0?=L./;F]>EG-NT4,A3G+M`/MB:?.,J"[MB\>
MW/Z]+.-HH9!SEV@'VQ-/G&5!=VPX]N?UZ6<;10R#G+M`/MB:?.,J"[MAQ[<_
MKT\XVBAD.,>4IY/T3;XZP-/0G^R&Y$%GL#(-O#=(,8/?6XWCJT7RZ"[31R%G
M.2\GSN@7UOM/.Z!RG`/TD00AOD*4A#;5OKBE*`!]#&2W[N=*"KTH=)-HH9#E
M#E*^3^#+_KA:>^U`2A_23!;"F$HF#^[=`1*'8Q>/;G]>GG&T4<A:GRD_)])%
M,1/5]IY(0QS*&*6Y$&`&4.;>,<0X;ZXQ@S'KX<>W1_\`T4\YHUTOB[RX.4JY
M/TH%`NL#3V7=`"D_I)@LB@&60%^_;,@#![^W0\=>F^LREK2)QF:@<8<I-R?0
M*`J&K_3R"@$.GP@7(@=_<.<JAR[W#9B!CD`?HA@M_;G6*O3SFW:*.0Y`Y2OD
M_P`!S#6%I[`<S#G^DF"Z)Q`3#_=NB80VX<?W0\=>GG&TT<A=SEV@'VQ-/G&5
M!=VPX]N?UZ6<;10R#G+M`/MB:?.,J"[MAQ[<_KTLXVBAD'.7:`?;$T^<94%W
M;#CVY_7I9QM%#(:'U-\HGH0G-/%^XN-U96)E)"8LQ<F,8,8^X\0L[?/'-+/F
MS-DU23.;^_'SQV1(,@$3=J`[.A5O_<JQUZ><;11R'?TV\HOH1@-.E@(*7U=6
M#92L)9*U$3)LW-QH1)PTD(Z@X!F];K)F6`R:J+E$Q3`.0@(8G'MSQ?\`YZ<(
MVA7BCSP-T\Y=H!]L33YQE07=L./;G]>EG&T4,@YR[0#[8FGSC*@N[8<>W/Z]
M+.-HH9!SEV@'VQ-/G&5!=VPX]N?UZ6<;10R#G+M`/MB:?.,J"[MAQ[<_KTLX
MVBAD'.7:`?;$T^<94%W;#CVY_7I9QM%#(.<NT`^V)I\XRH+NV''MS^O2SC:*
M&0<Y=H!]L33YQE07=L./;G]>EG&T4,@YR[0#[8FGSC*@N[8<>W/Z]+.-HH9#
M3-]=5_)5ZC:*1H"]&IO3Q6E#C/0]0J4V[N@P3CG\K3KH'L8,FW9/4PD(Y!SV
MRB2Q3(C_`&6*M_[FA_FI1Z1M%'(;$I;7WR:]!04?2M&ZG]+])T[%-TV\;!TW
M6E*PT0R;%`3)I-&$>9)LDB&_L``Z>,>/;FYJ].'3\AM%#(1)Y0+7[H@K/3%4
MT%36J>QD_,O+B62<HQD;<.*=+JEC;O4)*++D2(H?(C2-;F<+9%RW"".>,EO[
M<J<77IPZ43:*.0FR;E+M``F$0UB:?<A$<L[DP0#EGTPX?8.,5OW<\/\`/2SE
M5XHI0P%.<NT`^V)I\XRH+NV+Q[<_KTLXVBAD'.7:`?;$T^<94%W;#CVY_7I9
MQM%#(.<NT`^V)I\XRH+NV''MS^O2SC:*&0<Y=H!]L33YQE07=L./;G]>EG&T
M4,@YR[0#[8FGSC*@N[8<>W/Z]+.-HH9!SEV@'VQ-/G&5!=VPX]N?UZ6<;10R
M#G+M`/MB:?.,J"[MAQ[<_KTLXVBAD'.7:`?;$T^<94%W;#CVY_7I9QM%#(.<
MNT`^V)I\XRH+NV''MS^O2SC:*&0<Y=H!]L33YQE07=L./;G]>EG&T4,A"'5=
MK_T25-=C0I*0VJBR4FPI/58M/U`NPN'$N4XB*/9FZ4"VE'NZH)4F`R$LU(.8
M@4#K@.?3Q5O[<L'I5Z;<+2;11R$WN<NT`^V)I\XRH+NV,>/;G]>EG+M%#(.<
MNT`^V)I\XRH+NV+Q[<_KTLXVBAD'.7:`?;$T^<94%W;#CVY_7I9QM%#(.<NT
M`^V)I\XRH+NV''MS^O2SC:*&0<Y=H!]L33YQE07=L./;G]>EG&T4,@YR[0#[
M8FGSC*@N[8<>W/Z]+.-HH9!SEV@'VQ-/G&5!=VPX]N?UZ6<;10R#G+M`/MB:
M?.,J"[MAQ[<_KTLXVBAD'.7:`?;$T^<94%W;#CVY_7I9QM%#(.<NT`^V)I\X
MRH+NV''MS^O2SC:*&0<Y=H!]L33YQE07=L./;G]>EG&T4,@YR[0"&T-8NGPN
M6T3?I(@C9`'1V"N`#LZ^)Q[<W/7IYQM%#(0XT6<H%H?I&C[V-9[5=8J&4E]6
M.HRHXI!_<6&*J^IV8KMRZAI-(RJI#BB_9*)K`.60@?KXR>_]RMQ5:FL%HVBB
MW'`3'YR[0#[8FGSC*@N[8G'MS^O2SC:*&0<Y=H!]L33YQE07=L./;G]>EG&T
M4,@YR[0#[8FGSC*@N[8<>W/Z]+.-HH9!SEV@'VQ-/G&5!=VPX]N?UZ6<;10R
M#G+M`/MB:?.,J"[MAQ[<_KTLXVBAD'.7:`?;$T^<94%W;#CVY_7I9QM%#(.<
MNT`^V)I\XRH+NV''MS^O2SC:*&0<Y=H!]L33YQE07=L./;G]>EG&T4,@YR[0
M#[8FGSC*@N[8<>W/Z]+.-HH9!SEV@'VQ-/G&5!=VPX]N?UZ6<;10R#G+M`/M
MB:?.,J"[MAQ[<_KTLXVBAD'.2Z!7(@5'6)I^X0HYD`MR8,P"8W:%WB=])`<`
M$V>6?1VXPJ^X-T24*C56G,M'#R@92WBAB_+A(7<G[<:@KK\HURDU>VVJRFZZ
MHVHH?3RK!U12LNUEXA^A'P$VP>`@NU653$2/DC@8P``&$.GCYWVG>Z=[O5>I
M1:=.+A#G_-C#GEG_`$0B8#_K`2**^G"PB:R2*Z"FI"FRF262(HDH`TM4XF*H
MDH4Q%"F'(1`0$!Q^?_O#1WO=KDJUWJ-2X;%9_J-5_>KI94?GX&G:?,8P%IFE
M3"`&.($I6&,($*8`$XE+'B($*)@`1Z`9AC^2J>__`'3+--)3J5')'#"+6='P
M]6_5-?HRQA'+\"T*=I\0*8*;I?<.&:9TZ5AAW\P$0X(PL-P^>72SV8R>_P#W
M,L=2IG^9GME3FCF9;X@IL`S\GZ>RR$<_):!`,@R$1S[QZ``.,Z.^?<EYGU>N
MF76OB;:5[J3.#C#H9=Y/4Z;(/)RG!S`!*"M*PF0@.8`)=UAF(CD.72'(<=6U
M^Y/7?]R\QT[1-E+BTU3AB`<:8ID2#]:H2E(D2&VY#D<(\2CD(9='HXT5K][H
MEAH5IFLC3_\`<:*UZG34(\NHH-/4V40!.G:<#,-[).EH3:`]`1`[#/(>ETL<
M[WG[I6.M-G^9HVNIES,H-/T^&>]3D"&[]<)J4@@W=N6T18;-H]G$XI[G?_YW
MG7F&V5%_!@:=I\!R&FJ7WMNQ6E84%-F8#F`,.EEAQ/W1Z\V=>8;9/:^TJ>G:
M93`@KTY3"(J!VO"4O#I%..P/O8G8%`^T0Z&?1QZ"O'N9RJ::K/A5O_W#:Y\N
M9_`>3U/]*G('+(PAE2L'EN$R`Q@$6'UI,PS'I9[<1WOW&E':'_<O,57RI'GQ
MV,N1IN#<*%2;4Q#.5CB($1;TA#+JG$"B<0(DE''4.($`1'(!V`(]#'"MY^Z9
MOTUV^AI_^XZ]I=I9Y/T[F)1IV!W@#:7R5@MX`'9M+WAF`#B/>ONA8'7:?2O,
M-JCSE@T_309@:G:>`0$"B`TK`Y@81R`H@+#/>$VS+HYXR6\?=<V&6K,UR_U%
MVEG(6GZ<.($&G*?,`B8X$&E840$V69C%*1@)A-NAF(AT@VX+>/NMN"K3QR?Q
M-56]3J6*B4&GZ9()BDIVFRG*(`<I*7A0.3/+(#E.P`2YB8.CU0Q'O+W2OU5I
MET_Q-&UU<N9_`KX@@-O^3L#L$2B'DK!9@(#D(9=X=$!V"'5QBMZ>YWBKO.O,
M-LJY<S*>(:?[;_)Z`[4,S?Y+0/:AM#,W]X=J&8#T>IC+B?NGUINSS#;*F7,S
ME4IF'1%,J]+1"!EDP61*M1\,B99$>@NB"D<4541RV'+F4>KB<3]T>L\Z\Q'?
M9UC9P^(J>R$?)^GQ`H9F$*7@1`H=#,V3'8&?3Z&)Q3W/Z[SKS$VZ:TKXAI\<
M\J=@1RV#E2L$.0]0<F&P<7B?NCUWG7F&W3VE/$-/B`#Y/0`@;ZT0I:!R-]`>
M\<APXI[H]=YUYC*6_316'G*^3]/99^3L!EL#,U*P>YM'(`,(,.@([,.)^Z?7
MFSKS'9M+*#`TX&7^3U+`([0W:9A=\0#HB0#,LARQ>)^Z<;K30Z5\3"I>FI&U
MC*^(:?\`-Z`V]#_):!\!Q.*>Y_7>=>8Y-NGM>9CQ!`>;L#\%H+P##BGN?UWG
M7F&W3VO,QX@@/-V!^"T%X!AQ3W/Z[SKS#;I[7F8\00'F[`_!:"\`PXI[G]=Y
MUYAMT]KS,>((#S=@?@M!>`8<4]S^N\Z\PVZ>UYF5""@0Z%/P0?0I>"#J=1CU
M@[&'%/='KO.O,-MGM>9E/$$!YNP/2#_BM!=``R`/]P=``##BGNCUWG7F&VSV
MO,QX@@/-V!^"T%X!AQ3W/Z[SKS#;I[7F8\00'F[`_!:"\`PXI[G]=YUYAMT]
MKS,>((#S=@?@M!>`8<4]S^N\Z\PVZ>UYF/$$!YNP/P6@O`,.*>Y_7>=>8;=/
M:\S'B"`\W8'X+07@&'%/<_KO.O,-NGM>9CQ!`>;L#\%H+P##BGN?UWG7F&W3
MVO,QX@@/-V!^"T%X!AQ3W/Z[SKS#;I[7F8\00'F[`_!:"\`PXI[G]=YUYAMT
M]KS,!3]/@83A3L`!A*)!,%*P(&$AOKB"8&&>Z/3#H#AQ3W1Z[SKS#;9[7F90
MM/T\4`*6G*?*4.@4M*P(`'6``8``8<4]S^N\Z\PVV>WL9>$%`%Z%/TN&T#=M
M3,,4V\`!D8P%9`&^&Z&WI98<4]S^O-G7F+ML]K+?$-/^;L!]*EH++Z6;'/+#
MBGN?UWG7F&VSVO,QX@@/-V!^"T%X!AQ3W/Z[SKS$VZ>UYF/$$!YNP/P6@O`,
M.*>Y_7>=>8;=/:\S'B"`\W8'X+07@&'%/<_KO.O,-NGM>9CQ!`>;L#\%H+P#
M#BGN?UWG7F&W3VO,QX@@/-V!^"T%X!AQ3W/Z[SKS#;I[7F8\00'F[`_!:"\`
MPXI[G]=YUYAMT]KS,>((#S=@?@M!>`8<4]S^N\Z\PVZ>UYF/$$!YNP/P6@O`
M,.*>Y_7>=>8;=/:\S'B"`\W8'X+07@&'%/<_KO.O,-NGM>9CQ!`>;L#\%H+P
M##BGN?UWG7F&W3VO,RXL%!%RW:?@BY9;N[2\$7=R#(-W)B&[D&S9AQ3W1Z\V
M=>8;=/:\S+?$%/\`F[`?!:!\`PXI[G]=YUYAMT]O8QX@@/-V!^"T%X!AQ3W/
MZ[SKS#;I[7F8\00'F[`_!:"\`PXI[G]=YUYAMT]KS,>((#S=@?@M!>`8<4]S
M^N\Z\PVZ>UYF/$$!YNP/P6@O`,.*>Y_7>=>8;=/:\S'B"`\W8'X+07@&'%/<
M_KO.O,-NGM>9CQ!`>;L#\%H+P##BGN?UWG7F&W3VO,QX@@/-V!^"T%X!AQ3W
M/Z[SKS#;I[7F8\00'F[`_!:"\`PXI[G]=YUYAMT]KS,>((#S=@?@M!>`8<4]
MS^N\Z\PVZ>UYF/$$!YNP/P6@O`,.*>Y_7>=>8;=/:\S'B"GQV#3L`/\`_JT#
MX!AQ3W/Z[SKS#;I[>QE1@8`>C3T"/1';2T%T39;P_P"X>B;(,^KEAQ3W1Z[S
MKS#;9[>QE/$$!YNP/P6@O`,.*>Y_7>=>8;=/:\S'B"`\W8'X+07@&'%/<_KO
M.O,-NGM>9CQ!`>;L#\%H+P##BGN?UWG7F&W3VO,QX@@/-V!^"T%X!AQ3W/Z[
MSKS#;I[7F8\00'F[`_!:"\`PXI[G]=YUYAMT]KS,>((#S=@?@M!>`8<4]S^N
M\Z\PVZ>UYF/$$!YNP/P6@O`,.*>Y_7>=>8;=/:\S'B"`\W8'X+07@&'%/<_K
MO.O,-NGM>9CQ!`>;L#\%H+P##BGN?UWG7F&W3VO,QX@@/-V!^"T%X!AQ3W/Z
M[SKS#;I[7F8\00'F[`_!:"\`PXI[G]=YUYAMT]KS,XEJ>IHZ>2U,4XL4#IB!
M5:7@BE*;?+D8!!CGO98Z[K[FW]NZ6I->JLTTD\L$NN/-$U5;_424&\>4^R'(
M&IM6U[];#-BU;,F;>%LOP+1FW1:-40.UJ`3`DV;D313`QMH[H!F./ZP_9*^U
M+]N^K6J1TFEWGTNZ*SJRMNPD#_K`VZ&G'3_O#NE#4K2XF$<QW2A2]3B8P@&T
M0*&T<L='[U)U?;\SEPX^Y&S?G^.7I?X$`N3^E*<IBY=WJPK"EV-6P-*V`K^>
M6AG[%E)L'\='S%,2#H44W>:[)XNP:*F((!OY$$0Z`X_#?VFOETFH5MWWQI4*
MD5-'%#.L1YUPG4LK;44DR8L_I)M-+O;(4L>5;R=L?(F^5]:7"$(=G)U7!*OH
MV?H*CW+Z$3>2R`PK66,ADBFJMNMSE`@B!BX_1=Y^V?:]66&LDPIM89<*_N.U
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M[:W.:1%TM0%7:=X=D>Y9A<TLWB:=1E#5/,CWEORSU.38+"4H;2B)<QQS7/\`
M;WVI5NRO$U211G:QK%_<<<^KJU4VVI7-#H1$_4[:6UE(6[L_<&U,55U.M*YE
M+M4K*QE2U,$X^=R5IZH;P2<ZA*B"9&J%0D(LZ5;B!1+O&(.T!QXM]]N^VKCB
MJ2<_/+S?[C1/+!*9<\>S\#Z;78-8JI*NI73C6\A"5"]N/*Z9H.A*'I6@RT_/
MVLCG<'#R-;S[JO48L0DBU0HAPJ:.^*B(`)C;`SQ]A?KM[7O.[J-U=22.KE24
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M!1;B7)NLFHH`V$P1IU2JB4NTNP<?.^Y/VV]NWFOK;K4E=9)M0:QK_<S'ADE&
M76X<$K>8VM;G3]82A[SV/H&;L3<VOO*&EJ7E)*\TC4!T+85A45=6]>U%XE1A
MS11T%9&,>*B5(Y'@"FZ3*(YB42X[;G[?N>Z;FJ3F3P*,&N=<W=$:N66K+(_S
M)P;AE2<.E8HF@=)C"(1UNS,7#4#(4K'1L+>%U35OZUC4IB;IT[2E)!G%LY./
MEFQPDW1Y!L"K=$R>^8JI0#88,_"]H4]W2>Y;S-O"92TG1:46L<<K1T7"?55W
M&QDI:>LS%ZD:'L;)ZDX!I1%W7;V\,K4,/`4\A;N=N3;VC(HCZ$//4]%QA)2$
M(O)(HD[Z;-%W1R)B5$HB.SZ_>7MGVOO;'4DBXX8RXO[CU-H3@YH)N/*!JIEI
M%L1=BK*OH2T#NHV]<'H^V=?TT2?-5%/QL5&.JC<1UUJ?(C6\93\]+HM6":KM
ME(.6B2AA[8PB`E''SU/V![6N<VA)4EC/AP-=?\UAR5*RGG2E3;AS=N91/;::
M7-)3VDJEK%T[JT:1J:LKMT=1LE'*5?4<Q1K*@(F0CX65<1M(P<PTEG50R;<7
M*QY9=NU2;K%$G;;1]F[>T/:VA@JRZ,<&&7%_<:'7DA%8HOL/:KFT]$U10=O[
MA5M2=8W;2M)I/M*UCK7V]>K0505MY55/(P"LLX?I,WDLT:0Z"Q53%1S.;:"@
M%QRWOVG[8J7QR.>2&BL36'_U&NK<9+U,J\RP:*Z\IV&>B6QD!4%?M5:'N;=E
MI`7ZM);N'IZF*B[WE*2@+GT_&OY9G69&,8J9ZPHI1<RCA=0`$B92F.)=N/7N
MG[4>T[[+I35)8Q7/+S_[L9KX-)!QC%-+/CZSJ4SI`TRL):F:,JUG7572=<7^
MOA96$J^G:T:L&4"PH)I*5&QDI%F5G_AATC&LP;J*$SWELPSSV8^?J^R_:U*J
MZ6LE_+/-+CEYO]Q)=S4VE'G;68PZE-*NG:XDU;2K(*'K:FZ(J&RMW;@O:'EJ
MC=S+^J*EMS5K:D6<8G+0,:M-LV3UD<SPR<9'JJ%3WA'/(1QJ^C_;+2A4DBT^
M=<W^XQX3+*E/+C@WF_@<(:>])\(G=ZMU(*YM84/24C8]G!TPTEYJB'T*ZKUT
M:%J".*^JV):RLM#M))^"J9W;)LY4+EN&`1`<=%U]G^U_U:V3!#GEY_\`<:U*
MFG-E7;$I=2R]G+=V'U*0$!:VI*PG;6:BV=(Q]=IRB[V2IV+F8)E.,I!^R1CQ
M41I>,;N1:+%.)4EESE.!LP#'-[O]M[BW?[;KWJY3RS7J6:5*#5L+6)Y(4YH_
MJEF@?*\IDQ4.8H9D,8P(Y#L*!1[8H_N@`/I8_$#D.;`#`#`#`#`#`#`#`#`#
M`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#`#
M`#`#`#`#`#`#`#`#`#`#`#`#`#`'&I]8/VR?_P!Z3&VG^B?H-53FZ3Z\\@M_
MIWUN_P");+?\$G\?UY^QG_65.A=Y]#NK$^C\3??^L""4^G33X)=I3:DJ:R$2
MB&?^2]3=$H@`Y;!QZ'[M0D]OSTZ[T*C3@GT<V,Z=[T:M6FE2E;:;_`^#3&1E
M(CQJ:)DG3(T@V7C9`S=THW6DH]P0R:[`Q""!58]=,PE.0VP2CT,?Q3NG>M7=
MZO%*6HZ=2:,,+3QY&>/))5I49I6G+.U@RGJLZUKF+7@7D56%5MGE)E*TIYVW
MJ-U'NH0J@[W>T&HD8P-H;MAWPRV"/0$,=TN_+Y-#3O4V!>*;!VG+_P#+P*$T
M%BR=!D:-X+M)S\O5"ESKA>4-0)D955/IU;(>4,C'MRY-V/?Q0*UE6S80+WL<
MI$S(9"..B[[_`+S=)G/2O3TFH8)IOB1*]+$IC$)>H:HG$4&\[4<O-((.7CU%
MK)3$C+E1?/E.$?R!5GIQ2*YD3`4RNZ4!$P#CS[_O6\7U0GO+@X_S3<X<MZ>!
MIP.HTE)IC'3$2SE9!E$SZ#=I/1;>0?LV,RV;+=\M"OTH]1-5R9@[`JJ0"/:&
MS'IXXMWWR\;OTE2O+6FTW^:;Y$T+QX69Z_NY=F6\2>-+J5Z_&G1,2$5<U9)J
M*0*YVX(NI"!*&2S87:8`D;A#&.).GELQZRWU>)L,][<4_%,90O<8PFC&)BJ-
M85JQ;,4HRKZLCN\IT]3-$6=22J:<941RF24GF``8`3E'C83D7.&T=X-N-TON
M.]TZ>HDO/_C_`*IOB;:<E6'YDXG4>34O*,4F4U*2\A&LUY!\QBUI!5^BB,LL
M=26(GWR8#-GLD0X"J8/KE,QSQQUKYM>&K>TGEFF^9GHU&H.,$7'J&J5I5K4#
MNH992HFAHU)C/)2:RDI&>*$>]H=PT<F.!P+'QPB@&W,.AC5>[[5EEEU-[TID
MN::;F-#5ZT].$T8XSW(2Y=QZ.=U,XHRN:QIT]5$5;U$K#5')PBE1-G9C*+IS
MJD4<W?RRYE!$728)N$A$0WAQZFZO<U]NDCEFO4RBG_--\22[7*])*:,<)PQ-
MQ[DTU%.8*F*^K2FXB4?K/)5G3]3ST(DY5<`*9WITXQ<R:[]?>$%Q/]>01SQ?
MJJ_T?\-Y?]TWQ-VUWY8I9N76=EI=*YL?`FI=C75<,*:5._64@6%72Q8\I90A
MFQF2;<YA1%NH83K.@$NWA!Z(XJ]V7ZC_`/(EKS35)?Y=*;#''SC:;W,M&I+,
MJ?9WE$;FW02BH""4N+6/B6CI--Y1T0WJ>5\44V]32.C'2L.@Y.8Z3EJW5,BL
M90QB;IQW0`<L<E;WWOBO^693Z/2_,8ZR6,8X4<)*[KD*@DJQ1K2JF-7.E0-*
MU#'S*C&>74$H%6.A)I)\.<'I2AO%`<C%#;T`QST=YU;S.YYJNKJ8XQ:CF+KM
M%Z2<9HEKVX%P'%3,:U<UY6*M6PXD)$54UJJ;-44*D?+-"$?'5X1JU6,`=\\$
M&\(9[!#'7Q:^4OT7EN'^J;XC:9N>.`[#JYEQY6IUJXF*[J]_6IT>\7-6'FGB
MLX]CRD,FE%*R3DY7CN*`AQ#=4``+F.71QKXY?JDZFJWERS+`OS38LYBYZ\[T
MZ6E@P8,I6!N1<>CH>2@:3K^MZ8@IDBZE11--5,];1TEW\H?OHBD:F^:ED>^B
M&W5R%W#B3^RZ6/1N^^W(EI7M)?U3&K1O-C+H.Y=QZ:ET9JGZ]KB"E6D0I3\?
M)PE83#1VRI]905RQ#`KUS(H,XY%WDIWN<3BGMW1#'/>=\SN\.K3O;<8?S3'1
M+>+[3E4DLLT(0Y8;3.H345=BD[:U7;>FZD?QQ:PK1K<"?JV(GY^,KE[-1T8Y
M;'13J59=;^\Y)=03*HF*/""<<A*40`.JC[UWG=I=&G>)FHQ_5-YD9;;?X-:$
MV./7G-7(UA6J`LS-ZSJMH,9).Y2-%K4LL48V>ETS(OJ@8F.<3E</&:IDW9_K
MC&$>CCSY]]UZLSJ37EJ:9M_JFQO&3:[]BT9N76=F-KZO()Q&+Q595-&O(!&1
M1IQW%34N08(\^H49-!@;A0X..6%/A%@`,A4-GD.,.,5>:\O%XI@KU?6X.6:#
MP=3Q\YVYFY%QJB<RCN:KFL)1]43IHI,/96J)%V$BO%JD79N))LD5)),K15,#
MM3``B0P`.S+&RAO>I+^J]0_W3%T9\4'`'N'<0$JB:^753+-JE<F=5$@K/R3A
MM5"SQ-%,Z\V@J;@W:T<1J0B>_F`!EU,=E\WU)7N<U&:]*?2A^72FPX>>))I:
MCE:PQ?:840,BD2!,"`D8YQ4$2_?3*!M$!SQ\_M-#Q(TZJIX6<N77#W1?JX;3
M0\2&IJ^%C+KA[HOU<-IH>)#4U?"QE]#W1?JX;30\2,)I7)@FP,9#UO=%^KAM
M-#Q(QBBANU*<PB&2:8*GR$!$J9E."*;=+F80%0,M@9X;30\:$4,A_P#E$`'Z
M8#D(8;30\2$4/IAV0^KC/6T[4,`RZX=D/JX:VFN="**Y#UO=%^KC#::'B0BA
MEUP]T7ZN&TT/$BRISN$N%C+KA[HOU<-IH>)&S4U?"QEUP]T7ZN&TT/$AJ:OA
M8RZX>Z+]7#::'B0U-7PL9=</=%^KAM-#Q(:FKX6,NN'NB_5PVFAXD-35\+&7
MT/=%^KAM-#Q(US?E>C-@8R'K>Z#ZN&TT/$B113Z8=D/JXSUM.U#`,NN'9#ZN
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MR.*89GR-];VH8P=XH+`YE$10RS#,!#(0SSW@Z'9PVF@_YD(H9=<.R'U<9ZVG
M:A%#+KAV0^KAK:=J$4,NN'9#ZN&MIVH10R^AV0^KB.M2EPN90$45R'K>Z+]7
M&.TT/$A%#+KA[HOU<-IH>)&<LDTZC*HH9=</=%^KAM-#Q(RU-7PL9#UO=%^K
MAM-#Q(US)RN$V!C(>M[HOU<-IH>)$BBGTP[(?5QGK:=J&`9=<.R'U<-;3M0B
MAEUP[(?5PUM.U"*&77#LA]7#6T[4(H9=<.R'U<-;3M0BBQ0HB0<LAR,F.0"`
MC_=2=`,\Q'K!C9+7HRR3:4R448S235&E(HGUWY!80&^^MT-XN\$+9;>)OEX4
MN;2H,A.EGPA`'I"(``X_K_\`8N:6;==1RN*@N\^CW92J2)Z2:P?B20Y>6GIJ
MKK*:9*5I]>*;2\[JEI*$C'DUWXHS3DWU-50U:`X*U**H-S.#9J'VB!"[-HX]
MS]RZ$N\**HO]&&'9T'KU<,I\P'')<ZY$#*D6NEI-^];P*`1C=T>@.Z;=RB,Q
MSQ^*W7]MKG>*,]>=8<?+\QX5?]:.,>2VUN`H"9KH:32'$PD*!VMW"@8P'`@[
MHC$9&#>-T>AEMQA]N+E9W^8UEI>2WUO'$,KEZ4@(*ID@5.SNT1$#E(90V9S1
M(`!`*0=O0SP^W%QY1\P+N:VUN=KG='26`G336`HH78`P(JJ`D14P#%=HF)Q`
M,QRRS##[<7*Q=OF!:?DN-;:9^"/<_2<1;=%3@1:W:X4$]XQ05$H1(_>S"4<A
MZ`AB?;FY6=_F!0O)=:V3"`%NCI,'>#M![VNR!53<*BB"20C$Y*+&47*`%#:.
MWJ#B_;BY6=_F*7DY+;6\H(E)<S2@<0(8Q@*TNT;=W"%4.0V42.2I2G#,O1SP
M^W-QY1\Q"AN2WUN%*4Y[GZ34R"0#B=1M=HI"`8`,0JAAB>T44`>U*.T1V8?;
MBX\H^8%`Y+G6T([+HZ3#;3AF5M=D0^]J`D;:$5]F.SJAMP^W-RL[_,"O-;ZW
M`V#<_2<!NCN"TNUOC]`GBG,<3[<W*Q=OF`'DM];H'W`N;I/4-FF!@3:7:/N"
MJ05"`?*)V9E#;T<AV8?;FY6=_F!0.2YUM;HG_2AI-W`V";O6[8`!AV;N?BGZ
M_/I8?;BY6=_F&CI_E.8G);ZW"K`!KH:30!(4U%A%G=Q0@I;P;Q0W(@<Q.79L
MZ&>'VXN63M\QCLN0PN8Y/'6?&U]1]O3W`TNK/JN@ZOJ)"0,G=@&D<A2ZL812
M/%`(G?4.X+)E$I^@&Z(8W4?VYN>DX0C#+YB;,9B/)<:VP'=_29I0SRS_`-RW
M<]Z<='VZNMB[?,-F10.2VUO'$"IW*TI**"!Q*D1G=LRI]PAE#;A/%.9A`I!V
M!M$=@8T5OVYN;:TDNWS&2IZO!S,MYKC6WD/]*&DX1*@FX$`:7;$W!JE`X=KX
MHS$Y,\CEZ)3`(#MQI^W-QY1\Q2@<ESK:%,50NAI-%,J953F[UNUVA#*%2+OA
MXIS*83F`,AVX?;BY<H^8'(')::WA/P?Z3M)Q5.$*ENG:W:(.\<1`HCG$["")
M?KNAA]N+ERCYBEH\EMK?*4QC7+TI%*04@$3,KM@'W[^YB'^"=H#^QA]N+CRC
MYA@`\EOK=*?@QN;I0W][<W09W:'M\L]W9$Y;V6W+#[<7+)V^88"P_)=ZV2?7
M70TGE$3@0"BRNX!A,(@`9%&(S$,QZ.)]N;E9W^8A3FO-;`"(#=#2<`@!AR%I
M=L![4!,.0#$9B.0?3P^W-RL7;Y@<YN2TUOD,H4]S=)Q3)%X10!;79#=2`')C
M+?\`X5M23*T.)C?V.0=4,7[<7'E'S`XQY+C6YN)J!<[2><BH;Q!(TNT?,H_6
MG'*)V%-TAZ>'VXN7*/F!0>2ZUM`82A=#2<<P',0`(UNT?>,4<A`N43D;,=@9
M=$</MQ<K%V^8%P<ESK;W-_\`2=I0`H"(&$6EVP$A@V"0X>*>T,'4';B?;BY9
M.WS!T=9A@6$Y+W6PH`B2Y^E`P`(E$0:7<RS#(>G$=?#[<7+)V^8FRJP\Z?Y-
M36G2M-5!5KNY&E5PG2L-451BU0;7;(HY2A80STJ!S#$;HEX9,Q@##[<W+E'S
M$V;H..GN35UKU/3U/U*C<?2L@E44%#3R:*[>[1UDB3$:UD"D4.6)$!,`./I=
M##[<7+)V^8JNJ/9YKC6W\9FE#^2W;]Z<=J_;JZPQ+M\Q-F60<UQK;^,S2A_)
M;M^].)-^W-U<KBEV^8;,LA:/)=ZVB@(FN?I/*4.B8S6[12AUQ$8G(`QQ_;BY
M9.WS%V56(H;DNM;9=XI[F:4B*$RX1(S*[O"I"83%*"I`A\TQ-EF`#MW=O0P^
MW%RR=OF"H:'YH%`Y+O6R81*6Z.DXPE^N$&EVQ`.L)O%.0#B_;BY6=_F,L!</
M)<ZVPR_I/TG#F(!L:7;'H[-N43L##[<7*SO\PP%0Y+?6X83%)<_2<<Y2&/P9
M&MVC*G*4Q"FX,@1.\<0$X;`VY8?;BY6=_F(6CR7.MO?.F%S])QU2*)I&2(UN
MT=4%%5!2*3<")S$0.&WJ8GVYN5G?Y@`Y+G6V)%%`N?I.X-$X)KJ=ZW:W$#&,
M8A>&-XIR3`QBB`"/1Q?MQ<K._P`P*AR7.MSA."&YFE(IMH@)F=VP*;;LW#^*
M=TV]T0R';B?;BY9.WS$=WTGI0QE.:[UN9Y?I*TJ;P#D)>\KN;P"'2$/%&8#B
MK]N+C'F[?,-ER%_-<:V_C,TH_P`DNV'['BG9CM7[=76&)=OF)LR'-<:V_C,T
MH?R2[?O3C&;]NKKHN*7;YALRR%.:YUM_&;I1_DEV_>C'']N+ED[?,795D,<K
M#DX=:E$4G4M9.KC:5'3>EH20G5FR;6[8'<)QZ!EC(@/BC^S`,L/MQ<LG;YAL
MJYH'KQ?)EZU)B$@I-&Y>EA).2A8V:2:J-KLF[S-,MRNUVICA$??N"S)NFVAM
M'#[<W/)V^8FRYCNAR7.ML?\`E-TH_P`DNW[TXWT?VYNBC!+M\P=V60<UQK;^
M,S2C_);M^].-_P!NKK8NWS#9ED+1Y+O6R`@7])VD_>-T"`UNV)\OLA+XIS`G
M7'9CFJ_MS<].+A'K\P5UCS%!Y+O6X"2RP7+TJ*)MN$[X,FQNZ<$13;+.Q*<0
MA\M\[=`PD`,Q-EET1QJ^W%RR=OF&RY$5YKG6WOB3])VD_?W`5W.];LB8$3=!
M<0"*'[SF.6]T,P$.EB_;FY<H^8RT=#\MA<7DMM;ITP63N?I-50,<4N&3;79,
MD"H*\`9$3^*@R5*IT0ZFWH8?;FX\H^8%@\EUK:`3@-T-)OWL1!0W>MVMPA@'
M+=,;Q3D!A'H!T\3[<W*SO\Q2@<EWK9$XI_I1TF[P%,8W]ZW:R(!1*!@,;Q3D
M`AOALQ?MQ<K._P`Q#E/R6FM](QR*W,TGHJ)J)I*$4:W9`R9E0#@A.`10[I%,
MP`##VN8@&>>'VYN/*/F!7FM-;Q/[M<W2<@H*1E@07;7:2<<&0PE$W!#$[^T0
MV!TPVXGVXN7*/F&AK/RG!S7VM?+>"Z&D\29%$5"M;MF3*!B@8HF.$0(``[V7
MT=F'VXN63M\Q-ER%Y>2[ULFSRN=I0-L`0$&EW,A`>@)1\4!F`XWT?VYN:3@E
MV^8FS9"[FN-;?QF:4?Y+=OWIQO\`MU=;%V^8;,L@YKC6W\9FE'^2W;]Z</MU
M=;%V^8;,LA3FNM;.\!?TFZ4<Q'(/[TNY[TX?;JZV+M\Q-F,1I/D]-9U35#<.
MF4+AZ6X]S;N98P;YPLC=E=L]>R<:WE4C-TR1`G(DJP<%-^Y'8.W''-^W-RTG
MBQY?,793+AY+G6R`B!;FZ4!+GD7)G=P`$O2R`8C,`RQ%^W%RTEBQY?,795D*
M\UQK;^,S2C_);M^]..W[=76Q=OF)LRR#FN-;?QF:4?Y+=OWIP^W5UL7;YALR
MR#FN-;?QF:4?Y+=OWIP^W5UL7;YALRR`>2YUMA_RF:4?Y)=OWIQJK?MS='+A
M2QY?,%=ED!>2XUNF'=+<S2B([ISY`TNWT"``C_\`E'1'/8'3''-]N+ED[?,7
M95842Y+C6VX,!4;G:3SF$QB;O>EW`$#%2!?(V]$%W=Y,<R]7#[<7+)V^8JIZ
MM0A@+R\EGK?,<J07,TG\(8$1`@MKL`;=7`3)F'_!7:E$`VB/0Z>+]N;CRCY@
M</->:V0(8XW/TGE(0AE#G%K=L`(0BO`F$W^"<P'?_8V]#$^W%RR=OF#H:?YH
M'-S6VMP#`4US])J8CP>7"-[M)@/#&,5+(31(`/""01#JAD/3P^W%RR=OF,=E
MR%A>2ZULG*!BW-THB`AF`]Z7<#]@8C':OVZNL%!+%E\PV9%>:XUM_&9I1_DM
MV_>G%^W5UL7;YALRR#FN-;?QF:4?Y+=OWIP^W5UL7;YALRR#FN-;?QF:4?Y+
M=OWIP^W5UL7;YALRR#FN-;?QF:4?Y+=OWIP^W5UL7;YALRR%P<EWK<+F4MRM
M)IA4$A`,JUN[N)_?"&$XB2)X4N0%RS)VVWZ.+-^W-SU,\\R4)5'E^8FJU<R:
MYR<O(KVUK2SNJ/7A;:X4C2LO5L!#6.-)R%%>-1IQ3OIA4"J169Y]JVFCFW!S
M'A,RAGLVYX_8?VIN-"X76K0HV?CUGMW7$R2W+*[:7T7=?6W;4/\`^UU/]7'1
M[]H5E)+-*TL+Y^@VU*LN@L?.;VNE4[FD*(N-6+%%JX>4I2-65$T;ORB+-=U!
M13R022=%*=(PH**MP`P`8HB`]$,?'7)WNENRI--/)HJ7F;B>1>)7*M9S(^5B
M>OR[2NF")J$:9HA'4BDZ3\J*95?O4J?@J%9T4RN`^K!-J:1(JZ9K0,PV;)J&
MX(AGZQ4P,(!O#Y>W5?$<.TRV30Z"8(:QK9(W+C[9C'2ZLJ:3@*5FZD9-8TL7
M"5O5%+QU?-V"<"N^5J=ZU0I\XE7632,@BJJ0#&$H[P-NJ^(;1+9-F-*R^M*7
MJ:0EJCI:G:AH.U9]/5X+RQ-1U/3D-(EK<U*59%0%/UE2\>,]PB\6ZCS.R$8N
MSLA$5"J`':Y@VVKXAM$MDT.@D/2>I)G4*\S$05#UM5+.W]-P@U[6D&W@XBD8
MVKW%!,ZT7@4RRLV@NTE7;1RD58@;[5%1=(!5`IA,#;JOB&T2V39C6:6K!:N:
M_LI`4;&J4P:0OTZMM<^.FPAY@>\VML).OF+:GY&+E'T6Y*`BV4=+(K&,B([N
M0B&6&W5?%VC:);)LQ1EJ_>TY5]T:2FJ,DJM>Q=_W-A[.4_;].,<R\TNQMC"W
M'<FE!E)2):(&!FY>CWPNL43B4I0#(!$&W5?$-HELFS'C7*URPY[2O*KLQ3%6
M3M72-F)&[3=R2,AW"-MX:,G!IYJ6KV3^:0;O5'M8(.F.['C(*@HF.X4Q,C"V
MZIXEG&TRV39C*RZGFL#/UO3\HSGJWJ(U4V5H2C;?4G2S!A)2%67#M$6LWD>Q
MJ&0F&+-9!@Y;NUW*KHS8Y"(FW2&R`!NVU?$LY=HEL>8S.H]3\52U94A1$U0=
M7,9NN';>(@V83]#NYA.HG],2=3QT`O$-ZI4F&_?B,0JV3=*(%9@MNB=4B9N$
MQ-NJ^+M)M$MDQIFD]:)9:!M/7MQ("2M+!5%;&]%>3=..HR/J<LG%VZ>Q)6\U
M!3\5++N*?2>FE$V[9`$EP6<@<AS)E`#BVZKXAM$MDV8SQ?6G2$)#U$\JVW5S
M(&J:=D;4M24(Z9PTC*3+"]3L[&WDPP/$3+^'=#+.TC$43%V11N8AN$*&6,I;
MW6GF4BF4>DWW:O)-6EE:>8W[9^[D1>2DIBHX^"J"E7M-UQ5-MJJINI6;5K-0
M%94FN9&3AI%&.>RC00`@<*FX264:G+D7A`4'<QNT[SXI<YZNE3L,8K#;J4LO
MD`[+=7A';_\`74CC.G6O,CCI2YRZ5.PWJ<P`83Y#EEEU^K_6QNVN\^*7.QI4
M["%^KB_\_9.9LK$Q514+1\;<27K="<JFOH5Y44=$MJ5I%Y/L4F,.Q?,7:TI+
M22"35$Z/#K$.J&28@(B'/6O=;22FF2CE."]U)%/+*N='BT#K;9O*::N+GVHK
MRAJJI^R\/>*[ZK1B88&@XR3AZ@D(AI(EDGY9Y"1JLM-J`V;=Z`!7+A-,P@41
M4#G5]J/^9+K.)5Y&\36`R@=:=)QI95M5-N+@4]63)Q:@D';=\R@EZDKUK>B3
M3;6V&%4;SZD*9>25*IPZ;EVW,S%(P+;IMT#3;:OB)M$JYILQXMH]5;FI'#:#
MN1`3D?5-:7FOO0-+P1F3/OB!CK5TXUJ*19U&JS?+'0=-Q.?@C-P<I'(8@[X`
M.&W5?$-HELFS&<P&J2GZWDZ9B+?V\KZMI.?MW`W3E(R)1A`"DJ0JMR_:4VYG
M5']0,T^^G;B+<$*W;"X6*9(0$H#LPVZKXAM$MDT.@U>;5[5LEI4I:]K6U*=,
MU?7]P("W-(TS4<D@:$<515U:/:+IZH'KJ+=/Y-&#24:&5=9I%.02"7=Z>+MM
M7Q#:);'F-@UM>FN=-=%GF+\-F->.F)'CF1E;9-XN@&L;!QQ"JR;HD17]4DD:
MA>)-CE,FUCN^%5C'*0HYFPVZJOYAM$MDV8X?7%H$]Q$:%3INNTXL;BT]:V0N
M4Y0A@HN)J^JJ7;U=!1RZSB81DEDI2)=`F59-J=$BP&`QB@&8S;JOB&T2V/,:
MFF]9LU/5.E(T93E4TA:8+*:EKD0E=S]+QDZRJ]U:61C6<?5%',V\TLI+(Q<B
MDZ.1H[[T!RD<I\N"$3!5?*UO,77KPS8HXNT[%;:QGH,*3BZ$B)B7D"5-IIC+
MF7)4BX!*@J8D+LN*?G7$#(D+/F<-)N:AY-+A`9HNFS-VJFV!015`<-MJ^+M)
MM$L<4V8S*XVL6(H1Y<VEHRVM2R]5T=1%<U_3$0$U2;SRMC;=2;1.HVZK-C4;
MB1I22CO&@N@;R";99=HDH8I<R`46VU4X:6'I#O$JP0FCT%76M^@820HJ%J^C
MJDA)R<IBW<_6T3&/X*0&AG]S)!=A3Q5D&DTO(U`VD"H`[4.P1=&:-U2<,4AS
M;@=%*>]5Y=*29065GHW.I)/3;:<8DWEDSI*J)*@J4Z2BB>XJ`[Q2$4,5,Q3[
MA$U4U2`!RF*(]J;(<C`8H;-"^>*7._@=>E3L-?W:$/T172V#_HVN#_FN\QKF
MFO4K@YI8](TJ=@M8(?HNMEL'_1U0W^:T3B:=Y\4N<1IV&=8[E5OD,<N=ETJ=
MA7$FJWS1>&7%:R:5.P9CD.Z!M[=,!>U3-D(E$`'=4*=,<NN`ACBT[SXI<XC)
M8?.F,UAN8F[^HZ(N+5=.0-"6$GZB;EHR/H2JI*KYF$A:(@9(U5A72+E"GVKV
M0F9,C9LT72,=4#F*!29@8,9ZUXIRZ<TRATFB]3R2T6X<YLF6UGTI3D5.)U-;
M:Z4!6E+SUL*>>6\%M".:IDEKRBZ+;]XW!K-KPJ*4HHQ4(<KEX@L@8N1R!F&>
MK;JOB/*VB1\TV8XJDUG0]*59(4HZM+>9X]@*JHV@:E781<*X:0E:W(I5I4M%
MTTY*>=2>.'LHA()I<(W26;)K%-O*`0-_#;JK_FP#:);)LQZ%-:R[:U*C![E+
M5RVE%J!O-6<E!RS-JE)Q+NP[T(>N*>>N6D@X8HS"4@_2X`4UE6:X`("N4Q1+
MB;=5\0VB6R8\"G]34TYKF[:WB\9RAJ?MM82L:#IU9]3%.2B#^Z44M*?X?F9^
M<BF+,1.W51)ON!!58`*F)\\\-MJVC:);)H=!Y"&M5I6#^GR6_MO4Y*(J&REX
M;GK7#>MXITE1A[6/92/ES2$(,T#>6(PF(Q5$H@J8%Q4(*6^`FW6W5?$-HELF
MS'L,M:%%1,1!O)FGZPJR-C:.M!4%VZYBH6)BX*@'UYD6XT2:7CE)\'Q!?E6!
M5R#%)X1F3,RPDZ&&V5?$>E2O%)4U&5Q@9A3^KBB*AN@UML>D*TBRRERZSM##
M5R\;1A*5F+A4+'N9.;@$54IA::27%FU,9)51DF@8!`1.4-N"OE:/ZNTV*\47
M@@\WS)8"`E$2CEF41`<CE.&8;!R.03$.&?3`1`>B`B&/656^0QRYV;]*G8,2
M:I?&FHRYV32IV#9U\<^A?/%+G?P&E)8:HOR7>LC=L`Z/Z/JF_P#1ZF,9E>Y5
M%S2PZ7\!I26&9T602T91XCYFTJ&S_$S0>IC#3O/BESB-.PR3L_3QOHU+THPF
MESL:5.PI_LZ.-^MOELN=ETJ=@R.8Z:8"!45!.#G=3`5E$B%WN"34_L1Z(Y;-
MF."\WJ\25(3-1AS,U3UJ,C@TXD0:9NK>>YEQ[PFMZXMA3-L[#5NXMC+,:CBI
M&=JFL*A90R$G/2<4_P#&R#&F2H)2@(1ZBC0X/#)J;VX``8=&VUK3':*/A>;Y
MFE;<ZTG49;V#KJ[*[Z679Z=Z4N3*4]2='QQ'02M5W5>6P@IZ(EDI1-.<EI-V
M9J@M&B5))(,UMX1'(;MU5?S+.>;5O$FLF@G")MEQJRA9F4H]-%K.VV=LK^N[
M-W(I6NH*$DI=H+6W2E:\`\=,I]5&GX[Q.GWP#E`'*W!]MN#B;=4\2->T2V39
MC)D]5*,C;1&Z["SMQ6%)2_>+FAG50/Z-IZ,KF"?(R3@D^@O-52R%NU29QG"E
M0<<"^4(NB)$#;X[K;JOB&TRXX39CPK,7_F+T75N/%TI(-4J`/9*R]R+?)S#5
MLVD(B8K=I4Q)`THD1R*KKO*0C/OB)3F`_!"4#9X;=5\7:-IEL>8U%16J:Z5'
M(W.FKMEIBL(2B[]-M--+TA9B@S0]55Q7D^Q2E(B<2<2=4K)DBUN^4FIH\PB"
MBRG"[Q`+AMM7Q=I-HELFS&[6FI-W#.KSN)2!E)EW;FY,!2;:C3^1]"JTRM+6
M_CJO=L`GIVJTV59ODVSLZ1T$%3+%=(J$*0P`!A;=5\1TW:\4]-Z2<(&J6VMV
M&;3U85MP4C*6:+9S3S5]'12$4SBI?QW=:I:T@SJU-*R+YK'Q\"T5CA[X=JK`
MS)P91!41W2BVVMXNT[MHHV/EUD\*:FTZDI^"J%%#O9M4$,QFVB/C6.F"%;OR
MF.F+1_$.'L4]99!D59NX63,.8`;9CLNMXO,Z>@UUMFR2K2G44F>Y_LZ..K6W
MRV7.S/2IV#_9T<-;?+9<[&E3L.$VQ0#](AR`/5S-EEEAK;Y;+G8TJ=AHFT^0
M73U0AD.RY%'=#H?\0(@=F.*:>\Z3_-+CM)I4[#?@"&0;!Z`?U,%/>8K\TN.T
M1IV#_9T<=NMOELN=ETJ=@_V='#6WRV7.QI4[!_LZ.&MOELN=C2IV%!,!0$1`
M<NMM''/>;Q>9)$YW+"-K)I4["(FLF]US['4-;Z:M'`4Y4=4U;="$I<T94@N"
MIK1*,?)5!)DC1;*IG\9K-8<Q4BB!BG-D`[H#F'#ME7Q=I=*G8:ZB=7[^N;_V
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M3QKV`<2T`_2"G+CNS-*;E&TPWEEHE69DY!0B!HP5PD&CE4J:B)0*8P-LK6X.
MDV[?=_!/F7Q)]MU5%V[==9FO'++H)++1[I1!5TP65(4ZK-RHU57;'<-E#"0X
MIG.3>`<A$,>K+5OCE33EA"UG8IZ32:3@SF_V='%UM\MESLNE3L'^SHX:V^6R
MYV-*G8/]G1PUM\MESL:5.P?[.CAK;Y;+G8TJ=A7H`)ND3=$>KD)REV=?,V-%
M[KWV6Y58-?IM9SUY54AH8(,B1R>^?.-<I-U"16GY,WVWB.;-LV;0R-CV?VFG
MO<U6OK6H0R^(ZJ$RDEFB>URR?;4KHMX+-4YM:]M542E#M5,HJI1$@J"(%3'(
M>GT1V8^D_<)5)Z$LM/'A_`PGPR2V1?X$D*OI1"JX:JJ2F6+U6(JB'GJ?E"(D
M616-'SK1PP=%25`F::H(N!R,&T!RQ^9[NN&\JMWFE@]7##A^9IJ+3E<MJ(UJ
MZ)K+'7FW"=/5.BYG;$16F]V^+*NA>'MI#(MTFKDQA;&3\K72:!4'+O+)1LDF
M0,A+CHX->;''EE./9>B)ES+311\+<*0N33X5A`/)@&"]1T;'2:HT/5\E'1+:
M#2>U(T=,'$LKWQ%MBH+`W<HB9,A0Z`8<&O-CY=8V7#S&O8?0S9^'93L4V"YK
MR+F;;UA:1I&3-5R,E'4G;JN9-K(S%(T:S5;\%!PT:9DF6/3+OF2',3&'/#@U
MY?,^765W:.,]Z9T=6RF5:R165N;'4_<"FF-*U=2,96;]I34T2'@VE-PU7NX]
M9BL"E<L8>/0+WR4Q4C'3`3%,7(`G!;S8^76392^D-'MLZ-FX"IXXM=R%14W7
M07'9RTK.\.H\JD*)-0)5)!O'1;!F5DG3H@B"::93&`H"81';AP:\V,;*9&33
M#;I&MG=Q$8JJ2U.M=^6OHW-XV>%CF]P96D`H,RRK9-`!=1"%,%!(B!Q[4^8A
ML'%>YKSS2N!=E4<&(UN]T(V>=0D53C0+F0$5'TM45$2/DW5LG#.JJHVH*@=U
M4%,5*H@V.1U'Q-0/5'#0Z8)JH@.X`[H8<&O'A8V50@9/46CZVE1+5))BE6]/
MU+4%2V\K)K55+S3Z)J"F*EM;29:,I1_3$CP:PQ8+08&3?!N'%?AE1Z)L%N:\
MIQ@^76%=8.*QG"PT;VW87":W*!W<5S/M*FIZL3IR-6+2"$Q5-.03RG"3L^NZ
M8&D'BTY#.N]Y%H11-FN4!.!"G$1PX->/#RSDV99#B8Z,+5-(V+AG;6N*AB(*
MGKFTK#1M2S;N5;LJ?NFZ;.YN%2.+=!1"/8+I&49@3:BH!#!];B<&O/A8V7H+
M8O1A;&.C7#-^M<JL9!Q4ENJ@-5%:U,_F:J*C:-R1];J`;RQ$&W>%/0+U(#':
M))[KD%%.$,(FQDMT7F5Z4'RZS93H:$ZFL-T4#:F"MF%>#2["82)7U=3UQIT7
M2CE<YI^HU3N9D4@$NZDP.MNF(W+VA3%WNCC+AUZY?Q.O`8#5Z+H=3%E2`U<&
M(M;:\JB*I$E#`<J:]'@8#E`F:1@$W0$<QPX;>N7\2&^CL7A@R[U=!_\`TZO4
M']SAPZ\\OXE-?59:*GZVJ^V5;S\=,+S5J).9E*6(B<4H\'50QAX237D62S)T
MC)"E&+'X!-0`(5;(P]#&+W5>9\,(PY6G/6I:QIX,!Y$Q8"@JCJ&ZM2U#3K^6
M>WJH>`MW<9JOWR$5.4W3R,@@Q%"-#[U$RR7C%18KA$V95C"(!NY`$X->/":-
MEZ#5QM%EM5:<J&&>/KI2U03GD4FVN7-58_D[B4XUMJ]1E+>,Z=FU6I$XYI2,
MBAF@F"8\(FLKPAC&$!P>YKT\+3CRRE=V;PMX2B^BRV:D-!Q*3FZ;=Y`5S6]P
M&-7!6\TK619JX\8E#5JBI-&0*HJQG&"(;Q!#-(1$I.T*4`/<UXYI7RZP[JN8
M]Z#TEV]I67H"9I%:Y%).*`H^"M^FT@*HD&D;65&TO*N)FGX.XC8S90]7M&#Q
MVL`E5,F*B:QP$W;#@MS7E<SY=85V:Z#G1TI6Z"T4_8N18U=.VUF)^0J*,B9F
M:D'<A1<D[DE)I@[HN9*BD^A5:?F5!<,"@8Q&XB(!F&)P:\^'EG([K&PP>I-$
M-NJU9Q[>LJCOC5<BQB*G@EJEG;@N)"?G(>M&C=A4D)-KN(%1`8QTU:)E2.V*
M@Z1VF(H4V0@X->>=/EUC98N+A$SH-)]L=P^]&U@NLO<>WMV7:SJ9=K]]UM:N
MG&U.42H9`S?@D(9HU1$'35/('A1#A!$<\5;FO*<='EG*KK!QP&+Q6B&ST*I)
MBU1N2\8N:7N-1,)`RU5R;NG:.I.Z3<A:MAZ6C`333C%'CT3KI.@S69Y@1+M`
MRPX->HXGRZQLSMY6'8=:,;5'F829;!<N-)#GM4X7A8NJGK&GJBE[-(Q[.BJG
MJF&39&9S53$BXI)H[<'``<HB)A*"@$,5P:\^%\NLFRPL.C%:([21DA.2"+.N
M%D9Z%NA"*T\ZG7:U.Q#.\1E7%<)4\46OC9@HX>B51JX5<+KMMXX%$`$`P>YK
MRW&#Y=97=HN.`]>.TB4;#3-.5-&U)=UM4,)3-.TC,OQJ0BKFX-/TB[76I:-K
MN35AU)&1-3S18&K9VW%NZ[W(!3B;HXZJ.Z[Y)*THX^7.=%*FY)8923PLW.9A
M!HYR,839]ZJ%,(FVCOB4!!0P=#?V"?HCM$<;>'7W+G^9M@S7UW4'2=I;I`HT
M=)HEMM72BZXMU1!%NM3KQN*P)@7?6,FH'UA>V$.ACFJ;NO6FXQCRR@OM6T>#
M:ZV8]ZN<OT>42!1*BH8#%+3,64IP'<#8<H`.71#/(=H8PX=>N7\2F>]YN_P1
MS_)U?N<=BW=?8<^?YDPCO-W^".OY.K]SB3;NONB\>*WYC"4[R=B`@+1UD("&
MQ!4!`1`0`0'=Z0[<<?#KUR_B4TN.G&WBE/WFI9U`R\G"7]GSU%<MK(J*J*2,
MFYBD(AX\8.TTBN6*_>S5,4`*;<15(50`WBA@]UWJ=:.-<LIKJR:<CE,-C]'M
MN46JR,XYN36<BK6UOJ\-5-85*^G:G<R%JLU:`A7;Q9NBBI3\&Z$3F()157`Q
M@.;H8QX->/"SEV5<YE,QILH::JFHJV<1U1)U+5%R+>77E723^0*B>L+7PB4!
M2BB"?US:+0CRF!5N3M5!RSV!AP:\V/EUDV7!#!`UW-Z&+-3#6,8)HW)B&K.0
MNNL\6A*HD8=]*0]Z9A6H:]IAVJT2W#04I,`D<J.P$B)B!=IAQ."WGPOEUC9>
M@].H-&UL:A[Y4795@S?.F-G&I9-G-OBO&*ECV#F/HA5F55LJU5[R0<;F2Z:H
M9!O9;^W%X->(?I<2[*H90TT96QC&E+,8=Q<V,1I>`NI37#(U(Z5=U+!W@=2K
MRL8>K3J-01FF[IQ+'537%,BZ"A2BGD`!B<&O-CY=9-E.FMHLM,9>.23:U^R@
MVT/;&#J"E8^HW[>F;B,[0)%;4$I<B+%LH6JGL,V13(94YTA<D+N+`8H!B\&O
M7,G#EE,7*Y'H<R,P8:7K>QL["U(Q8U:C)P%Z*VO]&&\<OSD+<2OH*0@YM5<Q
MD!44@S(/LR-/K"%#=#9EBK<UYL9%$W_WFZ#9WHX#+9D#94`#+I`&X&0!CN6[
MK[#GS_,]#".\W?X(Y_DZOW.'#K[ES_,L&.\W?X(Y_DZOW.'#K[ES_,09JJ^K
M1P6R5W#*(+I)EM[4YE%#-UNT($>H)C`4";RA@#H%#:([,:ZN[KYHX8X^7.,)
MFE'-'@T51@@T<CO4=2YS@"*@\&F,,S[W,8=WZYP7,=WHDRVXY^'7KE_$&0]Y
MN^FU=?R=7[G&ZCNZ]X81Y=8'>;O\$<_R=7[G&[AU]RY_F(,N!L_(FJ5)JX`R
MQD<SF;+"*:29'1%`3R+VJB@KE'/J%QRUMT7N>>+3C#ESG)6_7U$>'>ERC5;D
M2]T8F1N;1\U5"K1_6U/T95<E!497<Q%Q2D5%2-2P:;90IET4E1%91$Q5%Q`!
M,.88U<&O4,3Y=9IPF-!HFLR6GB4N$%5@PJ=`TI;?O1:9?N%'%,4=7J5S(9LL
M_43*Z2=-JN2!4'"6ZJ=$`3,.08<&O-CY=9GLT<.#"9<XTL6O<56XK):%JEY,
MO+M(WL?%>R;@[%]6Y:,/;E9-RV*WR/!'HD_>I4,\RFVYY8<&O%CB795UFN?4
M?MKXFIF!+,7>!A14^XG*#2/5QW`V_;NH>8IU>EJ16=PKH$*=/#SBI<W":[HI
MTT]TY0*&#W-7A^EE=UEA@QFUK5:<*$LS(FDZ&C:F:.#4%2-N-Q]).GR8TW0K
M^5D*<#?6;BJ5Z"TTN"Z@#VX&V98G!;S8^768[+T'3=:8Z`=#*J#&U,1:9OS'
MZD78A*/0*A<^&8(QL0Y9@1$IDXELW0*8R(CF90H#GEGAP:\V,;+AB>#6VD&V
M5<R]05"^0K:&GZCN8E=%[+4[*K,5F\V6D!H1TT8-G#1VR;1\C3BJ@+@"8G,N
M;?`Q<5;FO'/*X\LHU*IJ//$Z,9HXMS3T3(Q%+/;FTP65MQ2-K'<C#U(NF_"D
MZ%=5.M3[)%%W'OHW[XC5*Y7(G2,!C=L0"B`"#@UZL?+K,#?-!V\AK:493U`4
M?%R3*EZ48$BX)H],XD'B#(@BH(.9%5,JSI55P<ZAMA2%$W:E`,=-'=5\D3@G
MAY6G30C!])E?>;O\$<_R=7[G&[AU]RY_F=$&.\W?X(Y_DZOW.'#K[ES_`#$&
M<1F3LP[G>KCMSD-GP"NS<Z66[GMQ>&WVQY_F,)H6TS1T>ZVJ(I6Z^?Z2:.S+
MP*H&#^C^'V`42=L/T,<DV[;UI/''EE&`W\#)X&0=ZNNI_N=7^INXQ6[KU'E\
M05[S=_@CG^3J_<X[.'7W+G^8@QWF[_!'/\G5^YPX=?<N?YB#'>;O\$<_R=7[
MG#AU]RY_F(,M,Q>&`0!JY_DZOW.-5;==[GEA,G"/+G$+3`*[M'3UR5:#7JN-
MF5E+<UFUKRG.\%EV10GF3!['HB\W4CBNT%!\<IB=,!''+P:\6,8#4E+Z-+,4
M=%,(2GZ3G&<4QK"Y=<]X^,GPMW$U=J%?054LG/!I)++4\SCWO`L6@'(":21"
MF-VN6*MS7A<S--6DIVG8GG/"IS0K9RG2-4^#N1-`T>VK727F*@5.NDQL[//Y
MRAXZ/(R8LT(MM%&D5$P!,#&53R*H<P8QX+>;'RZSGV7H,FJO1_:*LZTJZX4_
M3<^[JRN955]4\BA(O(XDO&/Z4"D)VF';9FB5)6DZCBBD[^C3;[9=9(BW:J%S
MQ>#7FP.ZQL.J;2/1*EN):UK^;NQ+4^^>T@\AG[ZJ!+4M#FHEQWW3Y:)G640T
M7B#13HI%$3J$75,<G;G-F(X<&O*Q)\NLJNS6(DJSC';5HU:B65>BV;(-Q>2!
M%'#]V**94Q<OG`)$!=XON[RI\@WCB(Y;<=ZW;?4H8<_S.Q)I0.QWF[_!'/\`
M)U?N<.'7W+G^98,=YN_P1S_)U?N<.'7W+G^8@QWF[_!'/\G5^YPX=?<N?YB#
M'>;O\$<_R=7[G#AU]RY_F(,H9LN1-3A&SDA#;A14X(I=P15)N9E750,H!CY!
MDGOG#//=$`'+MN^ZJ\]VO&N6!4_Q$&1%Y/HG!\HURE:9SI]\$C]/W?*!3*"9
MLH,!,[J8\,D@HH`DV[P$`N>S,<>U^VEVV>I7CCA_[C.3],W1^)WN6=I>*K"F
M=$U+S1I$L3/ZV;81+XL5).HAX"+^#JDJBC9\R,1TU6(4!W3IF(<HCF4P"`#C
MUO<<TM3>4ESF7Y7-CS<QTS4$Y5AP8221^2QTJF4%07NHG>$1_P#:LU$9;<_L
MKC&$?IB(X^PN]RNERH*Z22)RU,#;C%?@%1D3CA*<UGI6_#-1/RK-0WI%QGPN
MYF>KE+B\EGI6`?\`=FHCH=/57J''^I<;#A=SYAH2HJ/)::5A_P!^:B`^AJKU
M#^D;#A=TRDT$5+R6FE4N>;K4,?/[/53J'-E]#^D;9GAPNZ6,:$H-R6FE4V63
MK4,3+I$U4ZAR@/T?Z1L.%W2QC0E+.:RTJ_ANHGY5>H?TBX<+NEC&A*.:RTJ_
MANHGY5>H?TBX<+NEC&A*.:RTJ_ANHGY5>H?TBXTS;NH)P4C:Z1H(NYK/2G^$
MZA!ZXZI]0V8_1'](O1P6[Z#<')@Z1H2EO-9:5?PW43\JO4/Z1<;N%W2QC0E`
M\EEI6Z3W43\JO4/Z1<8S;IND\KEPJ)'3E:@XP.(W)::5PS_OS45\JO4,'_K$
MQI7MZZ/^9C9J4(X2/E8<FMIE;:F;)4RFYOZ$=)V\O*_<''5#J"[[!PP<445'
M@W/Z1.$33$'1]XH"`&V9YY8XJ>Z[M/7=##H0CEQM?QM,=1)EA`D2;DL-*Q<O
M[_U$CG__`-5:AO2+CIX#=+6-GIY>744YK+2M^&ZB1_\`>KU#^D7&ZGNBZ4U!
M1>$R5*25041S66E;\-U$_*KU#^D7&WAEUL9="4<UEI6_#=1/RJ]0_I%PX9=;
M&-"4<UEI6_#=1/RJ]0_I%PX9=;&-"4<UEI5_#=1/RJ]0_I%Q>%W2QC0E'-9:
M5?PW43\JO4/Z1<.%W2QC0E+QY+72MD/]^:A_I:JM1'I&PX9=,I=!%G-9:6!V
M@\U$99[1'59J'S['Z1,::^[[I2IN=*+P$5--EG-::5P,!3.]1`".>[_UK-0X
M[V71R_I%#H8UTKE=JC@Y8=9=7*<@<EGI6#;WYJ('Z.JO4/Z1L=/"[K",&30E
M*CR6>E8?]^:B`^AJKU#^D;#AEUL9="4MYK+2M^&ZB0_]ZO4-Z1<1[KNCYF83
M49)L<2G-8Z5OP[45\JO4-Z1<3A5TL9CL]/*:[N]R8NF"&M1<N19/-00NF=`U
MB\;BZU2:A'*)5DX%X4HJ(*7&X-4FW:4>U'J8X:VZKKK'")=1)#!&)6T/)@:7
M)6TUKI-=YJ%(O(VYHA\L1'5/J%31(J[IB+74*DF6XH%(0#J#D`;`#&$VZKK'
M#&+PY\)-13YX\NHV'S6.E;\.U%?*KU#>D7'H+=5TASEV>GE'-8Z5OP[45\JO
M4-Z1<'NFZ-0PC9Z>4<UCI6_#M1/RJM0WI%QS\!N=K)L]/+RZBO-9:5OP[43\
MJO4-Z1<;*>Y;I3FTE%F2HR2N*B.:RTK?ANHGY5>H?TBXW\,NMC,M"4<UEI6_
M#=1/RJ]0_I%PX9=;&-"4<UEI6_#=1/RJ]0_I%PX9=;&-"4<UEI6_#=1/RJ]0
M_I%PX9=;&-"4<UEI6_#=1/RJ]0_I%PX9=;&-"4J')9Z5@_WYJ'^GJJU#Y_\`
M2,&'#;K8SGGN=.>9S-N++>:QTK9Y]_:B0ZP:JM0V7_2-APVZV/.8[#2MF[!S
M6.E;\.U%?*KU#>D7&/"KI8S=L]/*.:QTK?AVHKY5>H;TBX<*NEC&ST\HYK'2
MM^':BOE5ZAO2+APJZ6,;/3RFG]0?)D:88&Q=W)AB\U!&>1]OZF<MN^M4FH1R
M@"R4:L=,RB![B[BH%,`#D.P<::^Z;KJVU&(U$G-$S&@^2_TNR%$44\</M0_?
M#NCJ;?.!2U4:ADDU%WD.R.J/!!<42E*4Q>U`-A0'(,:J>Y+I4YVL!5=Z;QQ,
MN#DLM*P_[^U$_*KU#>D7'1)N2Z4K7$.[TU:5YK'2M^':BOE5ZAO2+C/A5TL9
M-GIY1S6&E;\.U%?*JU#>D7&2W9=4H09KGN=*=Q;93FL-*WX=J*^55J&](V+P
MVZ^'M,=@HVS=A=S66E;\-U$_*KU#^D7$X9=;&=,M*6652J,$.:RTK?ANHGY5
M>H?TBX<,NMC+H2E_-:Z5OPO4/\JO41Z1L.&76QET$6<UEI6_#=1/RJ]0_I%P
MX9=;&30E'-9:5OPW43\JO4/Z1<.&76QC0E`\ECI6'_?NHD/_`'J]0_I%PX9=
M;#"I0DJ2Z,T8%O-8:5OP[45\JK4-Z1L7AMU\/::-@HVS=A7FL=*WX=J*^57J
M&](N,7NNZ/F9LDNE*10464-R66E8`$0>ZB3"&W+UJ]0P;.@`_P"D7IB.,>%7
M7FB9;/3R\NHL#DMM*9A.4DAJ&.9$P%<`&J[4(`H")0,/";UQ@R`"CF'5PX5=
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M]0_I%Q.&76QF2I2K`HCFLM*WX;J)^57J'](N'#+K8RZ$HYK+2M^&ZB?E5ZA_
M2+APRZV,:$I<')::5@#+OS40/T=5>H?TC8<,NMC+H(M'DLM*PB(]_:B0SZFJ
MO4-Z1<8\*NEC-;H2-QPE.:QTK?AVHKY5>H;TBX<*NEC)L]/*.:QTK?AVHKY5
M>H;TBX<*NEC&ST\HYK'2M^':BOE5ZAO2+APJZ6,;/3RCFL=*WX=J*^57J&](
MN'"KI8QL]/*5#DMM*Z7;%?:C,S!P?::L=1Z`Y*"!#=NUN6@KT!^R_9QC5W7=
MU=JLLD5&3YEV>3FB13Y.RVU-V@Y1#E(;=4>K42M-0$-I["-\JJLJ6N)PH.(&
M:45[[J:KY2:J%_F<=G#.3[H;`Q\[[1NDEVO-X4C;46NTNH2;2;@S/.5UVIZ"
MP#H^O=:++\BU7CA]P?\`?4_ZO@;_`.5=?X'U;KNLHN@Z-J>M99=$D93<._EU
MC'$X%/WHB?@F^9`.<RCMX`)$`I1$1-D`"./M+]4U=*2I81+#A(LP&J*JIBE[
M(2DE032FZIK:\[NS=U*,<R"LB^M]/Q5,U9.R;&.61(U4FGIRP395(2(F("+D
M`,&?;!YBW@W,I<.DW!KDRP+*JUE4_%U%;)E3U/3LQ"U?7M:V[J@KBFI]I54#
M/TI0Y*P%I#T\+<59MVD"A2NDBF*")-_MM\@E'?=[\YY\;@1HSUYJRLX@A3+U
M"J".XNK(BDYR/EVD9(KL8J&KF1&*I:;JU0Z;=.F8J:?)*E;G<&`52I'$,A+D
M/;M.40,6;:S+7Q<:*M9S+9K(D;3LZ^/2L54=0PT%2,/5\I1BM13[T\8S6C(N
M.F(M1%Z[43!HB<,P.)3`.&TY<(,L-JIMD:*>3#5>=6!C4T921H%:EI]M5LA+
MS,>[F85&GJ;[T5E)X)V$:F>LCI)@@X:%,J"F098;3E$#H):JJ#J@@PEL7#VN
M*YDZ$>5?3<1&4_+N8U8YS3$7$)3K],I4X-)>IX9=FJ1<Q%B&;J`(%R`<%>6W
M`0,_M_=UI6CB5@`;*J5-2"C:#KE:-C98U*QE:),VZ\Q343.NFZ:,K)1ZKHH'
M1#=!,`$!.(A@KRWSX1`T?<'6135.7`I.A:73;37C*H;BPM4U`_CYUK3$"-O+
M=U/5DHFA4Z#56%?/64O#(I/$DE%5D43'`J9SALTS;YNTCT6U%8.6$0-D4SJ5
MH2=AY.34FF!VE*4;$U=7=41;*97H2FDI*GXZI2-EJC>-&:'?RT5))N4VIP(L
M#0Y53[HB)`+?-UF<$^6<*4X&^JFVCF#EYMNE5[I2GGK)G/0#2C)QU54(G)PQ
MZ@B9.:IIJBO+Q49*PZ"KE!11(=Y),3=#&[:<H/<BM0MOIQXJRB)E=^BSHYC7
MLI4+6!E5Z7BJ7E(]W+QLC*312E8L`>1S)403.IPH'2,&X(8Y[S?72H33QQ%2
M4<)W;87THJ[KZ1CZ5>K"ZAXJ'F'S&3C)")DEXJ<[Y\2U#'-'B)2/:8FP:*"U
M>D.)5-P2@78(AWW"]*\45-'"3%B,&KC_`+7-@!__`&POE_PJ@L::4B5Z<RYY
M?Q)\"5:G2^G_`%L=P./`#`#`&%UY7=/6VI6=KBK7Q8REJ:;%>3+\4%5CMD.%
M1;!P:*6:CA5RZ=)II@0!S,.6`-1*ZIK5(2<#"+R,LUDZA<0K1(KRGY)LW@GM
M4+*HTLRJTXE.I3JU1<'PC,5RE*X2,!B[!#'$[S"9J/.4X874W0U;2<I2]#/1
M6JUO3DU4<6C5$3.T]34I%P#E"/DI]A4KI@#)]3;>4>)-S.2;I`,!Q`1RV3:&
M\"8@:UI'5A-N8PU17`A*%I*DAFZZ7CJF9SU4R;*H+<V\@0D:EKZ.2<4FQ59L
M6<FJFDEWP((/&YN&;JG`2@,VEPCS`YJGU(&JAQ1?Z)),JR4A=RC;?U@E4U&5
M,W<QD)5].SM2,YZ-13<,S\"JVB2`1PL'`!F;/:)0QJKUG/2:C@B@8I8_5+="
MY,[IPA*AHN,BEK@4O5CZYZI(B=8GI^:9T@G5E,)0Q7CMPFT:/6IN#<%<'6.*
MFPHE'&VZX^HA]!L>C_*!C$#`#`&G[]N.`LM>%8YRD0:VOK5913@S*BB"=/2B
MZRATRF*94A4D0$"ER$=OTN&K_D8/E!:_EON3SINV5N:>D+F5<#^"H*CX9Z"-
MMZJ<)`[C*=CF3DJ:Z#4Z*I2K(&#>*(@/5QBW*\.'$NX8#.N?8Y.;XS:SXL:N
M\"QWK$!S[')S?&;6?%C5W@6*!S[')S?&;6?%C5W@6`'/L<G-\9M9\6-7>!8`
M<^QR<WQFUGQ8U=X%@!S[')S?&;6?%C5W@6`'/L<G-\9M9\6-7>!8`<^QR<WQ
MFUGQ8U=X%@!S[')S?&;6?%C5W@6`'/L<G-\9M9\6-7>!8`<^QR<WQFUGQ8U=
MX%@!S[')S?&;6?%C5W@6`'/L<G-\9M9\6-7>!8`<^QR<WQFUGQ8U=X%@#5E\
M.6OY/^M[.W-I"GKD5>M-U'14]$1:2MLZM*11Z^9*((%,(LR[!.?JAC37?_C?
M2N\&5T=RX?)X0E)TK$/+E5H5W%4S!P[H`MA5QB%<1<8T;K@!P9[NU8!`.KEC
M.ZK2<)<<"IF3ARZ_)S!_RFUGQ8U=X%CIJR32I-P#97GV.3F^,VL^+&KO`L:2
M#GV.3F^,VL^+&KO`L`.?8Y.;XS:SXL:N\"P`Y]CDYOC-K/BQJ[P+`#GV.3F^
M,VL^+&KO`L`.?8Y.;XS:SXL:N\"P`Y]CDYOC-K/BQJ[P+`#GV.3F^,VL^+&K
MO`L`.?8Y.;XS:SXL:N\"P`Y]CDYOC-K/BQJ[P+`#GV.3F^,VL^+&KO`L`6FY
M=7DYLCJ#<^L@*!4RY?HPJ[,1X4!V#WB/T^AD&`/@YKBY4^K%]:J=^]%-[*GC
M:'&W=*4U(L9:+D&%,S<S$R$X\>QLY1U0-E"BU51?(AWZ@5!53/=W^TV`?3'2
M+_K`MK:S;Q=*ZL*3-:2I5'#>.&X5+INIVWCETL.ZDI,-`67FJ=,Z.(9'*#MN
M&>9C);2@!]:M,%7TI7=PM3E64;4L)55-SESJ1=Q<[3TDREXIZ4UM(!`A47D>
MX<);4B%SS',##D(=(/&N$SVRK9IQ[RDS2Y@4`$,A`-H9YY#TPSR#/'K7G$OZ
MD'C+L9D&`&`&`&`&`&`&`&`&`&`&`&`&`.-3H!]N3^W+C&K_`(*G]+[F5'Q[
MT>_^*3RG?^)M.O\`F_-8^6]L_P#)O']3[V5_J?26\KJ.2>@L<L\M=UHAR#HC
ME"56.09[,QQXWN#_`+ZG_5\!_*NO\#Z57BM+$7DI=*C)V0=-Z:5J"G)6IHQK
MP6Y4$;3LXA/>3+XQ3%5;1\HL@";@R9@.=$1*(Y8^TOM*6K2DI31T'\"&ES:1
MZ:95`:;I.II:DT"W'8W6CH7O5M--(:O6M`U+0;V40<21UUSGDTZD3=K`)Q!9
M9J7>SSQYW"[JN:;.PCL43I>&G#VG>2%:R$U(6CJBNZC82`4_%1C^KGE<4NI3
M,K)U7WNF0',T9RX5=*.A$%'(F[?9LQTW?=]WE>C^:&%XWDCW(-X#$J:T8TU1
M[FAB,*A8S+"#IJD*/J%C5M'1-1HU)'T')R3R%<-P=@8C%VFXEA0WLC!T%0#?
M*`X[=ANZ<8/.R'"VT34RRIRMZ?0K:I3DK6UE36D7=&9129&K.J*\J*X+F:3,
MW`BY^"E:C7;"4XY"4A<@`0S'16NE*6"ECARLIG-?Z4J<N"^E9H]1.FTPYJ>E
MJJB#OXJ.G6$4YIFD'U&-"*Q+D>]7Z"T7)+'2WLA;G,`E^M#&EW>1X<,09S;:
MPD+;:L)"K(MZ5()&AJ5HM6`AXB-@:=;I4M)STL$@V9QY")M7$B]J%8ZB1>TW
MLQZ)A''53N=&:1.9./2QA+(*RGB"Z]1W96J`[M><B7T?X@BXI&#;R17RC$P.
M:C\7J%;SDDR2CT4TG*B8+@4HB)AWASSV*[V/.R<^`U/):0F$Q+IHN;B39J.C
M9JY\W!T>UB*?!&*>W>IR7@YQ21D3M._7[>);S*YX_A!%0#F#>,;(,>+5W+<9
MIVX3_J;_`%/GQF2;.%?1O!RK?O":K&1>Q86C7M1WLVA&$)(R$4I3$-2S*1J9
MS'F(E4#MLI$`Z2%PD)TC*"0H@GVN,>"7**FA/%?ZGS8NX-MXSC<:/FSRG&,0
MO646Q<D?@O+.86AXN+C:C8K4Z\IR.0FXIL<J4J^A6#L_>2ZIC"W$<R@&._9I
M,L.LAV871M#Q;"D:><5C(K4M2EO2VZ5CHV&CX*9J:$2I.;I-=&HY:/X-><C_
M`/#9G"""X&!$_P!8(8PJW*C6INE4CH.QM`VO9"P<59=!^DW6@GSA5E$Q#)Y$
MTM$4V[3@H!-VA",I1>-(1>768-WJI"J+";Z\1R`1QZ=UNE"[44J2:P<[;Y@8
M[6__`&N;`]:V%\?^%4%CBNM6>>]N6;$I?Q#YN@E8ITOI_P!;'JD./`#`#`&L
M;J6^_2A3R=)O)$T;$#4%*3$B/>R+E.48P$VVG%HA4BP"3<=.X]',1#8`"'0$
M0P!I\FFN,&Y=R*[&8:*L[FBHI-L'E-Q+NI8I4:31I,AH6JETS2<8W:*-2.&Z
M:.Z5)3>$OUPX\F:A*YW-:V4U!):)YQ]2SNGQOE-I2BE%45;-E*'I"D3QS"@*
M7J!69=TPI$E1327:URX.1-V;,3F*GU\L%=Y6U*VX8L;Q#";$D=,+JKH:$B:Z
MN4ZG'$714E02`PM*T[3<`$#-3T4ZF"(4]&)%8($4A(9&%`,LB-Q$P%`1$<=>
MQ7=\SSLD3=U!VXBJ4J*Y,^59=[)7`J6.F'H.2D3&'BH6GF-.4Y!MRE$Q#M6:
M,>NHF8HY@+@<\57.@N9YV6)L]%@S;B04&Z2?!9\'N))%X,!3*D`$W2`)`(B4
M"%RRR)VO0QNDI22?I)$[F-L<$`,0#`#`&H+\E27LQ>!D<ZI!<VMKHAE$MU-5
M)%2G))N91N=8.`,NGPPF`#=/(!QQ5?ULO,?G@MU_J\=G:MM[0-5.=2]U&KFI
M:(I*?<-TZ<HHZ:*TO3T<_433,HQ.<2%,OD&8B.6-;4"0,Q_5PK+^T]=?X,T1
M[W8]!8@/U<*R_M/77^#-$>]V*!^KA67]IZZ_P9HCWNP`_5PK+^T]=?X,T1[W
M8`?JX5E_:>NO\&:(][L`/U<*R_M/77^#-$>]V`'ZN%9?VGKK_!FB/>[`#]7"
MLO[3UU_@S1'O=@!^KA67]IZZ_P`&:(][L`/U<*R_M/77^#-$>]V`'ZN%9?VG
MKK_!FB/>[`#]7"LO[3UU_@S1'O=@!^KA67]IZZ_P9HCWNP`_5PK+^T]=?X,T
M1[W8`P"ZO^KYV>M[;6N:Z::C+H3#RDJ9EI]G&.:?HEN@]=QS4Z[=!58L>`D*
MHJ4`SZHXYKVVJ,5:@>]2W^KK6:GJ>@9XVI:[+,TY!0\LJU+3]$+(-SR3!!X#
M0AACQ$QFIU3APGUQP$,^@&+=IYI'@:>`&0_JX5E_:>NO\&:(][\=D]2:=)/F
M`_5PK+^T]=?X,T1[W8U@?JX5E_:>NO\`!FB/>[`#]7"LO[3UU_@S1'O=@!^K
MA67]IZZ_P9HCWNP`_5PK+^T]=?X,T1[W8`?JX5E_:>NO\&:(][L`/U<*R_M/
M77^#-$>]V`'ZN%9?VGKK_!FB/>[`#]7"LO[3UU_@S1'O=@!^KA67]IZZ_P`&
M:(][L`/U<*R_M/77^#-$>]V`*'_U;^S)R@4FINZXF,58`$::HG=WBI@)>U"/
MR'=';@#X<ZZ]";G2[JICM,5FWMQKW2,U1U)U*Q:-H)D]K"2D9M[+M#Q;:&@F
MR:+M@V-'@?>.9`0X4V9Q````/H'I*Y`:[EPU8^KM552C9BD%P!<EO:4.UE[D
M/VIU!7.PD994BD)1Z3P<N&0%-PY()Q*!P$,\`???0/I\M7IDG=2]J+/TZ2G*
M/@;JTF@U:]^.I!PL8]KJ?<G<.WCQ559=PHLL8PFV!F.P`#+'C7&5*]UK54\P
M/HR`;I<LQ'(!#,1S$<ARS$>F./5O.*7I17C*XV$&`&`&`&`&`&`&`&`&`&`&
M`&`&`.-3H!]N3^W+C&K_`(*G]+[F5'Q[T>_^*3RG?^)M.O\`F_-8^6]L_P#)
MO']3[V5_J?2>!RRTV>FZ>T4SXQ,S-)0NM6VDH:+@&*<M,/G#:%JC@HZ,:&7:
M@NZ4#>!,HF*`FR`3!T<>+O\`CQRE@_FQYL!7^E0)6&UW@`F_ZFVN,@B([^5D
M:;`PCM*.^8MS`WA#/'W\\JFGHQYW@S<]G:8''Z]Y-W=]3?7'N[NYE^A*GOK>
MIG^D[//K]''9LZL6?Y%.0NO+(-FCG7)LRR_H2IT1V!NAF(W-$QL@ZN,9Z6@H
MP1"SU[2;PG]3C7(!A`0S+92GRAD)1*.10N<!0S`W2#H[>B`#C6"TVNQ(VZ(Z
M-M<0B0`*4?T)4[F!2F*8I<_TF@(@!B@.W/;]/&R2GIJ.#`"\FO$J89$T<:XR
M_0LC3FP,@#(/Z3<P#(H;.AC+9U8L_P`BE0UXAVP^IQKC[<0$P?H2IP0$0SV[
MHW,$,]O1Z.-<\N@X$!=>`$$XET<ZY0X0V\?^A.GA`39`&>0W-$`V!TL@QB"P
M==R0B(CHUUP9B)#&$+'TV`F%,,DQ.(7,#?X,![7//+I8W*@IOS04>GY%`:[B
M!O9:-]<8;YA,?^A.GAWA,&0B.=SAV9=+H!ALZL6?Y`>O>39_U.-<G:G`X?T)
MT]D!REW"B`?I.RV%V9=##9U8L_R!4NNXA=S=T<:Y,R!V@C9.GC"7(HEZ(W.$
M1[4<MN-5>BI:3F<%"S#\`4-KP``_['.N8!$<MXMD*<,8!,;(3;;EF'(,]O4#
M&4B>HBOTPY8"$?:PUL)+:G;+S1=)VM+?CK>7A8A$FLQ`A)N#.W-$F%XV1-<1
M(AVB((""AP,.0F*&6W,/"N;6WSI1_1^)62)/KS-O9&T<ZY`R`/\`D1IW+;UQ
MN9CVB%OKYC['6N3B2ISTF8`>OF/L=:Y.)*G/29@!Z^8^QUKDXDJ<])F`+?7P
M`0,4='.N42GSW@_0G3V0[P9#_P`INS,`P!0=>)1-O>IQKBW@_LOT(TYF.S=V
MC^DWM@W1Z>-VH3PP6?Y%+0UW)[?^IMKAVCF.=D*<',<]X,\[FB':B&8?8]++
M#4)88*/3\@!UVIB.?J;ZX\]XQ]EDZ>#(Q@$IA``N:`!O`.T.@([>CMQI(7!K
MN(42F#1QKC`Q=X"C^A*G<\C=';^DS,>CT^K@"_U\Q]CK7)Q)4YZ3,`/7S'V.
MM<G$E3GI,P`]?,?8ZUR<25.>DS`#U\Q]CK7)Q)4YZ3,`/7S'V.M<G$E3GI,P
M!KN[.N!*6M?<J//I'UL,Q>T%5Z9EI"R=/I,FI0@G6\Y77-<-9(@$*&P,^CTL
M<=6&F[06V=UT=XVAM.S+I`UN+E;6QH!$%VEEZ=5:J@6DHC)1!0+DH@=(P=`=
MTOT,8O1CA;3Z/F(FQO7S'V.]<W$I3WI-QVK$!Z^8^QWKFXE*>])N*!Z^8^QW
MKFXE*>])N`'KYC['>N;B4I[TFX`>OF/L=ZYN)2GO2;@!Z^8^QWKFXE*>])N`
M'KYC['>N;B4I[TFX`>OF/L=ZYN)2GO2;@!Z^8^QWKFXE*>])N`'KYC['>N;B
M4I[TFX`>OF/L=ZYN)2GO2;@!Z^8^QWKFXE*>])N`'KYC['>N;B4I[TFX`>OF
M/L=ZYN)2GO2;@#3>HC7$26L/=^-6TC:WF*3RWM3-SO'5FJ?;(-RJQRI!547+
M<A84P+O=3'+?'"@\K7>$9K0.N<&-$40V#2+K@<G9T52S-0[>RD$HBMP,*R`C
MA)<UQTRJ$5#,0$!'//;B7=Q@W&,"F7^OF;V.]<W$I3WI-QVM8(D'KYC['>N;
MB4I[TFXQ`]?,?8[US<2E/>DW`#U\Q]CO7-Q*4]Z3<`/7S'V.]<W$I3WI-P`]
M?,?8[US<2E/>DW`#U\Q]CO7-Q*4]Z3<`/7S'V.]<W$I3WI-P`]?,?8[US<2E
M/>DW`#U\Q]CO7-Q*4]Z3<`/7S'V.]<W$I3WI-P`]?,?8[US<2E/>DW`%A]=Y
M3B43Z.=<PB01$O\`0K`!D(AD/UMS@SV=79@#%V^KBC&M6R%>M]".LA.MI5@T
MBI"K/T`TH>H'48QX46<<>54N29V5BV%8XD2*8I`$PCEF(X`RGU\`SS]3C7)F
M``4#?H2IW>`H9=J!OTF;P!LZNW`$=[-ZUF\3=#4V^#25K0<GE+D4B[[Q867@
ME'C%52W<&W`CY`MPA216*5/(P;V660]$<>-<6MLJJV=_CCL!(D->8Y!_U.M<
M@[.B-D:<S';U`N8&0X]>\RP@IK5BPCG*^OF/L=:Y.)*G/29C(#U\Q]CK7)Q)
M4YZ3,`/7S'V.M<G$E3GI,P`]?,?8ZUR<25.>DS`#U\Q]CK7)Q)4YZ3,`/7S'
MV.M<G$E3GI,P`]?,?8ZUR<25.>DS`#U\Q]CK7)Q)4YZ3,`/7S'V.M<G$E3GI
M,P`]?,?8ZUR<25.>DS`#U\Q]CK7)Q)4YZ3,`/7S'V.M<G$E3GI,P`]?,?8ZU
MR<25.>DS`#U\Q]CK7)Q)4YZ3,`6FUX"?+_J=ZX@`!WA`UE*:()P+VP$3$USR
M!PAC`&0=MF'2Z8)I=*[U)OY5)AZ,6+G[`0^Y/FM27%Y1CE(ZQ+25;4(:6@M/
M`K4I<:(:P%81BB4%.)AW_$,Y*60;IK$*!BB"Y\Q''RGMEQO%=VS/O9D_U&8<
MKJ0@DT#J"4HJ)Z[[3&3/D&^0RD+5@'$INB`G#H]7'A>[&Y=]T-'!^;X%>)=?
MX'V/$1ZH]GZ&/T*7#2IS/&8<Y3,>J/9'&X#,W5$>SA&`&\/0S'/Z>&FL@&\/
M5'LCB:<N0#>'JCV1PTY<@&\/5'LCAIRY!`;P]4>R.&G+D`WAZH]D<-.7((#,
M1V9C](1Q=.7(`&]T<S#U=N(JU*;](8S'JCV1QKK1U;:!QJ9B!BB(B42B`@([
M!`<P$!#I@(8W2):J//#\"\Q%FM@RU<V`RV;MK[XE+ETB]]4!L#K=J'8QXMS;
M=]FCX/\`W,/FZ"5QQ$,LA$.C_6Q[)#CS'JCV1P`S'JCV1P`S'JCV1P@TX\P`
MB8>@8>SB:ZE+^J`C`;P]4>R.&G*\4(`KF8>AF/9Q=)9`,S=?Z>>7T\-)`P*X
M=>Q=MJ*J"M9]O-.(>G8M_-2@PC!65D"1T>@=R\5:,45D57!T6Q#&W2F`2E*)
MNEC1>;Q)1HNH\2L'2:+<:N[.DBZDEW4]/Q"5&U31E'U&Q?P4@A)-JAKQI%.:
M=8F8%X=4J;I&;:'.<#@5(%!$V?3YJ&\J4V/"7!S$IF_"%,8ACB;=%0!$%S*@
M`\(.YO`<PJ$.)-N70#H8]#6R5/RRI10.UF/5'LC@09CU1[(X`9CU1[(X`U1?
M8`/9BZY#AO$/;>M`,4VTI@"#=[#`.P>CCBJMZ;!S6.V64L\`;`"UEO?\T8C&
M$[<>I=R!M',>J/9''H+$!F/5'LC@!F/5'LC@!F/5'LC@!F/5'LC@!F/5'LC@
M!F/5'LC@!F/5'LC@!F/5'LC@!F/5'LC@!F/5'LC@!F/5'LC@!F/5'LC@!F/5
M'LC@#16IW;IWO4`B(@-MJJ`0'I@,6N`A],!QIKJ-)QR=Z!G-M>UM_0.6S*@:
M/`,MF0>)6FSZ&+=TF\-ADC.@,;;M'LCCHG21&79CU1[(XP(,QZH]D<`,QZH]
MD<`,QZH]D<`,QZH]D<`,QZH]D<`,QZH]D<`,QZH]D<`,QZH]D<`,QZH]D<`,
MQZH]D<`!4W0^N#/,HY#T1*8P$V=;>'LX`@#=CE(],UD=2`:9+PU:[MI5+VF8
M2I(6KY]N"%"OBSKN09MHUS4)>^4H=^"L:?,SQ--`2G+NGSSR`G3!3$;/Q#&9
MA99C.14B@#EC+13UK(QSUNH([BK5\Q67:.D]F6^F;=$0Z`=#!8P1GL08PWGU
M9@)C9!=NDB99CEN?HJIH^YE]COB(Y=#/;CQ[E_RZW_\`IY@2MS$`RS'(,\@Z
MF0[,OH8]2\8%+"U%>,9CU1[(XV$&8]4>R.`&8]4>R.`&8]4>R.`&8]4>R.`&
M8]4>R.`&8]4>R.`&8]4>R.`&8]4>R.`&8]4>R.`&8]4>R.`&8]4>R.`&8]4>
MR.`&8]4>R.`.);MB@4VT!,3,!V@/;EZ6,:O^"?\`I?<RH^/>CS9RI'*>`&P!
MB-.IQ`.F;R>F@WAZ^6/EO;7_`":_]3[V5_J?26<KI_<=!7_?NM'_`.AJKQX?
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M2DI*,ZPBI1/Q@?),6KE$QR`8#Y`VBR/+J',<M0:GKX'/44Q3:M!L8JG0TGMC
MQ<E3U02CN7?ZD6T"U>J)2R51MSLHJ#FI\AD5."$W`)&3/L`3XLU=IPPXEVJ(
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M*3KJD(]I"3,LC47?%0`Z;N%`?.%2M%DED%-PAB[,85+Q"FVHQ<KYNDG3B,R0
MNU7==ZBM-Z3ZJJ50A&UYKTT<-`Q'?:-3M&E&4A+MF]23\J6HU._FTH<A1*Q6
M9E2(!RBF<XAD'F[OO%6>:72C%S/FP\V'%BPX.AE=I]6>F'T_VL?4U(.[M<\#
M$L/T_H?UQQMD:5+"UB_`O,1:K?\`[7-@?^;"^/\`PJ@L>)<O^;-_0^\/FZ"5
MA^E]/^MCV8HAQY#U,(H#(>IA%`=4.MC*9K0QK$"*^HV\4[:F3MRVAB1[H]>R
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MBZT,B7)2.C<A,0#.%`+DZ\N-1+!8S9=$5Y<6^$S'VZKL*>-:Z]-MKV*##4Y%
MRK*8@:#@ZK7HRG*A<U$XGGJ<BXK>-=D6V(%W>%S#9T,9H7J5T7@4R[LW03N-
MTNM(EII=:I7+IO/E7J><CIZ7.$B)B+2,0PI*&8+"0"!P@)M*"9[HB&9=XV0A
MF.-MWW9)*DVU'EE!*=L!Q.`JE+P@)F`#9#P@G,IO+`;H%$I0X,`Z?1QZBHR4
MOS*:+?*TC.[D/4Q8H#(>IA%`9#U,(H&F=0ISI6,O,OF9,$K6U\8NZGWSO`E2
MTFN57O?,N9DURY;N?;!]'')5CIMK$7F/Q/TSRS/*6TU3=/T]&5LU3C82$BHN
M-(M8N(<*ECF+%!NP`Z[JF7;A8>]"$[<RAQ,&W/++&J,^4D6>]SVW*>>?L.'6
M&PL)F'T<J1RSQWIJ`'/;<IYY^PO$)"?FCBQ0'/;<IYY^PO$)"?FCA%`<]MRG
MGG["\0D)^:.$4!SVW*>>?L+Q"0GYHX10'/;<IYY^PO$)"?FCA%`<]MRGGG["
M\0D)^:.$4!SVW*>>?L+Q"0GYHX10'/;<IYY^PO$)"?FCA%`<]MRGGG["\0D)
M^:.$4!SVW*>>?L+Q"0GYHX10'/;<IYY^PO$)"?FCA%`<]MRGGG["\0D)^:.$
M4!SVW*>>?L+Q"0GYHX10,=J_EC.4@KFEJ@HZI:ZAST_4L2]AY@"V+@VV4>]1
M,DZ,9P>E"$1("0CF8P@`!C37F2IXUC0/5CN6?Y2Z(CF#.,K:/0C&;-HRBFZM
MAX,Q&<4S:H,F20J%I(05,L1MO`/4QG='+.X3-0Z0=T.6VY3SS]AN(6%_-''7
M6EIRRIRXQ$<]MRGGG["\0D)^:..>*`Y[;E///V%XA(3\T<(H#GMN4\\_87B$
MA/S1PB@.>VY3SS]A>(2$_-'"*`Y[;E///V%XA(3\T<(H#GMN4\\_87B$A/S1
MPB@.>VY3SS]A>(2$_-'"*`Y[;E///V%XA(3\T<(H#GMN4\\_87B$A/S1PB@.
M>VY3SS]A>(2$_-'"*`Y[;E///V%XA(3\T<(H%O/9<IVLJBB%>1F^H;ZY*PL"
M!"D3#A#"8QZ1R`=F$5:"`6H_4;>/5/<16YU]I5&;K16"CX`ZQ*39TB0L%&.7
MR\>W6AVD=&HJ`FX?+&!8R0B?>RS'=#)%`VCI2UTZM-+E41T78RX%22S"0D&A
MALY*H2]>4U5`*'*F+*+HI83#&N%Q,/\`?,<8@IF$3&#>SPBK0?L=Y..YEV;N
MM;_5O>FSCZR=>3=QJ36E*-?S2TJ=$Y[?0JPN#(.0*[C\T0`P(*]N!3%#I!CQ
MKC';*L4\,_Q*?3<N6X40Z`EV;!+T<LNU':'T,>O>4W#^I!XR[(>IC**(,AZF
M$4!D/4PB@,AZF$4!D/4PB@,AZF$4!D/4PB@,AZF$4!D/4PB@,AZF$4!D/4PB
M@,AZF$4!D/4PB@,AZF$4#C5Z`?;D_MRXQJ-.A4_I?<RH^/>CW_Q2>4[_`,3:
M=?\`-Z:Q\O[::VF\?U/O97^KK+.5T$!1T$FS#=]>RT1L^ENA"U5VV?4QQ;\F
MU6_*<SP?F^`?Z5U_@?8HQB@8>V+M$?[(OT>KC[&M>*>E3I-_J<.PD&UT`#DS
M^O+[HO2QEJ:5I#PJA@8"J8Y:-J**B9R*4W17BYJ.9S$>N9,V^DHK'/47#=<Z
M)]I<R")1VAEC"K2I*7"T7G/$\BJ2,^A9(U(TN1[313(4VY"$BC.XM`H%,B$0
M[3:)JPB!50`12()2;.AGMQH4E%-/!$11S-:5IUH1H@WB(U)NU%\"3=&-9MVY
M$9$Z@S20)BV.`EDEU]]<H`4'6Z7/>W<;:5.E#!`%2TK30G.FI!Q:@YQ'#JF8
MM3*+>3YP-3JIUBH)]\'BC?W$NW@"=J&SH[M52YV02='4K)I=YR=+TU-,S/QE
ME&\A$1#QN,JLH!UY/O9^T7;@^.<H"94N2@Y!U,\35TK4#E6ING55')SPD0KW
MV,<#HZL>W4!0T*;A(,%DQ1`70QC@<T399(ER`.@&*J5+G!60IN#E5XQY+0$)
M,.X57OB-7EV4;)N8QR<1,9W'.WC-PZ:+D$1RX$P#TL\%3I<[4!A.!.BZ.3&6
M.A2=+IJ5`)S5"<(:.04J`Q@,!E)=3Q?ONU#F,)A%03")A$<\\35TN8'*VIFG
M&TL>H&\!!(3;I),Z\JE#1B4@?ZQ,$CRB;(LHIP9.@4YM@!EBZNG;@[098)R[
M>W*/TR_UAQ9:5).*81:<Y`+EO%VB4H!F&8B8P``!U1$1QIO%.DUC4>D=Y%JM
MA*;5Q8`Q3%$H6OOD(F`0$`_ON@BYY]3,,<MTI4M8VGAT?Q:*R51CI[,CDZ?]
MD4?Z^.[54GC9"S?)]F7LEPU-*T#?)]F7LEPU-*T#?)]F7LEPU-*T'AR41&23
MADZD&$?)*1L@WD8XKYL@[,TD&J2I&;Z..J)O%KU$5C@*Y0`VZ.6>W%U=+%$'
MC+T/1B\6A#/*6IE[!MW!72<*X@XU>';/"+&5%XUB3LU$0?\`"&$W#@&^81SW
MAQR34J,7A4(E+EZ1IEX5]WU3\.LD[6*=RDZAHEP1^<L8$.0[A(R!M]).$,:/
M`!`?[V,)>AAJZ.0L3RH6V]NJ=4!6FK?T=!'!\21,$/3,+!]\OV;3Q>W?J#'Q
M[<G?"<:[422$VT`S`!Z.5U=')`AD$5`QD<NP581T6Q+'1WBAJLV9(LSH0A%3
MJ,8=B0@`9HQ:'(3?2V%.8`-EC*G3HZ7,#*-\GV9>R7&_4TK2#?)]F7LEPU-*
MT#?)]F7LEPU-*T#?)]F7LEPU-*T#?)]F7LEPU-*T&J+Y'SLU=HHJI)_T>U=N
M'.`*DX(T`\,J"B?3(?@S`/6S'''5OE.A.Z:>(L,$3P;)TU2XV8M`/D[3YL[6
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MJ.%1B(W>.X-!LMX-K$0'+H]+(!Z`8QH24I5CEA!6`S/R7I?;_DY3H?\`Z-%^
M`8[)I9&N;L!7R7I;S=IW\CQ?@&,="3)F1!Y+TMYNT[^1XOP##0DR9D!Y+TMY
MNT[^1XOP##0DR9D!Y+TMYNT[^1XOP##0DR9D!Y+TMYNT[^1XOP##0DR9D!Y+
MTMYNT[^1XOP##0DR9D!Y+TMYNT[^1XOP##0DR9D!Y+TMYNT[^1XOP##0DR9D
M!Y+TMYNT[^1XOP##0DR9D!Y+TMYNT[^1XOP##0DR9D!Y+TMYNT[^1XOP##0D
MR9D#B5I6ES;@A35-G`.%X0HP\1VQ!3RW,C1XB.^/2#+/#5TWA<.P'P:UQ\D+
M76MG6B%R%:TIFU5C8VWM'P*TC%1;24J^3E(AY,NI)A!0@!'QD?OH2"9>_7!E
MMN8`4=S;=31A%M1Z@?2/2OR>^ES2"Q2+:FW;'RL,F`/;A5,8M35W)*%V&7"<
MD"`A!E.8PCP#4$R%*``7/(,XJ5'K!G=BE"EO/JT$3!LN_2`".>09C:FER%#;
MTQ$P!UQQY2OLDM:>29IPG^)4HLE@)R#MWRY9YAVP;<>E2OE.90BB#?)]F7LE
MQLU-*T#?)]F7LEQ-32M`WR?9E[)<-32M`WR?9E[)<-32M`WR?9E[)<-32M`W
MR?9E[)<-32M`WR?9E[)<-32M`WR?9E[)<-32M`WR?9E[)<-32M`WR?9E[)<-
M32M`WR?9E[)<-32M`WR?9E[)<-32M`WR?9E[)<-32M`WR?9E[)<-32M!Q+*$
M`F>^3(HE,([Q=@%,41'Z09C]#&N\:NC=:DTK_E94?'[1UVW*D<IX<,A*6)TZ
M)&$-H%4"G)DXD-U#;I@'+J#CY+VL]9>[STO_`.HLWZFLIO\`U^:0:_U<T=:Z
M#MU<B,M55]JKLP-W(2J96`6J-@>3A&<NR:,RL^_4C`=(7X'-F&[L#J[-N_\`
M=M_O>\:5>ZT]*G+C>#):\EA8)K&D^LCP;29RL0B`CRD%$9[=I+"1>89]/(7H
M;0QMOUVWNYZ52[RZ3EQX<A4WAPJ!3U3.5C^<EH_B#B?#L8P]P>GVDP6KEU#U
M2^5C^<EH_P"E8.)\/QKJ2^X7+@IX>D=:[?@4]4OE8OG)*0X@XCP_&C5^Y/2>
M?YECEE[?@5]4OE8_G)*0^G8.)\/QNI2^XDGI4^TG6NWX#U3.5C^<EH_B#B?#
ML;8>X/3[1@M7+J'JF<K'\Y+1_$'$^'80]P>GVC!:N74/5,Y6/YR6C^(.)\.P
MA[@]/M&"U<NH>J9RL?SDM'\0<3X=A#W!Z?:,%JY=0]4SE8_G):/X@XGP["'N
M#T^T8+5RZAZIG*Q_.2T?Q!Q/AV$/<'I]HP6KEU#U3.5C^<EH_B#B?#L5+?[>
M&1YQUKEU%BFDSE9@`#)\I+1N\4Y#"![`Q9RF(4X"<@@60*;MR`(!D.S/&FM3
M]P/#)(X])4\JY=1C3S0_RH<G5D#6[WE$:*\I:9C)V&A)!*PS(O`151J,%95N
MLDK)G3.=4\8CD;(!#<QS7:A[DIU=*:FX:-N+#A6/*5Z,/U*)E'JF<K'\Y+1_
M$'$^'8[H>X/3[3'!:N74/5,Y6/YR6C^(.)\.PA[@]/M&"U<NH>J9RL?SDM'\
M0<3X=A#W!Z?:,%JY=0]4SE8_G):/X@XGP["'N#T^T8+5RZAZIG*Q_.2T?Q!Q
M/AV$/<'I]HP6KEU%/5+Y6+YR2D.(.(\/QRNG[CC_`(NWYB.5=OP'JE\K%\Y)
M2'$'$>'XFK]R>D\_S+'++V_`>J7RL7SDE(<0<1X?AJ_<GI//\Q'++V_`>J7R
ML7SDE(<0<3X?C.G)[B4T72P=).M=OP*^J9RL?SDM'\0<3X=CHA[@]/M&"U<N
MH>J9RL?SDM'\0<3X=A#W!Z?:,%JY=0]4SE8_G):/X@XGP["'N#T^T8+5RZAZ
MIG*Q_.2T?Q!Q/AV$/<'I]HP6KEU#U3.5C^<EH_B#B?#L(>X/3[1@M7+J/+F=
M&G*H5!#S,#,<HY1KR-G8N0B7B!K",2`+609+,UBB9*2*`@8C@V>?6QJFN.^*
MSTJDK3>7$7`UC0A=&?*HP,-#P45RCE&LXR#B8R%CVI+"QABH,HEBA'MDP,H_
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M)REO)R!3@)TQ$`V_1V8YKU2]Q5:.A)3>%KG"2?.CO1VC[E5HR/813#E':0;,
MHMJBRCTPL*P,*;)NBDW006,K(F!0R*:(`4<LP#&%"A[BE2EFIS0A;BR8S)P6
M)K,=[U2^5C^<EH_B#B?#L=KEW\L4CSF/6N74/5,Y6/YR6C^(.)\.Q(>X/3[1
M@M7+J'JF<K'\Y+1_$'$^'80]P>GVC!:N74/5,Y6/YR6C^(.)\.PA[@]/M&"U
M<NH>J9RL?SDM'\0<3X=A#W!Z?:,%JY=0]4SE8_G):/X@XGP["'N#T^T8+5RZ
MAZIG*Q_.2T?Q!Q/AV$/<'I]HP6KEU#U3.5C^<EH_B#B?#L(>X/3[1@M7+J'J
MF<K'\Y+1_$'$^'80]P>GVC!:N74/5,Y6/YR6C^(.)\.PA[@]/M&"U<NH>J9R
ML?SDM'\0<3X=A#W!Z?:,%JY=0]4SE8_G):/X@XGP["'N#T^T8+5RZAZIG*Q_
M.2T?Q!Q/AV$/<'I]HP6KEU#U3.5C^<EH_B#B?#L(>X/3[1@M7+J'JF<K'\Y+
M1_$'$^'80]P>GVC!:N748O!Z'N5%IR8JN9B.43H=L]K6;CYZHW)K"LS+/7T?
M$,H4IB@$F5-,#LV"8;`Z6."7=N^W5FJ.6&DXO#C98P6!J)DY=)/*Q;H?_$FH
M[H!M&P<4`CLZ8"^$0QZ5.Z;U4N&6$R(WE17U3.5C^<EH_B#B?#L80]P>GVC!
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,C&.'&6;]48I]!__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>11
<FILENAME>aen-20110630.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 3.0.1.2  -->
<!-- Based on XBRL 2.1  -->
<xbrli:xbrl xmlns:aen="http://www.adeonapharma.com/2011-06-30" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="aen-20110630.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_3ME_30-Jun-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-04-01
</xbrli:startDate>
<xbrli:endDate>
2010-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-01-01
</xbrli:startDate>
<xbrli:endDate>
2010-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_30-Jun-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-04-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_30-Jun-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_10-Aug-2011">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-08-10
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2009">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2009-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30-Jun-2010">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_30-Jun-2011">ADEONA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_30-Jun-2011">0000894158</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_6ME_30-Jun-2011">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_6ME_30-Jun-2011">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:TradingSymbol contextRef="Context_6ME_30-Jun-2011">aen</dei:TradingSymbol>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_10-Aug-2011" unitRef="Shares" decimals="0">28127644</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentType contextRef="Context_6ME_30-Jun-2011">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_6ME_30-Jun-2011">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_30-Jun-2011">2011-06-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_6ME_30-Jun-2011">Q2</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_6ME_30-Jun-2011">2011</dei:DocumentFiscalYearFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">2648853</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">8385933</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2009" unitRef="USD" decimals="0">2715044</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30-Jun-2010" unitRef="USD" decimals="0">3270656</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">338510</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">444664</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">343417</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">75547</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">3330780</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">8906144</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">511142</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">396144</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Goodwill contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">178229</us-gaap:Goodwill>
<us-gaap:Goodwill contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">178229</us-gaap:Goodwill>
<aen:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">90848</aen:DepositsAndOtherAssetsNoncurrent>
<aen:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">40300</aen:DepositsAndOtherAssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">4110999</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">9520817</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">265722</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">286836</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">210027</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">22718</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">0</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">88324</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">24400</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:CapitalLeaseObligationsCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:CapitalLeaseObligationsCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">500149</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">397878</us-gaap:LiabilitiesCurrent>
<us-gaap:AccountsPayableInterestBearingNoncurrent contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">32335</us-gaap:AccountsPayableInterestBearingNoncurrent>
<us-gaap:AccountsPayableInterestBearingNoncurrent contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">2335</us-gaap:AccountsPayableInterestBearingNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">532484</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">400213</us-gaap:Liabilities>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">23339</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">27998</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">47279416</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">56683202</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">-43724240</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">-47590596</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">3578515</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">9120604</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="0">4110999</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30-Jun-2011" unitRef="USD" decimals="0">9520817</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2010" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Jun-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2010" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30-Jun-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="0">23420189</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares" decimals="0">28079126</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2010" unitRef="Shares" decimals="0">23338707</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30-Jun-2011" unitRef="Shares" decimals="0">27997644</us-gaap:CommonStockSharesOutstanding>
<us-gaap:LicensesRevenue contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">2125000</us-gaap:LicensesRevenue>
<us-gaap:LicensesRevenue contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">2125000</us-gaap:LicensesRevenue>
<us-gaap:LicensesRevenue contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:LicensesRevenue>
<us-gaap:LicensesRevenue contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:LicensesRevenue>
<aen:LaboratoryRevenuesNet contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">69888</aen:LaboratoryRevenuesNet>
<aen:LaboratoryRevenuesNet contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">129927</aen:LaboratoryRevenuesNet>
<aen:LaboratoryRevenuesNet contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">355562</aen:LaboratoryRevenuesNet>
<aen:LaboratoryRevenuesNet contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">678700</aen:LaboratoryRevenuesNet>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">2194888</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">2254927</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">355562</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">678700</us-gaap:SalesRevenueNet>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">662627</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">1398456</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">694281</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">1967817</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">426572</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">733722</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">279641</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">511959</us-gaap:ResearchAndDevelopmentExpense>
<aen:CostsOfLaboratoryServices contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">132406</aen:CostsOfLaboratoryServices>
<aen:CostsOfLaboratoryServices contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">237825</aen:CostsOfLaboratoryServices>
<aen:CostsOfLaboratoryServices contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">301142</aen:CostsOfLaboratoryServices>
<aen:CostsOfLaboratoryServices contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">545000</aen:CostsOfLaboratoryServices>
<us-gaap:OperatingExpenses contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">1221605</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">2370003</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">1275064</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">3024776</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">973283</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">-115076</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">-919502</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-2346076</us-gaap:OperatingIncomeLoss>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">-775996</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-1491996</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">-16386</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">77471</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">3443</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-5692</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">6499</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">7336</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">-783</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">49187</us-gaap:OtherNonoperatingIncome>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">6499</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">7336</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">-760393</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-1520280</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_30-Jun-2010" unitRef="USD" decimals="0">979782</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">-107740</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_30-Jun-2011" unitRef="USD" decimals="0">-1679895</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-3866356</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_30-Jun-2010" unitRef="USDPerShare" decimals="2">0.05</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_6ME_30-Jun-2010" unitRef="USDPerShare" decimals="0">0</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_30-Jun-2011" unitRef="USDPerShare" decimals="2">-0.06</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_6ME_30-Jun-2011" unitRef="USDPerShare" decimals="2">-0.15</us-gaap:EarningsPerShareBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_30-Jun-2010" unitRef="Shares" decimals="0">21706472</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_6ME_30-Jun-2010" unitRef="Shares" decimals="0">21633985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_30-Jun-2011" unitRef="Shares" decimals="0">27885479</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_6ME_30-Jun-2011" unitRef="Shares" decimals="0">26560448</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_30-Jun-2010" unitRef="USDPerShare" decimals="2">0.05</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_6ME_30-Jun-2010" unitRef="USDPerShare" decimals="0">0</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_30-Jun-2011" unitRef="USDPerShare" decimals="2">-0.06</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_6ME_30-Jun-2011" unitRef="USDPerShare" decimals="2">-0.15</us-gaap:EarningsPerShareDiluted>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_30-Jun-2010" unitRef="Shares" decimals="0">21883414</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_6ME_30-Jun-2010" unitRef="Shares" decimals="0">23782010</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_30-Jun-2011" unitRef="Shares" decimals="0">27885479</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_6ME_30-Jun-2011" unitRef="Shares" decimals="0">26560448</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">236574</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">427166</us-gaap:ShareBasedCompensation>
<aen:StockOptionModificationExpense contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</aen:StockOptionModificationExpense>
<aen:StockOptionModificationExpense contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">397767</aen:StockOptionModificationExpense>
<aen:StockIssuedForConsultingFees contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">33269</aen:StockIssuedForConsultingFees>
<aen:StockIssuedForConsultingFees contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">58270</aen:StockIssuedForConsultingFees>
<aen:StockIssuedAsCompensation contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">46613</aen:StockIssuedAsCompensation>
<aen:StockIssuedAsCompensation contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">75840</aen:StockIssuedAsCompensation>
<aen:ChangeInFairValueOfWarrantLiability contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</aen:ChangeInFairValueOfWarrantLiability>
<aen:ChangeInFairValueOfWarrantLiability contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">77471</aen:ChangeInFairValueOfWarrantLiability>
<us-gaap:Depreciation contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">180076</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">108106</us-gaap:Depreciation>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">20147</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">188466</us-gaap:ProvisionForDoubtfulAccounts>
<aen:GainOnSettlementOfAccountsPayable contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</aen:GainOnSettlementOfAccountsPayable>
<aen:GainOnSettlementOfAccountsPayable contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">62996</aen:GainOnSettlementOfAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">153574</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">294620</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">-791</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-267870</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<aen:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</aen:IncreaseDecreaseInDepositsAndOtherAssets>
<aen:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-50548</aen:IncreaseDecreaseInDepositsAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">-27884</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">54109</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">191309</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-187309</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">416138</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">-1207980</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">2070</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">60890</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">1200</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">58820</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">1200</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">8503</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">24400</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">89157</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">7650</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">6960610</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">80654</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">6943860</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">555612</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">5737080</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">2169</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:InterestPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxesPaid>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">539390</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:NatureOfOperations contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;1.&amp;#160;&amp;#160;&amp;#160;Organization
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Adeona Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or Adeona&amp;#8221;) is a pharmaceutical company&amp;#160;&amp;#160;focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company&amp;#8217;s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer&amp;#8217;s disease. The Company is currently preparing to make the following products commercially available: &lt;font style="font-style:italic;display:inline;" &gt;reaZin
&lt;/font&gt;&lt;font style="display:inline;font-size:70%;vertical-align:text-top;" &gt;TM
&lt;/font&gt;, a medical food for the dietary management of zinc deficiency associated with Alzheimer&amp;#8217;s disease, and &lt;font style="font-style:italic;display:inline;" &gt;wellZin
&lt;/font&gt;&lt;font style="display:inline;font-size:70%;vertical-align:text-top;" &gt;TM
&lt;/font&gt;, a homeopathic over-the-counter drug for reducing the symptoms associated with the common cold. Adeona also operates a wholly owned clinical reference laboratory, Adeona Clinical Laboratory that provides a broad array of chemistry and microbiology diagnostic tests.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:NatureOfOperations>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;2.&amp;#160;&amp;#160;&amp;#160;Basis of Presentation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The financial information as of December 31, 2010, is derived from the audited financial statements presented in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2010. The unaudited condensed interim financial statements should be read in conjunction with the Company&amp;#8217;s Annual Report on Form 10-K, which contains the audited financial statements and notes thereto, together with the Management&amp;#8217;s Discussion and Analysis, for the year ended December 31, 2010.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended June 30, 2011, are not necessarily indicative of results for the full year.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has eight subsidiaries, Pipex Therapeutics, Inc. (&amp;#8220;Pipex Therapeutics&amp;#8221;), Adeona Clinical Laboratory (formerly Hart Lab, LLC), Effective Pharmaceuticals, Inc. (&amp;#8220;EPI&amp;#8221;), Solovax, Inc. (&amp;#8220;Solovax&amp;#8221;), CD4 Biosciences, Inc. (&amp;#8220;CD4&amp;#8221;), Epitope Pharmaceuticals, Inc. (&amp;#8220;Epitope&amp;#8221;), Healthmine, Inc. (&amp;#8220;Healthmine&amp;#8221;) and Putney Drug Corp. (&amp;#8220;Putney&amp;#8221;). As of June 30, 2011, EPI, Adeona Clinical Laboratory, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;3.&amp;#160;&amp;#160;&amp;#160;Summary of Significant Accounting Policies
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Principles of Consolidation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;All significant inter-company accounts and transactions have been eliminated in consolidation.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Use of Estimates
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives&amp;#160;for intangible assets and for property and equipment, the fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing operating losses.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates.
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Accounts Receivable and Allowance for Doubtful Accounts
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company estimates and reviews the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assesses the state of its billing operations in order to identify issues that may impact the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense. Receivables deemed uncollectible are charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Revenue Recognition
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&amp;#160;&amp;#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&amp;#160;&amp;#160;, The Company has two streams of revenue, license revenue and laboratory revenue.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;" &gt;License Revenues
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company&amp;#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&amp;#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;" &gt;Laboratory Revenues
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company primarily recognizes revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, are recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company maintains a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looks at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 18 months, otherwise known as the yearly average adjustment amount. The actual sales allowance taken for each period is the averaged yearly average adjustment amount for these prior periods multiplied by the period&amp;#8217;s actual gross revenues.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company generated reimbursements from&amp;#160;3 significant insurance providers for the six months ended June30, 2011 and 2010.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="40%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="24%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Customer
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="29%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="27%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="24%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;A
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="25%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;68
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="23%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;60
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="24%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;B
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="25%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;4
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="23%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;16
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="24%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;C
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="25%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;20
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="23%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;11
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&amp;#160;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Risks and Uncertainties
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company's operations are subject to significant risk and uncertainties including financial, operational, regulatory and other risks, including the potential risk of business failure. The recent global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions not only limit&amp;#160;the Company&amp;#8217;s&amp;#160;access to capital, but also make it difficult for the Company&amp;#8217;s customers, the Company&amp;#8217;s vendors and the Company to accurately forecast and plan future business activities.
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Cash and Cash Equivalents
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.&amp;#160;&amp;#160;As of June 30, 2011, and December 31, 2010, respectively, the Company had no cash equivalents.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company minimizes credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed the federally insured limit of $250,000 per depositor, per bank. At June30, 2011 and December 31, 2010, the balance exceeded the federally insured limit by $7.9 million and $2.1 million, respectively.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Warrant / Derivative Liabilities
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In&amp;#160;assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Net&amp;#160;Income (Loss) per Share
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Basic earnings (loss) per share is computed by dividing the net income (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of share equivalents.&amp;#160;&amp;#160;Common equivalent shares, consisting of options and warrants for the purchase of common stock, are not included in the per share calculation where the effect would be anti-dilutive.&amp;#160;The Company&amp;#8217;s share equivalents at June 30, 2011 consist of 2,781,093 stock options and 3,368,738 warrants, respectively, and for the period ended June 30, 2010 consist of 2,312,759 and 1,070,472, respectively. The&amp;#160;computations of basic and diluted net income (loss) attributable to common share are as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="6" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Three&amp;#160;months&amp;#160;ended&amp;#160;June&amp;#160;30,
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="6" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Six&amp;#160;months&amp;#160;ended&amp;#160;June&amp;#160;30,
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Net income (loss)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(1,679,895)
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;979,782
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(3,866,356
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(107,740
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Basic weighted-average shares
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;27,885,479
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;21,706,472
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;26,560,448
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;21,633,985
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Effect of dilutive securities:
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Stock options
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;175,527
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Warrants
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1,415
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Dilutive&amp;#160;&amp;#160;weighted-average shares
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;27,885,479
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;21,883,414
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;26,560,448
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;23,782,010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Net income (loss) per share:
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Basic
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(0.06
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;0.05
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(0.15
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(0.00
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Dilutive
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(0.06
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;0.05
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(015
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(0.00
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Research and Development Costs
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&amp;#8217;s product candidates.
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Share-Based Payment Arrangements
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Generally, all forms of share-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&amp;#8217; grant date, based on the estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. The expense resulting from share-based payments are recorded in cost of goods sold, research and development or general and administrative expenses in the consolidated statement of operations, depending on the nature of the services provided.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Recent Accounting Pronouncements
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In June 2011, the FASB updated the accounting guidance on Topic 220, entitled &amp;#8220;Comprehensive Income&amp;#8221;, relating to presentation of comprehensive income. This guidance requires companies to present total comprehensive income, the components of net income and the components of other comprehensive income, or OCI, either in a single continuous statement of comprehensive income or in two consecutive statements. Additionally, companies are required to present on the face of the financial statements the reclassification adjustments that are reclassified from OCI to net income, where the components of net income and the components of OCI are presented. This guidance is effective beginning 2012. The adoption of this guidance is not expected to have a material impact on the Company&amp;#8217;s financial position or results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&amp;#160;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In June 2011, the FASB updated the accounting guidance on alignment of disclosures for GAAP and the International Financial Reporting Standards, or IFRS, by updating Topic 820 entitled &amp;#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS&amp;#8221;, relating to presentation of fair value measurements reported in financial statements. The updated guidance requires companies to align fair value measurement and disclosure requirements between GAAP and IFRS. The updated guidance is effective beginning in the year 2012 and earlier adoption is not permitted. The adoption of this guidance is not expected to have a material impact on the Company&amp;#8217;s financial position or results of operations.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;Reclassifications
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;To conform prior period amounts to current year classifications, the Company has reclassified laboratory services, and research and development expenses to general and administrative expenses. These reclassifications had no impact on the Company&amp;#8217;s previously reported results of operations or cash flows.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;4.&amp;#160;&amp;#160;&amp;#160;Property and Equipment
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Property and Equipment consisted of the following at June 30, 2011, and December 31, 2010.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="80%" style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;June&amp;#160;30,&amp;#160;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2" style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;December&amp;#160;31,&amp;#160;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Leasehold improvements
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,070
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;864,429
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Manufacturing equipment
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;400,045
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;410,997
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Computer and office equipment
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;160,478
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;"
 &gt;160,478
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Laboratory equipment
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;213,908
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;213,908
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Total
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;776,501
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,649,812
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" style="padding-bottom:2px;text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Less accumulated depreciation
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(380,357
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(1,138,670
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" style="padding-bottom:4px;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Property and equipment, net
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;396,144
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font
 style="display:inline;font-family:times new roman;font-size:10pt;" &gt;511,142
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The decrease in leasehold improvements during the six months ended June 30, 2011, reflects the relocation of the Company&amp;#8217;s headquarters within Ann Arbor, Michigan.&amp;#160;&amp;#160;During the six months ended June 30, 2011, the Company sold equipment, with a net book value of $6,892, for $1,200, resulting in a loss of $5,692.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Depreciation expense for the six months ended June 30, 2011 and 2010 was $108,106 and $180,076, respectively.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;5.&amp;#160;&amp;#160;&amp;#160;Stock-Based Compensation
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During 2001, Pipex Therapeutics&amp;#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of June 30, 2011, there were 1,320,354 options issued and outstanding under the 2001 Stock Plan.
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;br /&gt;
&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On March 20, 2007, the Company&amp;#8217;s board of directors approved the Company&amp;#8217;s 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2011, there are 1,228,239 options issued and outstanding under the 2007 Stock Plan.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven years after the grant date. As of June 30, 2011, there are 232,500 options issued and outstanding under the 2010 Stock Plan.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the six months ended June 30, 2011and 2010, are as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;table cellspacing="0" cellpadding="0" width="90%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="32%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;&amp;#160;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="22%" colspan="6"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;June&amp;#160;30,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="42%" colspan="4"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Six&amp;#160;Months&amp;#160;Ended&amp;#160;June&amp;#160;30,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="32%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;2010
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="32%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercise price
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.73
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.21&amp;#160;-&amp;#160;$2.22
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.82 - $0.87
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="32%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected dividends
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="32%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;184
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;184% - 188%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;203% - 204%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="32%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk free interest rates
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.88
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.81% - 3.58%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;3.59% - 3.63%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="32%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected life options
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;7&amp;#160;years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5 years - 7 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;10&amp;#160;years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="32%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected forfeitures
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0%
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;immediate vesting,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;one-half vesting immediately and the remainder over three years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;quarterly over three years,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;annually over three years,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;one-third immediate vesting and remaining annually over two years,
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;one-half immediate vesting with remaining vesting over nine months; and
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div&gt;&lt;table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" &gt;&lt;tr valign="top" &gt;&lt;td style="width:18pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td style="width:18pt;" &gt;&lt;div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:symbol, serif;font-size:10pt;" &gt;&amp;#183;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td&gt;&lt;div style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;one quarter immediate vesting with the remaining over three years.
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During the six months ended June 30, 2011, the Company granted 332,002 options to employees and consultants having a fair value of $445.671 based upon the Black-Scholes option pricing model.&amp;#160; During the same period of 2010, the Company granted 425,000 options to employees having a fair value of $349,750 based upon the Black-Scholes option pricing model.
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On January 18, 2011, the Company amended the terms of 228,773 stock options held by a member of the Board of Directors.&amp;#160;&amp;#160;In connection with the modification, the Company extended the expiration date of the stock options by 5 years.&amp;#160;&amp;#160;The extension is considered a modification, which in substance is the issuance of a new stock option award.&amp;#160;&amp;#160;As a result, the Company computed the fair value of this award to be $397,767, using the Black-Scholes valuation model.&amp;#160;&amp;#160;&amp;#160;The fair value was based upon the following management assumptions:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;" &gt;&lt;div&gt;
&lt;table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="80%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercise price
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="20%"  style="text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$0.09
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="top" width="80%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected dividends
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="20%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="80%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="20%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;187.1%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="top" width="80%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected term
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="20%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="80%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk free interest rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="20%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.03%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;

&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;A summary of stock option activities as of June 30, 2011, and for the year ended December 31, 2010, is as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="52%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Options
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Weighted&amp;#160;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Remaining
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Contractual
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Life
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="11%" colspan="3"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Aggregate
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Intrinsic
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Value
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; December 31, 2009
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,561,332
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.26
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Granted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;743,332
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.80
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercised
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;( 255,954
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.44
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="padding-bottom:2px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Forfeited or expired
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(509,619
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.69
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; December 31, 2010
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,539,091
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.32
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Granted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;332,002
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.61
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Forfeited or expired
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(80,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.56
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="padding-bottom:2px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercised
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;(10,000
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.56
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="padding-bottom:4px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; June 30, 2011 - outstanding
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,781,093
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.38
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 4px double;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;6.38 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;431,508
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="52%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="52%"  style="padding-bottom:4px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; June 30, 2011 &amp;#8211; exercisable
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,299,189
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.50
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 4px double;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5.95 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;402,549
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The options outstanding and exercisable as of June 30, 2011, are as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;div style="text-align:left;" &gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;" &gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="43%" colspan="7"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Options&amp;#160;Outstanding
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="43%" colspan="8"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Options&amp;#160;Exercisable
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Range&amp;#160;of
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Number
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;outstanding
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;text-align:center;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="21%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Remaining
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Contractual Life
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Number
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercisable
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Remaining
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Contractual&amp;#160;Life
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;0.09 - 4.57
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt; &lt;font style="display:inline;font-size:10pt;" &gt;2,691,094
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.23
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:center;" &gt;6.48 years
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt; &lt;font style="display:inline;font-size:10pt;" &gt;2,209,190
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;1.32
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;6.06 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;4.58 - 9.05
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;89,999
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;5.93
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:center;" &gt;3.26 years
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;89,999
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;5.93
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3.26 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;2,781,093
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1.38
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:center;" &gt;6.38 years
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;2,299,189
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;1.50
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 4px double;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;5.95 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The options outstanding and exercisable as of June 30, 2010, are as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:left;" &gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="43%" colspan="7"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Options&amp;#160;Outstanding
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="43%" colspan="8"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Options&amp;#160;Exercisable
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Range&amp;#160;of
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Number
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;outstanding
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" colspan="2"  style="border-bottom:black 2px solid;text-align:center;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt; &lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="21%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Remaining
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Contractual Life
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Number
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercisable
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Remaining
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Contractual&amp;#160;Life
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;0.09 - 4.57
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt; &lt;font style="display:inline;font-size:10pt;" &gt;2,222,760
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;1.19
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="21%"  style="text-align:center;" &gt;3.65 years
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt; &lt;font style="display:inline;font-size:10pt;" &gt;1,763,593
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;1.31
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5.93 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;4.58 - 9.05
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;89,999
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;5.93
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="21%"  style="border-bottom:black 2px solid;text-align:center;" &gt;4.26 years
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;88,124
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;5.93
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;4.20 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;2,312,759
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;1.37
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="21%"  style="border-bottom:black 4px double;text-align:center;" &gt;6.56&amp;#160;years
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;" &gt;&amp;#160;
&lt;/font&gt;&lt;font style="display:inline;font-size:10pt;" &gt;1,851,717
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;font-size:10pt;" &gt;1.53
&lt;/font&gt;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="20%"  style="border-bottom:black 4px double;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;5.85 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<aen:StockPurchaseWarrantsTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;6.&amp;#160;&amp;#160;&amp;#160;Stock Purchase Warrants
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns.&amp;#160;&amp;#160;The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015.&amp;#160;&amp;#160;&amp;#160;Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost.&amp;#160;&amp;#160;The result of the transaction has a $0 net effect to equity. As of June 30, 2011, 30,303 of these warrants remained outstanding.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors.&amp;#160;&amp;#160;As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock.&amp;#160;&amp;#160;&amp;#160;Each warrant was exercisable&amp;#160;for thirteen months&amp;#160;at $2.00 per share. We have entered into an agreement pursuant to&amp;#160;which we have agreed to exchange the original warrants for new warrants with substantially the same&amp;#160;terms as the original warrants except that the expiration date will be extended two months. The warrants&amp;#160;had an anti-dilution&amp;#160;&amp;#160;price protection feature; if the Company issues securities at a price per share that&amp;#160;&amp;#160;is less than&amp;#160;&amp;#160;$2.00&amp;#160;&amp;#160;per share,&amp;#160;&amp;#160;the&amp;#160;&amp;#160;warrant&amp;#160;&amp;#160;holders&amp;#160;&amp;#160;will be ratcheted&amp;#160;&amp;#160;down&amp;#160;&amp;#160;to&amp;#160;&amp;#160;the lower&amp;#160;&amp;#160;offering&amp;#160;&amp;#160;price. However, the Company has instituted a floor price of $1.40 per share in connection with the price protection.&amp;#160;&amp;#160;On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40.&amp;#160;&amp;#160;Due to the re-set the floor price, the warrant liability was marked-to-market and reclassified to additional paid in capital since it ceased to contain the provisions of a derivative liability.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The warrants were recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&amp;#160;in the Company&amp;#8217;s statement of operations at each subsequent reporting period.&amp;#160;&amp;#160;At April 6, 2011, the fair value of the warrant liability was $1,481,143, which represented an increase in fair value of $765,143. The fair value was measured using the Black Scholes valuation model, which is based, in part, upon unobservable inputs for which there is little or no market data, requiring the Company to develop its own assumptions. The assumptions used by the Company are summarized in the following table:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Commitment
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Date
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Remeasurement
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Date&amp;#160;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;April&amp;#160;6,&amp;#160;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Closing stock price
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.39
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.08
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected dividend rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected stock price volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;117.1
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;104.6
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk free interest rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.28
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.29
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times
 new roman;font-size:10pt;" &gt;Expected life (years)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.08
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.85
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor.&amp;#160;&amp;#160;As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock.&amp;#160;&amp;#160;&amp;#160;The warrant was initially exercisable&amp;#160;for thirteen months&amp;#160;at $2.0725 per share. The warrant had an anti-dilution&amp;#160;&amp;#160;price protection feature; that provided if the Company issues securities at a price per share that&amp;#160;&amp;#160;is less than&amp;#160;&amp;#160;$2.0725&amp;#160;&amp;#160;per share,&amp;#160;the&amp;#160;exercise price of the warrant&amp;#160;will be ratcheted&amp;#160;&amp;#160;down&amp;#160;&amp;#160;to&amp;#160;&amp;#160;the lower&amp;#160;&amp;#160;offering&amp;#160;&amp;#160;price.&amp;#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&amp;#160;three months to August 12, 2012,&amp;#160;and (iv) the warrant&amp;#8217;s initial exercise date was changed to January 2012. &lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Due to this warrant exchange, the warrant liability will be eliminated on a go-forward basis since the new warrant no longer contains the provisions that cause it to be treated as a derivative liability. See Note 8 &amp;#8211; Subsequent Event.
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The warrant is&amp;#160;recorded as a liability at&amp;#160;its estimated fair value on the commitment date, which was $775,995 with subsequent changes in estimated fair value recorded as a warrant expense&amp;#160;in the Company&amp;#8217;s statement of operations at each subsequent period.&amp;#160;&amp;#160;At June 30, 2011, the fair value of the warrant liability was $88,323, which represented a decrease in fair value of $687,672.&amp;#160;&amp;#160; The fair value is measured using the Black Scholes valuation model, which is based, in part, upon unobservable inputs for which there is little or no market data, requiring the Company to develop its own assumptions. The assumptions used by the Company are summarized in the following table:
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"  style="padding-bottom:2px;text-align:left;" &gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Commitment
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Date
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Remeasurement
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Date&amp;#160;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;June&amp;#160;30,&amp;#160;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Closing stock price
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.08
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$0.86
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected dividend rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected stock price volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;112.1
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;105.4
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk free interest rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.29
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.19
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected life (years)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.08
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.77
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The following table summarizes the estimated fair value of the warrant liabilities:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="70%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="88%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance at December 31, 2010
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="88%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Warrant liability
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,491,995
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="88%"  style="text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Change in fair value of warrant liability
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;77,471
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="88%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Reclass to stockholders&amp;#8217; equity
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(1,481,143
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)&amp;#160;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="88%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="88%"  style="padding-bottom:4px;text-align:left;" &gt;&lt;div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance at June 30, 2011
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:4px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;88,323
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="padding-bottom:4px;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;A summary of warrant activities as of June 30, 2011, and for the year ended December 31, 2010, is as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;br /&gt;
&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;div&gt;&lt;div&gt;&lt;table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Warrants
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;&amp;#160;Exercise&amp;#160;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; December 31, 2009
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,070,472
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;3.27
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Granted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;60,606
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.32
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercised
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;-
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="padding-bottom:2px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Forfeited or expired
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;-
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; December 31, 2010
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,131,078
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new
 roman;font-size:10pt;" &gt;3.49
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Granted
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2,272,963
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.65
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Forfeited or expired
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;&amp;#160;(19,688)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.32
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="padding-bottom:2px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Exercised
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;(15,615
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1.19
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="padding-bottom:4px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; June 30, 2011 - outstanding
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3,368,738
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;2.27
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="76%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="76%"  style="padding-bottom:4px;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Balance &amp;#8211; June 30, 2011 &amp;#8211; exercisable
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3,368,738
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;$
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;2.27
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The warrants outstanding as of June 30, 2011, are as follows:
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="50%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="26%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Range&amp;#160;of
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Exercise&amp;#160;Price
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="26%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Number
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;outstanding
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Weighted
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Average
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Remaining
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;&lt;font style="display:inline;" &gt;Contractual&amp;#160;Life
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.32
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;30,303
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;&amp;#160;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;4.51 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.40
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1,428,572
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.85 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.0725
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;844,391
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.77 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;2.22
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;626,809
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;5.01 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;3.30
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;61,207
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;3.92 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;3.75
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;50,000
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;4.63 years
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;6.36
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="border-bottom:black 2px solid;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;327,456
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1.36 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="25%"  style="border-bottom:black 4px double;text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;3,368,738
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="45%"  style="border-bottom:black 4px double;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;1.80 years
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</aen:StockPurchaseWarrantsTextBlock>
<aen:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="Context_6ME_30-Jun-2010" unitRef="USD" decimals="0">0</aen:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
<aen:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital contextRef="Context_6ME_30-Jun-2011" unitRef="USD" decimals="0">1481143</aen:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;7.&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217; Equity
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;During the six months ended June 30, 2011, the Company issued 15,000 shares of common stock in connection with the exercise of stock options and warrants&amp;#160;for proceeds of $7,650 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company also issued 45,600 shares of common stock for employment service, having a fair value of $75,840 ($1.66 average per share) and 41,796 shares of common stock for consulting services, having a fair value of $58,270 ($1.39 average per share), based on the quoted closing trading prices.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&amp;#160;&amp;#160;1,428,572&amp;#160;shares of common stock&amp;#160;for $4,000,000. Direct offering costs were approximately $300,000.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On April 6, 2011, the Company sold 1,688,782 shares of common stock and warrants exercisable for 844,391 shares of common stock&amp;#160;for $3,500,000. Direct offering costs were approximately $250,000.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;br /&gt;

&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_6ME_30-Jun-2011">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" &gt;8.&amp;#160;&amp;#160;&amp;#160;Subsequent Event&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div&gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On July 28, 2011, the Company exchanged&amp;#160;the warrant issued in connection with the&amp;#160;April 6, 2011 financing&amp;#160;for a new warrant with substantially the same terms as the original warrant except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional three months to August 10, 2012,&amp;#160;and (iv) the warrant&amp;#8217;s initial exercise date was changed to January 2012.&amp;#160;&amp;#160;&amp;#160;Due to this warrant exchange, the warrant liability&amp;#160;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;will be eliminated on a go-forward basis since the new warrant no longer contains the provisions that cause it to be treated as a derivative liability.&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div&gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;The Company measured the fair value of the warrant at $253,317 using a Black-Scholes valuation model;&amp;#160;As a result of modifying the terms of the warrant, it was not&amp;#160;considered&amp;#160;indexed to the Company&amp;#8217;s common stock.&amp;#160;&amp;#160;The fair value of this warrant upon exchange was based upon the following management assumptions:&lt;br /&gt;
&lt;br /&gt;

&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;&lt;div style="text-indent:0pt;display:block;" &gt;
&lt;/div&gt;&lt;div style="text-align:left;" &gt;&lt;table cellspacing="0" cellpadding="0" width="50%"  style="font-family:times new roman;font-size:10pt;" &gt;&lt;tr&gt;&lt;td valign="bottom" width="82%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="bottom" width="16%" colspan="2"  style="border-bottom:black 2px solid;" &gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Remeasurement
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;Date&amp;#160;
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;&lt;div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&lt;font style="display:inline;" &gt;July&amp;#160;28,&amp;#160;2011
&lt;/font&gt;
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="82%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Closing stock price
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;$
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="15%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.84
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="82%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected dividend rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="15%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="82%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected stock price volatility
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="15%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;105.6
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ffffff;" &gt;&lt;td valign="bottom" width="82%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Risk free interest rate
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="15%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;0.21
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;%
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;&lt;tr style="background-color:#ccffcc;" &gt;&lt;td valign="bottom" width="82%"  style="text-align:left;" &gt;&lt;div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;Expected life (years)
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:right;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;&lt;td valign="top" width="15%"  style="text-align:right;" &gt;&lt;div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;1.04
&lt;/font&gt;
&lt;/div&gt;
&lt;/td&gt;&lt;td valign="top" width="1%"  style="text-align:left;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;&amp;#160;
&lt;/font&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;br /&gt;

&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;
&lt;/div&gt;&lt;div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" &gt;&lt;font style="display:inline;font-family:times new roman;font-size:10pt;" &gt;On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date will be&amp;#160;extended by two months.
&lt;/font&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>

</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>aen-20110630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.adeonapharma.com/2011-06-30" elementFormDefault="qualified"
xmlns:aen="http://www.adeonapharma.com/2011-06-30"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2011-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:net="http://www.xbrl.org/2009/role/net"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>01 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
<link:definition>02 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical" id="Balancesheetparenthetical">
<link:definition>03 - Statement - Consolidated Balance Sheets [Parentheticals]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
<link:definition>04 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
<link:definition>05 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
<link:definition>06 - Statement - Consolidated Statements of Cash Flows [Parenthetical]</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/Organization" id="Organization">
<link:definition>07 - Disclosure - Organization</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
<link:definition>08 - Disclosure - Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>09 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>10 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/StockBasedCompensation" id="StockBasedCompensation">
<link:definition>11 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/StockPurchaseWarrants" id="StockPurchaseWarrants">
<link:definition>12 - Disclosure - Stock Purchase Warrants</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>13 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.adeonapharma.com/role/SubsequentEvent" id="SubsequentEvent">
<link:definition>14 - Disclosure - Subsequent Event</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="aen-20110630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="aen-20110630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="aen-20110630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="aen-20110630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="aen_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DepositsAndOtherAssetsNoncurrent" id="aen_DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="BalanceSheetParentheticalAbstract" id="aen_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LaboratoryRevenuesNet" id="aen_LaboratoryRevenuesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CostsOfLaboratoryServices" id="aen_CostsOfLaboratoryServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOptionModificationExpense" id="aen_StockOptionModificationExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedForConsultingFees" id="aen_StockIssuedForConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedAsCompensation" id="aen_StockIssuedAsCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfWarrantLiability" id="aen_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="GainOnSettlementOfAccountsPayable" id="aen_GainOnSettlementOfAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInDepositsAndOtherAssets" id="aen_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" id="aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsolidatedStatementsOfCashFlowsParentheticalAbstract" id="aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockPurchaseWarrantsAbstract" id="aen_StockPurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockPurchaseWarrantsTextBlock" id="aen_StockPurchaseWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReclassWarrantLiabilityToStockholdersEquity" id="aen_ReclassWarrantLiabilityToStockholdersEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>aen-20110630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_Goodwill" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_aen_DepositsAndOtherAssetsNoncurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_aen_DepositsAndOtherAssetsNoncurrent" order="80" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent" order="80" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableInterestBearingNoncurrent" xlink:label="loc_us-gaap_AccountsPayableInterestBearingNoncurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableInterestBearingNoncurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="80" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="loc_us-gaap_LicensesRevenue" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_LaboratoryRevenuesNet" xlink:label="loc_aen_LaboratoryRevenuesNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="loc_aen_LaboratoryRevenuesNet" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_CostsOfLaboratoryServices" xlink:label="loc_aen_CostsOfLaboratoryServices"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_aen_CostsOfLaboratoryServices" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="40" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="40" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>aen-20110630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#DocumentAndEntityInformation" roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#Balancesheetparenthetical" roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"/>
<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_OtherAssetsCurrent_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Goodwill_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_aen_DepositsAndOtherAssetsNoncurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_aen_DepositsAndOtherAssetsNoncurrent_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_AccountsPayableCurrent_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_17" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableInterestBearingNoncurrent" xlink:label="loc_us-gaap_AccountsPayableInterestBearingNoncurrent_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableInterestBearingNoncurrent_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_Liabilities_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_StockholdersEquityAbstract_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_PreferredStockValue_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_CommonStockValue_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_24" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_20" xlink:to="loc_us-gaap_StockholdersEquity_25" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_26" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Balancesheetparenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_RevenuesAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2" xlink:to="loc_us-gaap_LicensesRevenue_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_LaboratoryRevenuesNet" xlink:label="loc_aen_LaboratoryRevenuesNet_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2" xlink:to="loc_aen_LaboratoryRevenuesNet_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2" xlink:to="loc_us-gaap_SalesRevenueNet_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_CostsOfLaboratoryServices" xlink:label="loc_aen_CostsOfLaboratoryServices_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_aen_CostsOfLaboratoryServices_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_6" xlink:to="loc_us-gaap_OperatingExpenses_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_OtherNonoperatingIncome_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_12" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasic_18" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_19" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_20" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetIncomeLoss_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ShareBasedCompensation_5" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockOptionModificationExpense" xlink:label="loc_aen_StockOptionModificationExpense_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_aen_StockOptionModificationExpense_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockIssuedForConsultingFees" xlink:label="loc_aen_StockIssuedForConsultingFees_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_aen_StockIssuedForConsultingFees_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockIssuedAsCompensation" xlink:label="loc_aen_StockIssuedAsCompensation_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_aen_StockIssuedAsCompensation_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ChangeInFairValueOfWarrantLiability" xlink:label="loc_aen_ChangeInFairValueOfWarrantLiability_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_aen_ChangeInFairValueOfWarrantLiability_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ReclassWarrantLiabilityToStockholdersEquity" xlink:label="loc_aen_ReclassWarrantLiabilityToStockholdersEquity_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_aen_ReclassWarrantLiabilityToStockholdersEquity_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_Depreciation_12" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_13" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_14" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_GainOnSettlementOfAccountsPayable" xlink:label="loc_aen_GainOnSettlementOfAccountsPayable_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_aen_GainOnSettlementOfAccountsPayable_15" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_aen_IncreaseDecreaseInDepositsAndOtherAssets_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_aen_IncreaseDecreaseInDepositsAndOtherAssets_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_25" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_23" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_26" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_29" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_30" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_27" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_31" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_32" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_33" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_34" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_34" xlink:to="loc_us-gaap_InterestPaid_35" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_34" xlink:to="loc_us-gaap_IncomeTaxesPaid_36" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_37" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_37" xlink:to="loc_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_38" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4" order="10" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>aen-20110630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_DocumentAndEntityInformationAbstract" xlink:label="loc_aen_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_DocumentAndEntityInformationAbstract" xlink:to="lab_aen_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable - net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Goodwill" xml:lang="en-US">Goodwill, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_aen_DepositsAndOtherAssetsNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_aen_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_aen_DepositsAndOtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Capital Lease Obligations, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Current portion of capital lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CapitalLeaseObligationsCurrent" xml:lang="en-US">Current portion of capital lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_CapitalLeaseObligationsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Long Term Liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableInterestBearingNoncurrent" xlink:label="loc_us-gaap_AccountsPayableInterestBearingNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableInterestBearingNoncurrent" xml:lang="en-US">Accounts Payable, Interest-bearing, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableInterestBearingNoncurrent" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableInterestBearingNoncurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableInterestBearingNoncurrent" xlink:to="lab_us-gaap_AccountsPayableInterestBearingNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 28,079,126 issued and 27,997,644 outstanding and 23,420,189 issued and 23,338,707 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 27,997,644 issued and 28,079,126 outstanding and 23,420,189 issued and 23,338,707 outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_BalanceSheetParentheticalAbstract" xlink:label="loc_aen_BalanceSheetParentheticalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_BalanceSheetParentheticalAbstract" xlink:to="lab_aen_BalanceSheetParentheticalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RevenuesAbstract" xml:lang="en-US">Revenues:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">Licenses Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">License revenue, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LicensesRevenue" xml:lang="en-US">Licenses Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue" xlink:to="lab_us-gaap_LicensesRevenue"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_LaboratoryRevenuesNet" xlink:label="loc_aen_LaboratoryRevenuesNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_LaboratoryRevenuesNet" xml:lang="en-US">Laboratory revenues, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_LaboratoryRevenuesNet" xml:lang="en-US">Laboratory revenues, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_aen_LaboratoryRevenuesNet" xml:lang="en-US">Laboratory revenues, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_LaboratoryRevenuesNet" xml:lang="en-US">Revenues from Laboratoty and related activites; net of (reduced by) , returns, allowances, and discounts.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_LaboratoryRevenuesNet" xlink:to="lab_aen_LaboratoryRevenuesNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Sales Revenue, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Total revenues, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_SalesRevenueNet" xml:lang="en-US">Total Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="lab_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_CostsOfLaboratoryServices" xlink:label="loc_aen_CostsOfLaboratoryServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_CostsOfLaboratoryServices" xml:lang="en-US">Costs Of Laboratory Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_CostsOfLaboratoryServices" xml:lang="en-US">Costs of laboratory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_aen_CostsOfLaboratoryServices" xml:lang="en-US">Costs of laboratory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_CostsOfLaboratoryServices" xml:lang="en-US">Total costs related to services rendered by an entity during the reporting period for the laboratory purpose.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_CostsOfLaboratoryServices" xlink:to="lab_aen_CostsOfLaboratoryServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Warrant expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xml:lang="en-US">Warrant expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Change in fair value of warrant liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net Loss Per Share - Basic (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net Income (Loss) Per Share - Basic (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Basic (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Basic (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net Loss Per Share - Dilutive (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net Income (Loss) Per Share - Dilutive (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Dilutive (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Dilutive (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Recognition of stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockOptionModificationExpense" xlink:label="loc_aen_StockOptionModificationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_StockOptionModificationExpense" xml:lang="en-US">Stock Option Modification Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_StockOptionModificationExpense" xml:lang="en-US">Stock option modification expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_StockOptionModificationExpense" xml:lang="en-US">The source line item represents the charge relating to the modification of certain stock options, prior to expiration, held by a member of the Board of Directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_StockOptionModificationExpense" xlink:to="lab_aen_StockOptionModificationExpense"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockIssuedForConsultingFees" xlink:label="loc_aen_StockIssuedForConsultingFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_StockIssuedForConsultingFees" xml:lang="en-US">Stock issued for consulting fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_StockIssuedForConsultingFees" xml:lang="en-US">Stock issued for consulting fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_StockIssuedForConsultingFees" xml:lang="en-US">The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_StockIssuedForConsultingFees" xlink:to="lab_aen_StockIssuedForConsultingFees"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockIssuedAsCompensation" xlink:label="loc_aen_StockIssuedAsCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_StockIssuedAsCompensation" xml:lang="en-US">Stock issued as compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_StockIssuedAsCompensation" xml:lang="en-US">Stock issued as compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_StockIssuedAsCompensation" xml:lang="en-US">The noncash expense that accounts for the value of stock options distributed to employees as compensation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_StockIssuedAsCompensation" xlink:to="lab_aen_StockIssuedAsCompensation"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ChangeInFairValueOfWarrantLiability" xlink:label="loc_aen_ChangeInFairValueOfWarrantLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change in fair value of warrant liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_ChangeInFairValueOfWarrantLiability" xlink:to="lab_aen_ChangeInFairValueOfWarrantLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for uncollectible accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (loss) on the sale of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">(Gain) loss on sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_GainOnSettlementOfAccountsPayable" xlink:label="loc_aen_GainOnSettlementOfAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_GainOnSettlementOfAccountsPayable" xml:lang="en-US">Gain On Settlement Of Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_GainOnSettlementOfAccountsPayable" xml:lang="en-US">Gain on settlement of accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_GainOnSettlementOfAccountsPayable" xml:lang="en-US">Gain (loss) arised from settlement of accounts payable classified as accrued liabilites.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aen_GainOnSettlementOfAccountsPayable" xml:lang="en-US">Gain on settlement of accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_GainOnSettlementOfAccountsPayable" xlink:to="lab_aen_GainOnSettlementOfAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_aen_IncreaseDecreaseInDepositsAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease in Deposits and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_aen_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_aen_IncreaseDecreaseInDepositsAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments under capital lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xml:lang="en-US">Repayments under capital lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from issuance of common stock for stock option exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from the issuance of common stock, net of offering costs of $539,390</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from the issuance of common stock, net of offering costs of $539,390</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net increase in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information :</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental disclosure for non-cash item:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification Of Derivative Liability To Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of derivative liability to additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of derivative liability to additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xml:lang="en-US">Reclassification of derivative liability to additional paid in capital assumed in noncash investing or financing activities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:to="lab_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract" xlink:label="loc_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract" xml:lang="en-US">Consolidated Statements Of Cash Flows [Parenthetical] [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract" xml:lang="en-US">Consolidated Statements Of Cash Flows [Parenthetical] [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract" xlink:to="lab_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering Cost (in dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature Of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">General Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis Of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Basis Of Presentation Of Financial Statement Text Block [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockPurchaseWarrantsAbstract" xlink:label="loc_aen_StockPurchaseWarrantsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_StockPurchaseWarrantsAbstract" xlink:to="lab_aen_StockPurchaseWarrantsAbstract"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockPurchaseWarrantsTextBlock" xlink:label="loc_aen_StockPurchaseWarrantsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_StockPurchaseWarrantsTextBlock" xml:lang="en-US">The entire disclosure for stock purchase warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_StockPurchaseWarrantsTextBlock" xlink:to="lab_aen_StockPurchaseWarrantsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ReclassWarrantLiabilityToStockholdersEquity" xlink:label="loc_aen_ReclassWarrantLiabilityToStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_aen_ReclassWarrantLiabilityToStockholdersEquity" xml:lang="en-US">Reclass Warrant Liability To Stockholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_aen_ReclassWarrantLiabilityToStockholdersEquity" xml:lang="en-US">Reclass warrant liability to stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_aen_ReclassWarrantLiabilityToStockholdersEquity" xml:lang="en-US">The total amount of warrants liability was reclassed to stockholders' equity during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_aen_ReclassWarrantLiabilityToStockholdersEquity" xlink:to="lab_aen_ReclassWarrantLiabilityToStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementScenarioAxis" xml:lang="en-US">Statement, Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="lab_us-gaap_StatementScenarioAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>aen-20110630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#DocumentAndEntityInformation" roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#Balancesheetparenthetical" roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.adeonapharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#Organization" roleURI="http://www.adeonapharma.com/role/Organization"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#BasisOfPresentation" roleURI="http://www.adeonapharma.com/role/BasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#PropertyAndEquipment" roleURI="http://www.adeonapharma.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StockBasedCompensation" roleURI="http://www.adeonapharma.com/role/StockBasedCompensation"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StockPurchaseWarrants" roleURI="http://www.adeonapharma.com/role/StockPurchaseWarrants"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#StockholdersEquity" roleURI="http://www.adeonapharma.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="aen-20110630.xsd#SubsequentEvent" roleURI="http://www.adeonapharma.com/role/SubsequentEvent"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_DocumentAndEntityInformationAbstract" xlink:label="loc_aen_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aen_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" order="100" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Goodwill_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_aen_DepositsAndOtherAssetsNoncurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_aen_DepositsAndOtherAssetsNoncurrent_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaap_CapitalLeaseObligationsCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_CapitalLeaseObligationsCurrent_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableInterestBearingNoncurrent" xlink:label="loc_us-gaap_AccountsPayableInterestBearingNoncurrent_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_AccountsPayableInterestBearingNoncurrent_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Balancesheetparenthetical">
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_BalanceSheetParentheticalAbstract" xlink:label="loc_aen_BalanceSheetParentheticalAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aen_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_RevenuesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3" xlink:to="loc_us-gaap_LicensesRevenue_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_LaboratoryRevenuesNet" xlink:label="loc_aen_LaboratoryRevenuesNet_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3" xlink:to="loc_aen_LaboratoryRevenuesNet_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_3" xlink:to="loc_us-gaap_SalesRevenueNet_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_CostsOfLaboratoryServices" xlink:label="loc_aen_CostsOfLaboratoryServices_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_aen_CostsOfLaboratoryServices_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7" xlink:to="loc_us-gaap_OperatingExpenses_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingIncomeLoss_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13" xlink:to="loc_us-gaap_OtherNonoperatingIncome_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_13" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasic_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetIncomeLoss_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockOptionModificationExpense" xlink:label="loc_aen_StockOptionModificationExpense_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_aen_StockOptionModificationExpense_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockIssuedForConsultingFees" xlink:label="loc_aen_StockIssuedForConsultingFees_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_aen_StockIssuedForConsultingFees_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockIssuedAsCompensation" xlink:label="loc_aen_StockIssuedAsCompensation_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_aen_StockIssuedAsCompensation_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ChangeInFairValueOfWarrantLiability" xlink:label="loc_aen_ChangeInFairValueOfWarrantLiability_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_aen_ChangeInFairValueOfWarrantLiability_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ReclassWarrantLiabilityToStockholdersEquity" xlink:label="loc_aen_ReclassWarrantLiabilityToStockholdersEquity_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_aen_ReclassWarrantLiabilityToStockholdersEquity_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_GainOnSettlementOfAccountsPayable" xlink:label="loc_aen_GainOnSettlementOfAccountsPayable_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_aen_GainOnSettlementOfAccountsPayable_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_aen_IncreaseDecreaseInDepositsAndOtherAssets_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17" xlink:to="loc_aen_IncreaseDecreaseInDepositsAndOtherAssets_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_17" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_24" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_24" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_24" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_31" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_32" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_35" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" xlink:to="loc_us-gaap_InterestPaid_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" xlink:to="loc_us-gaap_IncomeTaxesPaid_38" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="loc_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_39" xlink:to="loc_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract" xlink:label="loc_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aen_ConsolidatedStatementsOfCashFlowsParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_2" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Organization">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/BasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockBasedCompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockPurchaseWarrants">
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockPurchaseWarrantsAbstract" xlink:label="loc_aen_StockPurchaseWarrantsAbstract_0"/>
<loc xlink:type="locator" xlink:href="aen-20110630.xsd#aen_StockPurchaseWarrantsTextBlock" xlink:label="loc_aen_StockPurchaseWarrantsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_aen_StockPurchaseWarrantsAbstract_0" xlink:to="loc_aen_StockPurchaseWarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SubsequentEvent">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EBBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets [Parentheticals] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">28,079,126<span></span></td>
        <td class="nump">23,420,189<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">27,997,644<span></span></td>
        <td class="nump">23,338,707<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0ETUAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenue, net</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 2,125,000<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 2,125,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_LaboratoryRevenuesNet', window );">Laboratory revenues, net</a></td>
        <td class="nump">355,562<span></span></td>
        <td class="nump">69,888<span></span></td>
        <td class="nump">678,700<span></span></td>
        <td class="nump">129,927<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total Revenues</a></td>
        <td class="nump">355,562<span></span></td>
        <td class="nump">2,194,888<span></span></td>
        <td class="nump">678,700<span></span></td>
        <td class="nump">2,254,927<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">694,281<span></span></td>
        <td class="nump">662,627<span></span></td>
        <td class="nump">1,967,817<span></span></td>
        <td class="nump">1,398,456<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">279,641<span></span></td>
        <td class="nump">426,572<span></span></td>
        <td class="nump">511,959<span></span></td>
        <td class="nump">733,722<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_CostsOfLaboratoryServices', window );">Costs of laboratory services</a></td>
        <td class="nump">301,142<span></span></td>
        <td class="nump">132,406<span></span></td>
        <td class="nump">545,000<span></span></td>
        <td class="nump">237,825<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
        <td class="nump">1,275,064<span></span></td>
        <td class="nump">1,221,605<span></span></td>
        <td class="nump">3,024,776<span></span></td>
        <td class="nump">2,370,003<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
        <td class="num">(919,502)<span></span></td>
        <td class="nump">973,283<span></span></td>
        <td class="num">(2,346,076)<span></span></td>
        <td class="num">(115,076)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Warrant expense</a></td>
        <td class="num">(775,996)<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(1,491,996)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">16,386<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="num">(77,471)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income (expense)</a></td>
        <td class="num">(783)<span></span></td>
        <td class="nump">6,499<span></span></td>
        <td class="nump">49,187<span></span></td>
        <td class="nump">7,336<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), net</a></td>
        <td class="num">(760,393)<span></span></td>
        <td class="nump">6,499<span></span></td>
        <td class="num">(1,520,280)<span></span></td>
        <td class="nump">7,336<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
        <td class="num">$ (1,679,895)<span></span></td>
        <td class="nump">$ 979,782<span></span></td>
        <td class="num">$ (3,866,356)<span></span></td>
        <td class="num">$ (107,740)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (Loss) Per Share - Basic (in dollars per share)</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="nump">$ 0.05<span></span></td>
        <td class="num">$ (0.15)<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding during the period - Basic (in shares)</a></td>
        <td class="nump">27,885,479<span></span></td>
        <td class="nump">21,706,472<span></span></td>
        <td class="nump">26,560,448<span></span></td>
        <td class="nump">21,633,985<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (Loss) Per Share - Dilutive (in dollars per share)</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="nump">$ 0.05<span></span></td>
        <td class="num">$ (0.15)<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding during the period - Dilutive (in shares)</a></td>
        <td class="nump">27,885,479<span></span></td>
        <td class="nump">21,883,414<span></span></td>
        <td class="nump">26,560,448<span></span></td>
        <td class="nump">23,782,010<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_CostsOfLaboratoryServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to services rendered by an entity during the reporting period for the laboratory purpose.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_CostsOfLaboratoryServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_LaboratoryRevenuesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenues from Laboratoty and related activites; net of (reduced by) , returns, allowances, and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_LaboratoryRevenuesNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=6945512&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 20<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 7<br> -Paragraph 18<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 36, 37, 38<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 11, 12, 36<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 20<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 7<br> -Paragraph 18<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 21<br> -Article 9<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 7<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Audit and Accounting Guide (AAG)<br> -Number AAG-BRD<br> -Chapter 4<br> -Paragraph 80<br> -Subparagraph Exhibit 4-4<br> -IssueDate 2006-05-01<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141<br> -Paragraph 51<br> -Subparagraph g<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 2<br> -Paragraph 12, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 86<br> -Paragraph 11, 12<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SalesRevenueNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 40<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6920599&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 171<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 40<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 128<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 07-4<br> -Paragraph 4<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E5EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Aug. 10, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ADEONA PHARMACEUTICALS, INC.<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000894158<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">aen<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text"> <span></span></td>
        <td class="nump">28,127,644<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
         2011<span></span></td>
        <td class="text"><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q2<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2011<span></span></td>
        <td class="text"> <span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_StockPurchaseWarrantsTextBlock', window );">Stock Purchase Warrants [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >6.&#160;&#160;&#160;Stock Purchase Warrants
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns.&#160;&#160;The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015.&#160;&#160;&#160;Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost.&#160;&#160;The result of the transaction has a $0 net effect to equity. As of June 30, 2011, 30,303 of these warrants remained outstanding.
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors.&#160;&#160;As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock.&#160;&#160;&#160;Each warrant was exercisable&#160;for thirteen months&#160;at $2.00 per share. We have entered into an agreement pursuant to&#160;which we have agreed to exchange the original warrants for new warrants with substantially the same&#160;terms as the original warrants except that the expiration date will be extended two months. The warrants&#160;had an anti-dilution&#160;&#160;price protection feature; if the Company issues securities at a price per share that&#160;&#160;is less than&#160;&#160;$2.00&#160;&#160;per share,&#160;&#160;the&#160;&#160;warrant&#160;&#160;holders&#160;&#160;will be ratcheted&#160;&#160;down&#160;&#160;to&#160;&#160;the lower&#160;&#160;offering&#160;&#160;price. However, the Company has instituted a floor price of $1.40 per share in connection with the price protection.&#160;&#160;On April 6, 2011, the Company entered into another Common Stock Purchase Agreement that triggered the ratchet provision and re-set the price of these warrants to $1.40.&#160;&#160;Due to the re-set the floor price, the warrant liability was marked-to-market and reclassified to additional paid in capital since it ceased to contain the provisions of a derivative liability.
</font>
</div>
</div><br />
<div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The warrants were recorded as liabilities at their estimated fair value on the commitment date, which was $716,000 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent reporting period.&#160;&#160;At April 6, 2011, the fair value of the warrant liability was $1,481,143, which represented an increase in fair value of $765,143. The fair value was measured using the Black Scholes valuation model, which is based, in part, upon unobservable inputs for which there is little or no market data, requiring the Company to develop its own assumptions. The assumptions used by the Company are summarized in the following table:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Commitment
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Date
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Remeasurement
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Date&#160;
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >April&#160;6,&#160;2011
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Closing stock price
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.39
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.08
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected dividend rate
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected stock price volatility
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >117.1
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >104.6
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk free interest rate
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.28
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.29
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times
 new roman;font-size:10pt;" >Expected life (years)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.08
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.85
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor.&#160;&#160;As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock.&#160;&#160;&#160;The warrant was initially exercisable&#160;for thirteen months&#160;at $2.0725 per share. The warrant had an anti-dilution&#160;&#160;price protection feature; that provided if the Company issues securities at a price per share that&#160;&#160;is less than&#160;&#160;$2.0725&#160;&#160;per share,&#160;the&#160;exercise price of the warrant&#160;will be ratcheted&#160;&#160;down&#160;&#160;to&#160;&#160;the lower&#160;&#160;offering&#160;&#160;price.&#160;On July 28, 2011, the warrant was exchanged for a new warrant with substantially similar terms except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional&#160;three months to August 12, 2012,&#160;and (iv) the warrant&#8217;s initial exercise date was changed to January 2012. <font style="display:inline;font-family:times new roman;font-size:10pt;" >Due to this warrant exchange, the warrant liability will be eliminated on a go-forward basis since the new warrant no longer contains the provisions that cause it to be treated as a derivative liability. See Note 8 &#8211; Subsequent Event.
</font>
</font>
</div>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The warrant is&#160;recorded as a liability at&#160;its estimated fair value on the commitment date, which was $775,995 with subsequent changes in estimated fair value recorded as a warrant expense&#160;in the Company&#8217;s statement of operations at each subsequent period.&#160;&#160;At June 30, 2011, the fair value of the warrant liability was $88,323, which represented a decrease in fair value of $687,672.&#160;&#160; The fair value is measured using the Black Scholes valuation model, which is based, in part, upon unobservable inputs for which there is little or no market data, requiring the Company to develop its own assumptions. The assumptions used by the Company are summarized in the following table:
</font>
</div>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;" ><div><div><div><table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%"  style="padding-bottom:2px;text-align:left;" >
</td><td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Commitment
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Date
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Remeasurement
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Date&#160;
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >June&#160;30,&#160;2011
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Closing stock price
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.08
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$0.86
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected dividend rate
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected stock price volatility
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >112.1
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >105.4
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk free interest rate
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.29
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.19
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected life (years)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.08
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.77
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div>
</div>
</div>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The following table summarizes the estimated fair value of the warrant liabilities:
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><br />

</div><div style="text-align:left;" ><div><div><table cellspacing="0" cellpadding="0" width="70%"  style="font-family:times new roman;font-size:10pt;" ><tr style="background-color:#ccffcc;" ><td valign="bottom" width="88%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance at December 31, 2010
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="88%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Warrant liability
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,491,995
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="88%"  style="text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Change in fair value of warrant liability
</font>
</div>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >77,471
</font>
</div>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="88%"  style="padding-bottom:2px;text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Reclass to stockholders&#8217; equity
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(1,481,143
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:2px;text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)&#160;
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="88%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="88%"  style="padding-bottom:4px;text-align:left;" ><div style="text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance at June 30, 2011
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:4px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >88,323
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:4px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >A summary of warrant activities as of June 30, 2011, and for the year ended December 31, 2010, is as follows:
</font>
</div><br />
<div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><br />

</div><div style="text-align:left;" ><div><div><table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Warrants
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >&#160;Exercise&#160;Price
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; December 31, 2009
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,070,472
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >3.27
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Granted
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >60,606
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.32
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercised
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="padding-bottom:2px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Forfeited or expired
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; December 31, 2010
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,131,078
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >3.49
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Granted
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,272,963
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.65
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Forfeited or expired
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;&#160;(19,688)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.32
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="padding-bottom:2px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercised
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(15,615
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1.19
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="padding-bottom:4px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; June 30, 2011 - outstanding
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3,368,738
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >2.27
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%"  style="padding-bottom:4px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; June 30, 2011 &#8211; exercisable
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3,368,738
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >2.27
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The warrants outstanding as of June 30, 2011, are as follows:
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="50%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="26%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Range&#160;of
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise&#160;Price
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="26%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Number
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >outstanding
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Remaining
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Contractual&#160;Life
</font>
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.32
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >30,303
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;&#160;&#160;
</font>
</td><td valign="bottom" width="45%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >4.51 years
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.40
</font>
</div>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,428,572
</font>
</div>
</td><td valign="top" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.85 years
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.0725
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >844,391
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.77 years
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.22
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >626,809
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5.01 years
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >3.30
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >61,207
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >3.92 years
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >3.75
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >50,000
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >4.63 years
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="25%"  style="text-align:right;padding-bottom:2px;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >6.36
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >327,456
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1.36 years
</font>
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="25%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3,368,738
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="45%"  style="border-bottom:black 4px double;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1.80 years
</font>
</font>
</div>
</td>
</tr>
</table>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_StockPurchaseWarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_StockPurchaseWarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_StockPurchaseWarrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis Of Presentation Of Financial Statement Text Block [Text Block]</a></td>
        <td class="text"><div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >2.&#160;&#160;&#160;Basis of Presentation
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The financial information as of December 31, 2010, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2010. The unaudited condensed interim financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K, which contains the audited financial statements and notes thereto, together with the Management&#8217;s Discussion and Analysis, for the year ended December 31, 2010.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended June 30, 2011, are not necessarily indicative of results for the full year.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has eight subsidiaries, Pipex Therapeutics, Inc. (&#8220;Pipex Therapeutics&#8221;), Adeona Clinical Laboratory (formerly Hart Lab, LLC), Effective Pharmaceuticals, Inc. (&#8220;EPI&#8221;), Solovax, Inc. (&#8220;Solovax&#8221;), CD4 Biosciences, Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals, Inc. (&#8220;Epitope&#8221;), Healthmine, Inc. (&#8220;Healthmine&#8221;) and Putney Drug Corp. (&#8220;Putney&#8221;). As of June 30, 2011, EPI, Adeona Clinical Laboratory, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.
</font>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><div><div><div><div><div><div><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >8.&#160;&#160;&#160;Subsequent Event<br />
<br />

</font>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-indent:0pt;display:block;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >On July 28, 2011, the Company exchanged&#160;the warrant issued in connection with the&#160;April 6, 2011 financing&#160;for a new warrant with substantially the same terms as the original warrant except that in the new warrant (i) the anti-dilution price protection was eliminated, (ii) the exercise price was lowered to $1.00, (iii) the expiration date was extended for an additional three months to August 10, 2012,&#160;and (iv) the warrant&#8217;s initial exercise date was changed to January 2012.&#160;&#160;&#160;Due to this warrant exchange, the warrant liability&#160;<font style="display:inline;font-family:times new roman;font-size:10pt;" >will be eliminated on a go-forward basis since the new warrant no longer contains the provisions that cause it to be treated as a derivative liability.<br />
<br />

</font>
</font>
</div>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div>
</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company measured the fair value of the warrant at $253,317 using a Black-Scholes valuation model;&#160;As a result of modifying the terms of the warrant, it was not&#160;considered&#160;indexed to the Company&#8217;s common stock.&#160;&#160;The fair value of this warrant upon exchange was based upon the following management assumptions:<br />
<br />

</font>
</div>
</div><div style="text-indent:0pt;display:block;" >
</div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="50%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="82%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="16%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Remeasurement
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >Date&#160;
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >July&#160;28,&#160;2011
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="82%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Closing stock price
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</div>
</td><td valign="top" width="15%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.84
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="82%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected dividend rate
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="15%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="82%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected stock price volatility
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="15%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >105.6
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="82%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk free interest rate
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="15%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.21
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="82%"  style="text-align:left;" ><div style="text-align:left;text-indent:-18pt;display:block;margin-left:18pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected life (years)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="15%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.04
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On August 10, 2011, the Company entered into an agreement to exchange the warrants issued in connection with the January 28, 2011 financing for new warrants with substantially the same terms as the original warrants except that in the new warrants the expiration date will be&#160;extended by two months.
</font>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >7.&#160;&#160;&#160;Stockholders&#8217; Equity
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During the six months ended June 30, 2011, the Company issued 15,000 shares of common stock in connection with the exercise of stock options and warrants&#160;for proceeds of $7,650 and 10,615 shares of common stock related to a cashless exercise of warrants. The Company also issued 45,600 shares of common stock for employment service, having a fair value of $75,840 ($1.66 average per share) and 41,796 shares of common stock for consulting services, having a fair value of $58,270 ($1.39 average per share), based on the quoted closing trading prices.
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On January 28, 2011, the Company sold 2,857,144 shares of common stock and warrants exercisable for&#160;&#160;1,428,572&#160;shares of common stock&#160;for $4,000,000. Direct offering costs were approximately $300,000.
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On April 6, 2011, the Company sold 1,688,782 shares of common stock and warrants exercisable for 844,391 shares of common stock&#160;for $3,500,000. Direct offering costs were approximately $250,000.
</font>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 5<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Article 4<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 4<br> -Section 08<br> -Paragraph d<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 1<br> -Section B<br> -Paragraph 7, 11A<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EGDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering Cost (in dollars)</a></td>
        <td class="nump">$ 539,390<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18, 19, 20<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfStockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >3.&#160;&#160;&#160;Summary of Significant Accounting Policies
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Principles of Consolidation
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >All significant inter-company accounts and transactions have been eliminated in consolidation.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Use of Estimates
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives&#160;for intangible assets and for property and equipment, the fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing operating losses.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from our estimates.
</font>
</div><br />
<br />
<div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Accounts Receivable and Allowance for Doubtful Accounts
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period the related revenue is recorded. The Company estimates and reviews the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assesses the state of its billing operations in order to identify issues that may impact the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates are recorded as an adjustment to bad debt expense. Receivables deemed uncollectible are charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Revenue Recognition
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;, The Company has two streams of revenue, license revenue and laboratory revenue.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;" >License Revenues
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;" >Laboratory Revenues
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company primarily recognizes revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, are recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company maintains a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looks at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 18 months, otherwise known as the yearly average adjustment amount. The actual sales allowance taken for each period is the averaged yearly average adjustment amount for these prior periods multiplied by the period&#8217;s actual gross revenues.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company generated reimbursements from&#160;3 significant insurance providers for the six months ended June30, 2011 and 2010.
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="40%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="24%"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Customer
</font>
</font>
</div>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="29%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="27%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="24%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >A
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="25%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >68
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="4%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="23%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >60
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="24%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >B
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="25%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >4
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="4%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="23%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >16
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="24%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >C
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="25%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >20
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="4%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="4%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="23%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >11
</font>
</td><td valign="bottom" width="4%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
&#160;
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Risks and Uncertainties
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company's operations are subject to significant risk and uncertainties including financial, operational, regulatory and other risks, including the potential risk of business failure. The recent global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions not only limit&#160;the Company&#8217;s&#160;access to capital, but also make it difficult for the Company&#8217;s customers, the Company&#8217;s vendors and the Company to accurately forecast and plan future business activities.
</font>
</div><br />
<br />
<div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Cash and Cash Equivalents
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.&#160;&#160;As of June 30, 2011, and December 31, 2010, respectively, the Company had no cash equivalents.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company minimizes credit risk associated with cash by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed the federally insured limit of $250,000 per depositor, per bank. At June30, 2011 and December 31, 2010, the balance exceeded the federally insured limit by $7.9 million and $2.1 million, respectively.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Warrant / Derivative Liabilities
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Fair value accounting requires bifurcation of embedded derivative instruments such as conversion features in convertible debt or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option-pricing model. In&#160;assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if there is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments such as warrants, are also valued using the Black-Scholes option-pricing model.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Net&#160;Income (Loss) per Share
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Basic earnings (loss) per share is computed by dividing the net income (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of share equivalents.&#160;&#160;Common equivalent shares, consisting of options and warrants for the purchase of common stock, are not included in the per share calculation where the effect would be anti-dilutive.&#160;The Company&#8217;s share equivalents at June 30, 2011 consist of 2,781,093 stock options and 3,368,738 warrants, respectively, and for the period ended June 30, 2010 consist of 2,312,759 and 1,070,472, respectively. The&#160;computations of basic and diluted net income (loss) attributable to common share are as follows:
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;&#160;
</font>
</div><div style="text-align:left;" ><div><table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="6" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Three&#160;months&#160;ended&#160;June&#160;30,
</font>
</div>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="6" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Six&#160;months&#160;ended&#160;June&#160;30,
</font>
</div>
</td><td valign="top"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="top"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Net income (loss)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(1,679,895)
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >979,782
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(3,866,356
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(107,740
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Basic weighted-average shares
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >27,885,479
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >21,706,472
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >26,560,448
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >21,633,985
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Effect of dilutive securities:
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Stock options
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >175,527
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Warrants
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1,415
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >-
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Dilutive&#160;&#160;weighted-average shares
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >27,885,479
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >21,883,414
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >26,560,448
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >23,782,010
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Net income (loss) per share:
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Basic
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(0.06
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >0.05
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(0.15
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(0.00
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Dilutive
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(0.06
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >0.05
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(015
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="top" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >$
</font>
</font>
</div>
</td><td valign="top" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >(0.00
</font>
</font>
</div>
</td><td valign="top" width="1%"  style="text-align:left;padding-bottom:4px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</div>
</td>
</tr>
</table>
</div>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Research and Development Costs
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.
</font>
</div><br />
<div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Share-Based Payment Arrangements
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Generally, all forms of share-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date, based on the estimated number of awards that are ultimately expected to vest. Share-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the share-based payment, whichever is more readily determinable. The expense resulting from share-based payments are recorded in cost of goods sold, research and development or general and administrative expenses in the consolidated statement of operations, depending on the nature of the services provided.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Recent Accounting Pronouncements
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In June 2011, the FASB updated the accounting guidance on Topic 220, entitled &#8220;Comprehensive Income&#8221;, relating to presentation of comprehensive income. This guidance requires companies to present total comprehensive income, the components of net income and the components of other comprehensive income, or OCI, either in a single continuous statement of comprehensive income or in two consecutive statements. Additionally, companies are required to present on the face of the financial statements the reclassification adjustments that are reclassified from OCI to net income, where the components of net income and the components of OCI are presented. This guidance is effective beginning 2012. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s financial position or results of operations.
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >&#160;
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In June 2011, the FASB updated the accounting guidance on alignment of disclosures for GAAP and the International Financial Reporting Standards, or IFRS, by updating Topic 820 entitled &#8220;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS&#8221;, relating to presentation of fair value measurements reported in financial statements. The updated guidance requires companies to align fair value measurement and disclosure requirements between GAAP and IFRS. The updated guidance is effective beginning in the year 2012 and earlier adoption is not permitted. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s financial position or results of operations.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="font-style:italic;display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >Reclassifications
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >To conform prior period amounts to current year classifications, the Company has reclassified laboratory services, and research and development expenses to general and administrative expenses. These reclassifications had no impact on the Company&#8217;s previously reported results of operations or cash flows.
</font>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 22<br> -Paragraph 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Text Block]</a></td>
        <td class="text"><div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >4.&#160;&#160;&#160;Property and Equipment
</font>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Property and Equipment consisted of the following at June 30, 2011, and December 31, 2010.
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><br />
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="80%" style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="76%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >June&#160;30,&#160;2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2" style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >December&#160;31,&#160;2010
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Leasehold improvements
</font>
</div>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,070
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >864,429
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Manufacturing equipment
</font>
</div>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >400,045
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >410,997
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Computer and office equipment
</font>
</div>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >160,478
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;"
 >160,478
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="padding-bottom:2px;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Laboratory equipment
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >213,908
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >213,908
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:9pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Total
</font>
</div>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >776,501
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1,649,812
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="76%" style="padding-bottom:2px;text-align:left;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Less accumulated depreciation
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(380,357
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(1,138,670
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="76%" style="padding-bottom:4px;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:justify;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Property and equipment, net
</font>
</div>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >396,144
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%" style="border-bottom:black 4px double;text-align:right;" ><font
 style="display:inline;font-family:times new roman;font-size:10pt;" >511,142
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap" style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The decrease in leasehold improvements during the six months ended June 30, 2011, reflects the relocation of the Company&#8217;s headquarters within Ann Arbor, Michigan.&#160;&#160;During the six months ended June 30, 2011, the Company sold equipment, with a net book value of $6,892, for $1,200, resulting in a loss of $5,692.
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Depreciation expense for the six months ended June 30, 2011 and 2010 was $108,106 and $180,076, respectively.
</font>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>29
<FILENAME>0001144204-11-047255-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-11-047255-xbrl.zip
M4$L#!!0````(`)"##S_AC4H*'EH``)OW!0`0`!P`865N+3(P,3$P-C,P+GAM
M;%54"0`#;X%)3F^!24YU>`L``00E#@``!#D!``#L75MSVT:6?I^J^0]8;VTV
MJ1(EW(B+G&2*EN1$&]G26/9.=E]2+:!)=H(+IQN01/_Z/:<!D``)$``)VIJM
M^,$VT9?S]>ES[6XTOO_;<Q@HCY0+%D<_O-).U5<*C;S89]'LAU>?/KX=.:_^
M]N-?__+]OXU&RJ]O/MPH?NRE(8T2Q>.4)-17GE@R5ZX^CV1IWI-BG*JGVJFN
M**-1T?H-$5`;RF1%_50K"I\?>,#.\6\%P$3BG%"`,D^2Q?G9V=/3TRGQ:1R1
MQ9SPD)QZ<7BFJYHV4JV1`6BS)@&+_JBTP>Y.8SZ#NJIQAL4/0+^HCJ4^6S4H
M5[;.LL)5U:VNGPQ95W-=]TR6KJH*5E<1.M7.?GUW<^_-:4A&+!()B;P*%K8#
M^V9])F)3U^Q=+;(:18,HCJ(TK*_O)_PL62[H&50:02W*F;=JU]ZHVL"G"TX]
M%(I&<.X9X1Z/`WHV)5XRHL^+@$0DB?GR+?PN.N)TVMB#=0:E*X@TV4%*TH$J
ME5E/:F=]G,WZJJH7IU'"E]6Z@GJGL_CQ+"_,Q5`;&=JJ6<HYJ$]3N[RTIJ%/
M67T;**BI3I^]>7U]+*EIP*)'*I+Z)EE93:.(,$_4MY%%-4T$\^H;0$%=]63!
M&^I#24V#5(QFA"Q6;:9$/,@YS`N:FXQ(DC0W@T+.'M*$BE(SE'%1VT:6U-!Z
M#G:HY:\W:"O0XJ'1.!?2''R@4T4:D?-<,7:;FK,%CQ>4)PS(EXR:[`!!_?!*
ML'`1K)[-I2J!01TA6-4RU--GX;\Z*XSR11PE]#E1[JF7H-VNF&0O+V2@SWG%
MWXQW5[\9ZNB_4MFC^FI=&WP"2Y;KW\S')U-&N2*'6AU9,<\7U[^\^E&%/XYK
M:F/G^[/-QMCA63T%8`2+_?5OL),\N03[`X\0W$@U87K6[<OE*]!^I0'ZE#+!
MHK1XLB9Y5N'1;J99_U),TUX&TR;BM]OI;X8VNJ3>RV-;YI63@@>:#E9@W7I=
M>A@/JMJFO2@.;`B.UE?;M"^C;2^=:?VT[6A,R[7MA;*MHFU;/!A*VS(>@#9/
MTMG+YX$STH[&@Y755=T7RP/5/9;5W=2%%^UY#M(%#`$_1:PA_DNQ!!ES#ZDW
M1,8_YL]#2D3*Z8^YR9*%1>=%6?$;^ZCI\=/]Y59W>=IZ#F7]>[NC7*)<]>JS
M1V#OCZ6J[S%;Q5QS3\);[?'A)8WBD$5UW79E3Z6+LRKZC7'C?%T%5*Z_E*?L
M>T@3SZ^DX'R@,R82#C+PGH14R2?[`Z8!C0YR<GEU^WZBW/T\^?!N<G'UZ>/U
MQ>3F_D2Y?G]Q^OU94]\(:%UV`9@X":XCGS[_0I?=")=5HK&K@LZ%3)^3MTQX
M)/@?2OA5YONZD1IEUB*CT]15=4AO64#Y!3R>Q;SC@.Y#$D`CY0-=Q)"E13/(
ML,(%B9;E\57Z+4A^Y`07W>Z7X4,<=",&:5W6;:7MQK3$81A']TGL_9%I\6V:
MH(7`^K54MIV@@M(GZ^1V0/&IQV"@D!N#:=0=3;<MTZS,X`ZJ!;[+?"'Q(Z2M
MW<8+H/Z>42FW+?J;P`,?'[X-2/W0MCJ<PAAHUF.E]2;$.VE">XG;.DZI(JYT
MM4DGD\>LREMX)KK1^KM>I;'533T=E/L>5/#O.CJK;I!*OIYR?D'$?!+Y^,_5
M/U/V2`*H+R;)!>%\"4+PWR1(ZSFYG?:MY0^]QH;P6:;CC(WOSWH1'A1IB4>[
MD#J&,W:-KXJT%-3MY*FMC574YQ?`T]VS;^BV:HVM`Y!./+F8*SY0CT+UAX"^
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M*J'#H'1D@^Y8CF'UA,)3ZM\P\L`"AGMT`S)&4U7=KJ"IIW4PH*[L@3#1Z8GG
M$E*21Y*P1WH4'I5\Z"Y*0R#JZF$=0S?[H[H@"Y:0X(8206\?`C8CN-(SI#29
MIJJ6P^9=](9!UI%C>Z$ZBC2-554S2Q9W]Y0=17P,UW9LIRN$#0-U#10Y%<D;
MR,\A]1G421NZ88P;36,CY:'1=C55!X,M,7X(R0*CX)BUT[H'T<X1C*IK1BO1
M.TZG%,;OR\6[H99IU'(0O47@`/K]K4H+_=+*Y6!K5)#AE>S()H5]J7<5?MMU
MG6[4)[[/T,22X(XP_SK*#7"IR1"1K`V(3*T<6+62'0YD1Z:-+8C]=%7?%^0'
MFA`64?^*\`B,B@";DX9I@$<C+^F4>6P((SPR#5LW=;,DW.UTAT/9D94CTQZ[
MZMBU]D4IF3N/`Y]R@1EW4K\5T].!C6UGK)6\PC:5_3%TS;,T7;54LRN&DL&&
MU/,H7-G*,MMH#H5OW\RT#[ZJX;\C_);?)RAST@X6^\?[<'&U]UQ":X#3.84(
MLLGQ--$?%G$37[\,XFSK;Y(F\YBSS]3OS=O:_49-S?XTX=RD.@R^6DY^$7S7
M0J1#\:X%5$;J<$#=F34(H&Y;VL.Q:6,S>P!H@S&L`5HI3/GRAJ\#\0&Q'F;R
M]L=Z7&.GUD+<94KVA-;?S@T`;4@3IQLF5'/J$ZXFJ[('HNZ,TAW5AEC/.@S1
MX$8.TU+'5NT=L-JMR9&L'":MV9FBOMANF$<C0<4'^DBCA@1Z\QV6W>ON^K@B
MXQL$^M+>?!7D2]+>?)N@XXK)H",^A"KNOMV0AU@>PESF!:)IK[?/+%NNX^2;
MCK4$^E/O,\^:[KJXMS,@^3Y3;8S'8TL_XNAWD[=LL$)J"_E5BDR"E4@,,?&Z
MYIIRZAL(]*7=2[WUL>F6]_0.I+W/G!]EV-WFNP/IGVA$.0D@M9_X(8ODV6/<
M/;MZ7J!M.%SM+=TJ3T`+O4.A];()ANN8Y:-M1\;61W@LU]0=[2NQK>4`BPOB
MI>TWI1^HH(1[>(#P$L0QB.79GJ%DS91'&\J+H#NH'0:KCYS9AE$Y<'%$6'U$
M#`)`R]2^`K=:]@4TS1V[/6"A4[N(12)NIVO?=D_Y(T0W];MZ?61*,W13M3+7
MV4AE/QB]')EA._KX*#!Z^30U.T5X=&ZTR(B9!>VM,`HANEW@:T60Q^1R,X!<
MZ+IFJ:7=C2T2_>GW%`A@@3$H_3Z2H.GV6"T?<!Y\_&V2J)NV;?6E?QUY<4AO
M8G&X!+BVH3MU$["FL0^$/D(PTK2Q6LN$PS#T$821"_:ZO(U[%#ZT8-`-T^K#
MB)\(B_#9;;0^+W8=0>`B7[K!C.B.TX0\'RPDI2"\*\W!</:1I*^)LY>TV?;8
M+6]T?V6NMJ#53-".0^&""',\H'=)LW^OH]I#CD/*:D>20Z'<4U*_,,I><JI9
MAF.]$(:VO)ECF[9V$-*U4.-"P^VT\A+'Z@V.@V?>,$VC3I-V$3T*S):I'UNN
M?@A.^<K#^SB*JS[L\*48LWSNI('*OD!Z)L36T8#T\R:5`.Z8'&DY.>IJSN;;
M<;N1;)<.MF)7$9-&.ON#V5]4C@"FG[A8JN$:7Y`Y;4YFK*MZ^;W&;H!H,F@:
MY-I.R=Y5>N]'ME_JHX+C4@>AV].QVZ[CCH\PX!;"$$]81GFYNI%P<>BS.$[Q
MA@CF]9_HNN,<NCS.41I]+:W]P.R<_CHPU6AP0"0[!:*!+2/@B_4%^-(9C=9G
MEOY!V6R>4'_R"-9C1M^GX0/EM].M<P#[B%+]\0/-5BVSO%K?"\*PV)LEKP&[
M91BN,WX1V)MEM>'8A^.,3=M]$=B;);L>NS6V5--T!L"^J1"7+$B3AM-(PQO)
MG-J^@`8VE`>B.8*Q')0_@QC,&D0-LI?7['9JJ[?1=!S#U,Q6!6@",33^OH83
M=['4\FTM7QG_L8SGU^'_<`:T"_XBD*`^WK\&289\=WB`C2UK;)??V*DE,PB0
MEIQ<MS7+Z@($MR'EL<G;!3YZ%_MLRCQ9/%0>G&]V[J8R&);65Z9MR^X-*#N`
M^S;F0%.D`::H;^D`"\*&H5MN"4T#G8&PM&Q,.[JM[H5E(@;5(M.R\$WDG42&
M0-%VZ9-C;K.C'L7%G$0S>AV])8S+EP%NI_\@'"_"+%:=N]P/V4F+.I`:%E6G
M!?@>R`J3="F_!L*&$1G-42M;J.7.#R#:<HQ`=32U`]$['C\R_.P-Z-)EG#XD
MTS0H;ADXW.6H6OENLEVT!L34PAC',<O>IPT42@]N-=Q&]S1)LOMK;Z<;%S$,
MI4"MA(9$U')04I?[JYU1-6]S;=_0=[A*C8U*+-.%Z!%`MIP#=$U+W[FKVA>D
MW+[(;T_9<656K^5>V]VY1[E-\@@0VPZAR&/7_5&B[-;MNM;=@3:4!G>E=P1\
M;;NGZKBXG*X/R';I'<H&CC`+[*34O<S.4`9Q;&JJ.R2ZC3O'#C>*KF:T(MP@
M>@20;=L\CGT02KS=E8BY=-L^]=\L/T'B"!:@V)V;>`E['(:AI@:QOE/9%^I(
M^FB`VYBKJ[;KJ(="!@F6IZ8^QA/OGRGCM/'VT`%"Q+)E[T[X:'"[7\:T'U8>
M>Y3ZXBV/PYIS*X/RUE(=M_+.?6?2QT/<=OA9/1QP@\Q?RT\%#FLAQHZCMVM;
M#>6CX>W#W_W@?J"+7/)OIS=Q-/M(>=APW>'!_'7&Y9/X/2@?#W!+S%^]G')/
MQ!7!7R\$BJMGRCTF]MF]VF2LJXWM!DVK(S@TNI:%&VO<9`;Z@,-5,?SZ[.VT
M[8:U/<_)MA(;&EG;NXV6:FG[XFNP!F]9!,V&-9N.:HW-5CM40_EH>%M?&C4<
MJ]URMB"N_\)#]JV3S3#X<-<T'EM:Z11('^)'!-V28]F&K9;CUWU1%S>CXH6'
M`]QE8542EG77!Y#L'&<VT\,C:A_),Q6#C+*ZP%+N^C"J/0;:2/5NY457VQUH
MR^0KBH,:]!UT!L33H@2&:[A[@'I/DI2#?<^3NZ[AS(_?!,EKGSU^,TM>;_]7
M$<D2/^R,34<$HI7H/*#3Y+7\S2+\"."YNL"J8A&0Y?E#`!!?AX3/6#3"FK(T
M_\UQ3UP^>*44-*8`JR!2=,*B@$54%HVF)&3!\CQA(1CRB#XIX,M(E)4)]IF>
M:]B?_/DD]]S/'^+`SPEHI]^0</'ZWS5+?5WWOUL^(Q'[G&VY_/4OB.<,N\*V
M^<\=[&@<_GIT#UPYRSJK[6XWHW]/(0R?+E\:K[/^)CZ-(Z+<S0D/B4?3A'D@
MP"<*:/&I\FTRITK&9D?7U=?YA^163[372LR5K(O2P^\4)A2B+"I]@A"7&E?G
M;XK?[H*`$V;/S]YAQP,=+(KB[+T:):0^`X<,PYD"0425@*](9+(:3Q6!C@0_
M(I9]M0_&S!_QMUB*A(8*\`@=BSA5/D++C4%H]FNHB%<RT-D2@2>Q$F07_R@+
M'ONI!_DPGN[PH0:4SDFBS`E@\BF$7UE#'T;K04)+6*0$.``$Y<&$R('3*6[[
M>TL%>BG&AV,(D10!VF1&LW[!/Z0!F![H!IZ#[,@#`S(A#T.,DB4;@R![EQN$
M_31G/N)><^X$9V5.A+(@/`%>`#YDF;^^'@#PG2@^3V>U0XPS[BHA[L@O`JH(
M+Z`\%@SD8LH>0)J6))@Q<J*0<!DGD,S/F:?@Y;G(_%5EY=O)S?UW<M23X/.<
M@CCR"M?S>:E,"XXDO_T\6`(ZR+SP3G0$%9(_J!S(%%@0/^'3'+TH,0A:D4?"
M`ER[/5<VU273`?S_.69OS'N]H4"95L#P_Y=MF9(NNB?URU;_X_4CR`-.?VX$
MI/(G\2(G\/'=9N?`S$S,@873./97DNXSFA"^A.%'("B%R']FD0<SBE<5TPAE
M2X@8]X5AKI]8,M_-\1,Y*7ORYHD&P==@SARBBGA!$I2U&#H8`7-&<JF>\DR6
MD6,@[*DG!098)Y;A(HE#L<4=+/1D_H3ZY*_4"$Q?K&1OB%`T84_S&`4J?HHP
M'2X4FN.EE\!UJ@2K6Q5.BBXNBEKK&Q<RY5YD609V"RI$P&9P3I;24H`MP%MA
M,@L1,H_'#RP.8K!'/B.S""($&#,@2L"$[71OW7^5DJ"M>*,<C;Q)!=I=<4F%
MQYG,V"&0Q_/"`M?QJ`!YE*T^PAR^";KFOS712C>?W.HF-R.<+Q2BZ"TABN08
M3G:99\<-5?;NK`^/B^#F.-$).@;BY9$#:G4:D=1G^<%F'YVT#]X2+``+P37)
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M+.CJK4YB'J>!#PH%<DTD/FCX>QIEWP%?26`_P"?@9YDWEXX#0FC1SB&4XRC.
MXG%PQ4E\`G(^H_AC#>+=*F"JX+AD`K(-46C-)"+!,@MMN[#M3P5I49"+/`\J
MJP8P%D+:!&<,0U`OB/$+]-`5UD#["B8W2/U,X)M4XOC&>^TKUMH`T..0)=#@
M1%FD'-=L$IDAM1GYO<TZ+[[;#E&I'"G\-X#X$CJ%>#!&N2_X!?%JD%O\JBLH
MN(VSY4'TAOD#4B,R"^=T#H/#O'I1"D80^!J%/$<$3T]622D4QZL04::8'A%S
M90JI&(2EUPG:N76.\I_0`')1V<,\?H+4DY]D<3!B#C%71#+$1VG,YOA;X#HH
MHIQ(()8)!Y#'=!"?E>I^5YJKD``C,@."][)O#GA*&*^3J<K8,VM8S$4QXL(@
M+.0Z=6X2((2EBJ%*<P!&09*$&2G(,BG-OCSG#PAA')N]35-@`-J8/VU)%V=;
MK`O@>H:,NA61/@@&B1$'W3I1[MB"/N/T<;*02TVKQ:O2PM5VI?)RU<[<[5O4
M+,IA6G\FX+>@Y$2YN;F`1E?3*?7D+#>LGI4`7-U=5RG>0W[W2)YKJN8EU>H7
MEZ;RAL5"9ONTC@+4J#:Y6C!(J3N!RVI6F_],29#,0YBWFA;KPLJR'YJ>NS2)
MP%!=8D)^$?/%QD3(TG(CL'+2MFSH%3!LU[24\97)HCI6DG995B,B*_XC9Z6!
MSMF%/83D]QAL]W(D^]BMITUI=?_$N?+.UGKQ;[)R;W=Q@,L]XN!4^__-QH#1
MDG7?IV&(K@#DJ\119<U2I>#IU]@V^**\;UW=.WPV[M;1%S`<7^D"YOI?;5?F
M7VXK!N*"\J*_#$=&^>)'$>5FT63"221(GN&O0R$:,#"()(]UO?($M"P<_BG@
M703\DY`1W14(42B3AY?!TQ<MU1C#9=G;*LM8"V93?I])+T9>^`*AS/*J65M-
M=E>?!G(J#_664Y/57A)=S2/J%!$B#1?YHIE,5&1\ERU&A)GN9;G9.I5L'XGL
MN;R"*=.R4^4^A7RE&0"#^EZ"&VPQ9D.XL"%.JIM?YR5DF%3%GD0!@YO%L?_$
M@B!K4!#QE5102#Z4`$)64=Y\E5DH)*<,WZ\@V7LJ61;)<=="'M65#VAQ3C>'
M@JG5H_Q(+,SJ4_8B9M94R)-P<3Z:&1;0K$-17'*-"63I/5>9:"ZR@!K3W35O
M\H0:D#P4KY0BB04P$J:;8#8)1C/!?#@3+I0!G.>@],)#L3"+</,\&?DH5Q$0
MEI]_R$S!>TUS'O@P,&!GUF,JT]+BP+T2Q$+N*/]I`5HMP#OR!W)L/:$-.DGS
M@Z`5)_A[ZL^P0K'"`'H94")PKYP(2`X><)<8YD+*KE3;LLP7LD,S589?1*[M
MY$L;`J1FM4(%4R[EAW$O#?%"!Z_8[O^_]KZUR6U;2?M[JO(?4'Z=+;N*HY#4
MW;E4^9:S226QR_;9?#S%H:`1-Q2I\#+CV5__=@.\2J1$:70!J=[:$TLC$F@T
MNI]N-(!N_M4)!<+(QF>%AG<"0!K;+`Q5A#EF/(EF(<B)V!&>>`"ARTBW1:0U
MB1HE>.-A:!*\@F4JFSXL?X#VI1]@8`$W\@1P.@"<R/)[)&$SC@2(%,4BMB)#
M$[*KF0-<"HK<!]Z*B+4?!_GT-9#Y<A"B_*V#;D%VJ;EPZU2>>B@B3'HKF66/
M$W;L]HE37@4%U@8\-\3BU`P,Y/_$3\(8:="HU/64_S+X-DLG('6E4]UTPH*1
ME.%<U)?<S"<!0!'SY:)(-/PKRXTY8?9T^1Q+V;;#XPY_"!/,<%U`H]26`:%.
M:8`AN[62TU`6\T3&&1&;!:7UT0N0P=_TC$-.VV-A)>#G.6EZ[+\!OOP@.80E
M^D[CQ"OKD>.9"6=Y&P>AA"?^%9L4QQL0;SVQ#KG#DSUXG"A#5#D\;&B%Q]/#
M,&,-GFK:P?G-XRJUD1X`?J!UED)V87<IB;IC:`X--OZ_//41)0"-;`4FNP7+
M+7PKA'O`7R3407$'Z8>AAG&*]TOK,7'`:N8+_AKRTHR)DR?HVO`B4'[B,B=!
MF.X8[.1+06J$E"=R:(F)R`/@V-ZMA:?);N6$>7B,ZE.!H!F'V027STMG/-4<
M,"C!'39YAUMM49FL:JI$RWCDQI'>6''@*Y1L/PYA$AX"W"?Q;OSY?(-Z&ZP=
M3L<Z'^HZ5`,:6VV5TH*(.'?H'U,49N\]!RG!80;V#PLNU@TI".8'$07R^K8X
MN3A[Q5X8+Q&8P]@2VVP<#WZAM*-1\L3!+^\N15L`9P#U%^9+"5YR>22.00(5
M+D\A$A`=/+Q`;''[V7TS>+&?O&A)=<27$RVS@<_^$IZ'QN;.5[F;.>/H/SKH
M.2?G`%\,7JYCG+!JF7^-"U,85F6L=9U=(&G_AYZ]`]1$Z)VF-^>P[W@%[B1N
MO:5_RT_3>GZ^<A/Q6&N-[<D[B<'E>)RBDB"M9(5QURAZ\/&`+[>6"7J)5K7L
ME&_:#?(B/]"7_ED5+#JITAP3CF0/2>U4EA;1O`8N'A%Z2B=6I*"*+?"[@">!
M)712D@,S^4%M[J:KSA#C2Q8>L0"Z^3SV9L)!CE<W4@7G''<1,T4L^&YR?;AP
M8.+2P\;H^#DV^EJY8B=^K?]HN1A@Z3&1(&[=K\.]6O!#Q2XINNI.^#<"HSBM
M`(!X(SW=8J.)XR!P9%9$@7@E3NL*3$P"B0+W<$LTP@6K=,+$00S47['X91A2
M@A]S7SYC88_]A;@2K:%%D>)"Y*=`=`%^0W"PT),L@[JVOCI(!H,N5.JS9XTE
M_GLRFE+3<LH9RD["*(S&X>$0`&:WU(JU@I]@UGKLWX(@<44B?V_)P8#,=M)5
M&$-)`//5407EV6)%+`M<:X5?L6]YXR/(I2KR([P.L:6Q7HH7)1F(&$[.RG?$
MIHALVT&U6#I%F9614'%RQ+LIA`$+0B[MAC"#B.R5`@"6Z"@RX$1%@Y@9F;"T
MC$0UA!6;*)(QNQ)C\U28S$R*B$UE""1%T`EF-PA7CXE#!.*0V'D0%&XO/#Q7
M[R1`D^\B%,2MXH19$NF+`K$D!/<IE#Z)F,FL?QLD0!R,Q+@SM)EZ6DE0(5N(
M;7.QV!=?Q!>U"K&,<@$6WI;H./-3E%DTM<U1R3T^\E4.6R;!HF,I3[Y5`%YI
MSR?`,W1H$6J,>20SEJ0AI1Y[DX1OUEI)XE5@?!Y+.B_B6:40V1_B2E4@O7OY
MQ9EI&_&)5(EJ8X<B-B[.7H&.1P\88TLW!3'$E.AX>;]-J.LJ2H!*>&22P*M0
MU6-*V-)RDJ/A5H+K>01)[-`E^XB\<&LNG3`$]&(D<(4H+N0(9PS:C`/1CIVM
M8@O1T%"$'U,DES%7I]![&:==W_];;%&%>-X5+_*E,5M\:NF'46EO"S=-TP"T
M\&!DDO$B[:FL%1R<+("7R%ORY[)2%(8%3HD#,E?P/L'3"I@Q`8*\:(%'>3&H
M\(`[;W][_H.7^BAX1E7<II14%:*/LDL9[TZVDC9FQ?J;RQ/.W$*YE[YB>:"S
MG5VDTQFF5,MVPG3%XZ00D#J0);<U(>TN\,-0.3.IXBF[3<63'I($LZ):"$C+
M@R[]M8-+J?`E=QZ#_/1SZ'Q-Y*YPGCH]]BED6MY.V7N26H!H.;\.'1Y><.=!
M@;Q(YL3DKANN++SWBJDGQ/<5[IDDWQ^<6;3XZ=E`_^X9*WE2>U&/W079IQEN
MM@%-/SV[]:/(7V:]F(-"+[=BI^5&/@+<M^R_F;GZRL2F>:'AK<-5;#)KXNT[
M.DANQZ0AV6H!V'K$.)KM9C[R'C`\L%8_/9/_YG.Q#CZ)A*23`]-R-E;M4H2F
M0TTI;/E0S"F,!=:'H,,>5MLA]:E1'V$D2'5(=7+5&9/J-%4=G52G@;RE7W)7
M)\AD"H0(5A.Q-[L!D?.#5__/MN=SVRYZ2,W\HE-GJ=@UXJ.?TWHB&C65G@LY
MYDV'H31Q+>2I.:RF6T#LB0@?35HMR]^1""M%MMF_@`C76?HNB/!>]GDN_H_L
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MX6NR`.</8-Z>4%P(MF4E/0WX&LD,_"([#[`!#T+BO:/L'&#E]:CTFF.HU3YR
MS[V9'^198-+C;7A5'2]M`N=<D3"4VYA;1%R-=RTO3:F13;B5%00[21:,MH,?
MUO<2S!,?"I6^"/[V.W:9IH@1)VK9`GH6&H:Z#RJ)=3WE*4QQ.\4'RAQ/Y$&*
MTI3#XCQ]P'EZUM)'$`G#-(6-N$*%%_OBP%Y@Q3?,)\!E0E^>3UOE!=O*=)TX
MZ16IS\LIG<I76F;BSN]ZCR0I>YZ,=SP`7KQPD9@.:1'7KF$*-M\^)H>D,<.&
MBQ<D92ZLQ,XE[_\36\6T)/)NQV,IYSVP)HKSM,E@[N0=Q(A)\O%J*O^*)2OE
M+7D^2VY9B8/!\%=A*["'Y^90UW1=1\+`;(FDTWZ@B:]HN7KL=;1Y0KA"T*("
M';+K'9T#,YZ/>U.\>NJFV5">FSTC_4-9=J]"+,]@(/Z2.>+8]S"'@9,4]RK6
MI;\"-C]5^W_)L^X54AYF.=5NG3F`>I9K$15EALHPRQDNZX,D!1V2>^)@<>[!
MWHBT]%Q4!$JS,(I:37C*7"2;P0L=TDDLM"+Q?PG>:!QDE\9!^S#S>DZMR,=>
M2-(8!Z#OO.J&37*?&;!'7.G)FBB;D#A-^/,&#_?=?+87OKCQ*9(.WF`F#&QM
MZ<^XBWT47$^1+2C#O?4AE@96R-N6W><$SLRK7UW@%9_\?9G%P\.+Z/+*]L8+
MPM-.LGK(1@.9=@G,L2>J>V5O%><FF6XQOISK,,IYH0!,2@&ZZ(6<<UL)*G,8
MDTBF%Z"YS$Z7YT],TSYE^9"*8F6%18$K&X_DF:O`U*<J^P<T:/E%8JW(U5)Z
MRR"]/24OQ`=\CI>-B^J'B0SQ*E967Z)0UT!+*FEXC]FR4N:*23XG*\Q":[=<
MHDZ>**VR3D1EYJIRWM!\1&%%KJ_RLW-P:=.\9KL0+<U'*B][BG6E:&>6)%9H
MBAQJ2&FK4U']R0N1`5D?F+WXW0]#D26)?5[@#*G!9Z71`*L'V*#%`=K)D+UP
M,Q:&@H5)TJ@XDM<B881.%L;">\U)-"=Y3RP(5T&:^%8\#5BP4?<DN6`IIQ7C
M5\EMS3PU85)*41`1EG,/OG-<0<[^1.]!\!,H7`OVY8EB)7&[%L-O9;OY8TD7
M&BL7LTDS(8LZ;6FBY(S/Z2J\0"CF3\ZKRQ3K(R4SDQ`(2SD[+>#V(+R'PC`>
MTF)=F,OD9H93`6A9&$A=QJ&-P:/U*"WYT_$AS:8VGAB:/NVS<MIG'&Q?ZX\F
MVK@_*>!Q.2J09IK>6FE'+_?7-Z#/X52\"SV/=6TP-M>7;#"X?*12Q/(23;="
ME41%WD1"-^7-BJ+`N8WE'4MYS3P3(FE4PB0%7/BJXQ=6GWYU=6W#J_#\7G=8
M#?VTEUC;L$4:^2T[XI'=SQIUZM[5%XRPYIR1H=;\NT"Q_"O"6>'&/.#:P=>O
M6B,`K2&TXY+ZV?E*<KKCE.(!1N$,=QE/IGV*T[ZAD'2U]SRWXMLL-&VFG01^
M+X$_WEWV-@M-FVDG@2>$)X$G@2>$/\O]J:&YY0+`&A,&)2:T+7_AGQN!W*=)
M3AIYW'8182L#+P\]=>.H@AV@753D<?D/6\.WK9*)1J#S_+B(D_![>A"_U^^W
M5#-</M5>CK\PM-%XJDVFPSHE/8G.[L8\=56V(\,@Y"'DN23'IP`[XXEY<M1I
MJ7H2RA#*$,H\W;_I:Y/12.L/ZS)^7,B]:9MXGW8)1PC7`A$@A%.2XR\,?:R-
M!T<.UA&^U?-KKP#A'OD/MP8(VP"%1//I:)Z>/PO+=3*::":![A2CB682Z$XQ
MFF@F@6X?H^E8P7$N7Z9W#&_2.X;)E4(Z8G#L`)5:0Z(8T);#6F-M,AEJ@_%4
MK2B06A)$RJWLD$BYMRBWH8WU$=ZO)N4FY2;E[I9RC[3A2-<&@[J:9Z3<I-RD
MW"U5;D,;]?O:=#*\>N6F/=,VQ*@Z1C,%,(GF3M%,`DTT=XIF$FBBN5,TDT"W
M?L^TO1ND[[/<J6FF419R.ZE(LB-!9NMEI6,T$Y`0S9VBF02::.X4S2301'.G
M:":![M".QU'6+M/SK5T^EPH7G/XP)\GSV8&C=9N\-[1D)MTAW3F(,\9XJ`W-
M,6D0:1!I$%D?TATE:2;=:>>47F1C;&NBYK:M-_]*:P">?JFI6H+KAN/8GA%=
M*75HB'"-1]1Z_-O1WG:0/!UFME032*-5&A%I=*U&&]K`N/A=@[9H`VFU2B,B
MK28[31I-&DT:?14:?9'=\4YE0WJ7'/'-&9Y_HAQ)=!F;+F-3CB3*M$#*?1W*
M;8!R][6!,2#E)N4FY>Z6<E..)%)N4NZ.*G<?JP!J1Z\VW4+EOLBA#E5U1MFC
M-QVCF2[]$,V=HID$FFCN%,TDT$1SIV@F@6[]3FI[MTW_Y!%S/-M?<O;"]</P
M)5OQ0.Z/4H:D5M%,,$(T=XIF$FBBN5,TDT`3S9VBF02Z]?L=IS\#>L9+K+(B
M)IWJ//;V<=L6M3O:DP\]/\D&*^UMUW/\A=[31]W=UGY)AU8(=0AU5.,X@,[I
M[P"W5#<)8PAC"&..XME</M%`N^_OO:1U&Z$;H9N*',=UFV+'D=LFV?N@VX5/
M,*B+@T0SA?);SVBBF02Z4XPFFDF@.\5HHID$NGV,IM,#Q\H@18$H"D11($I%
MCM,!`D(=0AU"'3I`H(IN$L80QA#&',.SH?,#='Z`P(W`K9/@1N<'+G5^(/UB
M@>35OI=\JV),+2/R<=X&['O9V.[F3LUGR3S\_,J)H#/[A\,Y+[[*U/&O;GUW
MEG3YB8?<"NP%L[P9>\?ON>NOEC`(]M8/=]7/.QN'_S<.(V?^J*8P?UEP8-9R
M97F/C']=<2^$=X(B6V<%MMJ"K5:(:2KB(."S'OM4]VS6FNU[H1-&;!4X,"B@
MC/ES!N*`O[(YYZ'&@+QX;ME1'`!*R%XT%EHN/(X_AQ%PZ.;6"OD,?EQBNU;D
M^)[H,^"N%<$/*QZ$ON=Q-WT?FV8KRYFQR!=$Q&XDRBKB6WX<A<Z,LY`']T`*
M$.??P_<@9',_8*X%=L.*_."Q."2-N?S.<DM\@C:1Y#FP&)@2<=?E,`QX"!H$
MBJ)'_!!R.\[H]:,%#XIM`/G8!!`)OT!_(0B-5NXWXJ%X!M_GWL+R;"YX#(R,
M\@F4GLK$-,8_A-CM++9ARN`=9P8<"GN[]2$7[G,!AF+J=`;,^HSY7&[>"&'^
M:#V*>7R-!3_OQ)P2:C5`K7]QCP>6ZSYJ#/Z+*KL,41E$KIP$*%:2MP`$`%9N
MC/Z'!!+FKX0RWHDBJQI[2,JM:JC/4>#8B";R2?F(4#OY!VNU"KCM2/01HX1?
M`\Z6W`ICP$-F1:B13L#F%OP'_*28,W@4M=2"CF9A04EE\PR54V.2Z.115/>E
M0#4O7MX"7,#8Y.OP,W2!72+RX#.N!&Y!-6#(/;S;8Y\+C"@CIFS%"<-8/N_Y
MW@U?KES_$>$2P2^!1(0FF'8Q*.@.AHVNM!@A=P2&(:7%84HPVGS=KWUT<[I@
M.A:.O0#P"X!(MO1%U]8,S<:,1SQ8.A[Z3SV&EBM!T74@KA*#\B`<3U@)).3.
M]X$A(2BH5F_X8`AW4N;$3]8,R`";!C8"-RDS,'?D]*&QP>I1EI0D^"=%:[0)
M8B)"1'AX2XAE,NN>!09PDX^):9HUP&_R&'=[C+8`7-OV8T](S,?`]^"S3>C;
M%'U_]=AOL<>9J1N&)F3UE]>?W[!X)05>8%W.W[L8%`'8BU+^Q5\Y-C--70,W
M)G(B%QY/`='4?T`_)N`+T"74JE]%*K3L9^,'K>0LK5!9O4C"&NB,77I9YE%#
ME``4R4@(^#^Q$PB?%#TF<"X++<%'$+K*=K1$K9<KWQ-2`OUY>;8VA(3-!Z2C
M5]T<X,F'M[]J*9(";E@LA(&Y`CQ@B+$?AV7HJ&H(VT',>9`.KG`SX<?L/?#Y
M7L/*&UDDK64^;@F'@AVS(A,2+`)O/$.B.4"N!T;/+30L?@`X=:TP=.:.G5B7
M&0IN^D!BJ/*GH">!SS!T87HR#B+J@ZDXA,O8%O:2T(\P69YS^,SG<["/R)E;
M#@KBH02!\)K2B%BSQ"$0PUU[U?.CDGE=6-"*Q=#P!L@1!_AI9URK<L1S[JW\
MT)$=!8G%"LLVX0"$/P5<;`0\KQ6NQ.!2_0,R;-='+T^Z2?]Z_?IC)I._@N0%
MGB45C?V23?DGOO(#T>YG6'O.T/<2RO_K+Y\^@\_W**G`WR4T3DR]$AE?`Q6S
M1*]\L%X+!YP3%+<ED/D+.E;_(QRK/Z0?*F@6,9&,:"!%*+ML!$#CW[W/O7P0
M2%!CJ"UX<LN\0_3X<+32O:H"#:EO*>-WH+)@?DU7TC_+QQ84QW;+HP?.O?+8
M:KJN`8?$CWL$9U``A5QX6X'K`%AG>)'`PPJ=TBA!GI;#"3F,%0YCR<:1A]@D
MJBC\$5R68]0/Y!-DTO%AW;1$F!7J+>*'T*/0L346:T7I!QT)RSY$(3J7+I*T
M)!2X*Q8)'3=8QPE%#C?]FQ!H@26YWT!-`3+O'?#A8-F:H6*EDJ+VVE:X8'/7
M?]BELMN^_?A]'-[<6=;JU6>0#T&S%^7KG(^P(+4!6K^`O+Q!V?CYVV]^3-_X
MF`0K/[KXCC=[#W`J.)<]+=Q2^/*)SW]Z]E9^_L_HC_?_Z>LW8%UOT+@^^SD1
MU[T58:>85@C^L26W1O\'O=P?JOJ4LD[(4\:WTV+$P8VIP&?97C7;TKT"#!HE
M:P_?!;T0L>](NG%]6#Q*5TYN^L#"'2-D?4/\6>\=C_7[<&MMM[[Y7,G7,2C!
M@^(E``QR,9N[;@A0`^/_Z9G^3'Q/]E+%]V3K=:)_]ZQD$O?=-B[<5*B]?#`>
MY9VH5K)[.^7&60FOP9%\)$\8",ZS[:-(P(]F-JKM)>SK=]J/(OD;HGM:-C8Y
MY(`XD?,;`"/_@LAQK-,/%6+F^0^!M?KIF?SW69TSW'(Q)'VZ+GU*C6Q!IXRR
M3NFD4[M$\527`H5=;K$G^#NW0KX`;N*J*O#O913GF`)TJ7NM1T'8\UQL?7XX
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MT;Q70LD6!.9+U^&RT+R&Z2].[P`,.@5AC;+I'G-,QSEC>GBBVF..I3\=:<9@
M<`G<.D<&YU,X`*0]K=>>;[\YUFB&!AC_P7G6_(KI3\GLIU^J4QWO9:3S,9WY
M`OPI(^4BT:L=X-4G3#;C5MZ!8C-Y$EQD`W2^LB4TM0@9IE6<K=^%#_@<,\^F
M>;E@L%:>A*8Z1<6"6[-_8BN(,.OM@Q,M@)#7'OPO`&W2V!^.O7#N+*\R_\&[
MYI054WE@EL6B>X.],DLD^;KU_;_S[)#/1]ID:FHBT=)S0S-U72LD>13ITEP_
M%*DTG@^UT=14X]K_.;6NQ4-[5XAO93D\YTF:T.WR)!QDO'#*'JP01$.?:(8^
M$G]];DQT31^/A*2L9$XG]W&[8)2_Y2E4=B=$*:9/R;-L?9B_+61;_2134XMD
MY"(CJ\CZFR3]S3.Q')I;I?ICG;E0+%&0^+IYEW:X(]W*9Y$*7&9/+K*:LC(U
M4#L)V@"F`,L?G17_BGF.P,7@<>38I<S$M[X5S&36.]#4R`\*29#13J')$(G.
MD@1ZV"83<X-I.S&#W3UGJ#SL!?Z<-FWB9?'L2?P]^\7XX662N7&%KZ%V6V$8
M+Z&#V\>$VB0MVP<@"%.^0%,CMN3!'7P6EN3S@L_G#G=G/?8Z3$T?9GQ+/\N'
MA4T*.'O`_QC:8#+5^L-^DA8ZRXV<9HG'O'W(MABS&>>#12IEPC>9-C1/U"RR
M#\MTU&*8@K0$DC`!E4APS(JIJ'=EF%Y:C^R6RW31,F\<&E,?8#'-W+QFYS&I
ME,7"^#9T9HZ%6>SEU">OW8BD6TE.KHIQX1!<-TE69W/HTAP"M.HZ\!7^GN20
M7L5!&%LB;^JZ#'S,&TE2-D>8?"_)EY7^J>"?R*'QDG\BQR;2`J%M0-K18?*!
M[:^3+-8BL3=/N5A.X"UF0:OGJH8,P!1E(C=?,FDX#YB-*TD>G8QT789?ES)Y
MIZ*[R0'$=<N!Z;7!EECHM8!BW,Q$;5N@0R1V#J7,)7F_[Y-DDU9"-RB\$Z6#
M`,AQ`%%$0NTDN:RUPKQWA;RK&E9GF/$Y`,0L;347U74"D]32,J&E)?))8B;#
M3)S>"!C`I&DB4WG"#I'TTL_2<<NTK?PK#VPGQ$2LCLTUD8=<N(CPC(9&WI$)
MSZ0^BN1K(!UR&/A,PGO?D^EJ,_65?1:3N%NVS=TD?5KZ5-H;LBY)<HX)HU!F
M$!I3/-AT37,8Z)NXYS'8$P9R9NY=7J%)L06E[<D'C_TATNV9@J/Z6*M=:U39
MDY58Z<QJW\$6&]N4<8U-R=Q*G$Z9UW4.2(3R:VI#7:!:`;%MF5%5ZAL\4T3=
M1>#'=PL4Q(26$H1KF$D?EE.NS%&X]ML6%,JT&M=%L`!"!$A_6R](4%&B(/:<
MM*2)T*5BK92T9("?7)<*,/FL+#^29OS7UBQ\L4[*FDW!G[&OS*PX,E-BR62G
MDPHVN^0LP(#_Q'6ML-M26M(4_D7<R*UFJH8E?2O.,J93S2!(=)@FA\Y\0KL:
MS^#+NW30,HM<8F`YSI]@5P#3SC$I*Z:Q3C-B.P$\&/P-B]52%8,JV2W)46+V
M!/#AASQ];");5^A'?$@(ON4BMW<B!2+IG8^U'^Y!O#`%NFP\E'G#B^Z<&(2<
MO;NT&H@T,^A@>"*O*/!C'B5$Y;4VMAH#2]@"TYQH9G^ZERT8[V<+:#GR81T2
M#%T:D/T7'X9>8RA*1B)[:@\CT4=Q)2/Q9".Q']"79JI30']2W`MQ_?`4Y#/[
MPBG:!_=*4T6XUZP>07FMYV6:5A*MPC*Y'$5_<,"HVF+O`$08:QK=>=!'627*
M854LVI3T(;0Q2++1XU*18R&_\LM9G22Q9G<`/3#A?+%<%:QJ(V[-M+K*3@6`
M22HP88<9K3,&ZS>0^D<I]?(5<?8Q7<E)!3BX(H:*(<_UN+X:U3Y.L+55S-P.
MYLP5A5]R&2E4VQ!Q!]>ME)?$,(6.J)T`_Q&@)(U)6>*X!8YP6G4A2`NZ9489
MBSQD!=6*&)W"*8O#=#?K#6X=WWRVP<]`8R_:O$&+A0\L_1EW)0'EYT2D,K5C
M81YYV;Z7D6YE:`)[K3!)=AV^.E0PGI9%>JH7*OCN+]9NLS32?;-YG>#M]ZW;
MH^A5GZX7V/8\#;'EW.V9]J1V#JS)4$RSF&MXM+U">9-DPR655TP@ZABYO8/4
M@`2\D+W[#P&?^??WB*/YUXU4WT>K;=[@8,X%3^2>4E0[I'6#DM8-2.OJM.ZS
M\Y5T[J2"6G$L_I3>TEDM^Y6ARD;=`$*5FDP2>&*+P(%4AU3G`-6INS]&JG.5
MJF,6XS.D+F1I2%U(7<BZG'W5ELG44RXSBX5=B[=YWI=W\X\I.ZU8P9[I<N03
MJ)U64WO2G$>]<?_(.0_.R^^CB8G2Q+60IQ<0YAN29*4EN>3?;=L$/RD@'Q]"
M32-GSTW^\;G9,TT221+)LXNDWIN8[(8]AW^/G1%,20'<R^7?(Y]A^UU^O'F`
MZ0F3P\@AN?T*DWT!E^G8"<_.R_7ONFJ62(#)Y^^&)%_$P:JG_.CX^50((OGK
MH/Q=AU10H'V'UWWONU;DN$[T2&ZWPF1?(NP^&;0:(<CQ5HML<KS)\5'!\3F?
MXPT(^AV[8<9D<A6^%@GB?I2;>A_%P]0'5R$>%`"O9M\G)_R;S0..MY%!V'@8
MX2UV3F%PE='L`LZ,V9M,6HT3Y)"K138YY.0'J>`'G<\A!P@UT.7J]X;DDI,H
M7E(4002G4A1'_:L018K$[XC$N\X\RSE]);Y_W:W-+=Y(]0S+IY2<WW'.*IE"
M[YA3VPK-;[.$DF=/GGTG)+FQ.]6FNXJRO6&2F_2&C1E!+`FF,H)IZ%=O^RGH
MO\/KG_O!G#M1'%#`7VD,I7/O%.TG`:8U09<DN>,AUNLXX4SR1U*QP^].OYRH
M;/;NYEK@D!<+#,@Z%2$KE@\H%;*0?\HJ3Q9J3&"A@8WZBX$LV,NLNX#+&MQ:
M6G9+%*Y(2PZFQ36R.AE9^X&%PV<X-.S<"?,"%UC/(ZV/L=&1K"J0%;_(*4M*
M$T%G.5%L8=WSK%1,4CWQ*>4#GBY%F4:*B@,RW596;*!!\0%#WPXQ^ZN?7,*F
M\!#YJ])J->E(]/[*F)1>*PSGK("P9?VX@]RZR;Q4)8#F[86/RUO?U5C(`V>^
ME6^3?AW?&K-Q.^J=TA8T:&_]'6>YY#,'RY0DJ/"$--O[&QG29])GTN=CZC/6
MRUQ8[CPS\IF"N[)LGO0+EI8CJJLE;@.>-MX6D2;E)^4GY5=>^?^)K0`D/Z]W
ME^DU6752;%+LUBJVY7FQ*,%*>DUZ37K=&;U&;SU:.,&,;:S#A;,N'77YK80`
M#S[I/^D_Z7\']%^LUC?5/]D02/4__;-0?P_C_K+B[P\")P@$"`0(!-H+`BQ9
MN=?A0!ZTRS"@L`BH*U]_$OV_\GWA=W&0%G'?7G9=$\^D6\AID?A^W]1TW<SN
M=44^X\N5ZS]RZ!J1W(:_QFYD)?NOPO5;JT/_?#`8]D9C8WW;N:JH/"L7E2\@
M4W$@UI*S%>BE/\/V9;'X*NH'YA"HUZNIKZ.V/YAJXZ%^`+7[[S`7]%M)Z6EJ
M&5JJ'!\\]IL%ZY3@D1F3*C4`01.:DAY4"(6\F1-M/.[+XQ69;"VX.V.W\`I;
M\N4M;E7(,PUO?"L08OK.";@=^0!_.5?S3[]ZJ$H>/(%RE8$H")8S=VQQ;*-,
M&O`SIXU_73F!/-LQ0S!.^BY3",0E5TTJ*?@BVH%&\80%<T*AV@YX2W@@8XV0
MAX5C+_!X2!C?AJ#\-L<7L$LG#&/Q'4BP!/^+1##K`;A1V?UKP!.P&0@FY8'B
MR94X2@9:UE58BH:R253M6P[*.QUKX]%88W&8HD59<?%=R:AUA*GC2:'+!RM<
MAP5YND1@@.59=^(D"K.`"4O)]0..G=3?'\G?E]YL0Q=V4O1@#_57:V\];+OK
M+)S;*BK.X]TT*L=5>6ZN2/AEZE?H/7UZGJLI!TQ2V^S8,8LT;(A&(SU6DBVU
M9TEWNMYG!H76RMLQTA-W2.",R;AGG$SH".2DT(DCM21N^<UJ`KE3<+<F\2-)
MWAUFZM)KTR(=$->J?/.,<87V1S)>PU)UN<25/JP;RTM26'+?.Y'#Q6T!^'4M
M+(91KN2Z@8"3)'CVCMMRG=\WM"0$Y3SQOL$I>+A_.',-E?9::98W2PY<:E8@
MP]HUIJ&Y!5#/4#R[87!LW]NXRI?]WC&4NG185&;^\`CEUGQJ^YO8+A>E)T4C
M13M8T?X2/?#]CB80+ZM]K7L>6'=U"P%BY4$^1A;+)JX^F:L?MVP'D$TEFTHV
M]:@VM;#)2Y;A:-&W['@5,?/)S'P+?PPL.XHME]CY=';^CJG`3VA>NV)SC*+-
MZ9/-.<;:X^XNX'?UVQ"DQWLP\U=`1<<+'9N8^71F_H\X0D:+CLN5VABV/.GN
M&\L51RLE&R>F8?RPO@U5>V;L:8;V3`DWC[XH52JGW7:R+U&13QN.#*W?-Z\A
MHR`)^Y$.IK9+QHV>.2+Q;BDFMI3L"XCY-;.[*SK:H)J8\F-HRU0<[5QQQY88
M_TIN3M(B0E'!5<[RC`=]6D*0J%^#J.N]2;MKVERSO+24;%I+D`-+:PFEIX*V
M*ZK9EYY8I-5$2\'P`K;G!3.'0VTZ'+0:.%[2,H)D?,LR8M!N\;YF>6DIV;2,
M(-^5EA%*3\5)MR0:G9AMX1KC%UE^'&L-!C(+WKF6&^V]9K[]=+%2.M'<J#4>
MU$E7+T-]JHV,[7G;C@=79Q/!DZUG2(DN/BCEE.CXRZU1G4)V13]/[FIW9R0*
MD[UUC=:=&6C?2#JJ[TT7=RT;5HLGC':2JMG7X.*+47<R@W:9VFSV3D.WJ0W[
M4TV?&M<05R)A5XCLB]R`H=.9K967TY#][3==%'2%&:Z4UZOR,&C#2='5!MV!
MH?6$*H*KG.5)J^1=`6B0J"M$]D56$R-:-;=57EI*-JTER(&EM8324T$[%]7L
MN]SY-,6E6DDI5LX,O9CHHH!UFQ&$+L.0A&\[G36D_%QME9>6DDWK"7)B:3VA
M]%2<=&\B;:EKEV'.?.%>M=-SS8="A_=/MF`QSKE@H0LPI$/=TZ$S+K&ZHI]T
M::$+"P6Z`*/H2#JJ[W0!1K61G70;J6;9-VC[LJ_J=LQOL<=97Q<W8PQVP_PX
M"B/+F]77"SSMXG!P:<EZFF,+Y+.9']^ZO$N>;?6HVN3:FMIX8FCZM*^$?]LB
M(2=]/>ZHCE451PTU-7K]R64\D!;)7<LHWZ>^=4'B=GE&:I9T/$U[(U2+1VX%
M83-S<S27:C]-N;QJD'4AZU(_FD'?T(;ZM1J8L^QLMFB10D>\U(FQ*DQW:TXN
MD+0K1#9)^\6'0623L'>2W03E)-U=@G+:>SO)WEOQ%RX/:%JPV*9=N!;$76@7
MKN$NG#F=:L9$C33++1)RTE>*DV[;A1M>Z"!UB^2N9933+MR3VQOVID/:A2/K
M0M;E:;MPNJD-!Q<J57-QT2LM=M,ON"[;!(YZU!4C4Q-S=W&AQ6/[LN#,7T6.
M[X6E8ZWP3VF!;<'/\_)B7&-6('Z8^Z[K/X2O#N7.46,2>TW)+D]@\Z&='X_4
ME5`?9G,7O1L;9N2G9_HS\3U1?O$]<X3T`B(>Y%,4`E7[^UL5!]_/'5+H[`G_
MDSCVIR!<?'W@0AUO?7=VQ)$,^D7!&S>]85BO<H>#S.8RX5Q\W-Z!?.B#1/*<
MYQ]R2#^A>Z^0^IQ0"KNJ3Q/2I\;Z]#YWB0[6IXJMH2/'.JYYRCY9WAW/)\R?
M[S-/U\2H-+\)\:>:/Q\#QSY<R<EH=LUH$@(W5)P_8ZPD1[!2S1V?//)+J^0V
M`2E(Y.5EY2_Q&I]M%Q16J4SJC.+U/0^LNT/\#'7&\`1G29U!G-JCZ8:=-YOG
MY;H^V]X,D:[7NA^.=5?!GD]\:3E>?=H4XM!;>""P["BV7/:[,Z<%*"U`:0%*
M"]#CN[)/"F$3N!"X7"FXD`=,'O!E`@E7P1_:=3E*#$.G&`8A."'X26,8Q*"=
M(8P<RYX4RZ@X,9.!VU,N4Y__\O[SXUQZ4.AJZV9]!'W*;MB@-QPWFN^VW?H_
MSF+Q[#D7CDZVXLQNB;;4#I4=TIJIC::8P'E`FK<QBG:B>?5=$?F4DO>)C)[9
M/\6><OL!L^2IC7J#)/GM52IC=V95<69?J1DT]:EF3'4R@Z1Y:MKU2RN<T>N;
MI!V;,=,VQFI2CT(?E3R*8\=5]LB>W1V-/=^%WP.4>-`;3M@-F_;TX45TN4NW
MH5MJ#]6J&WL<)6Q-V=C&C-C1V-/>KB1E,M6FTRFAPO%T26F[=;#*M"Z^U$B5
MAKUI31#JJ#&I*S0C)1>VWS-')PUBM19*KE`RR,$@!X,<#$(%0H4K1H7&CM=5
M8T+G3V?NX:IO^)#[.^S=.1UV\AV_"R2.O8C^JS^P&I]@T"V?X((U1D[G%*A9
M8D1AK\#4QA,\EJ:$:]`>:&A<Q:`E`<EF>M/-B*31ZT_.'Y&\"FNR=JZN?]IS
M=:U%DVL4#7(TKLW12$JGD:-!T'"YRC;7C@A8:HTT\,E1P$85RSH2!LS+D!TG
M#)A^J2Y"=(IO]6N7XQ7_.7^/QQ:&P\L-Z2TJ-]1@=DH:O<_'W0U2Z:`61*C5
MWJ'J3EXK*AW4T`)3Z:`32F%7]8E*!S77)RH=I/J44>F@AHRB)':4Q(Z,YAXC
M(01NICB4N7D;=ZATT''!I:65@YZ4*^/T4JH&%7LE^=P':=09HAI4-,H6>DBY
M#W6&J`85S9QNXO0YW?=3V-]NN+P*5]&Z%G=1#2I.9HAI#M6R\32%*D_AGI77
M:!:5G,6#JL/MXZ10R.`:G#.*1U(\DBK)J:62!"[7ICY4A^AXJXXK9`]MPM,F
M/%62(P17F#^$X,UB,L2@G>&.',NHDIQHK_LU"JB2'!7R4(#JEFC+TXX%5=RD
M-TUM/*(2.INC:!^:&SUCVGUX,6OH7LM9/1I2X;4V32M9C=98#0,L1E\;7BC1
MF[K"0)JGA!E40>&,7M\@[=@,,;8QM"';PYS75'CMV!I+A=>N))=$2^TA54!0
M2!\52D%(=5':47A-"=TIE,NX+B3=XW9(G1LWH.)CG10-,K)D9'<:V8EFF`,R
MLH0*A`J$"A7>%&'"]1[HV^-\$?B0.A4?.]>N5ZNR<W<V[3@E_F^-!K6W`H!"
M7H&I]0U3&P^5B,FU!QJNK_B8T>N/KQ)'=P;C&M7=&HYR6J@`5^>$A(PM&=LF
M!\`F0T,;&Y<YL$_0</&1*`$-5("K-U0B$J:V!E(!KH(9&/8F+2_`U?S;C]_'
MX<V=9:U>O7-"V_7#..`?YF_]Y8I[H85E&SYQUXKX[*T?1N'GA17P-U;(9Q^M
MQR5,5/@%)NX-SO'/WW[SH\6]5Y\C^/(Q#NP%//:7%016\2EF`^_@RR<^_^G9
M6_GY/Z,_WO^GK]_\%GLWIFX8SWY.9*L@9G425]`WQ6I\B:^;=SU'O5Q=JSX)
M]K&4?RQEX/[UO6HYD0_T-F#?R\8JF]O.\Z-6#CNVFG_PV&^Q^\C,M%Q:M.`,
MA=KR'IG`%SYCCA?YS,(_+WV/K3'^]5W`.4HX(&2T@,="P'*7PTOW/(S\H,=>
MAVQE!1'69HL63LBL](UR;TX8QM#90SJ1T.<J[62D:R-]Q$+4*E'DS9:TA((6
M>!(;`D;8DA+K3K3N!\R!AE8\6#H1:":SPA!F)*R4+"PRE_6]L.XYL[RTNART
MC7DAL./GL.(W1>4YB[G.7/PMP<`>*[6!PX<^@<K?+"^V@D=F""8;2=VZE1-P
M]HX#R;<\8'WYXW"7U#L>T`&C#0L]/<`LL3O\+,:8<1L'\$_L1(\LL&`0978#
M7UD4<$0L_/L27[38#(BR\>4Y#S#OGPU@5LLNF(O83>85B`("0LM&)!2-6^RY
M#N(7,0Z-09LP2Y(:(1%KA?I@]/"IK_>3UHK#"\2-=V1EGLJ^U\3"D-+7*WTB
MDN8D9?]3%3]:P%=X`\8=Q2@$EIMA0+7&'0$7#&T`(QB.S1IHV*%-[RU[D38,
M_X;%:I+Y4W/`$2`PB#CW&#0=+0H%FJR(/3=[NHXH(XGHL;^X!)`R&[U\@#B`
M,,9.(S]OZF'A(#G)R^+AF=":KS!8[TZH/6":`R("O,WX@>3AA.=P@-,1QK>H
M*Y%CN0#O^&9H+0N#`LJ6(>I\=:/0)U\!>0LK$D\(N!)>#IL!9$`?KLMN\>\1
M!^D&.A_\A#=E&,Q[7%@SP02@Z6;FN$)&JB9%0NTJ\",NP60.(`7.U@_,F6\*
M1LA";L>!$SGP$8BU$JC.ID.,H:H?D#B7A\@`JY(.,:V5!*9-:U6_`H55?T[X
M4?73`IP>'H25;R5L!M;;"PY07?70S'^H'$!1MDKT,=<'DU'U8XK[M?/28_\-
M[][S8-.8I*J/-HC-71_$LF@U!P45@6?1O_62"4[P([6R^=17JB^@UVMXT&6C
MW=#E^?!;L!/`I)B#$MR)=[&]A.-(S+T3(I5HM0-^$_*H0.NFM8)NQ6@K:7\7
M\]1;*3158)8<3`I)KF/=.BX:<`0GL`Y_\]E-Y-^(3U%"D>VB6S-W)%C@6CI!
MWY7ES`2GK943P?=0^`Y.Q&R."Q-\&A<98%N3`24C%2@*K@!(PCVH/&!11D=O
MNWN]:2AS(WH:*]PVTUOR$(7?!A.(403AN*5\3K`,9L4)&%A09RG<M+D%7^\M
M%X3(EW.&MLZ)A`PC+&LLL2'0UO.Q,=)T,$R9.0#O"Q^4Q@3UM;KI(D%6)HI@
M`&"=6X"V1&H2O9-_GYC&^`=`Y`C:%$2!(/F@]9:LW0Q#XFAQ"\0$?.4'$7J:
M\)CCSZH=A:A*XXO<F&]1F^?@)$P,S1CT4_9`I^`K<.DN>\`(.T"-0(Z4&WT^
M'@WQ16G2"K\)=81W8H2+&%<\@H`W(@+TV09$!P;CH])D+OT9=]/>P>[<HOYI
MV!\Z0!J+5_!0[/G`EN!>%&)VO%6<V';Y%N(8QW=A7)&+)IMY/DN``.;>TF!8
MX%X'*2TI((*6SP"P77\E%D-@*W`9%"]EI4DYLL(?8#0PI-O'4AL(V?`$]`;B
M+#!%3(`HJ2WZ0YH/**U]$OU_2F'KR5GJ6H]'6\YI7>!<8,W$589#(W_5Z+B9
MXL,X=?K94H1624O4*,#[-K<O^T1X.\R1=[CZ.3C:W4UEZL@P"!,::<`GGG@^
M!`ME6-@I=5?'%>&UYVP9%0(F(A!^[3AZJGL`6QW,70"UL4=X8TRV2IWX^4QB
M]];UQ6I+;OS(&,PIQ>8\QVA.86SWGF9EH.7Y<6:T86ZG:N[(IY1DC]'K3T\J
M\V<Y?WEDD2<])3U5C#UF3Y]T7$_W\E_VR$C67?_E_=<5MS'N#+0[0-T,-YK(
MA5%0MJ\0L?1SPE7;K-UWI*2DI`K((2GID924@B\'.R_%Z,N][UJ1W&TG@"2`
MO#P&&,:X5Q=:)I`D3X8451$Y-/1!;T2*>@%OAD(QT-XG)_R;S>6E!3PS'$84
MBR%P5$7W]9YYUNAQE[&1]/3R-'=83\^Z&]ME/:6(S#IWO_VF<4Q&7$9^(2XB
MOR1L)&Q40/>-[N^`D_I<GN:NJH^.V76ZK3XEBY]^J<[^4S^%2E_XW,F(+F65
M:'PONV$N&:\FG\01TDGD-UN+^20F@X'6GQJ'99,HW.T5%T0=STG2+QR<5F)L
M#HN))8H]/#V=@KCU+FY]XVW?\R=7@,%5$ER17J&45&$S*4_A\J_*N1-*.0QD
MVJ52^I5R)A)Y3WLF[@!;Q0P?50D^0@<4U0*!$FD]BMD[DLNZQ?=?."_%WTJR
MLY%\09+A0L,>7A'7X+7DO;4)P.<$5V1.@>?@]NGBZ>SQM=PA8GA)WA`Q.J^0
MMJ#(;0S.2LW`AE_'=X!_S)"YJLR">&`BA!?._<M-04ANI">JF%.>$9)R&=K/
M<N)`X[U&I:SW@<<L]0.H1GZI7G9?F_4AS;*2S0)>_+?8G7\#?(/G9WB5'!H,
MT[10I7GV?)@7:#Y(\SR$ZXD>A(385AR*O!!`WBW/DD+)?%"522`^P[S\"7+"
M)BQCL_$#^YS?ZW]_#_^M2=*TU9=IMPV\'FM?-$5.P7"5LT?DHEPT$YB'X."L
M%N.A-IT.U<YJL3V7Q5K>L[UR64PF6M^L3F0!NEJ;QV(T&6NCL5E)T7IN"X=2
M6^R9VN(:H:M1.'7[1]4S<VPO?E<8[2'+\,:-JQ%O.?7=^(XD1,[S9>SC^G28
M(7@O_@`OL,NJU)%A$"(T4H!2M@P"A0P4<J$CIHB'<%60,P66!_D77"=<.X@J
M=C;@26<!SL/8BE09="S@H%E^&K2<OV;->2[@'X4YIY0:O(#?[>U3TE+2TK9K
MZ7.]-QEU6TT5NYO1`M^E.DT&N2_*B?85`I9^P=/>JINZ[TA%245)13NBHA1S
M.=AOJ<Z00>A(Z'AY=#0,LU<33R:$)">&U%01-=6'O0&IZ=D=&0K`W-4FQR!D
M)&2\/#+BG7L"1O)?2$O5UE*#M)3B,)>-PQ2S8A`L$BQ>'A8-.I5"VD/:<[!3
M,1YW6WM*QC[]4IT2H_FWJKF6`[Z&.VE*CNW+YC7#_"*BO*A=?4>V^GZHP\,#
M"G"?@DE/KMA]A-N"XR/<%CR*BSV9=-7%?F.Y%B8=L"+VCMM\><L#UC?$I>9S
M;K^K97:[N52E`ZS;N'/3;6D_U=Y)=Y'QK_74#=T6D([1W%68,K3!U,#4*=V6
MQE/%2KL+5V]%YIS-I#$;&6B.)CAJ*KZZE'45DL9C;3`^WDFTMJ#.H4[27E>T
M6PA$G[CM6J%(]2>.SRY\=\:#L)"$BV$:J!/X4ZI??F\XC.VI-MHRHNDA(VH]
M%NYH3S[T`IRXB:$9@WXU;R^D$6V+9[S<E7SDG)OP#1U+M7146?>_8S0W]/S4
M(EI91E_"2QMTS4LKQ/U+B4Q/;8*V,U)=#:AR86`L;.;'MR[OD%5MY,'4;"4<
M;V>A.;NOPV64"8//["XJIZM'.E2QEY@\>4=<R6,+KY-#"H_%$*%E1\Y]4B5"
M5,U82W&-^?EEN0O.\"PFD[G_-_:--<P";87)N8@F!QIRUIZ+F2H<;[A`,N3U
M\50L$-M@C5LVC%,G696<2))?*H8WXNL#%^W?^NYL'ZN7;,&&-;P^W=Z7XO+4
MD6&06ARH%N(UL+S[J,4U,>CU/0^LN[H:\,2?7%W?)Y64\K]\%,E.KAUP3Q4F
M%L[8=G%3^BAW&C;*=O.,'];]?_VTA;0I:*K(N83B4TK*JJ'I8UT;C,V.5U^]
M2IK;%G!Y?APA[*JN]GOF6&4U_?8;A3>NVNY4_`L7^;7+&7(;U*2YJU`TTK61
M/E(9C.AR=R<8W54%,GK]KKO<%!ZH9E\:3B);KJ#07B$4W70<ATAW+D\SZ4X[
MI_2DJ_$M!_!;;>!_\8,Y=W"Q[@>,?UTYP5ELO6K;0PW'03=YV@M_.]K;CI&G
M@\R6:@)IM$HC(HTFC:;8QO&//A@ZQ3W4<_2O<.UF:$8?CS],.KZ&(QVZ/,UM
MUJ'MV_K]WN"T9]DN/Z]T)(&.)+1,9#L*1=LX8VKFV-2FHW['T8ATZ/(T=U6'
MC-YHV''UH96[4IL6JFJXLO)[A:B4<R;_],*8:J/)Y&7'T8K4ZO(T=U6MZ`@B
M'5^HXNTYSR>JMJ_3<!RTP]E>V-O1GGSHA3'41D;=6NAT:'D`EJA[G>^TSAD!
MR,5'1`!2"R!&SZC;%KD0>JCN?AU:S+<B'U^KW:^J(Q2E''/LAOEQ%$:6A^,^
M/\8.+BU63\#81ME(U1K2:3)^=@-E^UI_--'&_;HC'&>#VK;H1$>&<;1$PZJ[
MT(VTH"YMQM.DGW"GGN-F?2:.ZX&<LP37VF*E*1JO5C1>+:+;R&B2:)+H%C*:
M8@XGB3D4?^%R@TAD<:?H`T4?KG450-&'ZQP&11\H^D#1!Y6B#^D7A<L<*>W_
M?5GPM,!16-I<JBYQ%/#]*A>UD",[I7#?4DA[%3T:GJ7HD3FB6B*-`/>3Y=T5
MJC^`1NR#OM?$*2J5<<6UB0A/&FK)G['(AT$@4LV>W:=;KA8XUC1N,&Q\`N_Z
MM(PJ@.U@$%4`V^'V\:7E>/NBT#5QZ"T\$%AV%%MNCF>_._,G.'Q'V[^A<CD-
MS:$Y;+8!V;I@VA5<<-N?9MI6/C;-G=6?OJ[U]0ZD4ZGZ]%2GNXV67K8WZ`T-
M49F^KF+TDZWRMK-^9)6O'56,WN"(&4#5-`E$&9G17."U@3G1AL<LL:K.#';+
M-NJ]R?"TMI%6K&0;M^0P[.ECL^L9V&C->GF:.ZM!D\%`ZT^-ZU*AKAGA\9@6
MJ&2$+V>$30H;DPDF$WP@:T;F2)OH72\*T&D3/.SI)XX1TSJ83/"VHB+]TU:)
M4@X_R`23"3ZB"38T4Z^[(]11#>J6!>[WIB8M@LD"7T[^QA2')@M,%OC0%92N
MZ?J5^;#=LL"#WJA/:^"66^`#\JDK#"JC7G]T>DA1_`H4I897%?]KU9)RPY?S
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M=3.SP;BW_6IHD9/_E:8]'O_`)%?W3P?W]'2"VUFO=!Z]=W&`"32B!6>A\Y4M
MX9E%R#A0.5M/*XC/O/67*\M[9$X8QO"$,111]'!A!5QD(K3])30!Q*$@.Q[*
MLL=M5`VP-M%"M)&DI^;XO'S07^$3(;.\69;F,)_ON1^P5>#;G,]$'\_'VFBH
MBX<-752!K.D_X*Z%^64BGUG,ML*%R\.PU'W:68]]*0P.D,!/1S@8:J/Z$2)I
M?+ER_<<EQSGAP;UC<XTMK'N1G9'-+2=`NQMS2?E0FPQT]N*YT1N-F)7D=UGQ
M0';P4@QJ8&CCZ6A;E\#5,'8C["+I,JSO<SC1S+'LLS^MZ%-CMQ86DX4><';^
MB7WD&:*2$(S`$GF>5I@F#OC4Q`J2KE7KV@>/_69YL14\,G-2I54A@!HSM<EP
MK!F#09T$%+6DE.L=1*,*+[/[C?F?JELNJ]SS`>HV_J_'WCD!:#$\/^<"+FP_
MA+X?."8:78%N?@7S&7'WD3WOIZ^0H#Q)4%Z#PKEL5"LEAC::P.)F8AXB)2R]
MA=-(#OK:<'\Y,(<7EX/MOO7>?EG)F8MO0_Y/#)2]O^=%?_P(SMO3/Y[<_>N2
MMSG9Y6UF4\W$7)<EKE+^#I7U8_/N*-IU)O@L$'ELDQN[=?:6?X55M7?'9_ET
M1WFF[=0%K'9C\U=*4,WFCF=YF#^ZC**6H#1M6302@F1%\,VQ7*!0>.#6DK.(
M!\L0\W?C7WS@%33H9F\"R7P5P6]6A(3A,\6&7S@OQ=^PV9N9X\:"9N&\H0\=
MI8.`YKGK+*%I</8T>"UY+W..Y2OXG.LCO@LO&EQ(L`3X=/;XR@G$PIC-H"79
M[M=(+A_$L#UF96MC>"7@/%UC0'NOXSN0(_3BD7>FEK,,K=<+YU[VD@RNL-8+
M8>P.,BXG..L_F5)L/_.VH/$=:OX.O&5X(UHX89'7HBVM2`5STV5_H9DC2^V#
MX[KLEA>F"+USB]WY-\!4(&2&/CM0"BXZS-*Z$'@^3!K0+18*D>5X4I9@_N^=
M4"RTA/C85@Q\<R(<-W06!5ST!"RTV"R+<N3C[>T/?4]#PJ."3`,26NPQ%I>O
M2VZAXS(3DUY>#!;E&"0`O+2^UC?&+`[ETO$-QGMO/MO@#T&?^)I4[J4_XVY!
M6UZCC(#G"(M0;!9^!LZD<00)8.7>-)0SU$[/C_)F<!WKS!!=\K\A9[]*]2U`
M=4GWB[YJI5I_J1AX0:_C%;R=*K>@2JZ`Q=\%TT3E!!P/,!Q6RV)Q;X$U6,I`
MQ:L3.@$[3/)>7D1A>UB]Z@83L[U'(;IYHL.XIOSP>^P)?>()I"(.[&/H.LR3
M=^`KY$)'3!$/X5(C9PJL.0I?8&UP[>?)CG;X>A]+LO<![!MCLE7HQ,]GDKJW
M211>AO3$FNR44M.%^S/M"4@EQ^R/,Z%=O:>C]R:#;E_2.=JYSZM!Q?=?5]S&
M4`70#LM';\8"\$8(&)43[:L$K#.B5=MLW7<7N*AW?:A8<!;9O>]:D8C>$CP2
M/"H``88^[(T((L\.D>0X8B#/"?]F<]R#=##2Q,.(/$>"1E547^^9-2%"0D9R
M'L_D/+I8'/"%N`#SDG"1<%$!Q3=Z^C6%`-<OC.&W'4>=+WR*\$1'3-MV!@=/
M;9<.M*V?-A0^)YXGQ`LI'K/NP!,51TO@>W8<I7!H)MQ^`G'C,D%^]E"<O2L<
M"0L//W$8[CAR&%8?!)0GV'+YSTX%WD+'#WYR"+"WQV&9RWXK'!BO._O],VKG
MC]]_O0U<YQ7^%_[P_P%02P,$%`````@`D(,//^\<,PQE!@``(U8``!0`'`!A
M96XM,C`Q,3`V,S!?8V%L+GAM;%54"0`#;X%)3F^!24YU>`L``00E#@``!#D!
M``#M7-MNVS@0?5]@_\%PGQW%S:)H@F8+-Y>%`6]L..EBWPI:&MM$*5(E*5_^
M?DG%3FQ+HJC$*U%MGI(H,^3,.:.9X<7^]'D5DM8"N,",7K:[)Z?M%E"?!9C.
M+MM?'VX[']N?__S]MT\$T^\3)*"EY*FX;,^EC"X\;[E<GJPFG)PP/O/>GYZ>
M>5O!]J/DQ4K@/>GEV5:VZ_W[]^#>GT.(.I@*B:C_K*6'R=+KGI^?>\E_E:C`
M%R+1'S`?R<2#0KM:N1+ZK\Y6K*,?=;KO.V?=DY4(VAH#S@B,8=I*IK^0ZP@N
MVP*'$=%F)\_F'*:7;014J7>[IQ_.3K7RNWN))(1`Y7!ZBZGR$R,R8@)KDZ\(
M$@)/,03MEI[@Z[B_YP4*@%$4S1$/T8G/0D\+>98C>MIL'Q$_)@D^`V7DGOFP
MDD`#/??C4SWX\:9/`H?Y>S,2317C^XAM)DSXF"(Q24B)16>&4.1I*#T@4FR?
M).!V3KL;;MYM'G_K"0%27,6<*\NV$Q`T`9),^RU;SJO8RBLDYCT:Z!\W/V*\
M0$19(7KR"G&^5J_=/XC$8+#>3O^0^1[?=Q!Q?SN'^C5%^_Z;L9'P1!R&R6@=
MK.C?ZD\Y"TT`;^=E+_&CQ7@`_++]7B6F6"@C6:0-0*3=6@*>S:5*6I53V/-]
M%BMCQ^"#,GQ"X`ZD1=R9U-PGS.SUAJ<_7.)I*.?`;;-"AK#[G&1YN&'B0R$3
MWD%E^`6+16&5J#ZWO+R(U1NIN6DC,SJ=RN<CSB+@<CTBB$I5DW0]BG3$J@1G
MH,"HYC`C9G==3.1_,18L,2$&,IY$'`;^V0WK'&T%<FK!H1Y\NX9()UFA"-ZI
M$G>,^KFYQ4K-07SMW-U@_O&M+II>M0%&$TR4$6!1A#*$Z^K%1VBM6U+[+OQ`
MH=:PS@<]KPD_=-?%LJILY3$$I2(J7Z<Y!.4Y[6)EO0:NUG(2+Z`434:UAC!E
M=OVX%?I86T<1EH@,``D83@B>)8!8T%6@V!#"BMQ_*_`E"[Q=9:\\S(_2@C@0
MSGEQ;$@WKM7OW5ZC3R5P$/(+(([IS+B2*#V$ZYS98V%=Y7_I+'0OF?]]SHC"
M2NC]![DV1%&&</5;1#`%Q7"0V%)T1I,E76N$Y\.=WAS*<-3%['3%PI!1*SI2
MH@WA(NVBBTN(7A#@1RM&"`=]NFG3=HPW%8ABY8:090.#BXN*,4B$*00WB%-5
MRH2J='&HH8;@&J;8QZ;Z;J'<$/IL8'A;8)1LWWLT*%7H"U5K7(J462PYT,@:
MH3>L2-PL]D=I%YO&2I;DJU87Q[C`UJ<J_4"/J/4/33;/7GAM+3U.!9?5TI-6
M'<>(@!C#`F@,YL/E0\GJ,Y\/5#R98,Q^^Y+U%OQL@-,)[\"[XR:]S`/9`9HP
MKF77FUE%=@3DR[J,K,%#AW=$:D\(PP@48JKAO%E%242:;JBE9"N_AP%4F4!4
M%>L%(:982)Z@MC'(=#VC0+/6T,XE(76!H\A_%WNG,0A0B.C+MM?JM20LN>M3
M3)E9KQF$%?A^W.V4S*Q_Q804P^ES:KP'OE#5)^M%-\N[C7B!KPY?2G6G!CQ:
M,F#"J@KL2%>^''M=&UM[$*>!3JV]#CUT,;,?H7EH`!497A;G[<ZOFT[N&&7[
MZ!;7^GR=REM,A*F.AB%]OI_3IZK1BC6\>D$QXB#1RM1KV@Y1ZQM02%.J^;1&
MQL5<I5SD^N+.-3S^[.]X8;?+:CM"LUBUQL4^YU59@?15Z[3/ICJ4H]$LUG+]
M?NMS#84)I%6'NR]76U/UNFZ\ME#.`CFWI=H5=;%J_`^]C-/$&/RM_>1'?U+[
MEK"EZ-,`<_#E"T]^TN-4</*3GK3ZY*=M&'&VP,J3+^NO`H(^[=,%",UVSU<I
MN:@%*C%(Y1?DT#II0Q]8S_\1*XAS/V5HNC=G/TC=[W)),E/7[$K`59R8:^C\
ME+T^0"!N%3AZLV0X?1'A)49I.N-E`'/XR,S53+JY`?6Z3)HU2/7G-=$F.0RG
M`T9G#\##G(^^&$]O[$=Q\<TRT)D^Y"D!F/O)5-_Z&296B9L5<!^+Y]>U*(5F
MZC:<7@MP7+P6O6MV7XA8?[V9RIY6MZ*+=7\B3G/`<7@GI?82F/W=62/@F`6'
M&XJ&,"LU3.5+_^P@>]JZ>$V9SQJDUC?J)82F]@Y*`.;D7D\=*^2?D/!,P%RL
MD+4T\C\AX9F`O:I\/GU;JOKC/U!+`P04````"`"0@P\_$FEM/`0.``!)S```
M%``<`&%E;BTR,#$Q,#8S,%]D968N>&UL550)``-O@4E.;X%)3G5X"P`!!"4.
M```$.0$``.U=;7/;-A+^?C/W'SSN9T66U*1)IKF.8MD9S;F1QG:N=Y\X$+F2
M<*4`%2`=^W[]`92H5Q`$*4B`,OY45P'`??;!R^YB`?SZV_,LOG@"QC$EGRY;
M;ZXN+X"$-,)D\NGRV^-MX_WE;__X^]]^C3'Y<X0X7(CRA'^ZG";)_&.S^?W[
M]S?/(Q:_H6S2;%]==9IYP<M%R8_/'&^5_M[)R[::__[][B&<P@PU,.$)(N&Z
MEFQ&5:_UX<.'9O:OHBC''WE6_XZ&*,D0E,IU45A"_E\C+]:0/S5:[4:G]>:9
M1RNY1)DH67UFLX&WS<4_7DIU(18R&L,]C"^6?WZ[[^]7PR1I1GC67)9IHC@6
M7Y(R?$Q>YO#IDN/9/(;\MRF#<2'$_/M2\K=2YI]D:\T#I!%_`Y$=HQ'!&*5Q
M8E&V_;8M24IG")/C"+IH^B`YLR8:,YB-@-D4<JO=0R2<"F%8F(Z@L0)N44Y5
MZX=(2VC2M3IDE@UF,N4"E36.@(@&6JVK=YVKK)$>#5.!+NF2Z(8D.'GIDS%E
MLVR&NKS8!2>%0A%0@N93)$J]">FLF:'3MG.8B`\)2D"V/1C?8B)F7HSB(>58
M-GT=(\[Q&$-415C#%@\3^S.*Y2K!IP#)'#'QM2DD.$1Q%4F+&[&FT[Y80F?0
MC1-@1-#U!#4UN=^.-1&O$9_>QO0[[Y,(,PB3FB+NMW.8B->4<!KC2'P@6GV&
M;WQG6)?WBBUG,,3BA$G6A^^$S%MHX#D!$LE!LOA5?N/009U96C3<^DXL;1O*
ME!-:-IF-$1]E,UK*&Q.$YDVISR;$"<]_R33<N&HMC9F?EC\'*RT(<-`7?_+\
M*S$:09Q].R@N'%PME.1"XD<T6G<EG;19P:"U2V>7;<LL5I2\M>7B4LE:&S,Z
M,U!7_DE:(NP%91&P3Y>B1LJ%)'0N99;=?;%@?0PI240'O(FS:F)HP43^L?[W
MF'*(/ETF+(6:)'$(WTSH4S,"O.!'_+%+B_@I6/3B>YA@GC!$DJ]HIB*FJ&C0
M/@8U2D.K'DD:P7.:6GL\G4+EUT)NAF(Q[\+S/^%%J_.=LD'G;)2^+WFN]?:)
MM7Z=,KD^W&(NEH?_`&(W).H)*`6*+RH>_'P&NM<(GZN_XZ33W^(8V+609$*9
MOLMOE0S>GH'2U7+G^O[YQ/I^9$A&@1Y>9B,:%VAZJTSP[@QTO"MQKMVW;J9P
M.IM1\I#0\,\'82<"'Z2)#(1)$?7SN:9B\,L9\&`$(R?GW8G)R6WT1]%L`0V;
M18+W9Z#P'8%SU?YR8M5VA0R1E.,V1D5=?*M,\.$,E+LK<:[=]XXZ[A`8II'>
M/E&6#5I79Z#N0M%SO7]PI/>%O;00ZU;\IO*GM>6#UE$\U2/I7RG^VBER2H(T
M6LTI6)4.6N?@CVJ$7ZF_P"EM;H>TCA/D,@P&OX:[7L-=OH2[ZI/4Y1P2WAW)
MT%"8:$C:+NA]X*M0;-MAK_JJEZ'[+HGD?V[^2O$3BF5(OYM<(\9>A`_Q+Q2G
MNF%C5-]IL&Q?^6J23)$4#K63CYHPI*D0\1Y"$.**B>`K),NPDVX,::HYC:R9
M$E4"P)^Q-4BFP!:HRFG9+^PTXF9*AE)LV_'E0U<6@T&QA<!E&,YX%.Q(;#NH
M7%_G0T;GP)*788P6F[1B-IW+E5(,4PT%NFI.`W*FC)0`L!V%KD_0%TJC[SA6
MA:1WBS@-S)DJ?D-8&\'HO80*\4/0@[GTOKC@=6/*^TI)6#BWF%1S&ILKTZ\A
M`-LQYD-G^])IWFV(KMH$OQF3LQ5IKJ_@.XQ&.!8:`]DALEV'*8V%<%Q.=LF+
M@0MGVH3_<;PZB#RRC)96]!"]2!/:W&_8KN`VVE=)]7IO8A^63XX>2R':`&O$
MEKI.T'+IC-LAK!B9/\Y?#YAP3F7&:27>=-6"EDOWW`)U9>#\F1VOT1PG*+X#
MQ&$PBO$DRRXUX$]?,6BY].DM,%@.SQ\_M-*X4W5(EV$`"URI(?GCAF[(M_8G
MJEF0^_6"ELM0@5W6U.ALYUM9,R'[)`$&//D,B&$RT?K&59L(6BX#$>6<&-F6
M6G3>6)L;8,T&8=!R&<2P.^0D%G_B&;4<;(T*VB[C'A:(TD/S)TPR%&V!&-D+
ME&5;J(K20=MM\$.KYJ+HMQ*%-]/:1J)LZ9[V3M&@[3;1H`8;*@C^^,;=*,*+
M3P\1COIDZ55L"*TS&4HK!VVWAW-J\&4&RA__^!X2H0N(;A`CPI3APM))9VDL
M#X;VA-)#K%NARBL';;='?&HP:`;*'^]X'V0EFR)HNST/5(,A-0@O_6&E@73`
MIDK0_G%B&84`2XX,G"1MM_AFA-=,75.)7S-U_<W4W;;RAX@-6(8PRJS,(;#L
M$)JQLU/4P-ED]AK#\<?XWA9Y<6BPFR93RO#_UO-=*76[%;T_$&\,PQ\K6R5J
MG_.T,DV+2MZ?FS>"X(\)K1)3?_S8L*;W9^W-<?AC7F_XTC76+8/:WI_>KX;%
MGWVFO3/N1LN5II;WY_O-,/BS4;$G9^DJ55##^XL`RN7W9QNBXMT8)M6\OTO`
M$(0/L0+M+86OX8+7<,'YAPONX0E("B9'>W>+GDT(0"&X/\[^'0Z!<.!+(;4A
MY*V23MUYE4J+XL*[4EO8<%8>`+I#(\IDV9=<.O5QML*R3KWO<HWJY/:G/S^@
M>$6V_CCA3DFG+K5Y?]Z7VI]HU&`.HG,(^^GF>9X-.H-9O;#.V3C+.@3^</,%
MB!`S[I*H&\V$0J6(THY<"JUAJ*2F4U=9JWLU7>5PO,E(N@<.0B'RTHF>&/$Q
MS0X+ES.FK>?4@:[!5QD8&TN/<CV_IEQ>7;Y>\AZ`/0EK0N7X:,L[=8DK:+P,
MA#^3V1ZH*@N,V\.]-4:`$H$_FQPK\18QBCO*C>A8ESZ?@[P%POO#Q5=*Z+:,
MRSYC8(F5UO7_WKY*4/S9>/HB\,N^-"#K\X]](B3-+B"4+M:008*>=4::81-N
M#_>:\5)@MU5`Z(T%)T`R>1*R!XO_]C>$-SM&8]B"VY._A_!:`:`_48;LII-]
MU+IU3UW#[7G?0WC3`/+'4"P$6&<=='O>]Q"NM)`\LEX@,;(AM\JY/<];R2K9
M%=N?!(K\3$*>W?$9<1QJ&%"6=WL$MPH3A>+[DS#Q!^#)-(&H^R3&[02^IA+]
M8+RW55W&5*5VW![4K<)@95C^)%WL=KX>CM-$FPI34,/M:=U#QML&`-O/.%@?
M<4M9J^3'5&S)]5G>@T>=#EC)<Q&GSJ/9?TKS-8_F-8_F_/-HY`77HFL/&7W"
M8H!\?ODF9.F35<"R&PI_>G$ZSB`26+FQL\G%J07-G[A#/0_):<BOEL)-'"B/
MPGS=Z+\I3[(XY".]!S%3A#B[='XM[B.U-SZ/\3FGR4<V.\F1E.//')![K!!=
MTYF,XBP?O2]>EY45W#X><"22"M;Z(@4<*Q4PRRH?9(W]3B,\QF'VQ>+88WDE
MMT\.G(0N(R4<+=TC^_+BC,8M9?(A^S26DM]"8<:'KHK;!PE.RU>Q"FSL!)2Q
MU>4E\Z"VO-OW"USPM(??GPV`4VZ$.WU7X:3+7P65V,B)4"?331&9B*_>(LRR
M<Z2#\1^(,22=ML4>K^KV&L.:CI]K.-D@-E3%T9XX$>#DPY*[WWRD1E<156S!
M;5;8Z4BMJ!)_=JAZ,&<0XC+O8[.8VPRRT\ZZN[C]V8#*X''Q;6&Q]6@Z2L9I
MG%]$K"%25\UM6MEIB2W3@S\[6NN%7YX:&HRWWA];/3YF9$SI&G";>^;*EBK3
MB(UWTI6KL!1!?!Z2)%YN:NW<(EZP]I;6<YN+=KH5UT@1UI]8MYE$NH*\O`76
M(&9LWHC;-+?3#N=J6BE[]]UIG]A_]+92;]BO[C:QKB(SIO2J87JSD:1`+=-L
MEZ^SE+Y>:%+=;9;>D6A5PSQ:K%B5LZYZ!;-@)3:M[C8=[R"JJL+T)V6\>,XH
M-J^,Z[I-V3ORG+J!T9^0LE+<G><!JS*Z4]UM_M[Q2%7`].?,G'G*@)5$)[<O
M?%A.HJF`V9]YN4#N/GD";BO#3=.8ZR=##DYQ*\'F#]%B&5FZ?]WPKQ0SV(JQ
M"-/!)')EWHC;ET1JDE40F:P$VANG1T@9`D3\5FA'$54S9=R\%;=/D]BEO!IJ
M?[+8S+5@91IW^[Z)5<JK@?9G7B^0^Q831$)+"[BFL:!]1N=$:V#SQ^6ZA_ER
M(1J,[RB9/`*;%3P+K6&X0BM!VV5(JR9=:NXKHO9S#5_G</*;9V`AYB7O4934
M#=HNXV!6^37"ZL\JO2FNS!Z43U<-QF;/,);6#3HN@V%'H[40ZSDNQ5:6X*#C
M,D!FE>AJH/U9DZ70PAF0_Y$.P9-P%63$%ABFT6[P3\-YE6:"SKD<"JR*RI\H
MJ%KRKNBCC+V([ECZD+%)_:!S+J$O8SC^W+SRD,[GBS04%.>'T_MD3-DLL_),
MGG,W:R'HG,OC7A4`^9,-VR<),.&`R]>9M?M)ZV)!Q^DK7A6T7+1IM(W%&V=D
MD2KTB)Z!E]*Q53+H.+UTW`(C>W#\\25R2%\I"<6?ZW@5B13F4P]S>:%"RDRN
M+CVTZ:!S+K$A&TAM9*+KSH>L3FT.QOM7.;X\TH*G[`N290YK-.BX#`U986N[
M(]A1B7ZJ/LFE//*L*(UQ)%\67(T`OG%#S_#U=>S7:WI^L&MZ5G`>0B!(^)?=
M9VS4LS;+'^>RG:FHR<)T!`WQ*Q"^<:I+0^&*EA+Z=N3WQE3,Y?I&^!Q",:-"
MU,OF=ATI176.=-%.3D<CVI),P\JNM@O(T>#X40D*>C!&:9P<F:CE1T[`U`J0
M-XP-5QM8JTL'9#@\>UG$(&-'5>U\WB77@RAQQA1V5U-^9H0XB/_Y/U!+`P04
M````"`"0@P\_4,(`('DA``!0U@$`%``<`&%E;BTR,#$Q,#8S,%]L86(N>&UL
M550)``-O@4E.;X%)3G5X"P`!!"4.```$.0$``.5=;6_D-I+^?L#]!V)N@9T!
MVF,[DTLRV4T6/?8X,&YVVIAQ+G<(%H%:8K=U44L=26V[]]<?BY34>J$HZJW(
MN?L0Q-/-8E=)SU,DB\7B7__VO`O((XT3/PI_>''Y^N(%H:$;>7ZX_>'%S_<W
M9]^]^-N/__HO?PW\\/>UDU#"VH?)#R\>TG3__?GYT]/3Z^=U'+R.XNWY5Q<7
M;\[SAB]$R^^?$[_2^NE-WO;R_+_^_N&S^T!WSID?)JD3NB<IZ$8F=_GV[=MS
M_BUKFOC?)US^0^0Z*;>@4R_2V@+^=98W.X./SBZ_.GMS^?HY\5[`,XBC@'ZB
M&\)__OOTN*<_O$C\W3X`M?EG#S'=R'4(XO@<Y,]#NG52ZD'_WYVQGQ#]_UOV
M\0L"C7[^=%OTPGLX).>'Y&SK.'O12>"L:9!W]>+\1S*#=F_!^LMORMI]@)]M
MJEA_E&\K?0DAIB.&AG<T]B/O?3A,U9HTJLZ?4R=.1VA=DD?2^SY*G6"0QB5)
M)%T_TF'/MI##>J;,$]-AS_0D.:&N:5//W@_R]`1A'(&_/[#?KVA&GU,:>N#^
MQ*<@J?#EP@?"&,"'ILBM=!;`8!#%53L=&C)3+B\OOGESP0UA'_QV';F''0W3
M9<A(G_KI\3;<1/&.#R7+=9+&CIOFW7#%>>>_:8N>_YA;7%$PIDETB%W:RUKQ
MT*NZ.&M]76!@98(PK+-'\?/G%S_F8L0)/2($24F2_)K+_N.OXN>GLX9-.-91
M`?3_(T9YV4_S'T*UJF[*,JXRPHG=7!_V9X<M68MS-V+SL7UZ5D'>)HYV/4F0
M:Q+U?`KGVMPNSY0V3K+FMN3S)2#].0W28@;%W<#9Q64^\\H^_HT-H"D%K>Z=
M]<E+EFC?TA"!Y*TJUG%2-""_\B;HS)U.4PP,JU]]CECE>S>`3S9ZTEOV9Z*#
MT5-C$S@MJZI``#0CO)UYP(Y7V0AR&Z!H16\=$7T1G%#W]39Z//>H+\#+_JAC
MEGWTF_#LG^C6!X<>IA^=G<RKMC9%P*M"S?JKSP;=4SL"#;'1.KG"&%CM`D..
MU`XDS(O3*\:,V`ENV2KD^3_H40G4>EM4I#85;7GS64/"6Q+6U!Q8I],9%Z\M
MH&@"5HZ(N1![=8AC]H,W?N(ZP7]3)WX?>M?,N[>`MK4Y$FX5ZM9AD#4EHBV!
MQFRYXQ%H;@*^,ZF.A>(NH)2!W(&2>;WOC1_0^(K]VC:*U;ZWVA+5\]:5;/%A
MO!G)VYESNI.HB^MOI3!H>EL9!N;"YWWLP%[8Y^-N'36>=Z9\M0T2)NN*U5]O
M]CT1#4S`<)R&6,B3ON`RYF1O=^:Y:+3;1>'G-')___S@L+>S.J2P/0IJJ">F
M*D'<6:K:A+;I'Y<B7&Q!A"`I21J<P:+8@SR[U8"99*K;C;&YV)&'C>]9MRT\
MJ#1!0GQ-K=;8/7QO`L%C],-"I.S5EK$G>:]SH6S)?L>#W[H)G#9W6VV#A+.Z
M8O4767Q/H($)I(W3$`MKTA=<!IOL[<[MTXK4$\5"7MX6V<O5%6UU)Z*AT>7[
MU#IC>T,I*&1N48:(N1$K(@7BEV_89[+M*'5[9.3*%&Y%0A;&R0#!FYM$\-2Z
M8R.Y%2PR-+<A!0?1$/O2Q_.IM1$TEY7MP@,/25J"Y&GT-H/B!D#:,5Q'AX%L
M@=7FQ@^=T/49HZ+$[TAMZR5N(J-`;4[[AGVT(84@R24-IK@9,\Q(=H(&"%OS
M%;H1B,>J99+0--'@3ZTA(E,:*C868;R!!=#7U-0D@.7ONPY5Z<O&`^65DSPL
M0P_^]_Z/@__H!(PUR3*]<N+XZ(?;_W2"@RJ?44\>$<*Z!C6V8)D`SY#E?Y1$
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MTN@NCM@\/CW>L4?)3URRJ?`>`FMLJ%2P2BF&2+(.]>L0R9LO"!<0!V9S$3[G
M,47#@89P"^C)`F-3SLE?A`6+_AEL>E?$`=XY`92T,1<%F,&Z]SS/K\TT3,^K
MX];JCEC#I^'YY9^BR'OR`UE2>:,)HK\MJ54'2/Z5*0]J0K4>SD1#/:O<@Y:^
M]A"^SI<ZN6MD&5X4ANYAFS%A_J&T"/K(E&Q=B6B)816#Z5:_D7"1B7"/7U[U
MDY.8D1(P(TV)N"F.@06-]=IKU:KI;T"QJ_,(H7780G!V(O`(I[F3#66"'DDC
MDC[XL4?VS*OZ-"&;*"8)9=W"H8G](6:_RSY-'QPV"8DIH<][ZJ9"<$U)3--#
M'+)_,BEGOP]\_LV3$WL)Z_$HZN1L4O;PHI"2(V0/L99K>HS84V6&$)@$,,.9
MFN[1A4BHOR%!%&[A<;,F3I!$Q`_=X.`Q+9SM-N85MHB;&R=L6K!W`Q9"CVOA
M'DGR0&E*/-9Z`5^%Q;/*WB/[)&66,KM9D^!(/#]Q`V:LQWY/UA%[ALSF'6L<
M^TX`3X<YR\3WN/[LK]<EAN8_(7UB3/B?XHE!!^S5>_5']))]!QJ$4(@G4#RC
M5Z^-E1O2],R54D-Z;AD[JM49SL*/8VDG8.#&K5H#5N8#53U5PX]+J0-2Z-#_
MX#MKGWDQYO(9'?D1LH<H8,XL@858>M3(J]+N`I$^/<RJPZ4DRH>>LO"?B1"W
M(%-K9@M-$J4O)NM4Z@E(_#2#.^<(^Z+Z"08U`0.I!0V56[>SLY;FMUAZ:[X7
M+<UF#PQ_T#9LO2@!WI8I($4W*BOC`_5*7D.+F"TRN-QL55R"&FA+2HUM8&AO
M_8-38V,\G>2AV\%6-?`EA%6B'H^SUVSQ_<C6PH^T%VV58HC,[5"_&8/*FUO%
MWYY6_.+$O.9A3F&C<TP=`-7AKX$>S!,&>Q_<%742NEH'_E9$G[HYT"&(>J:@
MPX1F*),+$"Y!2B+&J=#?E"Q`N(]B?C@LVA`WLRZ`3DR=*YC9#-P\=1V&-!/4
M->AA)#[336VS@YK6(&#3^*6E<#43[X/IZ>?@AVS!?%-_I+5@?"VI<-J9Z!<-
ME<B9H:/4`"5H2EM85H4Z]2R)PBVYI_&N3-?O+4%^.Y@4)&A%DK'8Y6V84O;*
MTW?4B?UPJTS%Z-V%N?BFRJSN0%PN?;86X@N#R1I3&FA38'1*`PR&1COYTQ$L
M[2*/D8%2;U@T-`BJASP+QK;6R:=-D\XA2AH::37&50,E@`9LL-NQI=YKBUFZ
M:;Y,T]A?'U)^4#>-V+AIR01SM&EF"_KTW1^W:$?\CO7%$Q"Y3EU5462M48\]
MR91M'MG(6N4UIK-J&K=)<J#3UY_0/NG43_=$Z/ZGB]<7%Y>0%"K21_]"+B\6
M%Q?\/Y*(XMG.(7V(8LAE7$!V)24^MU0DS,Y8*%SSA-3X=V;%H:@IS+#HH,,T
M!MES$D+AR)HGGMJ\&.+NT:EB?&<IJGI3S!VBIIJ-'8A*/?]Y?6U:N@EZ`IT5
M/E;I9+_Z;G'Q[=O%Y5??E%WM5]\NWK[]=O'-UU^7O:[XZLWBZZ\N%I??O:T(
MO%F\>?/=XMN+;V=UT[H[:/,_MM,#*C^%T\.TZK'I[=>-XH<%X]I8`RP:T<::
M8L]8UC8X-+9*Y2,#8DS:\WCM42>X<WSO-LSV;DMZJ:+1W<*8<6@=4QKQS4*(
M@!0<6,KD%I5[;HS%GD<:M6=29\RH+*7`I*.:]?U8Y<=FMM0>-Z?O/1JQ>%W7
M@><*/]'4\4/JO7=B@%&R=-W#[A`X*?6NZ<9W?56`44,8T15JF5('8"Y$<BGR
MLB1',L%7ICSA()O*!GBBE9EIIK7:]W#@<Z+**O\]KZ'VN&]]CU=WW]KNSN2^
M4*_](+/[0./V?^S9]&G=V]39\L'QQ+8IW<,!3XT;JYSN],;9XVC;?5/WQJ)U
MY]GU4E3DHA:=7U<GLVB?ZL;RM0/,:625X!G5-R=F?I-L.GVOD5:CHL_@&F"9
M)_P,57B$DWR@J>\Z@2*#1D\.J0J8C@%UR&0RA`N1BI3!O)DOS!J=PEH3FV.J
M'),V2<KUF'098BHMB.FTBOG=8Q[?9[BC,;_F7#M3J+4#8\E#"I,Z<R#N1/$T
M(2UVD>!>47&7O1WY18/,R_9UBPU=\M(/B1<%@1,G<.V-V--MA/#,97ETX5*=
M^-$!2E-DXSHDRV+?7)MD#4%CY)*8T$DJ(4-.0G80J9<I&8$:J0_V,*8-7&JF
MM"#++$/$MGU/=F1"AIE1J*[+"IM25[5-J++!EYI@F@E5$.FPH((@LPQ8G;*?
M>M*@+&F8"U4C=`FQ,I\O-\:8*C4466RF^2&!F`Y)FO@RDED[8-VB(VTF_[;'
ME+Z:\&'E<F6485_`0J4'"A59?=8L44HZ]5B?J*3,D$AC.E\ECS7+DD%&V+@@
MT8"2@A'&ER(-73K7(6T2)AG0.GV7H=_TT;G>VNNL/'`VJ:9Y\!:4#NJ`?2=C
M#2V;&GKHK9F48B9YJUY@R#%DP5IIF!W:JZ319@P[,#/)*[$JBV9ZX^S)HM%Q
M!9UNS.3"]C9THQWEJX&=7BFT-@E$#]:N=!U,HB4IFEI0EF(6Y3$QWP&9.MS5
M>,$\2_%(PP.;YG=#O-$4]9Q$0\UF6K=H8@&8>VAKM%1?V\MO)I%+WSQFIJ-+
MPX0FF2(*D-9;HN8QUI5LIBV*%B1K8BY%45-3$HL6!J]]'O]4<1,*I4!MY@_*
M4#HX79`]PRB&ML><J?*[U=O;(J4%MBG:>*5%NQR!R3P0U$C^LT[GSIL_K=-8
M)RE15^EBF`?RD5PJNZ<^IN(,%QNC_$<_I<E?P!ZHU/XRIM[!95^MCZ_((KO#
MDYGK!$'T!.LE^)OU`#=B\MJ3QFZ95)*YG,JH8C+B:2XG*/R8W.NTM<0\Q]50
MLG%>!5KD(PB_;-[86:U.745NO4$GTU?5')]&3_;(<=HXUB,%*1Z=5OF]M^^?
M]WR*H+$P:Y=!I)A*\3HJBK8D;VS!HFV8`5=1DMV7G8L97=%UPJ>.]R[LX"'_
M)QHR58)EZ"V]G1_ZH`;</Y0IIL!_ER0B"[J-J$,ID^`0JLKDB#)%B'&V.!49
M,^/3G!9@LEJ3&G5NZ_$",]:84&;Y`U/HFHVP0;2'14$WO]5RJ%%(M0'-M8IH
MS^%4DC#-[%%V>"<)4Q5:IGT+%FSY:S&C&97MIL7@D!*?UZPVIS7F9QH_^J[T
MW@-U>Z30DDKAYF8J3-I6&W)J3?+F)D),_76/-B0XZ9[,I7MGJ,E:S75"3GV4
M%PM9EYN01YG2J-"??19Z-.;Q)>9G"/ME*'CA'>#"$I(^0"2=WQO(_B52!,@F
MBOD7I:>Q/\1[!A5CH:=.TI?#3UV,-[AF[K-6-KI&UEH;6[,@;J6%:CEL9HXP
MC^Y&5_+:*WAS_!-)#1^B1(N!I=8F.%A1MIV%6;K)2VAHK*2BGM+PL=@6R=I'
MH6GZC=;7".6:.&XE70/$>+3[&(5158W,`VB$C+ME$2FI8T@=.V69@J.9V"L+
MHLE#;%JQZ6#<,,9H/%D;8W6"Z`(,,;[L^"'P=!6>[K:_#9DR?)T`>Z=W,4V=
M9U6@6;<+S(BSOEF-8"<3S08V$H7D)$]*'?"]T`41G1@+10\W\A<GCITP)73J
MD-M;84%(M[`8-&<!:B"Z)X<:$>E^!$)-^(ZID]!K*OY_6U)0[])/W1YP$\(U
MC9+D6',)\C*7?05E[DL>PH+K1(>;=_7`_D7!HHWCYP>;HPUYRI@69-(3EEOL
MYRT,F(:<*]^';9+<^1Y40UP'P_RM.?%1K85;)##7PZU*RZ>GDHFWL55Q3]7]
M;&:=#:33K^;UUL83:XVZ0E8CO+%*5L+;@I7RD!6R%2OCOBMBZY;![?%8Z2+8
M8)+CK"98L9;OO8;')S!-M6++U7:81*TIV"`G3:N19*P+(K2N\=31/F!?&?,B
M&OI]F$,_/0?1]]T;=0(R)C6(+Z$1'MGSJVKR"DSOG,1W%:27MT<D?YO"=2`4
M]PT5)<$6A+<UQ2M=Q7-^G10G9T)SS7)@.$3L8T[5&0^U"Y.Y2EK4&:SB!!Z3
M?Z'^]B&EWI+AT=G2CX?=FL:K3:.^0Q?#^_6#R/R^!C9"NYD\R3H@H@<(V#2K
M;QIV%I/9ZF2VAH6M;E:$IE%]IIQ`E:5-E0DJ!`QYFR_G>6!ZJ4&4KWNO(7PW
M-S^Y]H-#JBQ+UR9A<(YR4EIGEI*UMF6>TJZ\=*;"F\.FA<V3%;5-[=.5GL:9
MG+'4B-(U9ZFRQ/BL)5.G3VV[OCV9G[DHC!PY=S'L0B:T=^QX76&LC5,86Q^*
M!?.8+B>@.9/I\`"8=_%F!<A6FRLG>;@)HB>=$^=*,=3[>97J-R\ES6O&,7R"
M`.$2%J0+SFX(:JD%#5`UKU/M1!3J=@,H<1='C[Y'O7?'GQ/JW89%TN]2E)?Q
MM:HS#.@,=^.BOZFR&2I'8=X-G()Z"3T1/WQ5.F)QZLT"SDUB>HE\-Z5,]HJM
M9C-X!V-9LBLP#,AXQ%UZ_W-(4IY+>!]]HO"(_(!6MC/NH^FH/<O/(9)_IL=5
MYTCI9V"GL_@ATES9LJ^_/$=BYC'&Q6,,L^U9^!3^=N$)'L1#(Z><$,<.AS0G
M1^LN:T:"(L[1LPT<ZEU%.\B_D)YI+L^_Y`*8\_(VE1L366AXMH:6I-S4V#Q<
M5W$`TS;TX5N8@_/Z^9D=[IQVZ-5E&_OX+2B)H49]8_F@@OS@(AB\&OUJ#UW]
M/?+\C>_R;MN3!S6$D,IA=*K>7%(R`2(D2%G$5+&:$59$PHI=V8K)S__T*#31
MVXS[!TJ$*H3U1XG/UL9008(I*(9_]KW+(+^EHA@%#Z=%_..*T1"&HW$*Y[R2
MTI-)%F0?^U!_(H+GXL<9Z1]H(`I8D!W-PWC0Y[O(B3WXQ[7/9AV,.^:JH^I1
MLERG0HN/XUR$N''G)HJOV+,]!/`Z;FAKJ1RE"*9[:%=;3BMQNQ,O7.(6$F1#
MS13-L=T$;<>@;P.XA>JQ'J98&OMNFE]T"K=/5IA.MG#L1Q2K":.0[O9!=*1P
M0UU"]LZ1QQ`E3\,LOSOXU&"WFDQ3<'N9=,R]U>WQ6=U06,D'!H999ZW]Z&R7
M[CUYW*D\D)@QD2_2LTD)&V2=E*W/1>7QHC)4P?(JHSTHY`BIXX+5%4J7GX0-
M');SIH7`4M(,KV#'3T+>AC?,8?(;75>;["1U?D;PV,)C'4FLJG9:1K0<`KT-
M"<AE]Q"O-B0_2?YA^O.M/8K=C3$)\\ANGTIR@VP"3^`7)ZV]XJ1U<W^<F<VG
M_*S/(WQ5F.^=3F3[IW/T6;$YX1R#TXG8S,_$E/T$/W2RIN!-H.8<G]X_^>D#
MA`S9BN-(G9B\S!Q1&,4[)RB%$MVC&]`%\3<DB)CA\2MS)>OT65XI7J=-<;PX
MWS6L[UR_*[I7:888TZNI5P=S^6M3T3N3*FH%YGHH:$$(3@;(>N!-@D8\QO"H
M?<)^F4W]KZ/#.MT<@F4VBU(P2"F&R*@.]>OH*)KS"6(N0'()4Z0;9<4A=*,@
MH&[JPS'(8@;,($79N,8^,U6!8]YW@\EB'9+46:W!$!.%N^!REM6&*<<F(NGQ
MCKV!]/T?!Y_7O5;P7;,#(T6[.DSJ*-D%TC!QR^4)[X`4/9BOUS7(OB"W#R:?
M268CG<THO;LDD%Y9R[B/Y?<&F_D2)%^)/`1(^^UZ:V;*ENEXD/:B91KN8W"X
M`GZ%_0)-TR#+@\P=[IUSA)&P)5C1+8<4JM`Q0,J-%2-%(05ABER.9((FHA2#
MK0'LGZQA#"@F-?N9K-$)4`PV)_/%3NQ#C(`7ZU6;1]S`21)_XXOH`_LZABAM
M'H60;"W,[=IP7R=6X$/;7Y3#'KK.PF3AQ2+UZLK9^VPDU,C#[-&)T?*+"M,T
M*S"6JM6++BQ(?QQEIPC$);5,Q81Q3I3B+T4OC68M]L=I=]7"#I":)&'N%CX5
M"_%>]).(&R6>U!Q-RA6SD4\S!"7&,DW+L*4]897Y+##K#-KYTNT&6LEB=!2&
M&G97AQB*DBVY.^XW_C;%S8Z\,G-TQUQ>SB\3)D+:'@^@99DPP<U,<"8V8:P+
MF,P$PQ."5LIH3`7:^#(XGB`KDKR/$C]-EJ''?ZZ5UKW$D:(+/<QII74N*TJ9
M"VD^R138,L/LD<95[(BX'5/3NT>8880AD`SA;+<Q=R+B&)-(^5#=H>=#DG=(
MCPG9^H\TA(!#0IF/\-/C@L#.$NLK=H(%I$7NG'@+)5(RA5Z399!$D'\1'#R:
M+,H_"8L1_B@;2Y(P2L573S[#D4<W?DB+](S4>8[":'<T$N'`P!!6;*.O[RJ'
M.'HZ+AL66>T!7GU9*Y97[;&TKK65H4CO&).6<\=UM;:E9GP9%F2@:'-&?Y5E
M3Z!S*4+C0Z^7D8B;=@)-<_2AQW<)K+Q51LNP96V?8PX+ACN$2?0W3OP6MFAQ
M7TX5&TO**)Q`CTZL+"$CP=V`TC'VUXM1V<E-NPUQ+-.M7S_E^WN7O[];S?=G
M9S6<-N_2FX/&?<QM^$B3J<I6J3HS[W/4IO;T/45G=E6;F<3T>MDJF:TVEJW2
MP+(F8;N!C)C'+@[B)O?1TOWCX,>TDF*V##V=+-<>G6#FN/<QK9%5G0G#4:5,
MO,B;7(C$R04/6AE/>!UG)E/J`19%T8;L\[10,,MPRBORNS.<^8K\"E&/`/3V
M+XT#`7V="^HA()=2+X%Q3)*@J^L]>_2">T2HAW&24RE<6N1MUC//+?.@$UIJ
MT;$!=+.0CQ;UI9[DI%%/WMFXGIID'67G^FF:=9/]BR7=V`:*=6/B-C/;9N<B
M</SBSQ;O<N.'3NA.%*U1=6;>VZA-[>EUBLZ^B&A-/]/KT1J9K39&:S2PK$G8
M;B#C$?<3S0JG):O-ARC<WM-XEV7P?X#]IM4Z\+<\2THU+^C3"R)5^QG7K(J;
M2\,<%>3/4M9!<5B%=T%*?9BBY61F'D(/TE(S^P*0-17`P+0)T[D,X%O=J_0G
MFZ'XQ:E6:?+^F<8NG+K4C5I(94W%*EH,Z8A0E&H0)Z20LR(D,<@@*%'(QBU:
MO@^+V[BIU>DD-.O3=*D0/2@J5_$*')IAU6WV%E:;*_X.N(::K)++&F)5FR%J
M$-Z60"CD!-%LH-4PBR`0UD8MD<C-/HPV&\HSQ]TH$?.1/_W[F[>+-V\OS$<"
MK3#;E&=1TE'E651<M''=/LEZW<YU^C3K<_L7Y;J1,Q3KQD0%9[;-SF##^"`#
MNG<!O9:A!_^#C8]')X!5RQT_[E1/;%7XEU[=('J8GN9)`V&P7<G_*/6P(*(/
M(DDP-^5E1MH*7"RJ`_LAO]7+C$LQ\=(L.'PRA(IU3S.`AX@7BQWV>U$'R`GR
M2U=OPPT4>X;5F\X]P)H]8%X]IFU4XU:!DN3I4EU2$K9@/V$B\SP_<8,H.?"K
MN3?BQL`-6.N7K#6ZI=`3G(T+P7HA$_,86$KATI8[QU<%]BK-4(]U5=1K'M\2
M7Q/XWMP)+:6.G+E[]AT/LOE98U.'L290%??<51.>S?-5#6RB'J.,=O3>>:9)
M)X6J+7$/1]:4E)R#A%MO>1/#9.I2M0K2%%H:.]DX7E7D0XPRK$K.*TJ`BKOD
MA.'QH[B4Z)0;$WJ2%?%U,7/0F!^.[AIY:3KR,;3F;2Q(UFLIQ0I61-*DE5/7
M%LPW9W@J+1-1SMDP"L_X<X(;+XW./Z=BA6Q%.`$E!M>%^D3S`KWB'LS5YKJX
M0ZBX^^8^6GH>O]S8"<`GW8;9;KF$ZQ-TBE1#:K3IDDN@*QU"\>I3EZ=KMLA]
M1$Z]\O$>C@!G'9NH.#7_HZA>3E5<SP7'@9S3H^"#-0]NS?,HE!.+_T\/0J=Z
MEZ7/`HI1,=WY1_G%B7XQC+)!8U.,HD[A.(U=2#:-?RU7M)K$N0Z_1C$*DRCP
M/<A`^\S@0[,TJGP<8W-6*%KX0%.FGJI8]XC.L"Y;'&IJ8]Y7ZHB<>H+AH93*
M^VNENW\8G.Q9;3S:38*C@%ZY7'`,RO%/G:\VQ1VLD%UQ!7DCJNPHE9B!D^4M
MZK>>1V9CD,@S+/*BN(CID^.:9JSR]!YH0%Y"04LH<QDGC6U.$P>,55!J.U*L
MP!$>%U;QU@G]?_+Q]41?V"@(O3OV]O.9TVJ3+=*<X,1LC4#(-/TCLFNJ!]+`
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M@T;4DY?R^DT:$\AN6=R3EYV&2`[LE6NK54NK63"QQ+0)^7RA'N@DYPNU$&<!
M?W1&*`UA&QBD<MX=<+-@7$(VRPH>=8Y&VLC#8](I?LI/#.]IF/`9Z"<*]X)Y
M?*?A\X,3T[634"_?C]`8ID9VC,C`T8^@<5?8*28MR@D479*L3[&=MB"\VS/>
M+RDVW\R/@%_.$\'D_314J?N$27ABH;]X5U979U@>V[.-'J/U(4Q-$`M&_"_J
MH5CI-]24&>PXE'P9G//&$Q+RDNZ_.''LJ.<%W3)(&6Q=BC<")3P1IBA>GTL8
M3D6;WPJLG#(M()53QW10-"VL5<.7AI!)8"M#@&V8,#B:?#F&Z&2+][8$;GAF
M?<)%(+53/Z(2WCZW\2GKS%@.MQY1.GEK<*<#U'F(`H_&"2S$T^/'*-4YL-<A
MB+FST66"E"B9P)^)$"$@8\&B$\48U)T++8`U=BQTT&6:):>YI]:6H'8?QKDC
M-TP?>>5T1`O69$:--,\U!4SU:->.4<P*1.N$_G%@LX+WCYJQUU81U!I#K6HW
M#SOG38EH:\-H-(_ZN-6!U,!IE@-2HL8<XK7&F%89@YA7NM<F:FP8,&:SP"3R
MN[U_!WK&5A+(5CNEDZC-\:8EMM"G!]P:`9I&M1QXSE?IU0H`Y1ZR.8?!H_\C
M+<S6Z-4SW$EE6D7G,;''2?:!-D*@@A<.(,X.TJH@0I_')$H&/SD)B<4/4:_-
M?.(=^'$]J-V]YV4?39],[\-7R3'T'F3%7,EE.;:?71HZ["DOGWW501QY>]05
MFESAYD(E:[<@>4LV`V-M#:](%(^[N?IH?]:(",E^_.<PV5/7W_C4NXYVCM_P
M(&4S6V4PD:)0O(&6K.V"E%J37T5[LXCI>OP-U*B?O3#E`Y/\D?W-_@?[H^R+
M_P502P,$%`````@`D(,//UPGX!X:$0``<@X!`!0`'`!A96XM,C`Q,3`V,S!?
M<')E+GAM;%54"0`#;X%)3F^!24YU>`L``00E#@``!#D!``#M75%SVS82?K^9
M^P\>]]F19;5IG6G:4>RXHZEK:6SG>O?$@4A(PI4"%(!TK/[Z`TA*HB0`!$2:
M$'EZBNMBX?WV`\#%8K'X^=?7>7CV`BE#!'\\[[Z[/#^#V"<!PM./YU^>[RY^
M.O_UEW_^X^<0X;_&@,$SWAZSC^>S*%I\Z'2^??OV[G5,PW>$3CM7EY>]SJKA
M>=KRPRM#6ZV_]59MNYU__W'_Y,_@'%P@S"*`_8V4Z$8FU[V^ONXD_Y<W9>@#
M2^3OB0^B!$&A7F?*%N*_+E;-+L2O+KI7%[WNNU<6G`L;4!+"1S@Y2_[\AVBY
M@!_/&9HO0J%V\KL9A9./YP!B+M[M7K[O70KA[VZ)'\\ACOHX^(PC%"T'>$+H
M/%'Y_$QT^^5QL*4[""#!8#$#O-4[G\P[HE%'VT^GE(I/$8B@Z'LXN4.84X%`
M."(,B:YO0L`8FB`8V"AKV&,YM3^!4`P;-H,P6@#*_]H,1L@'H8VFZDXJL^F`
MSZDY[(<1I)C3]0(/M.1^/Y6I>`/8["XDW]@`!XA"/SI0Q?U^RJEX0S`C(0KX
M'PC6?X;E_L[H4-XM>RX'8TBG`*._K>?\EES9R<(0AS>BD'%8UIK(Q$N.OG@^
M!W0YG#RA*>;+@0_XVN;[).:+&YZ..#<^@LQJ')KU6$[M$24+2*.E6(:_QF@A
MAHV-DE+YLO.8^']Q@F!P0^8+B)DUNXH>*E!K%%-_QCO^$U#*Z;#C4]I!!4K-
M2!APKT?8/UI::[0M7782C!G\&O,Q\/G%<B#MBEHI(O.#0DK3GC&<BE51>$'7
MP@OJOD]TS7Y]#\90L=+F7:KKK;Y2H<XO9W5H.((4$>XD':;JCG2M.O,/$8U*
M:)V3KTGO9Q*!\""-<Y(UZ?H`#[/M6JXNF_+5!1YFTXUDA;I&^WI:&W)C0;Y*
M+7)>Q#U78TM!^!I!'(CM1OI;T4'9[5&RB27^UM\)Q;:1T((%FO_"TW7='[.(
M`N$OI]V$`F;2N6<JZEVF:[>1@ID=$AM/`!LGAH[9Q12`14=HWH%AQ%:_2;!<
M7':SC>QWV:^]M</[#,:;P9#37=[0ZZ::YOGKTVVM`?57_?$?]\C;WG5G+3KI
MQNO"GZ%PS?N$DKFU(5>JD`(89X3R;_C'<RX1,ZXA68B.Q`Z"8YM`2K-/ED;W
M1/$P&]6.Z..3!P[XC\R$PG5C[\H)C6HR"DC+*WX,Q#'HOYN2ETX`4<H9_V&7
M*OXK+QVHCW"*Q/C$T0.8R^::JJG7.PZ:MLR_395&=251==C\AJM-03C@WY'7
MW^%2:_2=MM[W#;+ZONXKLW=KMOM-3`6\.\1\$/X'`LH=Z%L.16%Z57/OAT98
M7Z/^BH`K)P/_#H60WG!-IH3JA_U62^]](\PNUWQE\5[-%G^F0)R4/"WG8Q(J
M;+W5QONQ$5;>U7EEW^_=+.5D/B<X";P\<9<?LF$<B>,BH:)^7=<(>C\U@@DC
M("MZ?JB9GI5'_LR[51"1;^)=-\+D.RJOC/N^9N/VN0Z!T.,N!*IAOM7&ZUXV
MPKY[2J\L_*.CX;L.]VF\%6E;K^MF-WSHB-Y3?F7YGQQ9/O6>4K7N^.]DFUAM
M>Z][)!M90P:D`%8L7#ME0?BPYARL6WO=9NQ1->IO-DQR`CJ[P<I=N%4%,`U3
M)ER%FB1::6*?-N*G^*?M:-<;\Q0#/<5`CYBX/F,P8@9KQW;#!D1#E8I71=@+
MI&.R.>"KES>1&-7'@?A'I#Z\@%`D3/6C&T#IDF]%_P7"6+>4&LD[CK[N,R=G
MV!1+*XC/4JC8(_0AA\K7JP<891%0W?35B#D.\YK27`!!'6MO$KW#:`9I:I%B
M4O<;.PX=FU(I55P=J[<D,,KGLKCXG!I,QRWL;B/1QO-O1V=UI+])$VZ5`3H*
M09K/L$H#Y8N+AD"=F.-XMBF?!1#4!PU-HO<W0H)O*)2=".TV<1P3-Z4MIZ[Z
ML*$>BN3Y67`A=L&,CZC<,O]`L*]<%4W$7(?4B^@QQ:`^PVC:5Z[P\^8Z)F_W
M8<L'X?>//YI#SCT"8Q2B"$$Q#O=SY`WV^J9=-"'D?PBF=FPE5ONE$5B*S9+Y
M'G%;P/6I@A5Q^IWC/K"VA`1HS!7=&,J(:[F,UW4;]*F&;C6V=LSM6TC12W+K
MU(IUG9C7=1L&JH#X(GB511@<AWX72'@7$#`X'(=HFC!EP+Y>T.NZC1U5P'\Q
MP,IB%L?AX!5S+IL(;L--%?`L!]6.@$4.VV;C:.>S[\MY7;<AJ6HYE^-S'0QY
M$Z=]@"/(*8L^04`1GFJC*+9=>%VW`:]B1HV\>2V^JOS[XUCNS::_=^4V4E;M
M9!=HVA`S.R@0HS'>E=O86@4DZ\%5%HIS?+J4J9J`+4K*D+3VKER'V+0DJ4Z6
MI#A:$6S)W?\HS+'9:>I=N<Z:.H!+&8C*8BA1OD)"S8Y6$*!4Z1%`P0!G>\<<
M7)V+52CL7;F^N7H`UV:PVA%%>8010!@&GP'%W&UDW*N,YW$HZG;<P@GRD>Z[
M7"SL7;F^.WL`_V:PVA!#D16>LO#"O"O75W0/8%<.H[*HR7%LD:3.:(FC3N^J
M3=$R)43U[;.2HZ"V"SOJRJ'ETEFR?I]$OUM%*`MJ#17*G2[:&!0:,K&B<KD[
MW;`YW;!Q3]SV9I@/XB%-4`;)=FH$:5)&P#@JH.J@03=RC`&U(F"PC3:M&=&/
MHQFAZ._-5ZZ0]UW!!E1&,@;2CIP,&<P!8[$UR:E0`XHO&8%H1[A`!E%?^\90
ML@'%GLR1M.-*2"[>=<#GVD"Z`:6G[-"T(_5BK[23T6=:(]6`PE9F*-J16[&'
ML?#KK)!H0/6L8@25':H?%Z=F'V5M%;<&%.\RQ?&&I^@N2O'LO[E3\W!+%5AK
M9)#"H9`X1?\,9X/:?J>XWRGN=\3$/<(7B&-H4EMGMVF#8GD2U5L1M;M'/L0,
ML@R?]@1QJZ7CN)R,#]6QX*[>CHF3'K_Q3@@5;9<K9/*Z#,JVCL-HQ7SH-*\N
MT<IAJ@4(UX-,7U-CIZ7CR)CY3-K7NPVE;(8+R(<DWT=\?ETD"X7!ATPITZ"(
MEPY#.PXJ?H.80PS[..@'<X23ET+$9BH#K.&W0-)QO$O+G)SL8D"M\&8>.1_<
MEJ)*WBU?IT*2U/DIYELKYS@*=@#;17!<3V^I!W1#F'@)=^,B/$'ZPGTWV3Y0
MV]YU7,N"L$(<K?S`VGQ87=?6.6#V23&T(9EX#2R-5=T39D3EIG63ZN@HU&_#
MA'P@F&RCRT:J@>=;*.NZC(X-QT9@VG'6_QM`6(SA(=X4#QE@CC)YH4!LPT<4
M1N!5YQ0;=N&ZLHX9JPH_V0)C*SQF;B`JRHC<PO3?00ZXV8ULPQY<E]TI,RHL
M()9WK>5/F#NHSKQO,=W77B[ANMA.&=8UD%KM!1SR]7==;*<,SUI0;?#;^5?+
MR&/?:N>ZE(Z5'[>K>!LN^ZTNIZ[2#S\!AGP->]+VKFO?V+"H!%!95IY#-O^$
M:#KCW_,^]_;`%#[$\S&DP\E>,E,1RU;]N*Z08\.^-;`V%,O9'?*W*(PC;::F
M0L)UF9PR\SP'H0UUJ14#.4-ID[QIV9/[$CJE9[L.6O.O;N<2/,4;3G<A^<8&
M'!^%?N3PA<6U+G8O*^Z)G5(][5]4E!E1E7UQRO<\Y7L>`7'B,3(^:D>4O""^
M!GY:?F$P&.#U>4G?C]!+6H7#X#C!NK,&Y8P>!*X54>7#(@Z.CPT.8LLD(%'=
M48'3.G+_C5F4G((\DT?H$^RCY&7"#=!G4MW"\!9_SG&*;)4#[(W,XSHQJ"+7
M(HL>P>"&S$4D-V%:YUY(!5R_,?E&%"L<%94)CC%9/KD'.$P4^8,$:(+\1%OU
M^46QD.NW*6LAV\@,KM<`->/IE=X[0F\(9G$H4-]!97Z@3L3URY7ULJTV@NN:
M)45<]UG!"JYM[_JA2Q<L[UG@E+YDG=KC^`'.6K_[-E8I?ZI:+K=%GC8^`WC*
M5;X#B";E6H:3/P&E0.S0T\P<65E40TG7V<?U+2&&QG!=($4Z!+AA0L#8KK[/
MQ*A"KF4/KG.8ZQL2ED9I1YV56\B5]5'1CC'?S'7&<[T?C%WD;7F_A)N&<;VY
MEWQ+XG$TB</5^TN:8:`3<YT&7>^P*+)$9:>W1^*&BKO0PPE'S8T5+4<A7R'%
M4IA<M#-R0G4=N,Z5=N6"%MED-8BNC\D!%>ISU6$4A=FA[L[#;0J?HU#.=>YT
M?9Z&D2DV<:E&I];OWR58FRM[AL:LV)9A)ZX3L^M=2NSLLAY1S3[NV`>]FCW<
MWI#OZ?6I,2;BKI/!+7DU'1QRH*5//(YTF1'76;)GA/N,0:UC:R+N.K?\C0:%
M'*CK>UU2UT-V+VU!&(K$`S@)#B71-N*NT\A+$6T+M/R1R'%._V*GU%C6=;+Y
M&W\-<BC;<7@BA4ICKOJ!%WSWQ5WGGK_=D)``;</M,O-DI$JR-UT_"5MQ<I\%
MZE9<%98C'N`7R*I*^=5TYOZ-V=(YOP7H7.?<5!1$!\MLH]_WO\:(PJU('G>U
M3"*DYIVX?GKV0*H5\7,KV*W8HG*$/H0!N^.6E41^3<>+>2^N7[.M=L#8X6Y#
MA5US^U7R^7'])&ZEP\4.=HN=ECN$`?8K<EHTG7E7C:J?<0`ZU\FC596,762?
MWN'DGN#I,Z3S;,MX+S:!PW&(I@EYNE7%HA?ORFW8]$"RY2/'$G?[_)9--CW[
M_`JICUC!,Y@%LE[/;:RUTM%AA+8E>Y\<5)&)+5[S'DYRSU89#@JIK-=S&W!]
MLT&A1/O_Y8!4XGAX/;<AV$H'B1WL-A1I$W#YIDW\(S9N+WQ+)\XB($4DV`U,
M:\:+33=>KSEWZ6UQM>/D1HZZS^<&I4L^#9),?>O1L"/O]9H37C4&5-D9S2(9
M8EQ'&K5Z##3G%79C0)5=5DG'P&?L:,/Q%"\6:6(D"%<%@P9X0N@\I<F@;)-9
M#UZO.8^T6T!JQ\V4`8X@IR4:`:3;8>:;>3W'SU%9<*0ZDM]&4UDA%7>.7IKX
M^@Q>(2ND<JNEUW,<4:R`S3U`;3B76!GC@6"?_[B)J>-`LF&Y1<P/"8NIR7,;
M9;OV>LVI_UL%5M>WT73W4]>U-H:3_><#EL^D'P0H559,C@'.XJB*Y,URG7K?
MNPTS5L+U]C"JQBAO]8&IK<BHJ/%!0A2(^/AZ]K%<I<E10M`,1MQ&H7G94<6;
M;39_3+/>'=[9J>IHP90K95J5\]W26J1//L2`[_7ZK\BH'&F^?=,JDN[HWG`&
M,S!?,%M`GZ__,+@E<X"T5=]4,L=28G27(06A&A@-)[5DB>`C"6O:EPBN,"'4
M#7.C=5+`NC25..9+GCHUR/V4B3DNWBEG27'"J8?Q=A45:W,RAW0*,/H[K9)2
M]]MDN;^]\6O$:,#!*(=U.,EV$B#<N#PF;[M7T;\#K_0!1'R#-)QD]Q#T^4K[
MC1W7Q*_*ZJKS9!G>%DQ$\1H.$ZF_FZ[KGH_9M3F^81]QTGS#\LY*(0<SYU/,
M^*+.V"UD/D6+;-1)3/O,6?H4ZI-Y[#MS//.T5"BFTT$@6S#=GN+Y'-`E_["C
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MUYAW^_G%P09LY\\;/4JK$'$QH794,9I`*AG7S]2JS:J:*AHD-7]Y.D)!X2KR
M__@?4$L#!!0````(`)"##S^P?1@:(0<``)PT```0`!P`865N+3(P,3$P-C,P
M+GAS9%54"0`#;X%)3F^!24YU>`L``00E#@``!#D!``#E6EMOVD@4?J_4_V#Q
MLD_$$-IL@Y)4:=*LD-*`0KI;:;6J!OL`HPXS[LPX"?OK]\S8!H/'QI2L%,1+
M,OB<[UR^N7J.SSX^SYCW"%)1P<\;[:-6PP,>B)#RR7GCZ\--\T/#^WCQ]LV9
M"J8P(YXF<@+ZCLQ`122`\\94ZZCK^T]/3T<D!,%)-"5R1HX",?./6^UVLW72
M[!BK#&;`]8V0LVL8DYCI\\;/F#`ZIA`VO+=O,!"NN@1X?9MOWW@6M8)XZAP)
M.4&]5MO_]N5V:.-N>`OE+J/\QPKB>219ANGX1CPB"O(0HQ'J!2@/>.\GPA5U
M5F'_VRTZ6#=.*P"4*TUXL!I0(8DT[?;IZ:EOI4MZNAPF1$-8ZN/4EX*!GZKE
M_<2J.2$D6B#'1(TL*A6DW=%N=MH.6)-H70Y%H:2C6(/*0P,1<RWGJUPK"(XF
MXM%/A25>@UA*'+QEV%1:`@Z!NG$H*('`<S!U8XRD!$3Y(RCMAB6R$B`G-%!N
MG!65P!0-W"`4E/>>GD>@G%UG)66^="1+G*&D!"1A7#HP3WR4KO92)"'8,)B)
M#.QX'I-`-^$Y8H03+>3\!G^O,"HXCV=N0Z&6ODG51Z4F:H&DP0H6].;IM.IM
MLZN<&[/D$LZ%)AI7YHLS$D64CX5Y;"9WUWAX0)!G&E_O>]6+IHWG6@2Q68(O
M>?B9:ZKG/32(&L9!PZ/(:*7&PG4(8\JI#:O5]II>ALHW"0^]Q(27LW'FKQO(
M;,8*PCZ_L&WL884V+,*LE2DJ57$AE@;KZ0>$!3$K=^"O4+P+YT-,P^Y[_?$-
MY;B*4\(&0ME8KQA1*MW^#/LU=9W]<(SD+_#8OA)<"49#,U.\3X29_<,;3@&T
M.KQ.2/-7)OV(X":@IZ`I^D]X+Q<[J>[4I]K[>Y"WI_XY/.YS@[J'Y\H97#(-
M$M=C^@B%85_4</;`NZH>6`B4)\9>/P)ITSS`89\C]HJHZ0T33ZK'0XH;J"Y0
M7]1P4O^^/O7&HF=-'A[U>5J6K.18'A27H2TQSNXY^97N65NE#G"1ZLL)X?3?
MW$EHY8F3ZM_-<8>J@`D52\`?><CA4?B)*(J#=9!+*=M=BP(GH1_6";5(,U3S
MV,-C=AC/9D3.^^,AG7`\`@8$#^B!?1.F?#+`Z1U0\PIM%_1ZND[^3]?Y3XV9
M'LB9\Y;VO,S@X77*0`H\6>BY>5/Z&=/(+*M)%S@E+L+;K77",VCR]I2!#X_<
MH1;!#YS]$%Z)601<Y9:3$IF3X'9A1!MPTZ*]//Q`*1[$,I@B&7\1*7%FJQS#
M!9&3X&,GP5X&]C+T@?([%2P$J<Q,UO,<N:O/G<QVG,RFP-^\!'J`M,8C!3]C
M3.?SXV+%77_H)/1=<7?+4)Z%[3F9YH^I6MS#V+/7_UUSI7C>4'06,7S33IY-
M[64K`=XT=[&MDT[K.V9T]#QCF88Q7%&+L+VP3D+J-S.17K]65R?0B-WL\/2P
MK+CXNZ>#=&^;SFH/O:9D&!EMFPQ"@+VV/'!,;YO'VC1XV6S\[#8=6\L[=A1@
M(D)JCSO+FV55N:0R>BL":Z8"8GXU,US3/&JVCYN=]M&S"I/`MO"_R&A+_QEN
M.__NBF=-SQG`N'Q?PUEED;'$I_7G!/K`M,J>-)>FZF9=49RKBL4!2]L[Q."J
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MTX/(5+\5!MS74Y"72H%6=X(G^T8^M8V:^;1F`N<?D7-78F/"E#.SY-BF,]$H
MJ?-BQC"B^D7234O'MG*\4I`I=F4-U5?4C[=D)*1=5^X!W[1C4'>02Z9$O'./
M+7-8Z[)`0OA"?78EE"G1+5,8@GRD078=;]*K4/G_4GRY46GOG?J107P1H:T!
MF#9N%L`5+-/<I+<WN?:4BB&\$=+43F-FZAPWD._0:JT]R_-2%:_8UY)<5]F'
M#*^FA$^@QV\(E7\2%D-_G-Y%WU(RHFQQ'VMG:!WE?<CZ#T)YGP]!:Y9^U9'6
MZM2`S(WM9<XU5/=B`>YQ-$847$/RO\?=9X%EYO41>T'`/03IIX')@ML?7V,$
MC_;KJ<7P?1"786AO.`D;$!KV^!6)J,Z^/#&T[&IG+\C:[A.;XKGK5_&OZ##F
MK.X5,]V@]MH3>H!G_8FA8$-&.;TDI>23\*[.GO_B$'ZYB;V^$SV(LM)B;A;7
M`[W.+<U/WI?Q;?<_4$L!`AX#%`````@`D(,//^&-2@H>6@``F_<%`!``&```
M`````0```*2!`````&%E;BTR,#$Q,#8S,"YX;6Q55`4``V^!24YU>`L``00E
M#@``!#D!``!02P$"'@,4````"`"0@P\_[QPS#&4&```C5@``%``8```````!
M````I(%H6@``865N+3(P,3$P-C,P7V-A;"YX;6Q55`4``V^!24YU>`L``00E
M#@``!#D!``!02P$"'@,4````"`"0@P\_$FEM/`0.``!)S```%``8```````!
M````I($;80``865N+3(P,3$P-C,P7V1E9BYX;6Q55`4``V^!24YU>`L``00E
M#@``!#D!``!02P$"'@,4````"`"0@P\_4,(`('DA``!0U@$`%``8```````!
M````I(%M;P``865N+3(P,3$P-C,P7VQA8BYX;6Q55`4``V^!24YU>`L``00E
M#@``!#D!``!02P$"'@,4````"`"0@P\_7"?@'AH1``!R#@$`%``8```````!
M````I($TD0``865N+3(P,3$P-C,P7W!R92YX;6Q55`4``V^!24YU>`L``00E
M#@``!#D!``!02P$"'@,4````"`"0@P\_L'T8&B$'``"<-```$``8```````!
M````I(&<H@``865N+3(P,3$P-C,P+GAS9%54!0`#;X%)3G5X"P`!!"4.```$
:.0$``%!+!08`````!@`&`!0"```'J@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><div><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >5.&#160;&#160;&#160;Stock-Based Compensation
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During 2001, Pipex Therapeutics&#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of June 30, 2011, there were 1,320,354 options issued and outstanding under the 2001 Stock Plan.
</font>
</div><br />
<br />
<div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On March 20, 2007, the Company&#8217;s board of directors approved the Company&#8217;s 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of June 30, 2011, there are 1,228,239 options issued and outstanding under the 2007 Stock Plan.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven years after the grant date. As of June 30, 2011, there are 232,500 options issued and outstanding under the 2010 Stock Plan.
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the six months ended June 30, 2011and 2010, are as follows:
</font>
</div><div style="text-align:center;" ><table cellspacing="0" cellpadding="0" width="90%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="32%"  style="text-align:left;padding-bottom:2px;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;&#160;&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="22%" colspan="6"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Three&#160;Months&#160;Ended&#160;June&#160;30,
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="42%" colspan="4"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Six&#160;Months&#160;Ended&#160;June&#160;30,
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr><td valign="bottom" width="32%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2011
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >2010
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="32%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercise price
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.73
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.21&#160;-&#160;$2.22
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.82 - $0.87
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="32%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected dividends
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >0%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="32%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected volatility
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >184
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >184% - 188%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >203% - 204%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="32%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk free interest rates
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.88
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.81% - 3.58%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >3.59% - 3.63%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="32%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected life options
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >7&#160;years
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5 years - 7 years
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >10&#160;years
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="32%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected forfeitures
</font>
</div>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >%
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >-
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font><font style="display:inline;font-family:times new roman;font-size:10pt;" >0%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0%
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >immediate vesting,
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >one-half vesting immediately and the remainder over three years
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >quarterly over three years,
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >annually over three years,
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >one-third immediate vesting and remaining annually over two years,
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >one-half immediate vesting with remaining vesting over nine months; and
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div><table border="0" cellspacing="0" cellpadding="0" width="100%"  style="text-align:center;font-family:times new roman;font-size:10pt;" ><tr valign="top" ><td style="width:18pt;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div>
</td><td style="width:18pt;" ><div style="text-indent:0pt;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:symbol, serif;font-size:10pt;" >&#183;
</font>
</font>
</div>
</td><td><div style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >one quarter immediate vesting with the remaining over three years.
</font>
</font>
</div>
</td>
</tr>
</table>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >During the six months ended June 30, 2011, the Company granted 332,002 options to employees and consultants having a fair value of $445.671 based upon the Black-Scholes option pricing model.&#160; During the same period of 2010, the Company granted 425,000 options to employees having a fair value of $349,750 based upon the Black-Scholes option pricing model.
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >On January 18, 2011, the Company amended the terms of 228,773 stock options held by a member of the Board of Directors.&#160;&#160;In connection with the modification, the Company extended the expiration date of the stock options by 5 years.&#160;&#160;The extension is considered a modification, which in substance is the issuance of a new stock option award.&#160;&#160;As a result, the Company computed the fair value of this award to be $397,767, using the Black-Scholes valuation model.&#160;&#160;&#160;The fair value was based upon the following management assumptions:
</font>
</div><div style="text-align:center;" ><div>
<table cellspacing="0" cellpadding="0" width="80%"  style="font-family:times new roman;font-size:10pt;" ><tr style="background-color:#ccffcc;" ><td valign="top" width="80%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercise price
</font>
</td><td valign="top" width="20%"  style="text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$0.09
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="top" width="80%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected dividends
</font>
</div>
</td><td valign="top" width="20%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0%
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="top" width="80%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected volatility
</font>
</div>
</td><td valign="top" width="20%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >187.1%
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="top" width="80%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Expected term
</font>
</div>
</td><td valign="top" width="20%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5 years
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="top" width="80%"  style="text-align:left;" ><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Risk free interest rate
</font>
</div>
</td><td valign="top" width="20%" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2.03%
</font>
</div>
</td>
</tr>
</table>

</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >A summary of stock option activities as of June 30, 2011, and for the year ended December 31, 2010, is as follows:
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><br />

</div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="52%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Options
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Weighted
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Average
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;Exercise
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Weighted&#160;Average
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Remaining
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Contractual
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Life
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="11%" colspan="3"  style="border-bottom:black 2px solid;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Aggregate
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Intrinsic
</font>
</font>
</div><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Value
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; December 31, 2009
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,561,332
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.26
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Granted
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >743,332
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.80
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercised
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >( 255,954
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.44
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="padding-bottom:2px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Forfeited or expired
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(509,619
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.69
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; December 31, 2010
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,539,091
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.32
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new
 roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Granted
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >332,002
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.61
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Forfeited or expired
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(80,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.56
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="padding-bottom:2px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Exercised
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >(10,000
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >)
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >0.56
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="padding-bottom:4px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; June 30, 2011 - outstanding
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,781,093
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.38
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 4px double;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >6.38 years
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >431,508
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="52%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="52%"  style="padding-bottom:4px;" ><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Balance &#8211; June 30, 2011 &#8211; exercisable
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >2,299,189
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.50
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 4px double;" ><div style="text-align:center;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5.95 years
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:left;padding-bottom:4px;" ><font style="font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >402,549
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td>
</tr>
</table>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The options outstanding and exercisable as of June 30, 2011, are as follows:
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-align:left;" ><div style="text-align:left;" ><div><div><div><div style="text-align:left;" ><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="10%" colspan="2"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="43%" colspan="7"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Options&#160;Outstanding
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="43%" colspan="8"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Options&#160;Exercisable
</font>
</font>
</div>
</td>
</tr><tr><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Range&#160;of
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Number
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >outstanding
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;text-align:center;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise
</font>
</font>
</div><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="21%"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Remaining
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Contractual Life
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Number
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercisable
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Remaining
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Contractual&#160;Life
</font>
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >0.09 - 4.57
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font> <font style="display:inline;font-size:10pt;" >2,691,094
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >1.23
</font>
</div>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:center;" >6.48 years
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font> <font style="display:inline;font-size:10pt;" >2,209,190
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >1.32
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >6.06 years
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >4.58 - 9.05
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >89,999
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >5.93
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:center;" >3.26 years
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >89,999
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >5.93
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >3.26 years
</font>
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >2,781,093
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><div style="text-align:right;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >1.38
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:center;" >6.38 years
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >2,299,189
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >1.50
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 4px double;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >5.95 years
</font>
</font>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
</div>
</div>
</div>
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >The options outstanding and exercisable as of June 30, 2010, are as follows:
</font>
</div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" >
</div><div><div style="text-align:left;" ><div><div><div><div><div style="text-align:left;" ><table cellspacing="0" cellpadding="0" width="100%"  style="font-family:times new roman;font-size:10pt;" ><tr><td valign="bottom" width="10%" colspan="2"  style="padding-bottom:2px;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="43%" colspan="7"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Options&#160;Outstanding
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="43%" colspan="8"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Options&#160;Exercisable
</font>
</font>
</div>
</td>
</tr><tr><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Range&#160;of
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Number
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >outstanding
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%" colspan="2"  style="border-bottom:black 2px solid;text-align:center;" ><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font> <font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</font>
</font>
</div><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</font>
</font>
</div><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise
</font>
</font>
</font>
</font>
</div><div><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</font>
</font>
</div>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="21%"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Remaining
</font>
</font>
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Contractual Life
</font>
</font>
</font>
</font>
</div>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Number
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercisable
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="10%" colspan="2"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Exercise
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Price
</font>
</font>
</div>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Weighted
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Average
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Remaining
</font>
</font>
</div><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" ><font style="display:inline;" >Contractual&#160;Life
</font>
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >0.09 - 4.57
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font> <font style="display:inline;font-size:10pt;" >2,222,760
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" >1.19
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="21%"  style="text-align:center;" >3.65 years
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font> <font style="display:inline;font-size:10pt;" >1,763,593
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >1.31
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >5.93 years
</font>
</div>
</td>
</tr><tr style="background-color:#ffffff;" ><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >4.58 - 9.05
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >89,999
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" >5.93
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="21%"  style="border-bottom:black 2px solid;text-align:center;" >4.26 years
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >88,124
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:2px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 2px solid;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 2px solid;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >5.93
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:2px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 2px solid;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >4.20 years
</font>
</font>
</div>
</td>
</tr><tr style="background-color:#ccffcc;" ><td valign="bottom" width="1%"  style="text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="text-align:right;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >2,312,759
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" >1.37
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="21%"  style="border-bottom:black 4px double;text-align:center;" >6.56&#160;years
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >&#160;
</font><font style="display:inline;" >&#160;
</font><font style="display:inline;font-size:10pt;" >1,851,717
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="padding-bottom:4px;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="1%"  style="border-bottom:black 4px double;text-align:left;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >$
</font>
</td><td valign="bottom" width="9%"  style="border-bottom:black 4px double;text-align:right;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;font-size:10pt;" >1.53
</font>
</font>
</td><td valign="bottom" width="1%" nowrap="nowrap"  style="text-align:left;padding-bottom:4px;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >&#160;
</font>
</td><td valign="bottom" width="20%"  style="border-bottom:black 4px double;" ><div style="text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;text-align:center;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" ><font style="display:inline;" >5.85 years
</font>
</font>
</div>
</td>
</tr>
</table>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Statement of Position (SOP)<br> -Number 93-6<br> -Paragraph 53<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph 64, 65, A240<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0EB2AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (3,866,356)<span></span></td>
        <td class="num">$ (107,740)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Recognition of stock-based compensation</a></td>
        <td class="nump">427,166<span></span></td>
        <td class="nump">236,574<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_StockOptionModificationExpense', window );">Stock option modification expense</a></td>
        <td class="nump">397,767<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_StockIssuedForConsultingFees', window );">Stock issued for consulting fees</a></td>
        <td class="nump">58,270<span></span></td>
        <td class="nump">33,269<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_StockIssuedAsCompensation', window );">Stock issued as compensation</a></td>
        <td class="nump">75,840<span></span></td>
        <td class="nump">46,613<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Warrant expense</a></td>
        <td class="nump">1,491,996<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">77,471<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">108,106<span></span></td>
        <td class="nump">180,076<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for uncollectible accounts receivable</a></td>
        <td class="nump">188,466<span></span></td>
        <td class="nump">20,147<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">(Gain) loss on sale of equipment</a></td>
        <td class="nump">5,692<span></span></td>
        <td class="num">(3,443)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_GainOnSettlementOfAccountsPayable', window );">Gain on settlement of accounts payable</a></td>
        <td class="num">(62,996)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(294,620)<span></span></td>
        <td class="num">(153,574)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="nump">267,870<span></span></td>
        <td class="nump">791<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
        <td class="nump">50,548<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">54,109<span></span></td>
        <td class="num">(27,884)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="num">(187,309)<span></span></td>
        <td class="nump">191,309<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided By (Used In) Operating Activities</a></td>
        <td class="num">(1,207,980)<span></span></td>
        <td class="nump">416,138<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(2,070)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of equipment</a></td>
        <td class="nump">1,200<span></span></td>
        <td class="nump">60,890<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided By Investing Activities</a></td>
        <td class="nump">1,200<span></span></td>
        <td class="nump">58,820<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Repayments under capital lease</a></td>
        <td class="num">(24,400)<span></span></td>
        <td class="num">(8,503)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock for stock option exercises</a></td>
        <td class="nump">7,650<span></span></td>
        <td class="nump">89,157<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs of $539,390</a></td>
        <td class="nump">6,960,610<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">6,943,860<span></span></td>
        <td class="nump">80,654<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase in cash</a></td>
        <td class="nump">5,737,080<span></span></td>
        <td class="nump">555,612<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of period</a></td>
        <td class="nump">2,648,853<span></span></td>
        <td class="nump">2,715,044<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of period</a></td>
        <td class="nump">8,385,933<span></span></td>
        <td class="nump">3,270,656<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information :</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">2,169<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure for non-cash item:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of derivative liability to additional paid in capital</a></td>
        <td class="nump">$ 1,481,143<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_GainOnSettlementOfAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain (loss) arised from settlement of accounts payable classified as accrued liabilites.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_GainOnSettlementOfAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_IncreaseDecreaseInDepositsAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_IncreaseDecreaseInDepositsAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification of derivative liability to additional paid in capital assumed in noncash investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_StockIssuedAsCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that accounts for the value of stock options distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_StockIssuedAsCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_StockIssuedForConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_StockIssuedForConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_StockOptionModificationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The source line item represents the charge relating to the modification of certain stock options, prior to expiration, held by a member of the Board of Directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_StockOptionModificationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 5<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6935481&amp;loc=SL5618551-113959<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnDerivativeInstrumentsNetPretax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 27<br> -Subparagraph f<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 29<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A7<br> -Appendix A<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 130<br> -Paragraph 10, 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph 38<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Emerging Issues Task Force (EITF)<br> -Number 87-21<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 19<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28, 29, 30<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 17<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 15<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 16<br> -Subparagraph c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 123R<br> -Paragraph A240<br> -Subparagraph i<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 18<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 19<br> -Subparagraph a<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 03<br> -Paragraph 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 26, 31<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3291-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 28<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
        <td class="text"><div><div><div style="text-align:left;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;font-weight:bold;" >1.&#160;&#160;&#160;Organization
</font>
</div><div style="text-indent:0pt;display:block;" ><br />

</div><div><div style="text-align:justify;text-indent:0pt;display:block;margin-left:0pt;margin-right:0pt;" ><font style="display:inline;font-family:times new roman;font-size:10pt;" >Adeona Pharmaceuticals, Inc. (the &#8220;Company&#8221; or Adeona&#8221;) is a pharmaceutical company&#160;&#160;focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company&#8217;s strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer&#8217;s disease. The Company is currently preparing to make the following products commercially available: <font style="font-style:italic;display:inline;" >reaZin
</font><font style="display:inline;font-size:70%;vertical-align:text-top;" >TM
</font>, a medical food for the dietary management of zinc deficiency associated with Alzheimer&#8217;s disease, and <font style="font-style:italic;display:inline;" >wellZin
</font><font style="display:inline;font-size:70%;vertical-align:text-top;" >TM
</font>, a homeopathic over-the-counter drug for reducing the symptoms associated with the common cold. Adeona also operates a wholly owned clinical reference laboratory, Adeona Clinical Laboratory that provides a broad array of chemistry and microbiology diagnostic tests.
</font>
</div>
</div>
</div>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Name Statement of Position (SOP)<br> -Publisher AICPA<br> -Number 94-6<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
﻿<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=utf-8">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.3.0.11</span><table class="report" border="0" cellspacing="2" id="ID0E5CAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
        <td class="nump">$ 8,385,933<span></span></td>
        <td class="nump">$ 2,648,853<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - net</a></td>
        <td class="nump">444,664<span></span></td>
        <td class="nump">338,510<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
        <td class="nump">75,547<span></span></td>
        <td class="nump">343,417<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">8,906,144<span></span></td>
        <td class="nump">3,330,780<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">396,144<span></span></td>
        <td class="nump">511,142<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump">178,229<span></span></td>
        <td class="nump">178,229<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_aen_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump">40,300<span></span></td>
        <td class="nump">90,848<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">9,520,817<span></span></td>
        <td class="nump">4,110,999<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders' Equity</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">286,836<span></span></td>
        <td class="nump">265,722<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">22,718<span></span></td>
        <td class="nump">210,027<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Warrant liability</a></td>
        <td class="nump">88,324<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current portion of capital lease</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">24,400<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">397,878<span></span></td>
        <td class="nump">500,149<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long Term Liabilities:</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableInterestBearingNoncurrent', window );">Accounts payable</a></td>
        <td class="nump">2,335<span></span></td>
        <td class="nump">32,335<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">400,213<span></span></td>
        <td class="nump">532,484<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text"> <span></span></td>
        <td class="text"> <span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 28,079,126 issued and 27,997,644 outstanding and 23,420,189 issued and 23,338,707 outstanding</a></td>
        <td class="nump">27,998<span></span></td>
        <td class="nump">23,339<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">56,683,202<span></span></td>
        <td class="nump">47,279,416<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(47,590,596)<span></span></td>
        <td class="num">(43,724,240)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">9,120,604<span></span></td>
        <td class="nump">3,578,515<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 9,520,817<span></span></td>
        <td class="nump">$ 4,110,999<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_aen_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>aen_DepositsAndOtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>aen</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Subparagraph a<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableInterestBearingNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and due after one year (or beyond the operating cycle if longer) to vendors that bear interest at either a stated or an imputed rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 24<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableInterestBearingNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 20<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 12<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Topic 210<br> -SubTopic 10<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br> -Section S99<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Concepts (CON)<br> -Number 6<br> -Paragraph 25<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Section 45<br> -SubTopic 10<br> -Topic 210<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Paragraph 1<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 9<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 13<br> -Paragraph 7, 10, 13<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 19<br> -Article 5<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CapitalLeaseObligationsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7<br> -Footnote 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 8, 9<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 95<br> -Paragraph 7, 26<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name FASB Staff Position (FSP)<br> -Number FIN39-1<br> -Paragraph 10A, 10B<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 133<br> -Paragraph 4, 17<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 43<br> -Chapter 3<br> -Section A<br> -Paragraph 7<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13433-108611<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6947722&amp;loc=d3e13495-108611<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 45<br> -Subparagraph e<br> -Clause 1<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 43<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 68<br> -Subparagraph l<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 142<br> -Paragraph 45<br> -Subparagraph e<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 34<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6905597&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 141R<br> -Paragraph 72<br> -Subparagraph d<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Goodwill</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 32<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 25<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 21<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesNoncurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 129<br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 5<br> -Section 02<br> -Paragraph 29<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 7<br> -Section 03<br> -Paragraph 8<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Statement of Financial Accounting Standard (FAS)<br> -Number 12<br> -Paragraph 5<br> -Subparagraph b, c<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Principles Board Opinion (APB)<br> -Number 12<br> -Paragraph 10<br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher AICPA<br> -Name Accounting Research Bulletin (ARB)<br> -Number 51<br> -Paragraph A3<br> -Appendix A<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.3.0.11</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ReportType />
  <ContextCount>9</ContextCount>
  <ElementCount>92</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>true</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>01 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>02 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>03 - Statement - Consolidated Balance Sheets [Parentheticals]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/Balancesheetparenthetical</Role>
      <ShortName>Consolidated Balance Sheets [Parentheticals]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>04 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>05 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>06 - Statement - Consolidated Statements of Cash Flows [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>07 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>08 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>09 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>11 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>12 - Disclosure - Stock Purchase Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockPurchaseWarrants</Role>
      <ShortName>Stock Purchase Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>13 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>14 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <ContainEmbeddedReports>false</ContainEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 02 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Jun. 30, 2010'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2009'</Log>
    <Log type="Info">Process Flow-Through: 03 - Statement - Consolidated Balance Sheets [Parentheticals]</Log>
    <Log type="Info">Process Flow-Through: 04 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 05 - Statement - Consolidated Statements of Cash Flows</Log>
    <Log type="Info">Process Flow-Through: 06 - Statement - Consolidated Statements of Cash Flows [Parenthetical]</Log>
  </Logs>
  <InputFiles>
    <File>aen-20110630.xml</File>
    <File>aen-20110630.xsd</File>
    <File>aen-20110630_cal.xml</File>
    <File>aen-20110630_def.xml</File>
    <File>aen-20110630_lab.xml</File>
    <File>aen-20110630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>35
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R.5\P.#AC
M-&1A,C`P-#4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R.5\P
M.#AC-&1A,C`P-#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&$P
M.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;CPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D)A<VES7V]F7U!R97-E;G1A=&EO;CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?
M;V9?4VEG;FEF:6-A;G1?06-C;W5N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G0\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O
M;7!E;G-A=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-T;V-K7U!U<F-H87-E7U=A<G)A;G1S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?
M179E;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H
M965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C
M=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U
M8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C
M=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L
M5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI
M8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D83`Y,#0Q9%\Y8S`W7S0P831?
M.3<R.5\P.#AC-&1A,C`P-#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO9&$P.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U+U=O<FMS
M:&5E=',O4VAE970P,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P135%044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%U9RX@,3`L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!2
M96=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/D%$14].02!02$%234%#155424-!3%,L($E.0RX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L
M($EN9&5X($ME>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P
M,#@Y-#$U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R
M($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3;6%L
M;&5R(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4<F%D:6YG(%-Y;6)O;#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^865N/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T
M;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(X+#$R-RPV-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#YF86QS93QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@
M4&5R:6]D($5N9"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y*=6X@,S`L#0H)"3(P,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,C`Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9&$P.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1A,#DP-#%D7SEC,#=?-#!A
M-%\Y-S(Y7S`X.&,T9&$R,#`T-2]7;W)K<VAE971S+U-H965T,#(N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4U0T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED
M871E9"!"86QA;F-E(%-H965T<R`H55-$("9N8G-P.R0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!<W-E=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`X+#,X-2PY,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XF;F)S<#LD(#(L-C0X+#@U,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C
M96EV86)L92`M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#0T+#8V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,S."PU,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S4L-30W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S0S+#0Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@0W5R<F5N="!!<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.3`V+#$T-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,P
M+#<X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS.38L,30T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$Q+#$T,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W."PR,CD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S@L,C(Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1&5P;W-I=',@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#`L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.3`L.#0X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@07-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4R,"PX,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$Q,"PY
M.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3&EA8FEL:71I97,@86YD(%-T;V-K:&]L9&5R<R<@17%U
M:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(X-BPX,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-C4L-S(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPW,3@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3`L,#(W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#@L,S(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-U<G)E;G0@<&]R=&EO;B!O9B!C87!I=&%L(&QE87-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0L-#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#
M=7)R96YT($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS.3<L.#<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3`P+#$T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;VYG(%1E<FT@3&EA8FEL
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#,S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,R+#,S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`L,C$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3,R+#0X-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL("9N8G-P
M.R0P+C`P,2!P87(@=F%L=64[(#$P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ
M960L(&YO;F4@:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@)FYB<W`[)#`N
M,#`Q('!A<B!V86QU93L@,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L
M(#(X+#`W.2PQ,C8@:7-S=65D(&%N9"`R-RPY.3<L-C0T(&]U='-T86YD:6YG
M(&%N9"`R,RPT,C`L,3@Y(&ES<W5E9"!A;F0@,C,L,S,X+#<P-R!O=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L.3DX/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M,S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-38L-C@S+#(P,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#(W.2PT,38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U
M;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@T-RPU.3`L-3DV*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#0S+#<R-"PR-#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@4W1O8VMH;VQD97)S
M)R!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3(P
M+#8P-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-3<X+#4Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S(&%N9"!3=&]C:VAO
M;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)FYB<W`[)"`Y+#4R,"PX,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#0L,3$P+#DY.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&$P.3`T,61?.6,P-U\T
M,&$T7SDW,CE?,#@X8S1D83(P,#0U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T-2]7
M;W)K<VAE971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5"0D%%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R!;
M4&%R96YT:&5T:6-A;'-=("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@
M<W1O8VLL('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB<W`[
M)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@
M<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)FYB
M<W`[)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S
M(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@L,#<Y+#$R
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(S+#0R,"PQ.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPY.3<L-C0T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L
M,S,X+#<P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?9&$P.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1A,#DP-#%D7SEC,#=?-#!A-%\Y
M-S(Y7S`X.&,T9&$R,#`T-2]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5454%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E
M9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%531"`F;F)S<#LD*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N
M+B`S,"P@,C`Q,#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5V96YU97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@<F5V96YU92P@;F5T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD
M(#(L,3(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,BPQ,C4L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&%B;W)A
M=&]R>2!R979E;G5E<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-34L-38R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-CDL.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C<X+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.2PY,C<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!2979E
M;G5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4U+#4V,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M,3DT+#@X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8W."PW,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#(U-"PY,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG($-O
M<W1S(&%N9"!%>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Y-"PR.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-C(L-C(W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY
M-C<L.#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PS.3@L-#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W.2PV-#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,C8L-3<R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$Q
M+#DU.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<S,RPW,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;W-T<R!O9B!L86)O<F%T;W)Y('-E<G9I8V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#$L,30R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,R+#0P-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,S<L.#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&]T86P@3W!E<F%T:6YG($-O<W1S(&%N9"!%>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR-S4L,#8T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR,C$L-C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPP,C0L-S<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPS-S`L,#`S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F<F]M($]P97)A
M=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DQ.2PU,#(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3<S+#(X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L,S0V+#`W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,34L,#<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!);F-O
M;64@*$5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#<W-2PY.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-#DQ+#DY-BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@
M9F%I<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,38L,S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<W+#0W,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@:6YC
M;VUE("AE>'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-S@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L-#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#DL,3@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPS,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!/=&AE<B!);F-O;64@*$5X
M<&5N<V4I+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<V
M,"PS.3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPT.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q+#4R,"PR.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS,S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@26YC;VUE("A,;W-S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@Q+#8W
M.2PX.34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)FYB<W`[)"`Y-SDL-S@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD("@S+#@V-BPS-38I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XF;F)S<#LD
M("@Q,#<L-S0P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!);F-O;64@*$QO<W,I(%!E<B!3:&%R92`M($)A
M<VEC("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XP-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`N,#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B9N8G-P.R0@
M*#`N,34I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)FYB<W`[)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@
M8V]M;6]N('-H87)E<R!O=71S=&%N9&EN9R!D=7)I;F<@=&AE('!E<FEO9"`M
M($)A<VEC("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-RPX.#4L-#<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C$L-S`V+#0W,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#4V,"PT-#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PV,S,L.3@U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T($EN8V]M92`H3&]S<RD@4&5R(%-H87)E("T@1&EL=71I=F4@*&EN
M(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XF;F)S<#LD("@P+C`V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,"XP-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,"XQ-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF
M;F)S<#LD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@
M<VAA<F5S(&]U='-T86YD:6YG(&1U<FEN9R!T:&4@<&5R:6]D("T@1&EL=71I
M=F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(W+#@X-2PT-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,2PX.#,L-#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L-38P+#0T.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#<X,BPP,3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V1A,#DP-#%D
M7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T-0T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R.5\P.#AC-&1A
M,C`P-#4O5V]R:W-H965T<R]3:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0C)!1SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT
M<R!O9B!#87-H($9L;W=S("A54T0@)FYB<W`[)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$P/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@1FQO=W,@
M1G)O;2!/<&5R871I;F<@06-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H,RPX-C8L,S4V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)FYB<W`[)"`H
M,3`W+#<T,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE
M="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E8V]G;FET:6]N(&]F('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(W+#$V-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S-BPU-S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K(&]P=&EO;B!M;V1I9FEC871I;VX@97AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SDW+#<V-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!F;W(@
M8V]N<W5L=&EN9R!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU."PR-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,RPR-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!A<R!C;VUP96YS871I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+#@T,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#8Q,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#0Y,2PY.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W87)R86YT
M(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<L
M-#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&5P<F5C:6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#@L,3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3@P+#`W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O=FES:6]N(&9O<B!U;F-O;&QE8W1I
M8FQE(&%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$X."PT-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,"PQ-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA'86EN*2!L;W-S(&]N('-A;&4@
M;V8@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+#8Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,L-#0S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1V%I;B!O;B!S971T;&5M96YT(&]F(&%C8V]U;G1S('!A
M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8R+#DY-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D-H86YG97,@:6X@;W!E<F%T:6YG(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#(Y-"PV,C`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,34S+#4W-"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&-U<G)E;G0@
M87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C<L.#<P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-SDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$97!O<VET<R!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU,"PU-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-"PQ,#D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-RPX.#0I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3@W+#,P.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ.3$L,S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($-A<V@@4')O=FED960@0GD@
M*%5S960@26XI($]P97)A=&EN9R!!8W1I=FET:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q+#(P-RPY.#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$V+#$S.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M87-H($9L;W=S($9R;VT@26YV97-T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F
M('!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#`W,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!S86QE(&]F
M(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,"PX.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@0V%S:"!0<F]V:61E9"!">2!);G9E<W1I;F<@06-T
M:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PR,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M."PX,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&<F]M($9I;F%N8VEN9R!!8W1I
M=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297!A>6UE;G1S('5N9&5R(&-A<&ET86P@;&5A<V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(T+#0P,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#4P,RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S
M(&9R;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S=&]C:R!O<'1I
M;VX@97AE<F-I<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@Y+#$U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@=&AE(&ES<W5A;F-E(&]F(&-O
M;6UO;B!S=&]C:RP@;F5T(&]F(&]F9F5R:6YG(&-O<W1S(&]F("9N8G-P.R0U
M,SDL,SDP/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#DV,"PV
M,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T($-A<V@@4')O=FED960@0GD@1FEN86YC:6YG($%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.30S+#@V,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P
M+#8U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&EN8W)E87-E(&EN(&-A<V@\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L-S,W+#`X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4U-2PV,3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@8F5G:6YN
M:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPV-#@L.#4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPW,34L,#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&5N9"!O9B!P97)I;V0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,S@U+#DS,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C<P+#8U
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=7!P;&5M96YT86P@9&ES8VQO<W5R97,@;V8@8V%S:"!F
M;&]W(&EN9F]R;6%T:6]N(#H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@:6YT97)E<W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$V.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F
M;W(@=&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U<'!L96UE;G1A;"!D:7-C;&]S=7)E(&9O<B!N;VXM8V%S:"!I
M=&5M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5C;&%S<VEF:6-A=&EO;B!O9B!D97)I=F%T:79E(&QI86)I;&ET>2!T
M;R!A9&1I=&EO;F%L('!A:60@:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)FYB<W`[)"`Q+#0X,2PQ-#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XF;F)S<#LD(#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V1A,#DP-#%D
M7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T-0T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R.5\P.#AC-&1A
M,C`P-#4O5V]R:W-H965T<R]3:&5E=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1T1!0SX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT
M<R!O9B!#87-H($9L;W=S(%M087)E;G1H971I8V%L72`H55-$("9N8G-P.R0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@
M,C`Q,#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F
M97)I;F<@0V]S="`H:6X@9&]L;&%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B9N8G-P.R0@-3,Y+#,Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B9N8G-P.R0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&$P.3`T,61?.6,P-U\T
M,&$T7SDW,CE?,#@X8S1D83(P,#0U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T-2]7
M;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2#X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I;VXL($-O
M;G-O;&ED871I;VX@86YD(%!R97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A
M=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYA='5R92!O9B!/<&5R871I;VYS(%M497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX\9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z
M8F]L9#LG(#XQ+B8C,38P.R8C,38P.R8C,38P.T]R9V%N:7IA=&EO;B`-"CPO
M9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^061E;VYA(%!H87)M86-E=71I
M8V%L<RP@26YC+B`H=&AE("8C.#(R,#M#;VUP86YY)B,X,C(Q.R!O<B!!9&5O
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M;'D@879A:6QA8FQE.B`\9F]N="!S='EL93TS1&9O;G0M<W1Y;&4Z:71A;&EC
M.V1I<W!L87DZ:6YL:6YE.R`^<F5A6FEN(`T*/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9&ES<&QA>3II;FQI;F4[9F]N="US:7IE.C<P)3MV97)T:6-A;"UA;&EG
M;CIT97AT+71O<#L@/E1-(`T*/"]F;VYT/BP@82!M961I8V%L(&9O;V0@9F]R
M('1H92!D:65T87)Y(&UA;F%G96UE;G0@;V8@>FEN8R!D969I8VEE;F-Y(&%S
M<V]C:6%T960@=VET:"!!;'IH96EM97(F(S@R,3<[<R!D:7-E87-E+"!A;F0@
M/&9O;G0@<W1Y;&4],T1F;VYT+7-T>6QE.FET86QI8SMD:7-P;&%Y.FEN;&EN
M93L@/G=E;&Q::6X@#0H\+V9O;G0^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
M;&EN93MF;VYT+7-I>F4Z-S`E.W9E<G1I8V%L+6%L:6=N.G1E>'0M=&]P.R`^
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M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T-0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R
M.5\P.#AC-&1A,C`P-#4O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0F%S:7,@;V8@4')E<V5N
M=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VES($]F
M(%!R97-E;G1A=&EO;B!/9B!&:6YA;F-I86P@4W1A=&5M96YT(%1E>'0@0FQO
M8VL@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV
M('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!A8V-O;7!A
M;GEI;F<@=6YA=61I=&5D(&-O;F1E;G-E9"!I;G1E<FEM(&9I;F%N8VEA;"!S
M=&%T96UE;G1S(&AA=F4@8F5E;B!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I
M=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I
M;B!T:&4@56YI=&5D(%-T871E<R!O9B!!;65R:6-A(&%N9"!T:&4@<G5L97,@
M86YD(')E9W5L871I;VYS(&]F('1H92!5;FET960@4W1A=&5S(%-E8W5R:71I
M97,@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@9F]R(&EN=&5R:6T@9FEN86YC
M:6%L(&EN9F]R;6%T:6]N(&%N9"!W:71H('1H92!I;G-T<G5C=&EO;G,@=&\@
M1F]R;2`Q,"U1(&%N9"!!<G1I8VQE(#$P(&]F(%)E9W5L871I;VX@4RU8+@T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!F:6YA;F-I86P@:6YF;W)M871I
M;VX@87,@;V8@1&5C96UB97(@,S$L(#(P,3`L(&ES(&1E<FEV960@9G)O;2!T
M:&4@875D:71E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!P<F5S96YT960@:6X@
M=&AE($-O;7!A;GDF(S@R,3<[<R!!;FYU86P@4F5P;W)T(&]N($9O<FT@,3`M
M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3`N(%1H92!U
M;F%U9&ET960@8V]N9&5N<V5D(&EN=&5R:6T@9FEN86YC:6%L('-T871E;65N
M=',@<VAO=6QD(&)E(')E860@:6X@8V]N:G5N8W1I;VX@=VET:"!T:&4@0V]M
M<&%N>28C.#(Q-SMS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U++"!W:&EC
M:"!C;VYT86EN<R!T:&4@875D:71E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A
M;F0@;F]T97,@=&AE<F5T;RP@=&]G971H97(@=VET:"!T:&4@36%N86=E;65N
M="8C.#(Q-SMS($1I<V-U<W-I;VX@86YD($%N86QY<VES+"!F;W(@=&AE('EE
M87(@96YD960@1&5C96UB97(@,S$L(#(P,3`N#0H\+V9O;G0^#0H\+V1I=CX\
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M<'0[)R`^0V5R=&%I;B!I;F9O<FUA=&EO;B!O<B!F;V]T;F]T92!D:7-C;&]S
M=7)E<R!N;W)M86QL>2!I;F-L=61E9"!I;B!F:6YA;F-I86P@<W1A=&5M96YT
M<R!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@86-C;W5N=&EN9R!P<FEN
M8VEP;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E
M<R!O9B!!;65R:6-A(&AA=F4@8F5E;B!C;VYD96YS960@;W(@;VUI='1E9"P@
M<'5R<W5A;G0@=&\@=&AE(')U;&5S(&%N9"!R96=U;&%T:6]N<R!O9B!T:&4@
M4V5C=7)I=&EE<R!A;F0@17AC:&%N9V4@0V]M;6ES<VEO;B!F;W(@:6YT97)I
M;2!F:6YA;F-I86P@<F5P;W)T:6YG+B!!8V-O<F1I;F=L>2P@=&AE>2!D;R!N
M;W0@:6YC;'5D92!A;&P@=&AE(&EN9F]R;6%T:6]N(&%N9"!F;V]T;F]T97,@
M;F5C97-S87)Y(&9O<B!A(&-O;7!R96AE;G-I=F4@<')E<V5N=&%T:6]N(&]F
M(&9I;F%N8VEA;"!P;W-I=&EO;BP@<F5S=6QT<R!O9B!O<&5R871I;VYS+"!O
M<B!C87-H(&9L;W=S+B!)="!I<R!M86YA9V5M96YT)W,@;W!I;FEO;BP@:&]W
M979E<BP@=&AA="!A;&P@;6%T97)I86P@861J=7-T;65N=',@*&-O;G-I<W1I
M;F<@;V8@;F]R;6%L(')E8W5R<FEN9R!A9&IU<W1M96YT<RD@:&%V92!B965N
M(&UA9&4@=VAI8V@@87)E(&YE8V5S<V%R>2!F;W(@82!F86ER(&9I;F%N8VEA
M;"!S=&%T96UE;G0@<')E<V5N=&%T:6]N+B!4:&4@:6YT97)I;2!R97-U;'1S
M(&9O<B!T:&4@<&5R:6]D(&5N9&5D($IU;F4@,S`L(#(P,3$L(&%R92!N;W0@
M;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!R97-U;'1S(&9O<B!T:&4@9G5L
M;"!Y96%R+@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!#;VUP86YY(&AA
M<R!E:6=H="!S=6)S:61I87)I97,L(%!I<&5X(%1H97)A<&5U=&EC<RP@26YC
M+B`H)B,X,C(P.U!I<&5X(%1H97)A<&5U=&EC<R8C.#(R,3LI+"!!9&5O;F$@
M0VQI;FEC86P@3&%B;W)A=&]R>2`H9F]R;65R;'D@2&%R="!,86(L($Q,0RDL
M($5F9F5C=&EV92!0:&%R;6%C975T:6-A;',L($EN8RX@*"8C.#(R,#M%4$DF
M(S@R,C$[*2P@4V]L;W9A>"P@26YC+B`H)B,X,C(P.U-O;&]V87@F(S@R,C$[
M*2P@0T0T($)I;W-C:65N8V5S+"!);F,N("@F(S@R,C`[0T0T)B,X,C(Q.RDL
M($5P:71O<&4@4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[17!I=&]P
M928C.#(R,3LI+"!(96%L=&AM:6YE+"!);F,N("@F(S@R,C`[2&5A;'1H;6EN
M928C.#(R,3LI(&%N9"!0=71N97D@1')U9R!#;W)P+B`H)B,X,C(P.U!U=&YE
M>28C.#(R,3LI+B!!<R!O9B!*=6YE(#,P+"`R,#$Q+"!%4$DL($%D96]N82!#
M;&EN:6-A;"!,86)O<F%T;W)Y+"!(96%L=&AM:6YE(&%N9"!0=71N97D@87)E
M('=H;VQL>2!O=VYE9"!A;F0@4&EP97@@5&AE<F%P975T:6-S+"!3;VQO=F%X
M+"!#1#0@86YD($5P:71O<&4@87)E(&UA:F]R:71Y+6]W;F5D+@T*/"]F;VYT
M/@T*/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R
M,#`T-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D83`Y,#0Q9%\Y
M8S`W7S0P831?.3<R.5\P.#AC-&1A,C`P-#4O5V]R:W-H965T<R]3:&5E=#`Y
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-C
M;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\9&EV/CQD:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/C,N)B,Q-C`[)B,Q-C`[)B,Q
M-C`[4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4]
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M;&EM:6YA=&5D(&EN(&-O;G-O;&ED871I;VXN(`T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^
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M;V8@17-T:6UA=&5S(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE('!R
M97!A<F%T:6]N(&]F(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!I;B!C;VYF;W)M:71Y('=I=&@@56YI=&5D(%-T871E<R!G96YE<F%L;'D@
M86-C97!T960@86-C;W5N=&EN9R!P<FEN8VEP;&5S(')E<75I<F5S(&UA;F%G
M96UE;G0@=&\@;6%K92!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS('1H870@
M869F96-T('1H92!A;6]U;G1S(')E<&]R=&5D(&EN('1H92!C;VYS;VQI9&%T
M960@9FEN86YC:6%L('-T871E;65N=',@86YD(&%C8V]M<&%N>6EN9R!N;W1E
M<RX@4W5C:"!E<W1I;6%T97,@86YD(&%S<W5M<'1I;VYS(&EM<&%C="P@86UO
M;F<@;W1H97)S+"!T:&4@9F]L;&]W:6YG.B!T:&4@86UO=6YT(&%L;&]C871E
M9"!T;R!G;V]D=VEL;"P@=&AE(&5S=&EM871E9"!U<V5F=6P@;&EV97,F(S$V
M,#MF;W(@:6YT86YG:6)L92!A<W-E=',@86YD(&9O<B!P<F]P97)T>2!A;F0@
M97%U:7!M96YT+"!T:&4@9F%I<B!V86QU92!O9B!W87)R86YT<R!A;F0@<W1O
M8VL@;W!T:6]N<R!G<F%N=&5D(&9O<B!S97)V:6-E<R!O<B!C;VUP96YS871I
M;VXL(')E<W!E8W1I=F5L>2P@97-T:6UA=&5S(&]F('1H92!P<F]B86)I;&ET
M>2!A;F0@<&]T96YT:6%L(&UA9VYI='5D92!O9B!C;VYT:6YG96YT(&QI86)I
M;&ET:65S(&%N9"!T:&4@=F%L=6%T:6]N(&%L;&]W86YC92!F;W(@9&5F97)R
M960@=&%X(&%S<V5T<R!D=64@=&\@8V]N=&EN=6EN9R!O<&5R871I;F<@;&]S
M<V5S+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
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M(`T*/"]F;VYT/@T*/"]D:78^/&)R("\^#0H\8G(@+SX-"CQD:78@<W1Y;&4]
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M8V4@9F]R($1O=6)T9G5L($%C8V]U;G1S(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R
M("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^06-C;W5N=',@<F5C96EV86)L92!A<F4@<F5P;W)T960@870@<F5A
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M;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S+B`-"CPO9F]N=#X-"CPO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US
M='EL93II=&%L:6,[9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M4F5V96YU92!296-O9VYI=&EO;B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*
M#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M;&%B;W)A=&]R>2!R979E;G5E+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*
M#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L
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M+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
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M;W)Y(%)E=F5N=65S(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE($-O
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M9"!T:&4@97-T:6UA=&5D(')E8V5I<'1S(&9R;VT@<W5C:"!P87EE<G,N(`T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE($-O;7!A;GD@;6%I;G1A:6YS
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M9&5R<R!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N93,P+"`R,#$Q(&%N
M9"`R,#$P+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0T,"4@('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#X\='(^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(T)2`@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/D-U<W1O;65R(`T*/"]F
M;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E("!S
M='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Y)2!C;VQS
M<&%N/3-$,B`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/C(P,3$@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-"4@('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,C<E(&-O;'-P86X],T0R("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L
M86-K(#)P>"!S;VQI9#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT
M97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L
M87DZ:6YL:6YE.R`^,C`Q,"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4@;F]W<F%P/3-$
M;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@
M<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,C0E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D$@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)2!N;W=R
M87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(U)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C8X(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4@;F]W<F%P/3-$;F]W<F%P("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XE(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-"4@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0T)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C,E("!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^-C`@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0T)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M;W1T;VT@=VED=&@],T0T)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#0E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$-"4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(U)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C0@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T
M)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B4@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)2`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0R,R4@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XQ-B`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E(&YO=W)A<#TS1&YO=W)A<"`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)2`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL
M93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0R-"4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^0R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E(&YO=W)A<#TS
M1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-"4@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0T)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C4E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^,C`@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T)2!N;W=R87`],T1N;W=R87`@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B4@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0T)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
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M,2`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)2`-"CPO9F]N=#X-
M"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*)B,Q-C`[
M(`T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z:71A
M;&EC.V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/E)I<VMS(&%N
M9"!5;F-E<G1A:6YT:65S(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE
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M('!L86X@9G5T=7)E(&)U<VEN97-S(&%C=&EV:71I97,N(`T*/"]F;VYT/@T*
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M9#LG(#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(`T*/"]F;VYT/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.R`^/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU
M<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!H:6=H;'D@
M;&EQ=6ED(&EN=F5S=&UE;G1S('=I=&@@;W)I9VEN86P@;6%T=7)I=&EE<R!O
M9B!T:')E92!M;VYT:',@;W(@;&5S<R!A="!T:&4@=&EM92!O9B!P=7)C:&%S
M92!T;R!B92!C87-H(&5Q=6EV86QE;G1S+B8C,38P.R8C,38P.T%S(&]F($IU
M;F4@,S`L(#(P,3$L(&%N9"!$96-E;6)E<B`S,2P@,C`Q,"P@<F5S<&5C=&EV
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M)FYB<W`[)#(U,"PP,#`@<&5R(&1E<&]S:71O<BP@<&5R(&)A;FLN($%T($IU
M;F4S,"P@,C`Q,2!A;F0@1&5C96UB97(@,S$L(#(P,3`L('1H92!B86QA;F-E
M(&5X8V5E9&5D('1H92!F961E<F%L;'D@:6YS=7)E9"!L:6UI="!B>2`F;F)S
M<#LD-RXY(&UI;&QI;VX@86YD("9N8G-P.R0R+C$@;6EL;&EO;BP@<F5S<&5C
M=&EV96QY+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^5V%R<F%N="`O($1E<FEV871I=F4@
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M=&EV92!F:6YA;F-I86P@:6YS=')U;65N=',N(`T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^
M/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I
M9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^3VYC92!D971E<FUI;F5D+"!D97)I=F%T:79E(&QI86)I;&ET
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M.R<@/DYE="8C,38P.TEN8V]M92`H3&]S<RD@<&5R(%-H87)E(`T*/"]F;VYT
M/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^0F%S:6,@96%R;FEN9W,@*&QO<W,I('!E<B!S
M:&%R92!I<R!C;VUP=71E9"!B>2!D:79I9&EN9R!T:&4@;F5T(&EN8V]M92`H
M;&]S<RD@;&5S<R!P<F5F97)R960@9&EV:61E;F1S(&9O<B!T:&4@<&5R:6]D
M(&)Y('1H92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA
M<F5S(&]U='-T86YD:6YG+B!$:6QU=&5D(&5A<FYI;F=S("AL;W-S*2!P97(@
M<VAA<F4@:7,@8V]M<'5T960@8GD@9&EV:61I;F<@;F5T(&EN8V]M92`H;&]S
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M86QE;G1S(&%T($IU;F4@,S`L(#(P,3$@8V]N<VES="!O9B`R+#<X,2PP.3,@
M<W1O8VL@;W!T:6]N<R!A;F0@,RPS-C@L-S,X('=A<G)A;G1S+"!R97-P96-T
M:79E;'DL(&%N9"!F;W(@=&AE('!E<FEO9"!E;F1E9"!*=6YE(#,P+"`R,#$P
M(&-O;G-I<W0@;V8@,BPS,3(L-S4Y(&%N9"`Q+#`W,"PT-S(L(')E<W!E8W1I
M=F5L>2X@5&AE)B,Q-C`[8V]M<'5T871I;VYS(&]F(&)A<VEC(&%N9"!D:6QU
M=&5D(&YE="!I;F-O;64@*&QO<W,I(&%T=')I8G5T86)L92!T;R!C;VUM;VX@
M<VAA<F4@87)E(&%S(&9O;&QO=W,Z(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S
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M.R`^/&1I=CX\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4@('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\='(^/'1D('9A;&EG;CTS1&)O
M='1O;2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
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M/E1H<F5E)B,Q-C`[;6]N=&AS)B,Q-C`[96YD960F(S$V,#M*=6YE)B,Q-C`[
M,S`L(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
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M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R/CQT9"!V
M86QI9VX],T1B;W1T;VT@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T
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M/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR,#$Q(`T*/"]F;VYT
M/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL
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M<&QA>3II;FQI;F4[(#XR,#$P(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
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M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X
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M>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR,#$P(`T*/"]F;VYT/@T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@('-T>6QE/3-$=&5X
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M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DYE="!I;F-O;64@*&QO<W,I(`T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XF;F)S<#LD(`T*/"]F
M;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@
M9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN
M93L@/B@Q+#8W.2PX.34I(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ
M:6YL:6YE.R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT
M.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XY-SDL-S@R(`T*/"]F;VYT/@T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#XF;F)S<#LD(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG
M:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
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M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/BD@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O
M='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT
M97AT+6%L:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^)FYB<W`[
M)"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#XH,3`W+#<T,"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^*2`-"CPO9F]N=#X-"CPO9&EV
M/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC
M9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
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M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/D)A<VEC('=E:6=H=&5D+6%V97)A9V4@<VAA<F5S(`T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F
M=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L
M:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR-RPX.#4L-#<Y
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D
M9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN9RUB
M;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[
M=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@
M9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN
M93L@/C(Q+#<P-BPT-S(@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA
M8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
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M1&1I<W!L87DZ:6YL:6YE.R`^,C8L-38P+#0T."`-"CPO9F]N=#X-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N
M.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR,2PV,S,L.3@U(`T*
M/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN
M9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A
M8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CL@/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0U,B4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO
M='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/D5F9F5C="!O9B!D:6QU=&EV92!S96-U<FET:65S.B`-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
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M.C$P<'0[)R`^4W1O8VL@;W!T:6]N<R`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
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M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,3<U+#4R
M-R`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XM(`T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M;BUL969T.CEP=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/E=A<G)A;G1S(`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG
M(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^+2`-"CPO9F]N=#X-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H
M=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N
M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,2PT,34@#0H\+V9O;G0^#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ;&5F
M=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI
M9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/BT@#0H\+V9O;G0^
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR<'@[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ
M;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M
M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/BT@#0H\+V9O
M;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O
M='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#4R)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ-'!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y$
M:6QU=&EV928C,38P.R8C,38P.W=E:6=H=&5D+6%V97)A9V4@<VAA<F5S(`T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M
M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M
M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L
M93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR
M-RPX.#4L-#<Y(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P
M>"!D;W5B;&4[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P
M;&%Y.FEN;&EN93L@/C(Q+#@X,RPT,30@#0H\+V9O;G0^#0H\+V9O;G0^#0H\
M+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,C8L-38P+#0T."`-"CPO9F]N
M=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T
M=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT
M97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XR,RPW
M.#(L,#$P(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S
M='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0U,B4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F
M9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO
M<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HY<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y"87-I8R`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L
M:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^)FYB<W`[)"`-"CPO
M9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X
M(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[(#XH,"XP-B`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XI)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@
M-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL
M:6YE.R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T
M>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XP+C`U(`T*/"]F;VYT/@T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H
M=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@
M-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL
M:6YE.R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T
M>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XH,"XQ-2`-"CPO9F]N=#X-"CPO9F]N
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^*2`-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HT<'@[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N
M.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\
M9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^)FYB<W`[)"`-"CPO9F]N
M=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O
M=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[
M(#XH,"XP,"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@
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M="US:7IE.C$P<'0[)R`^*2`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO
M='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
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M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D1I;'5T:79E
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T
M=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E
M>'0M86QI9VXZ;&5F=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XF;F)S<#LD
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93L@/B@P+C`V(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/BDF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#XF;F)S<#LD(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG
M:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C`N,#4@#0H\+V9O;G0^#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#XF;F)S<#LD(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG
M:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
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M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/BD@#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN9RUB;W1T;VTZ
M-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
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M)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/B9N8G-P.R0@#0H\
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M:6YE.R`^*#`N,#`@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/BD@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO
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M;VUP86YY)B,X,C$W.W,@<')O9'5C="!C86YD:61A=&5S+B`-"CPO9F]N=#X-
M"CPO9&EV/CQB<B`O/@T*/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[)R`^4VAA<F4M0F%S960@4&%Y;65N="!!<G)A;F=E
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M:&4@<V5R=FEC97,@<')O=FED960N(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S
M='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^
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M;W5N=&EN9R!0<F]N;W5N8V5M96YT<R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@
M<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O
M/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/DEN($IU;F4@,C`Q,2P@=&AE($9!4T(@=7!D871E9"!T:&4@86-C;W5N
M=&EN9R!G=6ED86YC92!O;B!4;W!I8R`R,C`L(&5N=&ET;&5D("8C.#(R,#M#
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M:61A;F-E(&ES(&5F9F5C=&EV92!B96=I;FYI;F<@,C`Q,BX@5&AE(&%D;W!T
M:6]N(&]F('1H:7,@9W5I9&%N8V4@:7,@;F]T(&5X<&5C=&5D('1O(&AA=F4@
M82!M871E<FEA;"!I;7!A8W0@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!F:6YA
M;F-I86P@<&]S:71I;VX@;W(@<F5S=6QT<R!O9B!O<&5R871I;VYS+B`-"CPO
M9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#XF(S$V,#L@#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DEN($IU;F4@,C`Q,2P@=&AE
M($9!4T(@=7!D871E9"!T:&4@86-C;W5N=&EN9R!G=6ED86YC92!O;B!A;&EG
M;FUE;G0@;V8@9&ES8VQO<W5R97,@9F]R($=!05`@86YD('1H92!);G1E<FYA
M=&EO;F%L($9I;F%N8VEA;"!297!O<G1I;F<@4W1A;F1A<F1S+"!O<B!)1E)3
M+"!B>2!U<&1A=&EN9R!4;W!I8R`X,C`@96YT:71L960@)B,X,C(P.T%M96YD
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M9B!O<&5R871I;VYS+B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93II=&%L:6,[9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^4F5C;&%S<VEF:6-A=&EO;G,@
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M871I;VYS(&]R(&-A<V@@9FQO=W,N(`T*/"]F;VYT/@T*/"]D:78^#0H\+V1I
M=CX-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9&$P.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V1A,#DP-#%D7SEC,#=?-#!A
M-%\Y-S(Y7S`X.&,T9&$R,#`T-2]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4R2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A
M;F0@17%U:7!M96YT/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;5&5X="!"
M;&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ:G5S=&EF
M>3L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB
M;VQD.R<@/C0N)B,Q-C`[)B,Q-C`[)B,Q-C`[4')O<&5R='D@86YD($5Q=6EP
M;65N=`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0@8V]N<VES=&5D(&]F('1H92!F;VQL;W=I;F<@870@2G5N92`S,"P@
M,C`Q,2P@86YD($1E8V5M8F5R(#,Q+"`R,#$P+@T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ;&5F
M=#L@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N
M=&5R.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0X,"4@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-S8E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/DIU;F4F(S$V
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M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D
M:7-P;&%Y.FEN;&EN93L@/D1E8V5M8F5R)B,Q-C`[,S$L)B,Q-C`[,C`Q,`T*
M/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O
M;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E
M(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ
M=7-T:69Y.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/DQE87-E
M:&]L9"!I;7!R;W9E;65N=',-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C(L,#<P#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M.#8T+#0R.0T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC
M;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V
M)2`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ
M:G5S=&EF>3L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y-86YU
M9F%C='5R:6YG(&5Q=6EP;65N=`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XT,#`L,#0U
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
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M(#XT,3`L.3DW#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD
M+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-S8E(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG
M;CIJ=7-T:69Y.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D-O
M;7!U=&5R(&%N9"!O9F9I8V4@97%U:7!M96YT#0H\+V9O;G0^#0H\+V1I=CX-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<-"B`^,38P+#0W.`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$
M8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<V)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P>#L@/CQD
M:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.FIU<W1I
M9GD[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3&%B;W)A=&]R
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.G)I9VAT.R<@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ
M:6YL:6YE.R`^,C$S+#DP.`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR
M:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@
M<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C(Q,RPY,#@-"CPO9F]N=#X-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO
M=W)A<#TS1&YO=W)A<"!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG
M+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K
M9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$-S8E('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL
M93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.CEP=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y4;W1A;`T*/"]F;VYT/@T*/"]D
M:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M=#LG(#XW-S8L-3`Q#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
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M=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#Y,97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;@T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P>#MT97AT+6%L:6=N.G)I9VAT
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG
M;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E
M>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B@S.#`L,S4W(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
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M>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R
M<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B@Q+#$S."PV-S`@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIJ=7-T:69Y.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E!R;W!E<G1Y(&%N9"!E<75I<&UE
M;G0L(&YE=`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C1P>#MT
M97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@
M9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL
M93TS1'!A9&1I;F<M8F]T=&]M.C1P>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F
M=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M
M86QI9VXZ<FEG:'0[)R`^/&9O;G0-"B!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^-3$Q+#$T,@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
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M9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#Y4:&4@9&5C<F5A<V4@:6X@;&5A<V5H;VQD
M(&EM<')O=F5M96YT<R!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N
M92`S,"P@,C`Q,2P@<F5F;&5C=',@=&AE(')E;&]C871I;VX@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!H96%D<75A<G1E<G,@=VET:&EN($%N;B!!<F)O<BP@
M36EC:&EG86XN)B,Q-C`[)B,Q-C`[1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N
M9&5D($IU;F4@,S`L(#(P,3$L('1H92!#;VUP86YY('-O;&0@97%U:7!M96YT
M+"!W:71H(&$@;F5T(&)O;VL@=F%L=64@;V8@)FYB<W`[)#8L.#DR+"!F;W(@
M)FYB<W`[)#$L,C`P+"!R97-U;'1I;F<@:6X@82!L;W-S(&]F("9N8G-P.R0U
M+#8Y,BX-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#MT97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D1E<')E8VEA=&EO;B!E>'!E;G-E
M(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$Q(&%N9"`R
M,#$P('=A<R`F;F)S<#LD,3`X+#$P-B!A;F0@)FYB<W`[)#$X,"PP-S8L(')E
M<W!E8W1I=F5L>2X-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D83`Y,#0Q9%\Y8S`W
M7S0P831?.3<R.5\P.#AC-&1A,C`P-#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO9&$P.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U
M+U=O<FMS:&5E=',O4VAE970Q,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CQB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$Q/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I
M<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',L(%-H87)E
M+6)A<V5D(%!A>6UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ES8VQO<W5R92!O9B!#;VUP96YS
M871I;VX@4F5L871E9"!#;W-T<RP@4VAA<F4M8F%S960@4&%Y;65N=',@6U1E
M>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[)R`^-2XF(S$V,#LF(S$V,#LF(S$V,#M3=&]C:RU"
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M=7)I;F<@,C`P,2P@4&EP97@@5&AE<F%P975T:6-S)B,X,C$W.R!B;V%R9"!O
M9B!D:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R<R!A9&]P=&5D('1H92`R,#`Q
M(%-T;V-K($EN8V5N=&EV92!0;&%N("AT:&4@)B,X,C(P.S(P,#$@4W1O8VL@
M4&QA;B8C.#(R,3LI+B!4:&ES('!L86X@=V%S(&%S<W5M960@8GD@4&EP97@@
M:6X@=&AE($]C=&]B97(@,C`P-B!M97)G97(@=VET:"!3:&5F9FEE;&0N($%S
M(&]F('1H92!D871E(&]F('1H92!M97)G97(L('1H97)E('=E<F4@,2PT.#DL
M,S4S(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!U;F1E<B!T:&4@
M,C`P,2!P;&%N+B!4:&4@=&]T86P@;G5M8F5R(&]F('-H87)E<R!O9B!S=&]C
M:R!W:71H(')E<W!E8W0@=&\@=VAI8V@@<W1O8VL@;W!T:6]N<R!A;F0@<W1O
M8VL@87!P<F5C:6%T:6]N(')I9VAT<R!M87D@8F4@9W)A;G1E9"!T;R!A;GD@
M;VYE(&5M<&QO>65E(&]F('1H92!#;VUP86YY(&]R(&$@<W5B<VED:6%R>2!D
M=7)I;F<@86YY(&]N92UY96%R('!E<FEO9"!U;F1E<B!T:&4@,C`P,2!P;&%N
M('-H86QL(&YO="!E>&-E960@,C4P+#`P,"X@06QL(&%W87)D<R!P=7)S=6%N
M="!T;R!T:&4@,C`P,2!3=&]C:R!0;&%N('-H86QL('1E<FUI;F%T92!U<&]N
M('1H92!T97)M:6YA=&EO;B!O9B!T:&4@9W)A;G1E928C.#(Q-SMS(&5M<&QO
M>6UE;G0@9F]R(&%N>2!R96%S;VXN($%W87)D<R!I;F-L=61E(&]P=&EO;G,L
M(')E<W1R:6-T960@<VAA<F5S+"!S=&]C:R!A<'!R96-I871I;VX@<FEG:'1S
M+"!P97)F;W)M86YC92!S:&%R97,@86YD(&-A<V@M8F%S960@87=A<F1S("AT
M:&4@)B,X,C(P.T%W87)D<R8C.#(R,3LI+B!4:&4@,C`P,2!3=&]C:R!0;&%N
M(&-O;G1A:6YS(&-E<G1A:6X@86YT:2UD:6QU=&EO;B!P<F]V:7-I;VYS(&EN
M('1H92!E=F5N="!O9B!A('-T;V-K('-P;&ET+"!S=&]C:R!D:79I9&5N9"!O
M<B!O=&AE<B!C87!I=&%L(&%D:G5S=&UE;G0L(&%S(&1E9FEN960@:6X@=&AE
M('!L86XN(%1H92`R,#`Q(%-T;V-K(%!L86X@<')O=FED97,@9F]R(&$@0V]M
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M92`S,"P@,C`Q,2P@=&AE<F4@=V5R92`Q+#,R,"PS-30@;W!T:6]N<R!I<W-U
M960@86YD(&]U='-T86YD:6YG('5N9&5R('1H92`R,#`Q(%-T;V-K(%!L86XN
M(`T*/"]F;VYT/@T*/"]D:78^/&)R("\^#0H\8G(@+SX-"CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@36%R8V@@,C`L(#(P,#<L
M('1H92!#;VUP86YY)B,X,C$W.W,@8F]A<F0@;V8@9&ER96-T;W)S(&%P<')O
M=F5D('1H92!#;VUP86YY)B,X,C$W.W,@,C`P-R!3=&]C:R!);F-E;G1I=F4@
M4&QA;B`H=&AE("8C.#(R,#LR,#`W(%-T;V-K(%!L86XF(S@R,C$[*2!F;W(@
M=&AE(&ES<W5A;F-E(&]F('5P('1O(#(L-3`P+#`P,"!S:&%R97,@;V8@8V]M
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M<R!A<'!R;W9E9"!B>2!S=&]C:VAO;&1E<G,@;VX@3F]V96UB97(@,BP@,C`P
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M87(@<&5R:6]D('5N9&5R('1H92`R,#`Q('!L86X@<VAA;&P@;F]T(&5X8V5E
M9"`R-3`L,#`P+B!/<'1I;VYS(&)E8V]M92!E>&5R8VES86)L92!O=F5R('9A
M<FEO=7,@<&5R:6]D<R!F<F]M('1H92!D871E(&]F(&=R86YT+"!A;F0@9V5N
M97)A;&QY(&5X<&ER92!T96X@>65A<G,@869T97(@=&AE(&=R86YT(&1A=&4N
M($%S(&]F($IU;F4@,S`L(#(P,3$L('1H97)E(&%R92`Q+#(R."PR,SD@;W!T
M:6]N<R!I<W-U960@86YD(&]U='-T86YD:6YG('5N9&5R('1H92`R,#`W(%-T
M;V-K(%!L86XN(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@3F]V96UB
M97(@,BP@,C`Q,"P@=&AE(&)O87)D(&]F(&1I<F5C=&]R<R!A;F0@<W1O8VMH
M;VQD97)S(&%D;W!T960@=&AE(#(P,3`@4W1O8VL@26YC96YT:79E(%!L86X@
M*"8C.#(R,#LR,#$P(%-T;V-K(%!L86XF(S@R,C$[*2!F;W(@=&AE(&ES<W5A
M;F-E(&]F('5P('1O(#,L,#`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
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M('-T;V-K(&]P=&EO;G,@=6YD97(@=&AE(#(P,3`@4W1O8VL@4&QA;B!I<R!D
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M="!D871E+B!!<R!O9B!*=6YE(#,P+"`R,#$Q+"!T:&5R92!A<F4@,C,R+#4P
M,"!O<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@=6YD97(@=&AE(#(P
M,3`@4W1O8VL@4&QA;BX@#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$
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M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^5&AE($-O;7!A;GD@:&%S(&%P<&QI960@9F%I<B!V86QU92!A8V-O=6YT
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M92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,3%A;F0@,C`Q,"P@87)E
M(&%S(&9O;&QO=W,Z(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ8V5N=&5R.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Y,"4@('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\='(^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&1I=B!S='EL93TS1'1E>'0M
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M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
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M1&1I<W!L87DZ:6YL:6YE.R`^5&AR964F(S$V,#M-;VYT:',F(S$V,#M%;F1E
M9"8C,38P.TIU;F4F(S$V,#LS,"P@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^4VEX)B,Q-C`[36]N=&AS)B,Q
M-C`[16YD960F(S$V,#M*=6YE)B,Q-C`[,S`L(`T*/"]F;VYT/@T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M#0H\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S(E("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE
M/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X]
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M:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,C`Q
M,2`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
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M,T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL
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M;FQI;F4[(#XR,#$P(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB
M;VQD.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P>#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#(P)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R
M<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
M;&EN93L@/C(P,3$@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,C`E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P
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M:6YE.R`^,C`Q,"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
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M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/D5X97)C:7-E('!R:6-E(`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M;F)S<#LD(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XQ+C<S(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/BT@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C`E("!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0@#0H\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$N,C$F(S$V,#LM)B,Q-C`[)FYB<W`[
M)#(N,C(@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E("!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B9N8G-P.R0@#0H\+V9O;G0^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/C`N.#(@+2`F;F)S<#LD,"XX-R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-
M"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)2`^/&1I=B!S='EL93TS
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)2`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^+2`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XP)2`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
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M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"4@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^17AP96-T960@
M=F]L871I;&ET>2`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XQ.#0@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B4@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/BT@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E("!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M,3@T)2`M(#$X."4@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,C`E("!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/C(P,R4@+2`R,#0E(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/@T*/"]T
M<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,S(E(#X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E)I<VL@9G)E92!I;G1E<F5S="!R871E
M<R`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XR
M+C@X(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XE(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XM(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#(P)2`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
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M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C`E("!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^,RXU.24@+2`S+C8S)2`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^
M/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#,R)2`^/&1I=B!S='EL93TS1'1E>'0M
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M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E(&-O;'-P86X],T0R("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XW)B,Q-C`[>65A
M<G,@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XM(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.F-E;G1E<CL@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E
M<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XU('EE87)S("T@-R!Y96%R<R`-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(P)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.F-E;G1E<CL@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XQ,"8C,38P.WEE87)S(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S
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M="US:7IE.C$P<'0[)R`^17AP96-T960@9F]R9F5I='5R97,@#0H\+V9O;G0^
M#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)2`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE("!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^+2`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
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M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XP)2`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"4@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M(&9O;&QO=W,Z(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD
M:78^/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#X\='(@=F%L:6=N/3-$=&]P(#X\=&0@<W1Y;&4],T1W:61T:#HQ.'!T
M.R`^/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!S='EL93TS1'=I9'1H.C$X
M<'0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G-Y;6)O;"P@<V5R:68[9F]N="US:7IE.C$P<'0[)R`^)B,Q.#,[
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9#X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N="US
M:7IE.C$P<'0[(#YI;6UE9&EA=&4@=F5S=&EN9RP@#0H\+V9O;G0^#0H\+V9O
M;G0^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-"CPO9&EV/CQD
M:78^/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#X\='(@=F%L:6=N/3-$=&]P(#X\=&0@<W1Y;&4],T1W:61T:#HQ.'!T
M.R`^/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!S='EL93TS1'=I9'1H.C$X
M<'0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G-Y;6)O;"P@<V5R:68[9F]N="US:7IE.C$P<'0[)R`^)B,Q.#,[
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9#X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M:78^/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#$P,"4@('-T>6QE/3-$)W1E>'0M86QI9VXZ8V5N
M=&5R.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#X\='(@=F%L:6=N/3-$=&]P(#X\=&0@<W1Y;&4],T1W:61T:#HQ.'!T
M.R`^/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!S='EL93TS1'=I9'1H.C$X
M<'0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G-Y;6)O;"P@<V5R:68[9F]N="US:7IE.C$P<'0[)R`^)B,Q.#,[
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9#X\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N="US
M:7IE.C$P<'0[(#YQ=6%R=&5R;'D@;W9E<B!T:')E92!Y96%R<RP@#0H\+V9O
M;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X-
M"CPO9&EV/CQD:78^/'1A8FQE(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4@('-T>6QE/3-$)W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#X\='(@=F%L:6=N/3-$=&]P(#X\=&0@<W1Y;&4],T1W
M:61T:#HQ.'!T.R`^/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!S='EL93TS
M1'=I9'1H.C$X<'0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G-Y;6)O;"P@<V5R:68[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q.#,[(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[9F]N="US:7IE.C$P<'0[(#YA;FYU86QL>2!O=F5R('1H<F5E('EE87)S
M+"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/"]D:78^/&1I=CX\=&%B;&4@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQT<B!V86QI9VX],T1T;W`@/CQT9"!S
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ<WEM8F]L+"!S97)I9CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$X,SL@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-
M"CPO=&0^/'1D/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P
M;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/F]N92UT:&ER9"!I;6UE9&EA
M=&4@=F5S=&EN9R!A;F0@<F5M86EN:6YG(&%N;G5A;&QY(&]V97(@='=O('EE
M87)S+"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/"]D:78^/&1I=CX\=&%B;&4@8F]R9&5R/3-$,"!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)2`@<W1Y
M;&4],T0G=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQT<B!V86QI9VX],T1T;W`@/CQT
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ<WEM8F]L+"!S97)I9CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$X,SL@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D
M:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/F]N92UH86QF(&EM;65D
M:6%T92!V97-T:6YG('=I=&@@<F5M86EN:6YG('9E<W1I;F<@;W9E<B!N:6YE
M(&UO;G1H<SL@86YD(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/@T*/"]T<CX-"CPO=&%B;&4^#0H\+V1I=CX\9&EV/CQT86)L92!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E("!S='EL93TS1"=T97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R('9A;&EG;CTS
M1'1O<"`^/'1D('-T>6QE/3-$=VED=&@Z,3AP=#L@/CQD:78^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV
M/@T*/"]T9#X\=&0@<W1Y;&4],T1W:61T:#HQ.'!T.R`^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IS>6UB;VPL('-E
M<FEF.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,3@S.R`-"CPO9F]N=#X-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]T9#X\=&0^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^;VYE('%U
M87)T97(@:6UM961I871E('9E<W1I;F<@=VET:"!T:&4@<F5M86EN:6YG(&]V
M97(@=&AR964@>65A<G,N(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\
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M=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2P@=&AE($-O;7!A
M;GD@9W)A;G1E9"`S,S(L,#`R(&]P=&EO;G,@=&\@96UP;&]Y965S(&%N9"!C
M;VYS=6QT86YT<R!H879I;F<@82!F86ER('9A;'5E(&]F("9N8G-P.R0T-#4N
M-C<Q(&)A<V5D('5P;VX@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I
M;F<@;6]D96PN)B,Q-C`[($1U<FEN9R!T:&4@<V%M92!P97)I;V0@;V8@,C`Q
M,"P@=&AE($-O;7!A;GD@9W)A;G1E9"`T,C4L,#`P(&]P=&EO;G,@=&\@96UP
M;&]Y965S(&AA=FEN9R!A(&9A:7(@=F%L=64@;V8@)FYB<W`[)#,T.2PW-3`@
M8F%S960@=7!O;B!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M
M;V1E;"X@#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^3VX@2F%N=6%R>2`Q."P@
M,C`Q,2P@=&AE($-O;7!A;GD@86UE;F1E9"!T:&4@=&5R;7,@;V8@,C(X+#<W
M,R!S=&]C:R!O<'1I;VYS(&AE;&0@8GD@82!M96UB97(@;V8@=&AE($)O87)D
M(&]F($1I<F5C=&]R<RXF(S$V,#LF(S$V,#M);B!C;VYN96-T:6]N('=I=&@@
M=&AE(&UO9&EF:6-A=&EO;BP@=&AE($-O;7!A;GD@97AT96YD960@=&AE(&5X
M<&ER871I;VX@9&%T92!O9B!T:&4@<W1O8VL@;W!T:6]N<R!B>2`U('EE87)S
M+B8C,38P.R8C,38P.U1H92!E>'1E;G-I;VX@:7,@8V]N<VED97)E9"!A(&UO
M9&EF:6-A=&EO;BP@=VAI8V@@:6X@<W5B<W1A;F-E(&ES('1H92!I<W-U86YC
M92!O9B!A(&YE=R!S=&]C:R!O<'1I;VX@87=A<F0N)B,Q-C`[)B,Q-C`[07,@
M82!R97-U;'0L('1H92!#;VUP86YY(&-O;7!U=&5D('1H92!F86ER('9A;'5E
M(&]F('1H:7,@87=A<F0@=&\@8F4@)FYB<W`[)#,Y-RPW-C<L('5S:6YG('1H
M92!";&%C:RU38VAO;&5S('9A;'5A=&EO;B!M;V1E;"XF(S$V,#LF(S$V,#LF
M(S$V,#M4:&4@9F%I<B!V86QU92!W87,@8F%S960@=7!O;B!T:&4@9F]L;&]W
M:6YG(&UA;F%G96UE;G0@87-S=6UP=&EO;G,Z(`T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.R`^/&1I=CX-"CQT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E
M("!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F
M9F-C.R`^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#@P)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^17AE<F-I<V4@<')I8V4@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0R,"4@('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)#`N,#D@
M#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD
M+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.#`E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^17AP96-T960@9&EV:61E;F1S(`T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R,"4@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XP)2`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#@P)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D5X<&5C=&5D('9O;&%T:6QI='D@#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#(P)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$X
M-RXQ)2`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE
M/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#@P)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D5X<&5C=&5D('1E<FT@
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#(P)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/C4@>65A<G,@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/CQT<B!S
M='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0X,"4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y2:7-K(&9R964@
M:6YT97)E<W0@<F%T92`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,C`E(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^,BXP,R4@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M#0H\+W1R/@T*/"]T86)L93X-"@T*/"]D:78^#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D$@<W5M;6%R
M>2!O9B!S=&]C:R!O<'1I;VX@86-T:79I=&EE<R!A<R!O9B!*=6YE(#,P+"`R
M,#$Q+"!A;F0@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$P
M+"!I<R!A<R!F;VQL;W=S.B`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\8G(@+SX-
M"@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQT86)L
M92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P
M)2`@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-3(E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
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M)R`^3W!T:6]N<R`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
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M;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\
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M;VYT+7-I>F4Z,3!P=#LG(#Y796EG:'1E9"`-"CPO9F]N=#X-"CPO9F]N=#X-
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M(#Y!=F5R86=E(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.T5X97)C:7-E
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E!R:6-E(`T*/"]F;VYT/@T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A
M9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MF;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[
M)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E=E:6=H=&5D)B,Q
M-C`[079E<F%G92`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y
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M9F]N="US:7IE.C$P<'0[)R`^0V]N=')A8W1U86P@#0H\+V9O;G0^#0H\+V9O
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M<'0[)R`^3&EF92`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN
M9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O
M;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^06=G<F5G871E(`T*
M/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/DEN=')I;G-I8R`-"CPO9F]N=#X-"CPO9F]N
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M=#LG(#Y686QU92`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L
M9#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4]
M,T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$-3(E(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T
M:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/D)A;&%N8V4@)B,X,C$Q.R!$96-E;6)E<B`S,2P@,C`P.2`-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XR+#4V,2PS,S(@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$N
M,C8@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
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M1#(@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T
M>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4R)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M:G5S=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#Y'<F%N=&5D(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/C<T,RPS,S(@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^,"XX,"`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
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M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D5X97)C:7-E9"`-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XH(#(U-2PY-30@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/BD@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`N-#0@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
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M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$
M8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#4R)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D9O<F9E:71E
M9"!O<B!E>'!I<F5D(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^*#4P.2PV,3D@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R
M87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M
M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XI
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M
M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O
M;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XP+C8Y
M(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
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M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG
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M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/D)A;&%N8V4@)B,X,C$Q.R!$96-E;6)E<B`S
M,2P@,C`Q,"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XR+#4S.2PP.3$@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE("!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^,2XS,B`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=PT*(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E
M(&-O;'-P86X],T0R("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^1W)A;G1E9"`-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XS,S(L,#`R(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$N-C$@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
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M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N
M9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4R)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y&
M;W)F96ET960@;W(@97AP:7)E9"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XH
M.#`L,#`P(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XI(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XP+C4V(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E(&-O;'-P86X],T0R("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`]
M,T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CL@
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@('-T>6QE/3-$<&%D
M9&EN9RUB;W1T;VTZ,G!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S
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M86QI9VXZ<FEG:'0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE("!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.G)I
M9VAT.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XH,3`L,#`P
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP
M861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^*2`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI
M9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
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M)R`^,"XU-B`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W
M<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG
M+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,3`E(&-O;'-P86X],T0R("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-
M"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4R)2`@<W1Y;&4],T1P861D
M:6YG+6)O='1O;3HT<'@[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T
M:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/D)A;&%N8V4@)B,X,C$Q.R!*=6YE(#,P+"`R,#$Q("T@;W5T
M<W1A;F1I;F<@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K
M(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XR+#<X,2PP.3,@#0H\+V9O;G0^#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N
M;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M
M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M
M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)FYB<W`[)"`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#DE("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D
M;W5B;&4[=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^,2XS."`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
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M="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/C8N,S@@>65A<G,@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG
M+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O
M=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B9N8G-P.R0@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C0S,2PU,#@@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P
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M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R
M87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R
M/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0U,B4@('-T>6QE/3-$<&%D9&EN9RUB
M;W1T;VTZ-'!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#Y"86QA;F-E("8C.#(Q,3L@2G5N92`S,"P@,C`Q,2`F(S@R,3$[(&5X
M97)C:7-A8FQE(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
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M="US:7IE.C$P<'0[)R`^,BPR.3DL,3@Y(`T*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT
M+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B9N8G-P.R0@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@
M9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/C$N-3`@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D
M:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R("!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.F)L86-K(#1P>"!D;W5B;&4[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XU+CDU('EE87)S(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[<&%D9&EN
M9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D
M;W5B;&4[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF;F)S<#LD(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XT,#(L-30Y(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W
M<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
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M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H
M92!O<'1I;VYS(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!A<R!O9B!*
M=6YE(#,P+"`R,#$Q+"!A<F4@87,@9F]L;&]W<SH@#0H\+V9O;G0^#0H\+V1I
M=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78^/&1I=CX\
M9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E("!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R/CQT
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M1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,R4@
M8V]L<W!A;CTS1#<@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X
M('-O;&ED.R<@/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA
M>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT
M+6%L:6=N.F-E;G1E<CL@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IB;VQD.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[(#Y/<'1I;VYS)B,Q-C`[3W5T<W1A;F1I;F<-"CPO9F]N=#X-"CPO9F]N
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M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^3W!T:6]N<R8C,38P
M.T5X97)C:7-A8FQE#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M#0H\+W1R/CQT<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O
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M.R`^4F%N9V4F(S$V,#MO9@T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/D5X97)C:7-E
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M93TS1&1I<W!L87DZ:6YL:6YE.R`^4')I8V4-"CPO9F]N=#X-"CPO9F]N=#X-
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M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R("!S='EL93TS
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M9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^3G5M8F5R#0H\+V9O;G0^
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M87DZ:6YL:6YE.R`^;W5T<W1A;F1I;F<-"CPO9F]N=#X-"CPO9F]N=#X-"CPO
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M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIC
M96YT97([)R`^/&1I=CX\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N
M="UW96EG:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE
M.R`^5V5I9VAT960-"CPO9F]N=#X-"CPO9F]N=#X@#0H\+V1I=CX\9&EV/CQF
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M:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^4')I
M8V4-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
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M>3II;FQI;F4[(#Y796EG:'1E9`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N
M=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/D%V97)A
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M:6YL:6YE.R`^0V]N=')A8W1U86P@3&EF90T*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N
M;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF
M;VYT+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
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M87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M
M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IB;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I
M9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
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M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y796EG:'1E9`T*/"]F;VYT/@T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
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M:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y
M;&4],T1D:7-P;&%Y.FEN;&EN93L@/E!R:6-E#0H\+V9O;G0^#0H\+V9O;G0^
M#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
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M>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y796EG:'1E9`T*/"]F;VYT/@T*/"]F
M;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E
M>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN
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M/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S<#LD#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N="US:7IE
M.C$P<'0[(#XP+C`Y("T@-"XU-PT*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE
M/3-$9&ES<&QA>3II;FQI;F4[9F]N="US:7IE.C$P<'0[(#XF(S$V,#L-"CPO
M9F]N=#X@/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z
M,3!P=#L@/C(L-CDQ+#`Y-`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@
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M<'0[)R`^)FYB<W`[)`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M8V5N=&5R.R`^-BXT."!Y96%R<PT*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M
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M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[
M9F]N="US:7IE.C$P<'0[(#XF(S$V,#L-"CPO9F]N=#X@/&9O;G0@<W1Y;&4]
M,T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C(L,C`Y+#$Y,`T*
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R`^,2XS,@T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#(P)2`^/&1I=B!S='EL93TS1'1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/C8N,#8@>65A<G,-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F
M9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF;F)S<#LD#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I
M;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R`^-"XU."`M(#DN,#4-"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T.R<@
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^)B,Q
M-C`[#0H\+V9O;G0^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/B8C
M,38P.PT*/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N
M="US:7IE.C$P<'0[(#XX.2PY.3D-"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H
M=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\9F]N
M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^-2XY,PT*/"]F;VYT/@T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[=&5X="UA;&EG;CIR
M:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E
M("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT
M+6%L:6=N.F-E;G1E<CLG(#XS+C(V('EE87)S#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I
M;F<M8F]T=&]M.C)P>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H
M=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y
M;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/B8C,38P.PT*
M/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XF(S$V,#L-
M"CPO9F]N=#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R`^.#DL.3DY#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS
M1'!A9&1I;F<M8F]T=&]M.C)P>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG
M;CIR:6=H=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/B8C
M,38P.PT*/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XF
M(S$V,#L-"CPO9F]N=#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R`^-2XY,PT*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
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M1&1I<W!L87DZ:6YL:6YE.R`^,RXR-B!Y96%R<PT*/"]F;VYT/@T*/"]F;VYT
M/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD
M+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
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M:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I
M;F<M8F]T=&]M.C1P>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O
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M='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^)B,Q-C`[
M#0H\+V9O;G0^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/B8C,38P
M.PT*/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N="US
M:7IE.C$P<'0[(#XR+#<X,2PP.3,-"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93LG(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I
M9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF
M;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ+C,X#0H\+V9O;G0^#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E("!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C1P>#MT97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT
M97AT+6%L:6=N.F-E;G1E<CLG(#XV+C,X('EE87)S#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A
M9&1I;F<M8F]T=&]M.C1P>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^)B,Q
M-C`[#0H\+V9O;G0^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/B8C
M,38P.PT*/"]F;VYT/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[9F]N
M="US:7IE.C$P<'0[(#XR+#(Y.2PQ.#D-"CPO9F]N=#X-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ
M-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ-'!X.W1E>'0M86QI9VXZ<FEG:'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI
M9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB
M<W`[)`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L
M93MT97AT+6%L:6=N.G)I9VAT.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R`^,2XU,`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P
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M92`S,"P@,C`Q,"P@87)E(&%S(&9O;&QO=W,Z(`T*/"]F;VYT/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/@T*/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&1I=CX\9&EV/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Q,#`E("!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4@8V]L<W!A;CTS1#(@('-T>6QE/3-$<&%D
M9&EN9RUB;W1T;VTZ,G!X.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE
M/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T,R4@8V]L<W!A;CTS
M1#<@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.R<@
M/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.F-E
M;G1E<CL@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H
M=#IB;VQD.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y/<'1I
M;VYS)B,Q-C`[3W5T<W1A;F1I;F<-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV
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M='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^3W!T:6]N<R8C,38P.T5X97)C:7-A
M8FQE#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/CQT
M<CX\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R
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M8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^4F%N9V4F
M(S$V,#MO9@T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/D5X97)C:7-E#0H\+V9O;G0^
M#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[=&5X="UA;&EG;CIC96YT97([(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L
M87DZ:6YL:6YE.R`^4')I8V4-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@;F]W<F%P/3-$
M;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG
M:'0Z8F]L9#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P
M>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB
M;VQD.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R("!S='EL93TS1"=B;W)D97(M
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M93TS1&1I<W!L87DZ:6YL:6YE.R`^3G5M8F5R#0H\+V9O;G0^#0H\+V9O;G0^
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M.R`^;W5T<W1A;F1I;F<-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
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M;VQD.R<@/B8C,38P.PT*/"]F;VYT/B`\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L
M87DZ:6YL:6YE.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/E=E:6=H=&5D#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V9O;G0^
M#0H\+V1I=CX\9&EV/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT
M+7=E:6=H=#IB;VQD.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L
M9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^079E<F%G90T*
M/"]F;VYT/@T*/"]F;VYT/B`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/CQD
M:78^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y%>&5R8VES90T*/"]F;VYT/@T*
M/"]F;VYT/B`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/CQD:78^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O
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M;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG
M(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#(Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@
M<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M
M86QI9VXZ8V5N=&5R.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E
M:6=H=#IB;VQD.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y7
M96EG:'1E9`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI
M9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
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M9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@
M<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/E)E;6%I;FEN9R`-"CPO9F]N=#X-
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M1&1I<W!L87DZ:6YL:6YE.R`^0V]N=')A8W1U86P@3&EF90T*/"]F;VYT/@T*
M/"]F;VYT/@T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+V1I=CX-"CPO
M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO
M=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT
M.F)O;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L
M9#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4]
M,T1D:7-P;&%Y.FEN;&EN93L@/DYU;6)E<@T*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI
M9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/D5X97)C:7-A8FQE#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A
M<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O
M;&0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[9F]N="UW96EG:'0Z8F]L9#LG
M(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D
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M96EG:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^
M079E<F%G90T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O
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M87DZ:6YL:6YE.R`^4')I8V4-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*
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M1&)O='1O;2!W:61T:#TS1#(P)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P
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M:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^079E
M<F%G90T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@
M<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/E)E;6%I;FEN9PT*/"]F;VYT/@T*
M/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93L@/D-O;G1R86-T=6%L)B,Q-C`[3&EF90T*/"]F;VYT/@T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O
M=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C`N
M,#D@+2`T+C4W#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/B8C,38P.PT*/"]F;VYT/B`\9F]N
M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^,BPR
M,C(L-S8P#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M,T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^,2XQ.0T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#(Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.F-E;G1E<CL@/C,N-C4@>65A
M<G,-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A
M<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y
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M9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^
M)B,Q-C`[#0H\+V9O;G0^(#QF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[
M9F]N="US:7IE.C$P<'0[(#XQ+#<V,RPU.3,-"CPO9F]N=#X-"CPO9F]N=#X-
M"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E(&YO=W)A<#TS
M1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C$N
M,S$-"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
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M,T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D
M:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C0N-3@@+2`Y+C`U#0H\
M+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@=VED
M=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C)P
M>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/B8C,38P.PT*/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XF(S$V,#L-"CPO9F]N=#X\9F]N
M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^.#DL
M.3DY#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA
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M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C
M:R`R<'@@<V]L:60[=&5X="UA;&EG;CIR:6=H=#LG(#XU+CDS#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG
M+6)O='1O;3HR<'@[=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIC96YT97([)R`^-"XR
M-B!Y96%R<PT*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@
M;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D
M:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI
M9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@
M,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[
M9F]N="US:7IE.C$P<'0[(#XF(S$V,#L-"CPO9F]N=#X\9F]N="!S='EL93TS
M1&1I<W!L87DZ:6YL:6YE.R`^)B,Q-C`[#0H\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C@X+#$R-`T*/"]F
M;VYT/@T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[
M=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P
M>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II
M;FQI;F4[9F]N="US:7IE.C$P<'0[(#XF(S$V,#L-"CPO9F]N=#X\9F]N="!S
M='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^)B,Q-C`[#0H\+V9O;G0^/&9O;G0@
M<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C4N.3,-
M"CPO9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,C`E("!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.F)L86-K(#)P>"!S;VQI9#LG(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[=&5X="UA;&EG;CIC96YT97([(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C0N
M,C`@>65A<G,-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO
M='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D
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M-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
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M)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B
M;&4[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z
M,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K
M(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIR:6=H=#LG(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L@/B8C,38P.PT*/"]F;VYT/CQF;VYT('-T>6QE
M/3-$9&ES<&QA>3II;FQI;F4[(#XF(S$V,#L-"CPO9F]N=#X\9F]N="!S='EL
M93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^,BPS,3(L-S4Y
M#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.F)L86-K(#1P>"!D;W5B;&4[)R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/B9N8G-P.R0-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#DE("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K
M(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIR:6=H=#LG(#XQ+C,W#0H\+W1D/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG
M+6)O='1O;3HT<'@[=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1&)O='1O;2!W:61T:#TS1#(Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ8V5N=&5R.R<@/C8N
M-38F(S$V,#MY96%R<PT*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24@;F]W<F%P/3-$;F]W<F%P("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HT<'@[
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M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y
M.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/B8C,38P.PT*/"]F;VYT/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XF(S$V,#L-"CPO9F]N=#X\9F]N
M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R`^,2PX
M-3$L-S$W#0H\+V9O;G0^#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q)2!N;W=R87`],T1N;W=R87`@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I;F<M
M8F]T=&]M.C1P>#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y
M;&4],T1D:7-P;&%Y.FEN;&EN93MF;VYT+7-I>F4Z,3!P=#L@/C$N-3,-"CPO
M9F]N=#X-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E(&YO=W)A<#TS1&YO=W)A<"`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.PT*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$,C`E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L
M86-K(#1P>"!D;W5B;&4[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9&$P
M.3`T,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X
M.&,T9&$R,#`T-2]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R
M2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:R!0=7)C:&%S92!787)R
M86YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-T;V-K(%!U<F-H87-E(%=A<G)A;G1S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M4'5R8VAA<V4@5V%R<F%N=',@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/CQD:78^/&1I=B!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/C8N)B,Q-C`[)B,Q
M-C`[)B,Q-C`[4W1O8VL@4'5R8VAA<V4@5V%R<F%N=',@#0H\+V9O;G0^#0H\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[(#X\8G(@+SX-"@T*/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/D]N($IU;'D@,BP@,C`Q,"P@=&AE($-O;7!A
M;GD@96YT97)E9"!I;G1O(&$@0V]M;6]N(%-T;V-K(%!U<F-H87-E($%G<F5E
M;65N="!W:71H(&$@<VEN9VQE(&EN=F5S=&]R+B!!<R!P87)T(&]F('1H:7,@
M86=R965M96YT+"!T:&4@0V]M<&%N>2!I<W-U960@=V%R<F%N=',@=&\@<'5R
M8VAA<V4@-C`L-C`V('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=&\@=&AE('!L
M86-E;65N="!A9V5N="P@;W(@:71S('!E<FUI='1E9"!A<W-I9VYS+B8C,38P
M.R8C,38P.U1H92!W87)R86YT<R!H879E(&%N(&5X97)C:7-E('!R:6-E(&]F
M("9N8G-P.R0Q+C,R(&%N9"!A(&QI9F4@;V8@-2!Y96%R<RX@5&AE('=A<G)A
M;G1S('9E<W1E9"!O;B!*86YU87)Y(#$L(#(P,3$@86YD(&5X<&ER92!$96-E
M;6)E<B`S,2P@,C`Q-2XF(S$V,#LF(S$V,#LF(S$V,#M3:6YC92!T:&5S92!W
M87)R86YT<R!W97)E(&=R86YT960@87,@<&%R="!O9B!A;B!E<75I='D@<F%I
M<V4L('1H92!#;VUP86YY(&AA<R!T<F5A=&5D('1H96T@87,@82!D:7)E8W0@
M;V9F97)I;F<@8V]S="XF(S$V,#LF(S$V,#M4:&4@<F5S=6QT(&]F('1H92!T
M<F%N<V%C=&EO;B!H87,@82`F;F)S<#LD,"!N970@969F96-T('1O(&5Q=6ET
M>2X@07,@;V8@2G5N92`S,"P@,C`Q,2P@,S`L,S`S(&]F('1H97-E('=A<G)A
M;G1S(')E;6%I;F5D(&]U='-T86YD:6YG+@T*/"]F;VYT/@T*/"]D:78^#0H\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[(#X\8G(@+SX-"@T*/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
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M87)E<R!O9B!C;VUM;VX@<W1O8VLN)B,Q-C`[)B,Q-C`[)B,Q-C`[16%C:"!W
M87)R86YT('=A<R!E>&5R8VES86)L928C,38P.V9O<B!T:&ER=&5E;B!M;VYT
M:',F(S$V,#MA="`F;F)S<#LD,BXP,"!P97(@<VAA<F4N(%=E(&AA=F4@96YT
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M='=O(&UO;G1H<RX@5&AE('=A<G)A;G1S)B,Q-C`[:&%D(&%N(&%N=&DM9&EL
M=71I;VXF(S$V,#LF(S$V,#MP<FEC92!P<F]T96-T:6]N(&9E871U<F4[(&EF
M('1H92!#;VUP86YY(&ES<W5E<R!S96-U<FET:65S(&%T(&$@<')I8V4@<&5R
M('-H87)E('1H870F(S$V,#LF(S$V,#MI<R!L97-S('1H86XF(S$V,#LF(S$V
M,#LF;F)S<#LD,BXP,"8C,38P.R8C,38P.W!E<B!S:&%R92PF(S$V,#LF(S$V
M,#MT:&4F(S$V,#LF(S$V,#MW87)R86YT)B,Q-C`[)B,Q-C`[:&]L9&5R<R8C
M,38P.R8C,38P.W=I;&P@8F4@<F%T8VAE=&5D)B,Q-C`[)B,Q-C`[9&]W;B8C
M,38P.R8C,38P.W1O)B,Q-C`[)B,Q-C`[=&AE(&QO=V5R)B,Q-C`[)B,Q-C`[
M;V9F97)I;F<F(S$V,#LF(S$V,#MP<FEC92X@2&]W979E<BP@=&AE($-O;7!A
M;GD@:&%S(&EN<W1I='5T960@82!F;&]O<B!P<FEC92!O9B`F;F)S<#LD,2XT
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M;G0^#0H\+V1I=CX-"CPO9&EV/CQB<B`O/@T*/&1I=B!S='EL93TS1'1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE('=A<G)A
M;G1S('=E<F4@<F5C;W)D960@87,@;&EA8FEL:71I97,@870@=&AE:7(@97-T
M:6UA=&5D(&9A:7(@=F%L=64@;VX@=&AE(&-O;6UI=&UE;G0@9&%T92P@=VAI
M8V@@=V%S("9N8G-P.R0W,38L,#`P('=I=&@@<W5B<V5Q=65N="!C:&%N9V5S
M(&EN(&5S=&EM871E9"!F86ER('9A;'5E(')E8V]R9&5D(&%S(&$@=V%R<F%N
M="!E>'!E;G-E)B,Q-C`[:6X@=&AE($-O;7!A;GDF(S@R,3<[<R!S=&%T96UE
M;G0@;V8@;W!E<F%T:6]N<R!A="!E86-H('-U8G-E<75E;G0@<F5P;W)T:6YG
M('!E<FEO9"XF(S$V,#LF(S$V,#M!="!!<')I;"`V+"`R,#$Q+"!T:&4@9F%I
M<B!V86QU92!O9B!T:&4@=V%R<F%N="!L:6%B:6QI='D@=V%S("9N8G-P.R0Q
M+#0X,2PQ-#,L('=H:6-H(')E<')E<V5N=&5D(&%N(&EN8W)E87-E(&EN(&9A
M:7(@=F%L=64@;V8@)FYB<W`[)#<V-2PQ-#,N(%1H92!F86ER('9A;'5E('=A
M<R!M96%S=7)E9"!U<VEN9R!T:&4@0FQA8VL@4V-H;VQE<R!V86QU871I;VX@
M;6]D96PL('=H:6-H(&ES(&)A<V5D+"!I;B!P87)T+"!U<&]N('5N;V)S97)V
M86)L92!I;G!U=',@9F]R('=H:6-H('1H97)E(&ES(&QI='1L92!O<B!N;R!M
M87)K970@9&%T82P@<F5Q=6ER:6YG('1H92!#;VUP86YY('1O(&1E=F5L;W`@
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M1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#`E("!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R
M/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#Y#;VUM:71M96YT(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D
M:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y$871E(`T*/"]F;VYT/@T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X]
M,T0R("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI9#LG
M(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@
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M:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/D1A
M=&4F(S$V,#L@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P
M;&%Y.FEN;&EN93L@/D%P<FEL)B,Q-C`[-BPF(S$V,#LR,#$Q(`T*/"]F;VYT
M/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T
M;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U
M;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@]
M,T0W-B4@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HM,3AP=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C$X<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y#;&]S:6YG('-T;V-K('!R:6-E
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI
M;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
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M:7IE.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/C(N,#@@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F
M9F8[(#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-S8E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[=&5X="UI;F1E;G0Z+3$X<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HQ.'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^17AP96-T960@9&EV:61E;F0@<F%T92`-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/C`@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)2`-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/C`@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)2`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<V)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.BTQ.'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,3AP=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
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M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XQ,3<N,2`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM
M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XE(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,3`T
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)2`-"CPO9F]N=#X-"CPO9&EV
M/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC
M9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W1E>'0M:6YD96YT.BTQ.'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,3AP=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/E)I<VL@9G)E92!I;G1E<F5S="!R871E(`T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^,"XR."`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN
M9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN
M+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XE
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^,"XR.2`-"CPO9F]N=#X-"CPO9&EV/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT
M97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XE(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX\='(@<W1Y
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M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XQ+C`X(`T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@
M/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`N.#4@#0H\
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M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y/;B!!<')I;"`V
M+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VUM;VX@4W1O
M8VL@4'5R8VAA<V4@06=R965M96YT('=I=&@@86X@:6YS=&ET=71I;VYA;"!I
M;G9E<W1O<BXF(S$V,#LF(S$V,#M!<R!P87)T(&]F('1H:7,@86=R965M96YT
M+"!T:&4@0V]M<&%N>2!I<W-U960@82!W87)R86YT('1O('!U<F-H87-E(#@T
M-"PS.3$@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RXF(S$V,#LF(S$V,#LF(S$V
M,#M4:&4@=V%R<F%N="!W87,@:6YI=&EA;&QY(&5X97)C:7-A8FQE)B,Q-C`[
M9F]R('1H:7)T965N(&UO;G1H<R8C,38P.V%T("9N8G-P.R0R+C`W,C4@<&5R
M('-H87)E+B!4:&4@=V%R<F%N="!H860@86X@86YT:2UD:6QU=&EO;B8C,38P
M.R8C,38P.W!R:6-E('!R;W1E8W1I;VX@9F5A='5R93L@=&AA="!P<F]V:61E
M9"!I9B!T:&4@0V]M<&%N>2!I<W-U97,@<V5C=7)I=&EE<R!A="!A('!R:6-E
M('!E<B!S:&%R92!T:&%T)B,Q-C`[)B,Q-C`[:7,@;&5S<R!T:&%N)B,Q-C`[
M)B,Q-C`[)FYB<W`[)#(N,#<R-28C,38P.R8C,38P.W!E<B!S:&%R92PF(S$V
M,#MT:&4F(S$V,#ME>&5R8VES92!P<FEC92!O9B!T:&4@=V%R<F%N="8C,38P
M.W=I;&P@8F4@<F%T8VAE=&5D)B,Q-C`[)B,Q-C`[9&]W;B8C,38P.R8C,38P
M.W1O)B,Q-C`[)B,Q-C`[=&AE(&QO=V5R)B,Q-C`[)B,Q-C`[;V9F97)I;F<F
M(S$V,#LF(S$V,#MP<FEC92XF(S$V,#M/;B!*=6QY(#(X+"`R,#$Q+"!T:&4@
M=V%R<F%N="!W87,@97AC:&%N9V5D(&9O<B!A(&YE=R!W87)R86YT('=I=&@@
M<W5B<W1A;G1I86QL>2!S:6UI;&%R('1E<FUS(&5X8V5P="!T:&%T(&EN('1H
M92!N97<@=V%R<F%N="`H:2D@=&AE(&%N=&DM9&EL=71I;VX@<')I8V4@<')O
M=&5C=&EO;B!W87,@96QI;6EN871E9"P@*&EI*2!T:&4@97AE<F-I<V4@<')I
M8V4@=V%S(&QO=V5R960@=&\@)FYB<W`[)#$N,#`L("AI:6DI('1H92!E>'!I
M<F%T:6]N(&1A=&4@=V%S(&5X=&5N9&5D(&9O<B!A;B!A9&1I=&EO;F%L)B,Q
M-C`[=&AR964@;6]N=&AS('1O($%U9W5S="`Q,BP@,C`Q,BPF(S$V,#MA;F0@
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M3F]T92`X("8C.#(Q,3L@4W5B<V5Q=65N="!%=F5N="X-"CPO9F]N=#X-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M:G5S=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+V1I=CX\9&EV/CQD
M:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^5&AE('=A<G)A
M;G0@:7,F(S$V,#MR96-O<F1E9"!A<R!A(&QI86)I;&ET>2!A="8C,38P.VET
M<R!E<W1I;6%T960@9F%I<B!V86QU92!O;B!T:&4@8V]M;6ET;65N="!D871E
M+"!W:&EC:"!W87,@)FYB<W`[)#<W-2PY.34@=VET:"!S=6)S97%U96YT(&-H
M86YG97,@:6X@97-T:6UA=&5D(&9A:7(@=F%L=64@<F5C;W)D960@87,@82!W
M87)R86YT(&5X<&5N<V4F(S$V,#MI;B!T:&4@0V]M<&%N>28C.#(Q-SMS('-T
M871E;65N="!O9B!O<&5R871I;VYS(&%T(&5A8V@@<W5B<V5Q=65N="!P97)I
M;V0N)B,Q-C`[)B,Q-C`[070@2G5N92`S,"P@,C`Q,2P@=&AE(&9A:7(@=F%L
M=64@;V8@=&AE('=A<G)A;G0@;&EA8FEL:71Y('=A<R`F;F)S<#LD.#@L,S(S
M+"!W:&EC:"!R97!R97-E;G1E9"!A(&1E8W)E87-E(&EN(&9A:7(@=F%L=64@
M;V8@)FYB<W`[)#8X-RPV-S(N)B,Q-C`[)B,Q-C`[(%1H92!F86ER('9A;'5E
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M('1A8FQE.B`-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=CX\9&EV
M/CQD:78^/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0X,"4@('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\='(^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#<V)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[=&5X
M="UA;&EG;CIL969T.R`^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P
M)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R
M<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E
M>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
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M9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN
M93L@/D1A=&4-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$<&%D9&EN9RUB;W1T
M;VTZ,G!X.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$P)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.W1E>'0M86QI9VXZ8V5N=&5R.R`^/&9O;G0@<W1Y;&4],T0G
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4]
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M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^2G5N928C,38P.S,P
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M0VQO<VEN9R!S=&]C:R!P<FEC90T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^,BXP.`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T
M>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL969T.R`^/&9O
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M+7)I9VAT.C!P=#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^17AP96-T960@9&EV
M:61E;F0@<F%T90T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS
M1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S
M='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ<FEG:'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,`T*/"]F;VYT/@T*/"]D
M:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@
M<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.G)I9VAT.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT
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M969T.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.BTQ.'!T.V1I<W!L87DZ
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M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
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M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
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M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
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M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)0T*/"]F
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M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^4FES:R!F<F5E(&EN=&5R97-T
M(')A=&4-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4]
M,T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`N,CD-"CPO9F]N=#X-"CPO9&EV
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$
M=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W
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M:7IE.C$P<'0[)R`^)0T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX\
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M17AP96-T960@;&EF92`H>65A<G,I#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^
M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ<FEG
M:'0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG
M;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XQ+C`X
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,"XW-PT*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO
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M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!T:&4@97-T
M:6UA=&5D(&9A:7(@=F%L=64@;V8@=&AE('=A<G)A;G0@;&EA8FEL:71I97,Z
M(`T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP
M<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=CX\9&EV/CQT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S`E("!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@X)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UI;F1E;G0Z+3$X<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HQ.'!T.VUA<F=I;BUR:6=H=#HP
M<'0[=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,3`-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD
M:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.FQE9G0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F
M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^+0T*/"]F;VYT/@T*/"]D:78^#0H\+W1D
M/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@X)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z+3$X<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HQ.'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL969T.R`^/&9O
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M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#MT97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/C$L-#DQ+#DY-0T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T
M97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$
M8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#@X)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV
M('-T>6QE/3-$=&5X="UI;F1E;G0Z+3$X<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HQ.'!T.VUA<F=I;BUR:6=H=#HP<'0[=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D-H86YG92!I;B!F
M86ER('9A;'5E(&]F('=A<G)A;G0@;&EA8FEL:71Y#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I
M9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^-S<L
M-#<Q#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#$E(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@X)2`@<W1Y;&4],T1P861D:6YG+6)O='1O;3HR<'@[=&5X="UA;&EG
M;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.BTQ.'!T.V1I<W!L
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F
M;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M86QI9VXZ
M;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M
M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/B@Q+#0X,2PQ
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M.C$P<'0[)R`^*28C,38P.PT*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T
M<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-C8V9F8V,[(#X\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.#@E("!S='EL93TS1'1E>'0M86QI
M9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V
M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL
M93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^0F%L86YC92!A="!*
M=6YE(#,P+"`R,#$Q#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'!A9&1I;F<M8F]T=&]M.C1P
M>#MT97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X
M(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE
M.R`^)FYB<W`[)`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I
M=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4]
M,T1D:7-P;&%Y.FEN;&EN93L@/C@X+#,R,PT*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1P861D:6YG+6)O='1O;3HT<'@[=&5X="UA;&EG;CIL969T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-
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M($IU;F4@,S`L(#(P,3$L(&%N9"!F;W(@=&AE('EE87(@96YD960@1&5C96UB
M97(@,S$L(#(P,3`L(&ES(&%S(&9O;&QO=W,Z(`T*/"]F;VYT/@T*/"]D:78^
M/&)R("\^#0H\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&)R("\^#0H-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9&EV/CQD:78^/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X,"4@('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#X\='(^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#<V)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$,3`E(&-O;'-P86X],T0R("!S='EL93TS1"=B
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M="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^5V%R<F%N=',@#0H\+V9O;G0^
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
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M(#Y796EG:'1E9"`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6%L:6=N.F-E;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA
M>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@
M/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#Y!=F5R86=E(`T*/"]F
M;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D
M:7-P;&%Y.FEN;&EN93L@/B8C,38P.T5X97)C:7-E)B,Q-C`[4')I8V4@#0H\
M+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG
M+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C
M:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#<V)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
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M+7-I>F4Z,3!P=#LG(#XQ+#`W,"PT-S(@#0H\+V9O;G0^#0H\+V1I=CX-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S
M<#LD(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L
M87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,RXR-R`-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W#0H@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R
M('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#<V)2`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#Y'<F%N=&5D(`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI
M;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
M;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M-C`L-C`V(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG
M;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
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M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D5X97)C:7-E9"`-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
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M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^+2`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L
M;W(Z(V9F9F9F9CL@/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@
M('-T>6QE/3-$<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ:G5S=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C
M:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#Y&;W)F96ET960@;W(@97AP:7)E9"`-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M
M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED
M.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/BT@
M#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D
M:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O
M='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q
M-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E
M>'0M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O
M;&ED.W1E>'0M86QI9VXZ<FEG:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/BT@#0H\+V9O;G0^#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP
M861D:6YG+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE
M/3-$8F%C:V=R;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<V)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S
M=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#Y"86QA;F-E("8C.#(Q,3L@1&5C96UB97(@,S$L(#(P,3`@
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE
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M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<-
M"B!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XS+C0Y(`T*/"]F;VYT/@T*/"]D
M:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE
M/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#<V)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S
M=&EF>3MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#Y'<F%N=&5D(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,BPR-S(L
M.38S(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$.24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
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M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D9O<F9E:71E9"!O<B!E>'!I
M<F5D(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF
M(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[)B,Q-C`[*#$Y+#8X."D@
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z
M,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H
M=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,2XS,B`-
M"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\
M+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CL@/CQT
M9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W-B4@('-T>6QE/3-$<&%D9&EN
M9RUB;W1T;VTZ,G!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF
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M<FEG:'0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG
M;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L
M86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.FQE9G0[)R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.F)L86-K(#)P>"!S;VQI9#MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$
M9&ES<&QA>3II;FQI;F4[(#XH,34L-C$U(`T*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&1I
M=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES
M<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XI(`T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG;CIL969T
M.R<@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L:60[=&5X="UA;&EG
M;CIR:6=H=#LG(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,2XQ.2`-"CPO9F]N
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M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^0F%L86YC92`F(S@R,3$[
M($IU;F4@,S`L(#(P,3$@+2!O=71S=&%N9&EN9R`-"CPO9F]N=#X-"CPO9&EV
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O;3HT<'@[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.FQE9G0[)R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
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M9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^,RPS-C@L-S,X(`T*/"]F
M;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L
M:6=N.FQE9G0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^)FYB<W`[)"`-"CPO
M9F]N=#X-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@-'!X
M(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI
M;F4[(#XR+C(W(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT
M<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V9F9F9F9CL@/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W-B4@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S
M='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#DE("!S='EL93TS1'1E>'0M86QI9VXZ
M<FEG:'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/CQT
M<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0W-B4@('-T>6QE/3-$<&%D9&EN9RUB;W1T
M;VTZ-'!X.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT97AT
M+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R
M9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#Y"86QA;F-E("8C.#(Q,3L@2G5N92`S,"P@,C`Q,2`F(S@R,3$[(&5X97)C
M:7-A8FQE(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I
M;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U
M8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$.24@('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@
M-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T
M97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K
M.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
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M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG
M;CIL969T.W!A9&1I;F<M8F]T=&]M.C1P>#L@/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT
M+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ;&5F=#LG(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA
M>3II;FQI;F4[(#XF;F)S<#LD(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^
M#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Y)2`@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3IB;&%C:R`T<'@@9&]U8FQE.W1E>'0M86QI9VXZ<FEG
M:'0[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E
M;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/C(N,C<@#0H\+V9O;G0^#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HT
M<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*
M/"]F;VYT/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/"]D:78^#0H\+V1I
M=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA
M>3IB;&]C:SL@/CQB<B`O/@T*#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA
M;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!W87)R86YT<R!O=71S=&%N9&EN9R!A
M<R!O9B!*=6YE(#,P+"`R,#$Q+"!A<F4@87,@9F]L;&]W<SH@#0H\+V9O;G0^
M#0H\+V1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/B8C,38P.R`-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[(#X\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG
M/3-$,"!W:61T:#TS1#4P)2`@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
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M='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^4F%N9V4F(S$V,#MO9B`-"CPO9F]N
M=#X-"CPO9F]N=#X-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.F-E
M;G1E<CMT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F
M=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#MF;VYT+7=E:6=H=#IB;VQD.R<@/CQF;VYT('-T>6QE/3-$9&ES
M<&QA>3II;FQI;F4[(#Y%>&5R8VES928C,38P.U!R:6-E(`T*/"]F;VYT/@T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ
M,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG+6)O='1O;3HR<'@[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
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M96EG:'0Z8F]L9#LG(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^
M3G5M8F5R(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^/&9O
M;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@/F]U='-T86YD:6YG(`T*/"]F
M;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB
M;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0U)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB;&%C:R`R<'@@<V]L
M:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/E=E:6=H=&5D(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y
M.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M=V5I9VAT.F)O;&0[)R`^
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M<W!L87DZ:6YL:6YE.R`^4F5M86EN:6YG(`T*/"]F;VYT/@T*/"]F;VYT/@T*
M/"]D:78^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.V9O;G0M
M=V5I9VAT.F)O;&0[)R`^/&9O;G0@<W1Y;&4],T1D:7-P;&%Y.FEN;&EN93L@
M/D-O;G1R86-T=6%L)B,Q-C`[3&EF92`-"CPO9F]N=#X-"CPO9F]N=#X-"CPO
M9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO
M<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\
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M(#XQ+C,R(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*
M/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE
M.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG
M(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
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M+C4Q('EE87)S(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX\='(@
M<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S<#LD(`T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0R-24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4]
M,T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L
M;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C$N-#`@#0H\+V9O;G0^#0H\+V1I
M=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF
M;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#(U)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T
M.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP
M<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,2PT,C@L-3<R
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#0U)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD
M96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM
M<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/C`N
M.#4@>65A<G,@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/CQT<B!S
M='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0@#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS
M1#(U)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS
M1'1E>'0M86QI9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^,BXP-S(U(`T*/"]F;VYT/@T*/"]D
M:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,C4E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XX-#0L,SDQ(`T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-#4E(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIC
M96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE
M9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^,"XW-R!Y96%R<R`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
M9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F
M.R`^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[=&5X
M="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN
M93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[
M)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,C4E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XR+C(R(`T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR
M:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US
M:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,C4E("!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MT97AT+6EN9&5N=#HP
M<'0[9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT
M.C!P=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XV,C8L.#`Y
M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#4E(#X\9&EV('-T>6QE/3-$
M=&5X="UA;&EG;CIC96YT97([=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO
M8VL[;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^-2XP,2!Y96%R<R`-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC
M;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S
M='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^)FYB<W`[)"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
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M=#LG(#XS+C,P(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT
M/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$
M=&5X="UA;&EG;CIR:6=H=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL
M:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P
M=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T
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M(`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX\='(@<W1Y;&4],T1B
M86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@=F%L:6=N/3-$=&]P('=I
M9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL
M93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB
M;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF;F)S<#LD(`T*/"]F;VYT/@T*
M/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R-24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
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M,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F
M=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\
M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R-24@('-T
M>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L
M:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O
M;G0M<VEZ93HQ,'!T.R<@/C4P+#`P,"`-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#0U)2`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/C0N-C,@>65A<G,@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^#0H\+W1R/CQT
M<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z(V-C9F9C8SL@/CQT9"!V86QI
M9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[
M(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B9N8G-P.R0@
M#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T
M:#TS1#(U)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T
M=&]M.C)P>#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M
M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G
M:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@
M/C8N,S8@#0H\+V9O;G0^#0H\+V1I=CX-"CPO=&0^/'1D('9A;&EG;CTS1'1O
M<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MP861D:6YG
M+6)O='1O;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#MP861D:6YG+6)O='1O
M;3HR<'@[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ8FQA8VL@,G!X('-O;&ED.W1E>'0M
M86QI9VXZ;&5F=#LG(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN;&EN93MF
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H
M/3-$,C4E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#)P>"!S;VQI
M9#MT97AT+6%L:6=N.G)I9VAT.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL
M969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M
M<VEZ93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XS
M,C<L-#4V(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[<&%D9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#0U)2`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3IB
M;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N
M=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T
M.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ
M93HQ,'!T.R<@/CQF;VYT('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ+C,V
M('EE87)S(`T*/"]F;VYT/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T
M<CX\='(@<W1Y;&4],T1B86-K9W)O=6YD+6-O;&]R.B-F9F9F9F8[(#X\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-
M"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(U)2`@
M<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W!A9&1I;F<M8F]T=&]M.C1P>#L@
M/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O
M;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4]
M,T1T97AT+6%L:6=N.FQE9G0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M
M86QI9VXZ<FEG:'0[<&%D9&EN9RUB;W1T;VTZ-'!X.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.F)L86-K(#1P>"!D;W5B;&4[=&5X="UA;&EG;CIL969T.R<@/CQF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0R-24@('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ8FQA8VL@-'!X(&1O=6)L93MT97AT+6%L:6=N.G)I9VAT
M.R<@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
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M;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^)B,Q-C`[
M(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-#4E("!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#1P>"!D;W5B;&4[
M)R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ8V5N=&5R.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/CQF;VYT
M('-T>6QE/3-$9&ES<&QA>3II;FQI;F4[(#XQ+C@P('EE87)S(`T*/"]F;VYT
M/@T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M+V1I=CX-"CPO9&EV/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R.5\P.#AC
M-&1A,C`P-#4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&$P.3`T
M,61?.6,P-U\T,&$T7SDW,CE?,#@X8S1D83(P,#0U+U=O<FMS:&5E=',O4VAE
M970Q,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P13)(/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@
M3F]T92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y($YO=&4@1&ES8VQO
M<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.V9O;G0M=V5I9VAT.F)O;&0[)R`^-RXF(S$V,#LF(S$V,#LF(S$V,#M3=&]C
M:VAO;&1E<G,F(S@R,3<[($5Q=6ET>2`-"CPO9F]N=#X-"CPO9&EV/CQD:78@
M<W1Y;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O
M/@T*#0H\+V1I=CX\9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I
M9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^1'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L
M(#(P,3$L('1H92!#;VUP86YY(&ES<W5E9"`Q-2PP,#`@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&5X97)C:7-E(&]F
M('-T;V-K(&]P=&EO;G,@86YD('=A<G)A;G1S)B,Q-C`[9F]R('!R;V-E961S
M(&]F("9N8G-P.R0W+#8U,"!A;F0@,3`L-C$U('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@<F5L871E9"!T;R!A(&-A<VAL97-S(&5X97)C:7-E(&]F('=A<G)A
M;G1S+B!4:&4@0V]M<&%N>2!A;'-O(&ES<W5E9"`T-2PV,#`@<VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!F;W(@96UP;&]Y;65N="!S97)V:6-E+"!H879I;F<@
M82!F86ER('9A;'5E(&]F("9N8G-P.R0W-2PX-#`@*"9N8G-P.R0Q+C8V(&%V
M97)A9V4@<&5R('-H87)E*2!A;F0@-#$L-SDV('-H87)E<R!O9B!C;VUM;VX@
M<W1O8VL@9F]R(&-O;G-U;'1I;F<@<V5R=FEC97,L(&AA=FEN9R!A(&9A:7(@
M=F%L=64@;V8@)FYB<W`[)#4X+#(W,"`H)FYB<W`[)#$N,SD@879E<F%G92!P
M97(@<VAA<F4I+"!B87-E9"!O;B!T:&4@<75O=&5D(&-L;W-I;F<@=')A9&EN
M9R!P<FEC97,N(`T*/"]F;VYT/@T*/"]D:78^#0H\+V1I=CX\9&EV('-T>6QE
M/3-$=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[(#X\8G(@+SX-"@T*
M/"]D:78^/&1I=CX\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E
M>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM
M87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/D]N($IA;G5A<GD@,C@L(#(P,3$L('1H92!#;VUP86YY('-O;&0@,BPX
M-3<L,30T('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S(&5X
M97)C:7-A8FQE(&9O<B8C,38P.R8C,38P.S$L-#(X+#4W,B8C,38P.W-H87)E
M<R!O9B!C;VUM;VX@<W1O8VLF(S$V,#MF;W(@)FYB<W`[)#0L,#`P+#`P,"X@
M1&ER96-T(&]F9F5R:6YG(&-O<W1S('=E<F4@87!P<F]X:6UA=&5L>2`F;F)S
M<#LD,S`P+#`P,"X@#0H\+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y
M;&4],T1T97AT+6EN9&5N=#HP<'0[9&ES<&QA>3IB;&]C:SL@/CQB<B`O/@T*
M#0H\+V1I=CX\9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I9GD[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^3VX@07!R:6P@-BP@,C`Q,2P@=&AE($-O;7!A;GD@<V]L9"`Q+#8X
M."PW.#(@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@97AE
M<F-I<V%B;&4@9F]R(#@T-"PS.3$@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R8C
M,38P.V9O<B`F;F)S<#LD,RPU,#`L,#`P+B!$:7)E8W0@;V9F97)I;F<@8V]S
M=',@=V5R92!A<'!R;WAI;6%T96QY("9N8G-P.R0R-3`L,#`P+B`-"CPO9F]N
M=#X-"CPO9&EV/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.R`^/&)R("\^#0H-"CPO9&EV/@T*/"]D:78^#0H\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T-0T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R
M.5\P.#AC-&1A,C`P-#4O5V]R:W-H965T<R]3:&5E=#$T+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%,D@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N
M=#QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U8G-E<75E;G0@179E;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N
M=',@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
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M:6=H=#IB;VQD.R<@/C@N)B,Q-C`[)B,Q-C`[)B,Q-C`[4W5B<V5Q=65N="!%
M=F5N=#QB<B`O/@T*/&)R("\^#0H-"CPO9F]N=#X-"CPO9&EV/@T*/"]D:78^
M/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#MT97AT+6EN9&5N=#HP<'0[
M9&ES<&QA>3IB;&]C:SMM87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P
M=#L@/@T*/"]D:78^/&1I=B!S='EL93TS1'1E>'0M:6YD96YT.C!P=#MD:7-P
M;&%Y.F)L;V-K.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3MT
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M=&@@=&AE)B,Q-C`[07!R:6P@-BP@,C`Q,2!F:6YA;F-I;F<F(S$V,#MF;W(@
M82!N97<@=V%R<F%N="!W:71H('-U8G-T86YT:6%L;'D@=&AE('-A;64@=&5R
M;7,@87,@=&AE(&]R:6=I;F%L('=A<G)A;G0@97AC97!T('1H870@:6X@=&AE
M(&YE=R!W87)R86YT("AI*2!T:&4@86YT:2UD:6QU=&EO;B!P<FEC92!P<F]T
M96-T:6]N('=A<R!E;&EM:6YA=&5D+"`H:6DI('1H92!E>&5R8VES92!P<FEC
M92!W87,@;&]W97)E9"!T;R`F;F)S<#LD,2XP,"P@*&EI:2D@=&AE(&5X<&ER
M871I;VX@9&%T92!W87,@97AT96YD960@9F]R(&%N(&%D9&ET:6]N86P@=&AR
M964@;6]N=&AS('1O($%U9W5S="`Q,"P@,C`Q,BPF(S$V,#MA;F0@*&EV*2!T
M:&4@=V%R<F%N="8C.#(Q-SMS(&EN:71I86P@97AE<F-I<V4@9&%T92!W87,@
M8VAA;F=E9"!T;R!*86YU87)Y(#(P,3(N)B,Q-C`[)B,Q-C`[)B,Q-C`[1'5E
M('1O('1H:7,@=V%R<F%N="!E>&-H86YG92P@=&AE('=A<G)A;G0@;&EA8FEL
M:71Y)B,Q-C`[/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/G=I;&P@
M8F4@96QI;6EN871E9"!O;B!A(&=O+69O<G=A<F0@8F%S:7,@<VEN8V4@=&AE
M(&YE=R!W87)R86YT(&YO(&QO;F=E<B!C;VYT86EN<R!T:&4@<')O=FES:6]N
M<R!T:&%T(&-A=7-E(&ET('1O(&)E('1R96%T960@87,@82!D97)I=F%T:79E
M(&QI86)I;&ET>2X\8G(@+SX-"CQB<B`O/@T*#0H\+V9O;G0^#0H\+V9O;G0^
M#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.FIU<W1I
M9GD[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X-"CPO9&EV/@T*/"]D:78^/&1I=CX\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.W1E>'0M:6YD96YT.C!P
M=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z
M,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/E1H92!#;VUP
M86YY(&UE87-U<F5D('1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT(&%T
M("9N8G-P.R0R-3,L,S$W('5S:6YG(&$@0FQA8VLM4V-H;VQE<R!V86QU871I
M;VX@;6]D96P[)B,Q-C`[07,@82!R97-U;'0@;V8@;6]D:69Y:6YG('1H92!T
M97)M<R!O9B!T:&4@=V%R<F%N="P@:70@=V%S(&YO="8C,38P.V-O;G-I9&5R
M960F(S$V,#MI;F1E>&5D('1O('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N
M('-T;V-K+B8C,38P.R8C,38P.U1H92!F86ER('9A;'5E(&]F('1H:7,@=V%R
M<F%N="!U<&]N(&5X8VAA;F=E('=A<R!B87-E9"!U<&]N('1H92!F;VQL;W=I
M;F<@;6%N86=E;65N="!A<W-U;7!T:6]N<SH\8G(@+SX-"CQB<B`O/@T*#0H\
M+V9O;G0^#0H\+V1I=CX-"CPO9&EV/CQD:78@<W1Y;&4],T1T97AT+6EN9&5N
M=#HP<'0[9&ES<&QA>3IB;&]C:SL@/@T*/"]D:78^/&1I=B!S='EL93TS1'1E
M>'0M86QI9VXZ;&5F=#L@/CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$-3`E("!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/'1R/CQT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0X,B4@('-T>6QE/3-$=&5X="UA;&EG;CIL
M969T.W!A9&1I;F<M8F]T=&]M.C)P>#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ:6YL:6YE.V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I
M>F4Z,3!P=#LG(#XF(S$V,#L@#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[<&%D
M9&EN9RUB;W1T;VTZ,G!X.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI
M;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T
M.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#$V)2!C;VQS<&%N/3-$,B`@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3IB;&%C:R`R<'@@<V]L:60[)R`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ8V5N=&5R.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I
M;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G
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M:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^/&9O;G0@<W1Y;&4]
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M(#X\9F]N="!S='EL93TS1&1I<W!L87DZ:6YL:6YE.R`^2G5L>28C,38P.S(X
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M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P<'0[)R`^
M0VQO<VEN9R!S=&]C:R!P<FEC90T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N
M.G)I9VAT.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P
M.R`-"CPO9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E
M("!S='EL93TS1'1E>'0M86QI9VXZ;&5F=#L@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R
M9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[
M9F]N="US:7IE.C$P<'0[)R`^)FYB<W`[)`T*/"]F;VYT/@T*/"]D:78^#0H\
M+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q-24@('-T>6QE/3-$=&5X
M="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT
M.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
M;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ
M,'!T.R<@/C`N.#0-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X\=&0@=F%L:6=N
M/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N
M=#X-"CPO=&0^#0H\+W1R/CQT<B!S='EL93TS1&)A8VMG<F]U;F0M8V]L;W(Z
M(V9F9F9F9CL@/CQT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0X,B4@('-T
M>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&1I=B!S='EL93TS1'1E>'0M86QI
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M="US:7IE.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO
M9F]N=#X-"CPO=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$U)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M86QI
M9VXZ<FEG:'0[=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN
M+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N
M="US:7IE.C$P<'0[)R`^,`T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE
M9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT
M.C!P=#MD:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG
M:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B4-"CPO
M9F]N=#X-"CPO9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R
M;W5N9"UC;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#@R)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE
M/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.BTQ.'!T.V1I<W!L87DZ
M8FQO8VL[;6%R9VEN+6QE9G0Z,3AP=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O
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M+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)2`@<W1Y
M;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.FEN;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE
M.C$P<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$
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M;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B4-"CPO9F]N=#X-"CPO9&EV/@T*/"]T9#X-
M"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC;VQO<CHC9F9F9F9F.R`^
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E
M>'0M:6YD96YT.BTQ.'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,3AP
M=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II
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M<'0[)R`^)B,Q-C`[(`T*/"]F;VYT/@T*/"]T9#X\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA;&EG;CIL969T.R`^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO
M=&0^/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$U)2`@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.R`^/&1I=B!S='EL93TS1'1E>'0M86QI9VXZ<FEG:'0[
M=&5X="UI;F1E;G0Z,'!T.V1I<W!L87DZ8FQO8VL[;6%R9VEN+6QE9G0Z,'!T
M.VUA<F=I;BUR:6=H=#HP<'0[(#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.FEN
M;&EN93MF;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86X[9F]N="US:7IE.C$P
M<'0[)R`^,"XR,0T*/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\
M9&EV('-T>6QE/3-$=&5X="UA;&EG;CIL969T.W1E>'0M:6YD96YT.C!P=#MD
M:7-P;&%Y.F)L;V-K.VUA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T
M.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B4-"CPO9F]N=#X-
M"CPO9&EV/@T*/"]T9#X-"CPO='(^/'1R('-T>6QE/3-$8F%C:V=R;W5N9"UC
M;VQO<CHC8V-F9F-C.R`^/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#@R
M)2`@<W1Y;&4],T1T97AT+6%L:6=N.FQE9G0[(#X\9&EV('-T>6QE/3-$=&5X
M="UA;&EG;CIL969T.W1E>'0M:6YD96YT.BTQ.'!T.V1I<W!L87DZ8FQO8VL[
M;6%R9VEN+6QE9G0Z,3AP=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/D5X<&5C=&5D(&QI9F4@*'EE87)S*0T*
M/"]F;VYT/@T*/"]D:78^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0Q)2`@<W1Y;&4],T1T97AT+6%L:6=N.G)I9VAT.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/B8C,38P.R`-"CPO9F]N=#X-"CPO=&0^/'1D
M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$E("!S='EL93TS1'1E>'0M86QI9VXZ
M;&5F=#L@/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ:6YL:6YE.V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;CMF;VYT+7-I>F4Z,3!P=#LG(#XF(S$V,#L@
M#0H\+V9O;G0^#0H\+W1D/CQT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q-24@
M('-T>6QE/3-$=&5X="UA;&EG;CIR:6=H=#L@/CQD:78@<W1Y;&4],T1T97AT
M+6%L:6=N.G)I9VAT.W1E>'0M:6YD96YT.C!P=#MD:7-P;&%Y.F)L;V-K.VUA
M<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.R`^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3II;FQI;F4[9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M.V9O;G0M<VEZ93HQ,'!T.R<@/C$N,#0-"CPO9F]N=#X-"CPO9&EV/@T*/"]T
M9#X\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24@('-T>6QE/3-$=&5X="UA
M;&EG;CIL969T.R`^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3II;FQI;F4[9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N.V9O;G0M<VEZ93HQ,'!T.R<@/B8C
M,38P.R`-"CPO9F]N=#X-"CPO=&0^#0H\+W1R/@T*/"]T86)L93X\8G(@+SX-
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M9F]N="US:7IE.C$P<'0[)R`^3VX@075G=7-T(#$P+"`R,#$Q+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@86X@86=R965M96YT('1O(&5X8VAA;F=E('1H
M92!W87)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H('1H92!*86YU
M87)Y(#(X+"`R,#$Q(&9I;F%N8VEN9R!F;W(@;F5W('=A<G)A;G1S('=I=&@@
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M/"]D:78^#0H\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V1A,#DP-#%D7SEC,#=?-#!A-%\Y-S(Y7S`X.&,T9&$R,#`T
M-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]D83`Y,#0Q9%\Y8S`W
M7S0P831?.3<R.5\P.#AC-&1A,C`P-#4O5V]R:W-H965T<R]F:6QE;&ES="YX
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M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-"CPO
M>&UL/@T*+2TM+2TM/5].97AT4&%R=%]D83`Y,#0Q9%\Y8S`W7S0P831?.3<R
2.5\P.#AC-&1A,C`P-#4M+0T*
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
